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Abstract
The last decade has seen significant development in understanding the genetic basis of
myeloproliferative neoplasms (MPN), with the underlying somatic mutational landscape
revealed by genome and targeted exome sequencing. The aim of this research was to
conduct a series of original investigations to develop insight into the utility and clinical
application of these disease markers.
Initially, three recently identified disease-specific molecular markers (mutations
in JAK2, CALR and CSF3R) were utilised to measure the burden of disease postallogeneic transplantation using methods based on quantitative PCR, capillary
electrophoresis and Sanger sequencing. The measured variant allelic frequency of the
disease was compared against percentage donor chimerism – a short tandem repeat PCR
based method with high discriminatory power that enables a semi-quantitative measure
of engraftment based on the calculation of donor and recipient DNA in the blood. All
three mutation markers were shown to be stable and robust for monitoring purposes
throughout the disease course, inversely correlating with percentage donor chimerism.
The increased sensitivity of the JAK2 V617F qPCR used in the JAK2 study highlighted
the potential of these disease specific markers to detect molecular and haematological
relapse in patients several weeks before clinical manifestation and proved an
advantageous adjunct in the clinical assessment of transplantation efficacy.
In a second series of studies, the incidence and significance of recurrent MPN mutations
in specific clinical scenarios and MPN disease cohorts was investigated. A baseline for
the incidence of JAK2, CALR and MPL mutations in Irish patients referred for suspected
MPN was established and shown to be comparable with that of other Western European
cohorts. To extend this finding, the incidence and significance of these mutations was
investigated in specific clinically relevant disease cohorts, revealing a distinct molecular
III

pathogenesis in paediatric patients with essential thrombocythaemia (ET) when compared
to adults, a low incidence of CALR mutations in splanchnic vein thrombosis patients that
correlated with the aetiology of the disease and the presence of CALR driver mutations in
familial MPN cases. Additionally, the presence of a JAK2 V617F mutation in utero in ET
was established for the first time and the dynamic nature of MPN disease clones over the
course of disease was revealed, thus informing insight into the clonal evolution and
molecular heterogeneity of MPN patients. This information was collated with results from
a number of audits based on clinical referral patterns to a routine molecular diagnostic
facility to inform the development of a molecular diagnostic testing algorithm for patients
with suspected MPN.
In the third series of studies novel next generation sequencing (NGS) technology
was applied to investigate somatic mutations in acute myeloid leukaemia (AML) related
patient cohorts. A proprietary NGS panel for recurrently mutated genes possessing
diagnostic and prognostic significance in AML was evaluated on the Ion Torrent
(ThermoFisher) NGS platform across three molecular diagnostic centres in Ireland,
Northern Ireland and Scotland. This verified the technique to be robust and reproducible
for mutation detection in AML patients. The technology was subsequently deployed to
profile mutation status in a clinically high-risk AML patient cohort undergoing
transplantation therapy and in a familial AML disease setting to clarify the genotype,
reveal the diverse clonal architecture of patients and identify additional driver mutations
relevant for existing and emerging therapeutic interventions.
Taken together, the studies in this thesis inform clinical understanding and
decision making in MPN and AML related settings, provide novel insight into underlying
mutational status and clonal behaviour in myeloid malignancies and have the potential to
translate into optimised and improved treatment for these patient cohorts.
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1.0 Introduction
1.1 Development of the haematopoietic system
Haematopoiesis, from the Greek term for “blood making”, is the adaptive process by
which mature and functional blood cells are continuously replaced over the entire lifetime
of an individual. Erythrocytes, platelets, and the various subsets of leucocytes all have
finite although different life spans. As a consequence, the daily production of red blood
cells, platelets, and neutrophils in homeostatic conditions amount to more than 300 billion
cells (Aiuti et al., 2019).
Definitive haematopoietic stem cells (HSCs) lie at the foundation of the adult
hematopoietic system and provide an organism throughout its life with all blood cell
types. Several tissues demonstrate haematopoietic activity at early stages of embryonic
development, The ontogeny of the vertebrate haematopoietic system is characterised by
two waves: embryonic haematopoiesis, which generates transitory haematopoietic cell
populations, such as primitive erythrocytes and some myeloid cells; and permanent,
definitive haematopoiesis, which originates later in development from definitive HSCs
and which gives rise to all the mature blood (erythroid, myeloid and lymphoid) lineages
in the adult organism. It was Francoise Dieterlen-Lievre in 1975 (Dieterlen-Lievre, 1975)
who showed, using quail chick chimeric embryos, that the adult haematopoietic system
originates inside the embryo proper.
During human embryogenesis, three weeks after the formation of the zygote
caused as a result of fusion of a sperm and an egg, gastrulation occurs. Gastrulation is the
development of a single layered blastula into the three germ layers; ectoderm (developing
into the brain, spinal cord, hair nails, epidermis) endoderm (developing into epithelial
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lining of the digestive tract, stomach, liver pancreas, lung, bladder) and mesoderm
(developing into muscle, bone, connective tissue, kidney, gonads, circulatory system)
(Pansky, 1982).
The formation of HSCs during development occurs by a multistep process that
begins with the induction of ventral mesoderm. Following gastrulation, a subset of ventral
mesoderm is specified to become HSCs (Gao et al., 2018). Haematopoiesis, the process
by which blood cells are formed initially occurs first in the yolk sac outside the embryo
and later within the embryo within the paraaortic splanchnopleura. After approximately
5 weeks gestation, haematopoiesis transitions temporarily to the liver, with the long bones
developing sufficient marrow capacity after 12 weeks to begin definitive haematopoiesis
and the thymus maturing by 15 weeks gestation (Golub and Cumano, 2013) (Figure 1.1).

Figure 1.1: Ontogeny of haematopoiesis in humans. Changes in the anatomical location
of haematopoiesis during human development are shown on a circular timeline (Muench
and Bárcena, 2004).
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1.2 Normal differentiation in Haematopoiesis
In 1909 A.A. Maximow proposed the unitarian theory of haematopoiesis; that a common
stem cell was responsible for all blood elements (Maximow, 1909). During postnatal life,
a steady state is established in which HSC pool size is maintained by the regulation of the
multipotent HSC self-renewal and differentiation (Boulais and Frenette, 2015).
Haematopoiesis is understood to be organised as a cellular hierarchy derived from
multipotent HSCs that progress to terminally differentiated cells. As they differentiate,
HSCs give rise to a series of progenitor cell intermediates that undergo a gradual fate
restriction to assume the identity of a mature blood cell which is subsequently released
into the circulation. The common myeloid progenitor gives rise to platelets, erythrocytes,
granulocytes and monocytes, whereas the common myeloid progenitor gives rise to B, T
and NK lymphocytes (Figure 1.2). The end result is the continuous production of
sufficient, but not excessive, numbers of cells of all lineages (Boulais and Frenette, 2015).
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Figure 1.2. Overview of myeloid haematopoiesis and cell lineage differentiation. Stem
cells originate in the bone marrow before committing to particular lineages and
migrating to the peripheral blood or destination tissue upon maturity. B, Basophil; N,
Neutrophil; E, Eosinophil. Source:
https://commons.wikimedia.org/wiki/File:Hematopoiesis_(human)_ diagram .png A.
Rad [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0/)].
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1.3 Regulation of Haematopoiesis
The bone marrow contains specialised niches in which the multipotency of HSCs is
conserved through cell divisions, while their progeny are directed towards lineage
differentiation (Tweedell, 2017). Accumulating evidence reveals that various cell types
in and around the bone marrow participate in HSC function and its niche regulation
(Schofield, 1978; Morrison and Scadden, 2014; Flynn and Kaufman, 2015). A complex
and diverse group of cells have been implicated including stromal cells, osteoblasts,
neurons and glial cells, all of which produce growth factors and cytokines that impact
HSC regulation and maintenance (Anthony and Link, 2014) (Figure 1.3, Figure 1.4).
Some factors like stem cell factor (also known as kit ligand), FMS like tyrosine receptor
3 ligand (FLT- 3 ligand), Granulocyte-Macrophage colony stimulating factor (GM-CSF)
and interleukin 3 (IL-3) act upon stem cells or primitive committed progenitor cells early
on in haematopoiesis. Other cytokines are lineage-specific and only exert their activities
late in haematopoiesis on a single pathway, for example granulocyte colony stimulating
factor (G-CSF), Erythropoietin (EPO) and Thrombopoietin (TPO). Like all homeostatic
systems, haematopoiesis is regulated by a balance of positive and negative influences.
Direct inhibitory cytokines include macrophage inflammatory protein 1 alpha (MIP-1α)
and transforming growth factor beta (TGF-β). Action of these negative regulators ensure
that the number of cells produced do not exceed the body’s needs.
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Figure 1.3. Stromal populations in the bone marrow affect maintenance of HSCs.
Osteoblasts, spindle-shaped N-cadherin+ osteoblasts (SNO cells), endothelial cells,
mesenchymal stem cells (MSCs), and CXCL12- expressing mesenchymal progenitors
(CEMP cells) produce a number of factors that support HSCs, including CXCL12,
angiopoietin, and stem cell factor (SCF). Glial cells, through production of active
transforming growth factor-β (TGF-β) and adipocytes also regulate HSCs (Anthony and
Link, 2014).
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Figure 1.4 Overview of hematopoietic cytokines and the cell lineages they stimulate to
cause differentiation into the principle types of blood cells. IL, interleukin; SCF, stem cell
factor; TPO, thrombopoietin; EPO, erythropoietin; GM-CSF, granulocyte macrophage
colony stimulating factor; M-CSF, macrophage colony stimulating factor. Source:
https://www.sigmaaldrich.com/technical-documents/articles/biofiles/hematopoieticcytokines.html
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1.4 Regulation of haematopoiesis by transcription factors.
Several transcription factors play critical roles in HSC formation and function and in
lineage specific differentiation. Both temporal and lineage restricted expression of these
transcription factors is required to determine phenotype. These factors include stem cell
leukaemia haematopoietic transcription factors (SCL/tal1), PU.1, GATA Binding Protein
2 (GATA-2), and LIM Domain Only 2 (LMO-2), which are essential for primitive and
definitive haematopoiesis, in addition to AML-1 which is required for definitive
haematopoiesis (Orkin and Zon, 2008) (Figure 1.5). Other transcription factors such as
Lysine Methyltransferase 2A (KMT2A/MLL), Runt Related Transcription Factor 1
(RUNX1), ETS Variant 6 (ETV6), CCAAT Enhancer Binding Protein Alpha (CEBPα)
and GATA Binding Protein 1 (GATA-1) also play an important role in haematopoiesis,
with translocations and somatic mutations often occurring within the genes for these
factors in haematopoietic malignancies, intertwining cell fate and leukaemic origins.
Disturbance of the homeostatic balance of the critical transcriptional regulators is a
defining feature of leukaemia. Once HSCs divide and generate more differentiated
daughter cells, within 10 ± 15 divisions the genetic programs of the descendent cells
become fixed toward a single lineage (Doulatov et al., 2012).
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Figure 1.5 Critical transcription factors in blood development. The stages at which
haematopoietic development is blocked in the absence of a given transcription factor, as
determined through conventional gene knockouts, are indicated by red bars. The factors
depicted in grey have been associated with oncogenesis. LT-HSC, long-term
hematopoietic stem cell; ST-HSC, short-term hematopoietic stem cell; CMP, common
myeloid progenitor; CLP, common lymphoid progenitor; MEP, megakaryocyte/erythroid
progenitor; GMP, granulocyte/macrophage progenitor; RBCs, red blood cells (Orkin and
Zon, 2008).

1.5 The haematological malignant process
Physicians in the early 19th century had observed that some of their patients had
abnormally high levels of white blood cells, leading them to call the associated condition
weisses blut, or “white blood.” The first definitive descriptions of this phenomenon as
leukaemia came in the 1840’s from Rudolph Virchow, in Germany, John Hughes Bennett
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in Edinburgh and Alfred Donne in France. The first type of lymphoma was described in
a paper published in 1832 by Thomas Hodgkin (Hodgkin, 1832). Introduction of
histochemical staining methods by Paul Ehrlich in 1877 allowed discrimination among
leucocyte subsets, with Ehrlich first identifying a primitive cell, which he described as
the ancestor of the various hematopoietic lineages (Ehrlich, 1877). By 1913, leukaemia
was classified as acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML),
chronic lymphocytic leukaemia (CLL), and chronic myeloid leukaemia (CML) (Gaynon,
Zomorodian and Pinkel, 2012).
In 1914 Theodor Boveri observed that cancer cells acquire chromosomal
abnormalities, hinting at a genetic driver of tumour growth (Wright, 2014). The seminal
identification of a characteristic short chromosome in the neoplastic cells of patients with
CML, the so-called Philadelphia chromosome (Ph1) by Peter Nowell and David
Hungerford, was a landmark discovery in the understanding of leukaemia development
(Nowell and Hungerford, 1960). Evidence for the stem cell origins of cancer derived
from the studies of Philip Fialkow and colleagues in the 1970’s using X‑ linked
glucose‑ 6‑ phosphate dehydrogenase (G6PD) as a marker of monoclonality in female
patients, indicating that the cancer clone in CML, despite its relatively mature
granulocytic phenotype, originated from a lympho-myeloid stem cell (Fialkow, 1974).
In 1976 Nowell proposed that tumorigenesis in humans is a multistep process that
drives the transformation of normal cells into malignant derivatives and is analogous to
Darwinian evolution in which a succession of genetic changes, each conferring one or
another type of growth advantage, leads to the progressive conversion of normal human
cells into cancer cells (Nowell, 1976). However it took until the 1990s before formal
demonstration that a subpopulation of self-renewing cells can propagate cancer was first
achieved by John Dick and colleagues (Lopez-Bertoni, Li and Laterra, 2015).
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Defects in the molecular controls of haematopoiesis that perturb normal development lie
at the root of haematological malignancies and are best exemplified by somatic mutations
in factors responsible for stem cell control and differentiation such as GATA-1 in Down
Syndrome-associated megakaryocytic leukaemia, CEBPα in myeloid leukaemia and
Paired Box 5 (PAX5) in B-cell derived leukaemia (Pabst et al., 2001; Wechsler et al.,
2002; Mullighan et al., 2007). Leukaemic Stem cells (LSC) appear to retain many
characteristics of normal HSCs as evidenced by a hierarchical developmental pattern, a
mostly quiescent cell cycle profile, and an immunophenotype very similar to HSC (Jordan
and Guzman, 2004). With regard to myeloid lineage leukaemogenesis, the LSC may
result from mutations in cells in different stages of the haematopoietic hierarchy (Figure
1.6).

Figure 1.6. The leukaemic stem cell model. Normal haematopoiesis is outlined in the
green highlighted area, with a leukaemic cell of origin acquiring a first hit mutation at
various possible stages of maturation (yellow highlighted area) with the susceptible stem
cell then acquiring a specific second hit to drive creation of the leukaemic clonal stem
cell (peach highlight), which further develops into an expanded leukaemia clone with
potential to acquire further mutations and a specific phenotype. HSC, haematopoietic
stem cell; MPP, multipotent progenitor; LMPP, lymphoid multipotent progenitor; CMP,
common myeloid progenitors; CLP, common lymphoid progenitor; MEP,
megakaryocyte-erythrocyte progenitor; GMP, granulocyte macrophage progenitor; LSC,
leukaemic stem cell. (Riether, Schürch and Ochsenbein, 2015).
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1.6 Myeloid malignancies
Myeloid malignancies are clonal diseases of hematopoietic stem or progenitor cells, that
result from genetic and epigenetic alterations in HSCs and functional changes in bone
marrow niche cells that perturb key processes such as self-renewal, proliferation and
differentiation. They comprise a heterogenous group of diseases that includes chronic
stages such as CML, myeloproliferative neoplasms (MPN) and myelodysplastic
syndromes (MDS), with acute stages being represented by the various AML subtypes.
While there is considerable overlap of the underlying molecular mechanisms responsible
for driving these malignancies, each disease has its own genotypic and phenotypic
characteristics. A diagrammatic representation of the spectrum of myeloid disorders is
outlined in Figure 1.7.

Figure 1.7. Spectrum of myeloid disorders. Those diseases with lower proliferative
expansion and increased dysplastic features are located toward the bottom left of the
diagram, whereas the more proliferative clonally driven disorders are located toward the
top right of the diagram. ITP; immune thrombocytopenic purpura, PRCS; pure red cell
aplasia, PNH; paroxysmal nocturnal haemoglobinuria, LGL; Large granular lymphocyte
leukaemia, MDS; myelodysplastic syndrome, CMML; chronic myelomonocytic
leukaemia, MPN; myeloproliferative neoplasm, CML; chronic myeloid leukaemia, AML;
acute myeloid leukaemia (Tiu and Sekeres, 2014).
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Myeloid neoplasms continue to be organised into AML and chronic myeloid
neoplasms, based primarily on the percentage of peripheral blood or bone marrow blasts.
Chronic myeloid neoplasms are in turn classified into five operational categories: MDS,
MPNs, MDS/MPN overlap, mastocytosis and myeloid/lymphoid neoplasms with
eosinophilia and recurrent rearrangements of platelet derived growth factor alpha/beta
(PDGFRA/PDGFRB), Fibroblast Growth Factor Receptor 1 (FGFR1) or Pericentriolar
Material 1-Janus Kinase 2 (PCM1-JAK2); the latter mutations correspond to 5q33, 4q12,
8p11.2 or t(8;9)(p22;p24.1) cytogenetic abnormalities respectively. MPNs are generally
distinguished from both MDS and MDS/MPN, by the absence of morphologic dysplasia,
which includes dyserythropoiesis and dysgranulopoiesis and monocytosis (Barbui et al.,
2018).
1.6.1 Chronic Myeloid Leukaemia
The history of discovery, biological understanding and treatment of chronic myeloid
leukaemia (CML) is the paradigm for haematological malignancies and worthy of
discussion to frame an understanding of more recent developments in this field. The
identification of the Philadelphia chromosome (Ph Chromosome) led to identification of
the reciprocal chromosome translocation involving chromosomes 22 and 9 (Rowley,
1973) and subsequently the identification of the chimeric fusion gene breakpoint cluster
region- ABL Proto-Oncogene 1, (BCR-ABL1) (Heisterkamp et al., 1983) (Figure 1.8).
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Figure 1.8 A: Partial karyogram showing chromosomes 9 and 22 and a translocation
t(9;22)(q34;q11.2). The normal chromosome 9 and 22 are on the left side of each pair and
the abnormal or "derivative" chromosomes are on the right side. B: Schematic of BCRABL1
reciprocal
translocation.
Source:https://en.m.wikipedia.org/wiki/File:
T922_CML.jpg

CML has an incidence of 1–2 cases per 100,000 adults in the USA, and accounts for 15%
of newly diagnosed cases of leukaemia in adults (Jabbour and Kantarjian, 2018).
Diagnosis is confirmed in a setting of persistent unexplained leucocytosis by the presence
of the Ph chromosome and the associated t(9;22)(q34;q11) translocation and BCR-ABL1
fusion gene, by routine cytogenetics, fluorescent in situ hybridisation (FISH) or by
molecular studies such a polymerase chain reaction (PCR). A 210 kilodalton BCR-ABL1
transcript (p210) transcribed from the most common rearrangements between exons 13
or 14 of BCR and exon 2 of ABL1 (known as e13a2 and e14a2 respectively) is most
common, but rare cases will have alternative BCR-ABL1 breakpoints, leading to a p190
transcript, from the e1a2 rearrangement most typically seen in Ph-positive ALL or p230
transcript. The disease is classically staged into chronic phase (most patients at
presentation), accelerated phase (>15% blasts in BM and PB, >20% basophils in PB and
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<100,000/µl platelet count) and blast phase (>30% blasts in BM or PB), clusters of blasts
in the marrow or presence of extramedullary disease (Arber et al., 2016).
Clinically, up to 50% of patients are asymptomatic and diagnosed incidentally
after routine laboratory evaluation with clinical features when present, generally
nonspecific. Splenomegaly is present in the majority while fatigue, night sweats and
symptoms of anaemia and bleeding due to platelet dysfunction may occur (Thompson,
Kantarjian and Cortes, 2015). Effective treatment of CML began with the use of
radiotherapy directed at the spleen before being replaced with oral alkylating agents
developed after the second world war such as busulfan. Antimetabolites such as
hydroxyurea and immune modulators such as recombinant interferon alpha were next
introduced, which extend overall survival but are associated with severe toxicities
(Rushing et al., 1982; Silver et al., 1999). The development of bone marrow
transplantation in CML began with the treatment of four chronic phase (CP) patients by
high-dose chemoradiotherapy followed by transfusion of normal stem cells from their
genetically identical twins and resulted in disappearance of the Ph+ cells from the bone
marrow and development of a normal haematological picture up to 31 months post
transplantation. This raised the possibility that CML, until then regarded as a fatal disease
may be successfully treated and cured by transplantation (Fefer et al., 1979). Subsequent
development of this technique throughout the 1980’s and 1990’s to incorporate the use
of sibling and unrelated donors and the use of post-transplant infused donor lymphocytes
to induce a graft-versus-leukaemia (GVL) effect ultimately led to transplantation as the
treatment of choice for CML in those patients capable of tolerating the intensity of the
regimen (Hansen et al., 1998; Kolb et al., 2005).
Studies in the 1990’s with compounds that inhibited the BCR-ABL1 tyrosine
kinase fusion protein resulted in the development of Imatinib Mesylate, a small tyrosine
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kinase inhibitor (TKI) by Brian Druker, an oncologist at the Dana-Farber Institute, in
collaboration with Ciba-Geigy (now Novartis). This compound interfered with the
interaction of BCR-ABL1 protein and adenosine tri-phosphate (ATP) and resulted in
blocking proliferation of the malignant clone which dramatically altered the natural
course of the disease, improving 10-year overall survival from 20% to over 80% and
effectively turning a fatal disease into one capable of being managed proactively. The
majority of patients presenting with CP CML now achieve long-term disease control with
stem cell transplantation needed only in a small minority (Druker et al., 2001; Hochhaus
et al., 2017). Following the success achieved with imatinib, second generation tyrosine
kinase inhibitors such as dasatinib (Bristol-Myers Squibb) and nilotinib (Novartis)
(Figure 1.9), which have significantly increased potency for CML cells and the BCRABL1 fusion protein, were developed and approved, initially in patients that developed
resistance to prior imatinib therapy (Kantarjian et al., 2006; Talpaz et al., 2006).

Figure 1.9 Structure of ABL1 in complex with Imatinib, Nilotinib and Dasatinib
(Weisberg et al., 2007).
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Clonal chromosomal evolution, BCR-ABL1 amplification and pharmacogenomic
variations have been implicated in the development of imatinib drug resistance (Majlis et
al., 1996; Gadzicki et al., 2005; Polillo et al., 2015), however recognition that the
development of a clone carrying mutations in the BCR-ABL1 kinase domain was the
leading cause for development of resistance led to the mapping of mutations (Figure 1.10)
and understanding the associated levels of conferred resistance to therapy and resulted in
recommendations to rationalise mutation testing and help translate the results into clinical
decision making (Hochhaus et al., 2011; Soverini et al., 2011).

Figure 1.10. Map of amino acid substitutions in the BCR-ABL1 kinase domain with
highlighted structural motifs. P-loop; phosphate binding loop; A-loop, activation loop;
SH2/SH3, contact regions for SH2/SH3 domain containing proteins (Soverini et al.,
2011).

Response to TKI therapy is determined by measures at the haematological, cytogenetic
and molecular levels. Quantitative molecular testing for BCR-ABL1 transcripts using RQ17

PCR is more sensitive for low-level residual disease than cytogenetics or FISH
(sensitivity of 10−4 to 10−5). Levels of response to TKI therapy by RQ-PCR are clinically
relevant and are usually reported as a percentage relative to the transcript levels of ABL1
or BCR. There have been successful international efforts to standardise the testing and
reporting of BCR-ABL1 transcript levels to ensure harmonised reporting across
jurisdictions using an International Standard (IS) to develop individual reporting
laboratory specific conversion factors.
At present a major molecular response (MMR or MR3.0) corresponds to <0.1%
BCR-ABL1 on the IS, which represents a 3-log reduction from the standardised baseline,
rather than a three-log reduction from the individual patient’s baseline BCR-ABL1
transcript level (which can vary significantly). MR4.0 is <0.01% BCR-ABL1 on the IS
and MR4.5 is ≤0.0032% on the IS (equivalent to a ≥4.5 log reduction) (Hughes et al.,
2006; Branford et al., 2008; Müller et al., 2009; White et al., 2015; Cross et al., 2016).
These efforts have led to the development of criteria that have helped guide treatment and
dosage with TKI therapies (Jain et al., 2013). More recently, several studies have focused
on stopping treatment based on a prolonged complete molecular remission (CMR),
undetectable BCR-ABL1 transcripts for 24 months by standardised techniques with
approximately 40% of patients remaining in molecular remission for 2 years after
cessation of imatinib therapy (Mahon et al., 2010; Ross et al., 2013; Benjamini et al.,
2014).
The paradigm of CML and the BCR-ABL1 fusion gene established the modern
development of targeted therapies and the move towards personalised medicine. As
studies in related diseases such as MPNs, MDS and AML developed, it became apparent
that CML was novel for its singular causal molecular event and that greater understanding
of the molecular nature of these diseases was required to enable progress.
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1.6.2 Philadelphia negative Myeloproliferative Neoplasms
MPNs originate from a common ancestral clone that arises from a polyclonal, but disease
susceptible stem cell pool and have a propensity at late stage for transformation to AML
(Spivak, 2017). The concept of myeloproliferative disorders was first proposed by
William Dameshek in a 1951 editorial in the Blood journal, where he described the
conditions as being characterised by excessive proliferation of haematopoietic precursors
in the bone marrow and excessive production of mature blood cells. Dameshek’s augural
view grouped several diseases in the MPD category including CML, polycythaemia vera
(PV),

essential

thrombocythaemia

(ET),

primary

myelofibrosis

(PMF)

and

erythroleukaemia (Dameshek, 1951).
PV, ET and PMF present with overlapping clinical features and are kept as distinct
entities under the umbrella of classical Ph- MPN. Such disorders are rare, with prevalence
in the EU per 100,000 head of population estimated for PV at 0.4 to 2.8, ET from 0.38 to
1.7, and PMF from 0.1 to 1.0 per year. They generally occur in middle- or advanced-age
adults, with a median age of 65 years for PV, 68 years for ET, and 70 years for PMF
(Moulard et al., 2014). Unlike PV, which is the only MPN which causes an increased red
blood cell mass, ET and PMF do not display a unique clinical or biologic characteristic
allowing their unequivocal identification.
Thrombocytosis, a key feature of ET, can also be present in some PV or PMF
patients. Bone marrow biopsy morphology can discriminate between ET and PMF
however its universal reproducibility has been questioned (Wilkins et al., 2008). Fibrosis
and splenomegaly are often associated with PMF however they may also present in ET
and PV. Thrombosis and haemorrhage can occur across the Ph- MPNs (Figure 1.11)
(Kiladjian, 2012). Transformation to AML occurs at a rate of 5-15% per 10 years for PV,
8-23% per 10 years for PMF and 1.4% per 10 years for ET (Lee et al., 2013).
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Figure 1.11. Overlapping clinical features observed in each of the main Ph- MPN entities
(Kiladjian, 2012). Red blocks approximate prevalence in disease entity. Schematic
representation of the proportion of patients presenting with a specific feature. The top
panel shows clinical characteristics and the bottom panel, complications.

The occurrence of thrombotic events is the major risk for patients with PV or ET and the
main goal of therapy is to prevent these complications. Accurate diagnosis is important
in terms of both prognostication and treatment. The World Health Organisation (WHO)
classification system for haematopoietic tumours provides clear and concise guidelines
in distinguishing MPN from both reactive thrombocytosis and other myeloid neoplasms,
(Swerdlow et al., 2008; Arber et al., 2016) with differential diagnosis being essential to
determine survival and prognosis (Barbui et al., 2011; Barbui et al., 2018). Increasing
age, a history of vascular events and driver mutation status have consistently proven to
be independent predictors of thrombosis in patients with PV and ET classifying patients
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into low- and high-risk groups (Tefferi and Barbui, 2017). A number of national
consensus guidelines for the diagnosis, stratification and treatment of MPN patients have
been developed (Barbui et al., 2004; McMullin et al., 2005; Barbui et al., 2011; Reilly et
al., 2012; Lindgren and Larsen, 2013; Vannucchi, et al., 2015) with the gathered
consensus reflected in the recent issue of the WHO 2016 guidelines which also
incorporated the discovery of new molecular diagnostic and prognostic markers, allowing
novel insight into the understanding of the pathobiology of these disorders. (Arber et al.,
2016).
In representative cases, bone marrow morphology shows disease specific features,
for example in ET the presence of increased numbers of hyperlobulated megakaryocytes,
in PV a hypercellular marrow with erythroid proliferation, in overt PMF megakaryocytic
proliferation and atypia combined with reticulin/collagen fibrosis (Figure 1.11) (Rumi
and Cazzola, 2017).

A
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Figure 1.12. Representative bone marrow biopsies from patients with MPNs. A: Normal
Bone Marrow biopsy: heterogenous cell population; B: ET marrow: Proliferation of giant
megakaryocytes with hyperlobulated nuclei (black arrows); C: PV marrow: Hypercellular
marrow with erythroid proliferation and scattered pleomorphic megakaryocytes; D: PMF
marrow: Hypercellular marrow with granulocytic proliferation and collagen fibrosis
(black arrow) Rumi & Cazzola 2017.
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1.6.2.1 Diagnosis of Philadelphia negative Myeloproliferative Neoplasms
Diagnosis of MPN is according to the WHO 2016 guidelines, which have had four
important improvements for diagnosis made based on clinicopathological and molecular
genetic studies since the WHO 2008 edition:
(i) Discovery of novel molecular findings that provide understanding of the pathobiology
of MPNs and exert an impact on diagnosis and outcome.
(ii) Lowering of the diagnostic haemoglobin (Hb)/ haematocrit (Hct) threshold values
with introduction of masked PV (mPV) revealing that PV has been underdiagnosed in the
past.
(iii) Emphasising the need to discriminate “true” ET from pre-PMF by an accurate
evaluation of BM biopsy features, including the lack of reticulin fibrosis at onset in <5%
of cases which is of significant prognostic and therapeutic relevance.
(iv) Advancements regarding the characterisation and standardisation of morphological
BM features yielded an improvement in the differentiation of MPN subtypes, improving
pathologist agreement rates and decreasing the number of unclassifiable cases (Barbui et
al., 2018).
The current criteria for diagnosis of the Ph- MPN are outlined in tables 1.1-1.4 below.
Diagnosis of PV, according to WHO guidelines requires meeting either all 3 major
criteria, or the first 2 major criteria and the minor criterion. Diagnosis of ET requires
meeting all 4 major criteria or the first 3 major criteria and the minor criterion. Diagnosis
of pre-PMF requires meeting all 3 major criteria, and at least 1 minor criterion. Diagnosis
of overt PMF requires meeting all 3 major criteria, and at least 1 minor criterion.
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Table 1.1. Criteria for PV according to WHO 2016 guidelines
Major criteria
Haemoglobin >16.5 g/dL in men, Haemoglobin >16.0 g/dL in women
Or
Haematocrit >49% in men, Haematocrit >48% in women
Or
increased red cell mass (RCM)
2. BM biopsy showing hypercellularity for age with trilineage growth (panmyelosis) including
prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic, mature
megakaryocytes (differences in size).
3. Presence of JAK2V617F or JAK2 exon 12 mutation
Minor criterion
Subnormal serum erythropoietin level

Table 1.2: Criteria for ET according to WHO 2016 guidelines
Major criteria
1. Platelet count ≥450 × 109/L
2. BM biopsy showing proliferation mainly of the megakaryocyte lineage with increased
numbers of enlarged, mature megakaryocytes with hyperlobulated nuclei. No significant
increase or left shift in neutrophil granulopoiesis or erythropoiesis and very rarely minor (grade
1) increase in reticulin fibres
3. Not meeting WHO criteria for BCR-ABL1+ CML, PV, PMF, myelodysplastic syndromes, or
other myeloid neoplasms
4. Presence of JAK2, CALR, or MPL mutation
Minor criterion
Presence of a clonal marker or absence of evidence for reactive thrombocytosis.
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Table 1.3: Criteria for pre-PMF
Major criteria
1. Megakaryocytic proliferation and atypia, without reticulin fibrosis >grade 1, accompanied
by increased age-adjusted BM cellularity, granulocytic proliferation, and often decreased
erythropoiesis.
2. Not meeting the WHO criteria for BCR-ABL1+ CML, PV, ET, myelodysplastic
syndromes, or other myeloid neoplasms
3. Presence of JAK2, CALR, or MPL mutation or in the absence of these mutations, presence
of another clonal marker, or absence of minor reactive BM reticulin fibrosis.
Minor criteria
Presence of at least 1 of the following, confirmed in 2 consecutive determinations:
a. Anaemia not attributed to a comorbid condition
b. Leukocytosis ≥11 × 109/L
c. Palpable splenomegaly
d. LDH increased to above upper normal limit of institutional reference range

Table 1.4: WHO overt PMF criteria
Major criteria
1. Presence of megakaryocytic proliferation and atypia, accompanied by either reticulin and/or
collagen fibrosis grades 2 or 3.
2. Not meeting WHO criteria for ET, PV, BCR-ABL1+ CML, myelodysplastic syndromes,
or other myeloid neoplasms.
3. Presence of JAK2, CALR, or MPL mutation or in the absence of these mutations, presence
of another clonal marker, or absence of reactive myelofibrosis.
Minor criteria
Presence of at least 1 of the following, confirmed in 2 consecutive determinations:
a. Anaemia not attributed to a comorbid condition
b. Leukocytosis ≥11 × 109/L
c. Palpable splenomegaly
d. LDH increased to above upper normal limit of institutional reference range
e. Leukoerythroblastosis
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1.6.2.2 Treatment of Philadelphia Myeloproliferative Neoplasms
Treatment in PV requires a daily aspirin dose supplemented with phlebotomy to maintain
the haematocrit <45% in men and <45% in women with the addition of cytoreductive
therapy such as hydroxyurea in high risk patients. Very low risk ET patients might not
require any form of therapy while low-risk patients require at least once-daily aspirin and
cytoreductive therapy is recommended for high-risk ET patients (Barbui et al., 2011;
Spivak, 2017; Barbui et al., 2018). In patients with secondary myelofibrosis (MF) due to
either ET or PV, as well as in patients with PMF, longevity is compromised by
extramedullary haematopoiesis, marrow failure, and leukaemic transformation (Spivak,
2017). Myelofibrosis is associated with greatest symptom burden and largest effect on
quality of life among the MPNs, and has the worst prognosis with an overall median
survival of 5.7 years as measured by the International Prognostic Score System (IPSS)
(Cervantes et al., 2009). In this system patients are scored based on the severity of
cytopenia, bone marrow blast percentage and cytogenetic findings (Greenberg et al.,
2012).
The inclusion of spleen volume, which has been associated with an increased risk
of death and molecular markers such as ASXL Transcriptional Regulator 1 (ASXL1) and
Isocitrate Dehydrogenase 1 or 2 (IDH1/2) associated with high risk disease into the IPSS
is likely, however the only potentially curative approach is haematopoietic stem cell
transplantation which is associated with a high rate of mortality (20-40%) (Vannucchi
and Harrison, 2017). An orally administered inhibitor of Janus kinases (JAK) 1 and 2
(ruxolitinib) has been licenced for use in the management of patients with myelofibrosis.
Clinical trials have demonstrated marked and durable clinical benefits in terms of
reductions in splenomegaly and disease-related symptoms in patients with intermediate-
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2 or high-risk myelofibrosis and with improvements in health-related quality of life and
functioning (Vannucchi et al., 2015).

1.7 Paroxysmal Nocturnal Haemoglobinuria
In 1969, William Dameshek proposed that paroxysmal nocturnal haemoglobinuria (PNH)
should be considered a candidate MPN based on the evidence of red blood cell
abnormalities in the context of bone marrow pancytopenia, low leucocyte alkaline
phosphatase and the potential for leukaemic transformation (Dameshek, 1969). Further
similarities between MPN and PNH include expansion of subsequent or simultaneous
myeloid clones and an increased frequency of abdominal vein thrombosis. PNH is an
acquired stem cell disorder associated with mutations of the Phosphatidyl Inositol
Glycan-class A (PIG-A) gene that encodes a protein required for the synthesis of
glycosylphosphatidylinositol-inositol anchored proteins (GPI-AP). PNH blood cells are
therefore deficient in cell surface proteins that use the GPI anchor and may be detected
immunophenotypically by absent or reduced expression of CD55 and CD59 on red blood
cells (RBC) and CD16, CD24, CD66b and FLAER (fluorescence labelled aerolysin) on
granulocytes (Figure 1.13). PNH clones are also present in a significant number of
patients with the related marrow failure syndromes aplastic anaemia (AA) and
hypoplastic MDS. Although PNH originates from a multipotent haematopoietic stem cell,
PIG-A mutations are insufficient to drive clonal expansion and several models have
attempted to explain this phenomenon: GPI-AP may be immunogenic and their
deficiency enables evasion from immunological surveillance or the possibility that PIGA mutations themselves confer an intrinsic resistance to apoptosis (Brodsky, 2008).
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Another theory postulates the acquisition of a second genetic event that enables
clonal expansion in co-operation with the PIG-A mutation, some evidence for which
comes from the deregulated expression of High Mobility Group AT-Hook 2 (HMGA2)
in a minority of PNH patients (Inoue et al, 2006).

Figure 1.13 Pathogenesis of PNH. A somatic acquired mutation in the gene encoding
PIG-A is the pathobiological mechanism underlying the development of PNH. Affected
stem cells are deficient in all GPI-APs that serve as erythrocyte membrane-bound
regulators of complement. Deficiency of CD55 and CD59 proteins accounts for the
complement-mediated intravascular haemolysis and other clinical manifestations (Sahin
et al., 2015).

1.8 Chronic Neutrophilic Leukaemia related mutations
Chronic neutrophilic leukaemia (CNL) and atypical chronic myeloid leukaemia (aCML)
are rare haematologic neoplasms that are characterised by leucocytosis and
hypercellularity of the bone marrow consisting predominantly of granulocytic cells, the
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absence of the Ph chromosome with translocation t(9;22) (BCR-ABL1), and the absence
of rearrangements in genes encoding PDGFRA/B and FGFR1. CNL is diagnosed on the
basis of the expansion of neutrophils in both bone marrow and blood (segmented
neutrophils and band forms, >80% of white cells) and is classified as a MPN, according
to WHO diagnostic criteria (Maxson et al., 2013). Disease acceleration often manifests
with the development of progressive neutrophilia with resistance to previously effective
therapy and CNL can progress to AML with a mean time to blast transformation of only
21 months (Elliott et al., 2005).
Until recently, diagnosis of CNL was essentially a process of exclusion, by ruling out
basophilia, monocytosis, or a BCR-ABL1 fusion it could be distinguished from CML,
aCML, and chronic myelomonocytic leukaemia (CMML). Similarly, by eliminating
potentially confounding underlying clinical conditions such as infections or malignancy
it could, sometimes with difficulty, be differentiated from a leukaemic reaction (Szuber
and Tefferi, 2018). The fact that some patients with CNL have nonspecific cytogenetic
abnormalities such as 11q23 monosomy in granulocytes but not lymphocytes, reveals the
clonal nature of this disease (Froberg et al., 1998).

1.9 Bone Marrow Transplantation
Investigations into radiation induced bone marrow injury after the detonation of nuclear
weapons in Japan during World War II led in 1949 to Jacobson and colleagues
discovering protection of mice from total body irradiation (TBI) by shielding their spleens
with lead. A couple of years later, Lorenz and colleagues reported radiation protection of
mice and guinea pigs by infusion of marrow cells. Although the initial thought was that
the radiation protection was from a humoral factor in the spleen or marrow, this
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hypothesis was rejected after several laboratories demonstrated that the radiation
protection was due to seeding of the marrow by donor cells (Champlin, 1990). The
observation of dose-dependent toxicity of radiation on bone marrow supported the idea
of using high doses of radiation to kill leukaemia cells and then using donor marrow cells
to replenish the host marrow. In 1956, Barnes and colleagues successfully treated murine
leukaemia with a supra-lethal dose of radiation (1500-rad) followed by intravenous bone
marrow infusion and grafting (Barnes et al., 1956). One year later, Thomas and colleagues
reported treatment of acute leukaemia in six human subjects using supra-lethal radiation
followed by bone marrow infusion from fetal or adult cadavers (Thomas et al., 1957).
Only two of the six patients demonstrated hematopoietic recovery and all patients died
within the first 100 days. A review of 200 human marrow grafts reported between 1957
and 1967 showed all 200 patients died of either graft failure, graft versus host disease
(GVHD), infections, or recurrence of disease (Aiuti, Scala and Chabannon, 2019).
Continued research in animal models led to refinement of the process with
discoveries on the influence of histocompatibility antigens on graft tolerance, the use of
cyclophosphamide instead of radiation, the evidence of a leucocyte antigen system in
dogs (DLA) that determined risk of graft failure, with long term engraftment observed in
DLA-matched dogs, prevention of GVHD with methotrexate (Epstein et al., 1968; Storb
et al., 1969, 1970; Snell, 1992). After a return to human transplants in the 1970’s and
armed with an improved understanding of the underlying biology, in 1977, Thomas and
colleagues published their results of allogeneic transplantation for 100 consecutive
patients with acute myeloid or lymphoblastic leukaemia and demonstrated that a small
percentage of patients could be cured, establishing the important observation that patients
transplanted earlier in their disease course had better outcomes than those with advanced
disease (Thomas et al., 1977) . The observation that CD34+ stem cells were present in the
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peripheral blood at low levels led to the development of therapies that mobilised these
cells from the marrow into the blood using recombinant human granulocyte colonystimulating factor (rG-CSF) and provided a more convenient way to harvest stem cells
for transplantation. (Duhrsen et al., 1988). An schematic outlining the process of stem
cell transplantation is shown in Figure 1.36 below.

Figure 1.14 Overview of stem cell transplantation process. Encyclopedia brittanica:
https://www.britannica.com/science/graft-versus-host-disease/media/240689/123191.

An increased understanding of GVHD also led to an appreciation of the graft versus
leukaemia effect (GVL) effect, a donor T-cell mediated response to the recipient
leukaemic cells and the use of donor lymphocyte infusions (DLI) to enable remission and
prevent GVHD (Kolb et al., 1990). This development has led to transplant regimen with
reduced intensity conditioning that is less ablative than standard conditioning, can be
applied to older patients (>60 years) and results in the presence of both donor and
recipient cells post-transplant (known as mixed chimerism). Subsequent DLI as part of
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these regimen are used to encourage full engraftment of donor cells, however relapse is a
continuing challenge with this approach (Pasquini et al., 2015).
Understanding the effect of the dog leucocyte antigen system in canine
transplantation allowed for the extension of this idea to humans and the human leucocyte
antigen system (HLA) which are the genes and proteins that make up the major
histocompatibility complex (MHC) and define a person’s immunological profile. MHC
class I and class II molecules are similar in function: they present peptides at the cell
surface to CD8+ and CD4+ T cells, respectively. In allogeneic transplant, the most
important HLA molecules include class I molecules HLA-A, HLA-B, and HLA-C and
class II molecules HLA-DP, HLA-DQ, and HLA-DR (Neefjes et al., 2011). Every HLA
antigen mismatch between donor and recipient has been shown to adversely affect the
success of allogeneic transplant (Lee et al., 2007).
Recent developments in genetically engineering T-cells to target leukaemic cells
has resulted in engineered chimeric antigen receptors on the T cells (CAR-T). These
receptors, with the incorporation of costimulatory molecules or cytokines has enabled the
elimination of tumour cells, initially proven with CD19 on B-cells in the treatment of
chronic lymphocytic leukaemia (Porter et al., 2011). Following in the footsteps of
allogeneic transplant development, this approach could be powerful in developing safe
and effective cancer therapeutics and may be incorporated into future transplantation
regimen (Dai et al., 2016).
For patients with high-risk refractory or relapsed myeloid neoplasms, the
prognosis is poor and outcome after standard chemotherapy alone rarely results in cure.
Although ASCT offers a potential cure, relapse rates are high and patients can be
precluded from standard protocols on the basis of older age, refractory or relapsed disease,
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and presence of comorbidities. Reduced intensity conditioning (RIC) transplantation
regimens offer lower rates of non-relapse mortality (NRM) in aggressive disease although
they may not be sufficient to control disease until a graft versus leukaemia (GvL) effect
occurs. In an attempt to overcome this, intermediate sequential conditioning regimen
incorporating a short course of chemotherapy combining fludarabine, cytosine,
arabinoside, amsacrine, cyclophosphamide, and either total body irradiation or busulfan
(FLAMSA) to reduce disease burden prior to reduced intensity conditioning has been
designed and implemented in high-risk myeloid neoplasms (Schmid et al., 2005; Saure et
al., 2012; Malard et al., 2017) (Figure 1.15).

Figure 1.15 FLAMSA-BU regimen for high risk myeloid malignancies. Short course
chemotherapy is administered Day-12 to Day-9 followed by three days rest before
transplantation conditioning from Day-6 to Day 0. Immunosuppression is administered
with mycophenolate (MMF) for 30 days and cyclosporin for up to 90 days after infusion
of peripheral blood stem cells (PBSC), with donor lymphocyte infusions administered to
enhance engraftment if there is no evidence of graft versus host disease (GVHD).
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1.10 Molecular Pathogenesis of Myeloproliferative Neoplasms
The discovery of recently identified molecular features has yielded new perspectives
regarding diagnostic and prognostic markers that provide novel insights for the
understanding of the pathobiology of these disorders and has increased the reliability and
reproducibility of diagnoses (Wang et al., 2015; Arber et al., 2016). Recurrent mutations
in the JAK2 gene at exon 14 (JAK2 V617F), mutations in CALR exon 9 and MPL in exon
10 has focussed attention on the JAK-STAT pathway as a source of disruption in these
disorders.
1.10.1 JAK-STAT pathway
The JAK-STAT pathway is a common signalling pathway used by many cytokines. The
binding of a cytokine to its cell-surface receptor results in receptor dimerization and the
subsequent activation of JAK tyrosine kinases. There are four members of the JAK
tyrosine kinase family; JAK1-JAK3 and tyrosine kinase 2 (TYK) which are constitutively
associated with cytokine receptors. Specific tyrosine residues on the receptor are then
phosphorylated by activated JAKs and serve as docking sites for a family of latent
cytoplasmic transcription factors known as STATs. There are seven mammalian STATs:
STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6, which are highly
homologous in several regions. STATs are phosphorylated by JAKs, causing dimerisation
and subsequently leave the receptor and translocate to the nucleus, where they activate
gene transcription (Shuai and Liu, 2003) (Figure 1.17).
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Figure 1.16 The JAK-STAT signalling pathway. Regulation of this pathway occurs at the
post-translational level by suppressor of cytokine signalling (SOC) proteins, protein
tyrosine phosphatases (PTP) and ubiquitin mediated protein degradation (Shuai and Liu,
2003).
1.10.2 JAK2 Gene Mutations
1.10.2.1 JAK2 V617F
The landmark discovery of a recurrent somatic mutation in exon 14 of JAK2 at nucleotide
1849 that leads to a substitution of a valine to phenylalanine at codon 617; the JAK2
V617F (c.1849G>T) in 2005 (Baxter et al., 2005; James et al., 2005; Kralovics et al.,
2005; Levine et al., 2005) not only revolutionised the area of MPN molecular diagnostics
but also prompted disease re-classification, investigation into many new aspects of MPN
genetics and biology, and has led to the clinical introduction of novel therapeutic agents
(Pasquier et al., 2014; Arber et al., 2016). This mutation is found in ~70% of MPNs:
>95% of PV and 50% to 60% of ET and PMF patients.
The JAK2 V617F mutation arises in a multipotent haematopoietic progenitor as it
is present in all myeloid lineages and can also be detected in B and T lineage cells (Larsen
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et al., 2007). The variant allelic frequency (VAF) of the JAK2 V617F ranges from 1100% with a rising VAF across the diseases with ET the lowest (25%), PV (>50%) rising
to close to 100% in post-PV/ET myelofibrosis. In PMF the VAF is variable but generally
high (Rumi et al., 2014).
The JAK2 V617F abrogates the negative regulatory activity of the pseudokinase
domain JH2 of the encoded JAK2 tyrosine kinase, leading to a constitutively active JAK2
signalling, independent of cytokine stimuli when homodimeric type 1 cytokine receptors
such as erythropoietin receptor (EPOR) or granulocyte colony-stimulating factor receptor
(GCSF-R) are co-expressed indicating that JAK2 V617F requires a cytokine receptor
scaffold for its transforming and signalling activities (Lu et al., 2005). This state is
different from normal conditions where JAK2 is activated after dimerisation or
oligomerisation of cytokine receptors bound to their respective ligands (Baker, Rane and
Reddy, 2007).

1.10.2.2 JAK2 Exon 12 mutations
JAK2 mutations also occur in exon 12 and are predominantly associated with JAK2
V617F negative PV (Scott et al., 2007), isolated erythrocytosis, reduced serum EPO
levels at clinical onset and a clinical course similar to JAK2 V617F positive PV
(Passamonti et al., 2011). The functional consequences of these mutations are thought to
be equivalent to the V617F mutation (Them and Kralovics, 2013). Over 30 different point
mutations, small deletions, or insertions in JH2 of JAK2 have been shown to cause or be
linked to haematologic diseases (Silvennoinen and Hubbard, 2015). A schematic of JAK2
domain organisation is shown in Figure 1.17.
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Figure 1.17. The JAK2 protein. A: Domain Organisation of JAK2 highlighting positive
(green) and negative (red) regulatory phosphorylation sites. B: Structural schematic of
JAK2 protein with location of selected mutations. JH2 domain is coloured orange, JH1 is
blue (Silvennoinen and Hubbard, 2015).

1.10.2.3 JAK2 V617F Biological Characteristics
Transgenic mouse models have shown that expression of JAK2 V617F plays an important
role in determining MPN phenotype, with increasing mutant JAK2 expression changing
the phenotype from ET-like to PV-like and onward to MF-like (Tiedt et al., 2008). Exvivo studies using exogenous erythroid colonies from patients with ET or PV have shown
that JAK2 V617F homozygosity occurs in both PV and ET, however expansion of a single
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dominant homozygous clone occurred only in PV and was likely due to the acquisition
of additional genetic or epigenetic changes (Godfrey et al., 2012). JAK2 V617F is
predominantly found in classical MPN but is also found in myelodysplastic subtype
refractory anaemia with ringed sideroblasts and thrombocytosis (RARS-T) and rarely in
other haematological malignancies (Figure 1.18). The fact that the JAK2 V617F mutation
can be associated with different phenotypes has led to the idea of a continuum between
disease subtypes as documented by the increase JAK2 V617F VAF between ET and PV,
with the degree of erythrocytosis determined by physiological and genetic modifiers and
by the progression of ET and PV to secondary myelofibrosis (Campbell et al., 2005). The
JAK2 V617F has been detected at low levels in the general population and associated
with increased morbidity and mortality (Nielsen et al., 2011) reflecting previous reports
of the presence of leukaemia associated genes such as the BCR-ABL1 transcript in normal
leukocytes (Bose et al., 1998).
In ET, JAK2 V617F positive patients present with older age at diagnosis, higher
haemoglobin level and leucocyte count, more venous thrombosis, but lower platelet count
(Campbell et al., 2005). In a study evaluating JAK2 V617F mutation and phenotypic
variation in PMF, the mutation independently predicted the evolution toward large
splenomegaly, need of splenectomy, and leukaemic transformation and contributed to
haemoglobin and platelet count variability (Barosi et al., 2007).
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Figure 1.18. Frequency and distribution of acquired gene mutations in haematologic
malignancies. (Skoda, Duek and Grisouard, 2015)

In patients presenting with Budd-Chiari syndrome, a disorder causing primary
extrahepatic portal vein obstruction resulting in a swollen liver and ascites, the underlying
cause may be a MPN in up to 40% of cases. Testing for JAK2 V617F in this context can
help define the diagnosis and identify a latent MPN, with over 50% of well-defined
clinical cases testing positive (Patel et al., 2006; Primignani et al., 2006). As outlined in
the WHO classification, identification of the JAK2 mutation provides clear evidence for
malignant, clonal haematopoiesis, and provides pivotal evidence for PV in the case of the
JAK2 V617F, but further clinical and biological features are required to allow a final
diagnosis.
1.10.2.4 JAK2 V617F Detection
A wide variety of molecular techniques to detect and quantify JAK2 V617F have been
developed to meet clinical demand for this marker. However, decisions made in the preanalytical phase of testing are critical to success, with choice of blood anti-coagulant
types used affecting outcome (Yokota et al., 1999). Variability in sensitivity and
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specificity in the methods used to detect the JAK2 V617F mutation led to a
comprehensive evaluation of several prominent methods across Europe by the European
LeukemiaNet and MPN&MPNr-EuroNet study groups, identifying robust assays suitable
for quantifying JAK2 V617F (Jovanovic et al., 2011) and subsequently informing the
development of national guidelines for the molecular diagnosis of MPN (Bench et al.,
2013).
The detection rate of JAK2 V617F in patients does not differ significantly between
bone marrow and peripheral blood samples if a sufficiently sensitive assay is used for
detection (~1%), however as a myeloid disorder, the quantitative level in purified
granulocytes is approximately 15% higher than in whole blood (Hermouet et al., 2007;
Larsen et al., 2008). The capacity to detect a low JAK2 V617F allele burden of ≥0.1% is
important as it is of pathogenetic and clinical importance (Wang et al., 2008; Mason,
Akiki and Griffiths, 2011). In a study of JAK2 V617F positive PMF patients who
received allogeneic stem cell transplantation (ASCT) therapy, those patients with a JAK2
V617F allelic burden >1% at day 28 post-ASCT had a higher risk of relapse and poorer
overall survival, indicating a predictive role of JAK2 V617F burden in this setting (Lange
et al., 2013).
1.10.2.5 Myeloproliferative Leukaemia Virus Oncogene exon 10 mutations
Subsequent to the discovery of JAK2 V617F mutations, in 2006 heterozygous mutations
in exon 10 of the thrombopoietin receptor gene the myeloproliferative leukaemia virus
oncogene (MPL) were discovered in a subset of JAK2 V617F negative MF patients and
shown to result in constitutive activation of the Janus Kinase/signal transducer and
activator of transcription (JAK-STAT) signalling pathway, thus providing a common
convergent mechanism for activation of signal transduction in haematopoietic
malignancies (Pikman et al., 2006). Located on chromosome 1p34, the most frequent
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mutations in MPL are located at tryptophan W515 at the boundary of the transmembrane
and the cytosolic domains of MPL, with W515L and K being the most frequent, however
others substitutions W515R, W515A, and W515G have been described (Defour et al.,
2016). MPL mutations require the haematopoietic growth factor thrombopoietin (TPO)
for complete kinase activation in the heterozygous state (Spivak, 2017). MPLW515
mutations have a low incidence in ET and PMF (3-5% respectively) and can also be found
in RARS-T (Figure 1.19). The S505N mutation was first described in familial
thrombocythemia and was also identified as a somatic mutation in ET and PMF (Ding et
al., 2004; Beer et al., 2008) (Figure 1.14). Alternative mutations have been reported in
rare cases including V501A, S505C, A506T, V507I, G509C, L510P, R514K and R519T,
although the pathogenic significance of some of these mutations is not clear (Williams et
al., 2007; Schnittger et al., 2009). Mutations in MPL are usually heterozygous, but can
be homozygous during disease progression (Rumi et al., 2013).

Figure 1.19. Transmembrane structure of MPL protein. Gold balls represent the
membrane bilayer, MPL protein is in green with three key residues, W491, S505, and
W515, coloured red and indicated by the black arrows. The upper part of the figures is
the extracellular region while the lower part the intracellular region (Lee et al., 2011).
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1.10.2.6 Calreticulin exon 9 mutations
In late 2013, a second seminal breakthrough in the molecular pathogenesis of MPN
occurred with the application of whole exome sequencing to well characterised MPN
patients, leading to the discovery of somatic mutations in CALR, the gene encoding
calreticulin, a calcium binding chaperone associated with the endoplasmic reticulum
(Klampfl et al., 2013; Nangalia et al., 2013).
MPN-associated CALR mutations are insertions, deletions or insertions and
deletions (indels) and occur in exon 9 resulting in a +1 base pair frame-shift of the coding
sequence and generation of a translated protein with a novel C-terminus that lacks a
retrieval sequence (KDEL) typical of normal CALR and other endoplasmic reticulum
resident proteins. CALR exon 9 mutations are predominantly heterozygous with the
majority of cases (80–90%) carrying a 52-bp deletion: (CALRdel52/type I;
c.1092_1143del; L367 fs*46) or a 5-bp insertion CALRins5/type II; c1154_1155insTTGTC; K385 fs*47). Of the remaining cases, more than 50 different variations have
been identified to date (Figure 1.20).

41

Figure 1.20. Alignment of C-domain in wild-type and predominant mutant CALR
proteins. Mutation type is indicated on the left , the amino acid sequence starts from codon
A352: acidic, basic and neutral residues are in red, blue and green, respectively. All the
variants involve three different stretches of negatively charged amino acids, highlighted
in red. Type 1-like mutations predict deletion of stretches II and III (as happens with the
L367fs*46 or type 1 mutation), while type 2-like mutations predict conservation of all the
three stretches (as happens with the K385fs*47 or type 2 mutation); other types involve
deletion of stretches III exclusively (Pietra et al., 2016).

Extended screening in large cohorts has confirmed the presence of CALR mutations in
60–80% of patients with ET and PMF that are JAK2 and MPL mutation negative (Figure
1.21) (Klampfl et al., 2013; Nangalia et al., 2013; Andrikovics et al., 2014; Rotunno et
al., 2014; Rumi, et al., 2014). CALR mutations are occasionally present in RARS-T
(Broséus et al., 2014a), rarely observed in PV (Broséus et al., 2014b) and very rarely may
coexist with the JAK2 V617F or BCR-ABL1 (McGaffin et al., 2014; Cabagnols, Cayuela
and Vainchenker, 2015).
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Figure 1.21. Distribution of JAK2, MPL, and CALR mutations in Ph- MPN. Reproduced
with permission from (Klampfl et al., 2013), Copyright Massachusetts Medical Society.

1.10.2.7 CALR mutation; Biological Characteristics
CALR mutation status may also provide information on the clinical phenotype and
prognosis. In retrospective analyses of ET and PMF, CALR-mutated patients were found
to present with higher platelet count, lower haemoglobin and improved overall survival
when compared to JAK2 mutated, MPL mutated or triple negative patients (Klampfl et
al., 2013). In ET, CALR mutated cases are associated with a reduced cumulative
incidence of thrombosis, reduced major cardiovascular events and a higher incidence of
myelofibrotic transformation versus JAK2 mutated patients (Klampfl et al., 2013;
Andrikovics et al., 2014; Rotunno et al., 2014; Rumi, et al., 2014b).
PMF patients with CALR mutations have a reduced rate of red-cell transfusion
dependency with an improved survival as compared to JAK2 mutated patients (Tefferi et
al., 2014). The high prevalence of type 1 and type 2 CALR mutations in ET and PMF has
prompted investigators to assess the impact of mutation type on prognosis and phenotype,
with a higher frequency of type 1 CALR mutations noted in PMF compared to ET, an
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association in PMF of type 2 CALR mutations with higher circulating blast count,
leucocyte count and inferior survival compared to type 1, and a potential link between
CALR mutation type and megakaryocyte function (Tefferi et al., 2014b; Tefferi et al.,
2014c; Rumi et al., 2014c). CALR mutations are thought to arise in multipotent
progenitors, often as initiating events (Klampfl et al., 2013; Nangalia et al., 2013) with
mutational load increasing with myelofibrotic transformation (Lundberg et al., 2014).

1.10.2.8 CALR mutation Detection
The incidence and specificity of CALR mutations in ET and PMF require analytical
methods which can determine CALR mutation status accurately and rapidly to aid the
diagnostic workup of MPN. Given the multitude and complexity of CALR exon 9
mutations, methodologies that can accommodate this variability will provide most utility
in a diagnostic setting.
Whilst initial reports employed PCR of CALR exon 9 followed by fragment
analysis or Sanger sequencing to determine CALR mutation status (Klampfl et al., 2013;
Nangalia et al., 2013), subsequent studies have explored the utility of alternative High
Resolution Melting (HRM) techniques (Bilbao-Sieyro et al., 2014). A comparison of the
limits of detection for HRM, next-generation sequencing (NGS), and fragment analysis
techniques to detect CALR mutations found a bespoke NGS approach capable of detecting
mutations when present at a level of 1.25%, an improvement in sensitivity over HRM and
fragment analysis (Jones et al., 2015). The majority of CALR positive samples tested by
NGS had greater than 15% mutant alleles suggesting the more readily deployed fragment
analysis may be sufficient for routine molecular diagnosis in the majority of clinical
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laboratories. Further investigation by Sanger sequencing would be required to determine
the exact nature of the CALR mutation detected by screening approaches.
The value of quantitative assessment of CALR mutations remains to be fully
elucidated, yet preliminary data have shown a reduction in CALR allele burden in patients
treated with interferon-alpha therapy and a potential role for monitoring disease burden
post-ASCT (Cassinat, Verger and Kiladjian, 2014; Haslam et al., 2014).

1.10.3 Double driver mutations
Mutations in JAK2, CALR and MPL are generally found to be mutually exclusive and are
considered ‘driver’ mutations of MPN as they can recapitulate the MPN phenotype when
introduced into mouse models. However, in some rare cases a second driver mutation has
been found. Concurrent mutations found include JAK2 and CALR in ET or PMF (Tefferi,
et al., 2014; Lundberg et al., 2014) or JAK2 and MPL (Boyd et al., 2010). A recent large
study of 47 double mutant MPN patients found JAK2 V617F and CALR double mutations
most frequent, with the majority harbouring a low JAK2 V617F allelic burden (<5%)
(Mansier et al., 2018). JAK V617F and MPL, CALR and MPL, JAK2 V617F and JAK2
exon 12, and CALR double mutations were also found. In ET double mutation patients
the predominant clone appeared to determine the phenotype (Mansier et al., 2018). The
clinical impact of double driver mutations in MPN remains to be fully elucidated.
1.10.4 Triple negative Myeloproliferative Neoplasms
The 10-15% of MPN patients negative for mutations in JAK2 V617F, CALR exon 9 or
MPL exon 10 by conventional methods are often referred to as “triple negative” and have
been associated with a prognostically detrimental effect in PMF (Tefferi et al., 2015).
Recent studies comparing whole exome data from granulocyte (tumour) cells with T cell
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exome data in triple negative ET and PMF patients have revealed additional JAK2 and
MPL noncanonical mutations, (Cabagnols et al., 2016; Feenstra et al., 2016) highlighting
the limitations of standard clinical molecular diagnostic methods for this cohort of
patients and supporting the hypothesis of JAK-STAT pathway disruption in MPN.

1.10.5 JAK-STAT pathway disruption in Myeloproliferative Neoplasms
A functional consequence of recurrent somatic mutations in MPNs such as JAK2 V617F,
CALR exon 9 and MPL exon 10 includes disruption of the JAK-STAT signalling pathway.
JAK2 V617F is associated with ligand-independent activation of cytokine signalling
pathways, with tyrosine phosphorylation and activation of STAT5 and STAT3 playing a
central role in MPN pathogenesis (Chen, Staudt and Green, 2012). Gene expression
signatures from peripheral blood granulocytes suggests that mutations that lead to
constitutive JAK-STAT signalling are a common genetic event in MPN regardless of
clinical phenotype or somatic genotype (Rampal et al., 2014), however further studies in
megakaryocytes suggest that whilst a JAK2 activation signal may be present in CALRmutant ET granulocytes, downstream signalling mechanisms other than STAT3 and
STAT5 are likely involved in the pathogenesis of CALR-mutant MPNs (Lau et al., 2015).
A schematic of JAK-STAT signalling in MPNs is shown in Figure 1.22.
Constitutive activation of EPOR, MPL and G-CSFR by JAK2 V617F can cause
phosphorylation of Signal Transducer And Activator Of Transcription 3 or 5 (STAT3/5)
(dimerisation),

Phosphoinositide

3-kinases/AKT

Serine/Threonine

Kinase

1

(PI3K/AKT), RAS Related/ Mitogen-Activated Protein Kinase (RAS/MAPK) with
subsequent upregulation of gene transcription. Mutated CALR binds MPL directly with

46

JAK-STAT upregulation. MPL exon 10 mutations transform MPL receptor to remain
constitutively active with uninhibited JAK-STAT signalling.

Figure 1.22. Schematic diagram of JAK-STAT pathways involved in MPN pathogenesis.
JAK2 V617F constitutively activates EPOR (erythropoietin receptor), MPL
(thrombopoietin receptor), G-CSF-R (granulocyte colony-stimulating factor receptor)
leading to proliferation of all three cell lines and may lead to PV, ET or PMF. It
phosphorylates STAT3/5 (dimerisation), PI3K/AKT, RAS/MAPK with subsequent
upregulation of gene transcription. Mutant CALR binds MPL directly with JAK-STAT
upregulation leading to ET or PMF. MPL exon 10 mutations transform MPL receptor to
remain constitutively active with uninhibited JAK-STAT signalling (O’Sullivan and
Harrison, 2017a)..
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1.11 Gene Mutations in Inherited Haematological Malignancies
The inclusion of germ line predisposition to myeloid malignancies for the first time within
the recent WHO classification (Arber et al., 2016) has designated familial haematopoietic
malignancies as an essential component of leukaemia diagnosis (Table 1.5).
Table 1.5 WHO 2016 classification of myeloid neoplasms with germ line
predisposition. Adapted from (Arber et al., 2016).
Myeloid neoplasm
classification

Subtypes

Myeloid neoplasms with
germ line predisposition
without a pre-existing
disorder or organ dysfunction

AML with germ line CEBPA mutation; myeloid
neoplasms with germ line DDX41 mutation

Myeloid neoplasms with
germ line predisposition and
pre-existing platelet disorders

Myeloid neoplasms with germ line RUNX1 mutation;
myeloid neoplasms with germ line ANKRD26
mutation; myeloid neoplasms with germ line ETV6
mutation

Myeloid neoplasms with
germ line predisposition and
other organ dysfunction

Myeloid neoplasms with germ line GATA2 mutation;
myeloid neoplasms associated with bone marrow
failure syndromes; myeloid neoplasms associated
with telomere biology disorders; JMML associated
with neurofibromatosis, Noonan syndrome, or Noon
syndrome–like disorders; myeloid neoplasms
associated with Down syndrome

The role of germline mutations in children and adults with haematologic malignancies
(HM) has been underappreciated to date. Diagnosing an inherited predisposition to HM
can be used by clinicians to inform choice of therapy, risk of treatment-related
complications, evaluation of comorbidities, and surveillance strategies to improve clinical
outcomes (Furutani and Shimamura, 2017).
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To date leukaemia predisposition syndromes have been grouped into three types with
associated germline gene mutations, those with HM alone and mutations in CEBPA,
Autophagy Related 2B/GSK3B Interacting Protein (ATG2B/GSKIP) or DEAD-Box
Helicase 41 (DDX41), those with an associated bone marrow failure syndrome and
mutations in Telomerase RNA Component (TERC), Telomerase Reverse Transcriptase
TERT, Signal Recognition Particle 72 subunit (SRP72) or Shelterin Complex Subunit And
Telomerase Recruitment Factor (ACD7), and those with preceding cytopenia and/or
platelet dysfunction and mutations in RUNX1, GATA2, ANKRD26 or ETV6) (Tawana and
Fitzgibbon, 2016) (Figure 1.23).

Figure 1.23 The genetic landscape of inherited HM ordered by discovery and showing
prevalence in lymphoid and myeloid malignancies. Those with HMs alone (blue),
associated bone marrow failure syndromes (red), cytopenia and/or platelet dysfunction
(yellow) (Tawana and Fitzgibbon, 2016).
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1.11.1 Familial predisposition to Myeloproliferative Neoplasms
The majority of MPN are somatically acquired stem cell mutations that cause clonal
expansion of myeloid precursors. In adults, MPNs due to somatic JAK2, MPL, or CALR
mutations are usually sporadic. However, 7% of cases involve a familial predisposition,
with first-degree relatives of an affected patient at increased risk by a factor of 5-7, for
the same MPN (in some families) or for different MPNs (in other families), involving
JAK2, MPL, and CALR mutations or no identifiable mutation. These results support the
hypothesis that common shared susceptibility genes predispose to PV, ET, MF, and
possibly CML (Landgren et al., 2008; Spivak, 2017) however the causative germline
mutations underlying familial MPN remain largely unknown and are of low penetrance.
Other lines of evidence also support this hypothesis, such as the observation of
biclonality in MPN patients (Beer et al., 2009) and that some first-degree relatives of
JAK2 V617F mutation positive MPN patients are healthy with no MPN phenotype can
grow in vitro erythroid colonies that are hypersensitive to exogenous erythropoietin
compared to normal individuals (Tashi, Swierczek and Prchal, 2017). Consistent with the
existence of MPN predisposition loci, the recent finding that JAK2 V617F is not acquired
randomly but instead arises preferentially on a specific constitutional JAK2 haplotype
supports this. JAK2 V617F associated disease was strongly associated with a specific
constitutional JAK2 haplotype, in PV, ET and PMF compared to healthy controls. The
JAK2 V617F was found to be non-randomly distributed between two parental alleles of
the JAK2 gene and was preferentially acquired in cis with the predisposition allele
rs10974944 on a haplotype designated 46/1. This haplotype is found in approximately
50% of normal persons and thus is a common, very low penetrance predisposition allele
of the type that is typically detected by genome-wide association studies. This data
suggests a certain combination of single nucleotide polymorphisms (SNPs) renders
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haplotypes differentially susceptible to somatic mutagenesis or that a functional
difference of JAK2 on 46/1 positively interacts with V617F and thus provides “fertile
ground” for development of an MPN (Jones et al., 2009; Kilpivaara et al., 2009; Olcaydu
et al., 2009). Another example is a single-nucleotide variant located in the second intron
of the TERT gene: rs2736100_C, which is linked to activated myeloid haematopoiesis
and is associated with all three classical MPNs and significantly with their familial forms.
This variant, in combination with 46/1 and other single-nucleotide variants, has an
additive effect on susceptibility to MPNs (Jäger et al., 2014; Spivak, 2017).

1.12 Additional mutations in Myeloproliferative Neoplasms
As people age, changes in the haematopoietic stem cell compartment lead to an elevated
risk of myeloid malignancies and are attributes of the aging haematopoietic system
(Beerman et al., 2010). Aging is characterised by clonal expansion of myeloid-biased
haematopoietic stem cells and by increased risk of myeloid malignancies. Although some
of these mutated individuals may develop or possess an underlying MPN, many have
blood counts within the normal range and thus represent examples of what is now termed
age-related clonal haematopoiesis (ARCH) or clonal haematopoiesis of indeterminate
potential (CHIP). In this regard, mutations in DNA methyltransferase 3 alpha (DNMT3A)
and Tet methylcytosine dioxygenase 2 (TET2) were found to predominate in individuals
with clonal haematopoiesis without HM (Busque et al., 2012; Jaiswal et al., 2014;
McKerrell et al., 2015). Persons with CHIP have a markedly increased rate of
cardiovascular mortality regardless of their cancer risk, demonstrating that CHIP is of
clinical significance (Busque et al., 2012; Jaiswal et al., 2014).
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All MPN subtypes can progress into blast-phase disease (MPN-BP). Whereas no strong
predictors of MPN transformation to AML have been identified, some clinically useful
prognostic factors have been identified, in particular for patients with MF. For ET,
reported risk factors for leukaemic transformation include advanced age, extreme
thrombocytosis, anaemia, leucocytosis, and sequence variants/mutations involving
Tumor Protein P53 (TP53) and Enhancer of zeste homolog 2 (EZH2); for polycythaemia
vera, advanced age, leucocytosis, abnormal karyotype, mutations involving Serine And
Arginine Rich Splicing Factor 2 (SRSF2) and Isocitrate Dehydrogenase 2 (IDH2), and for
PMF, increased blast percentage, thrombocytopenia, abnormal karyotype, triple-negative
driver mutational status, and sequence variants/mutations involving SRSF2, RUNX1,
CEBPA, and SH2B Adaptor Protein 3 (SH2B3) (Yogarajah and Tefferi, 2017). Five
mutated genes (ASXL1, EZH2, SRSF2 and IDH1/2) have been identified in PMF patients
who are at risk for premature death or leukemic transformation, with the number of
detrimental mutations detected in a patient associated with worsening survival
(Vannucchi et al., 2013; Guglielmelli et al., 2014).

1.13 Paroxysmal Nocturnal Haemoglobinuria related mutations
Recent work in PNH has discovered that it is in fact a complex genetic disorder
orchestrated by many genetic alterations in addition to PIG-A mutations for example
mutations in TET2, Polycomb Repressive Complex 2 Subunit (SUZ12), JAK2, and U2
Small Nuclear RNA Auxiliary Factor 1 (U2AF1), many of which have been observed in
other myeloid disorders such as AML or MDS and indicate that PNH has a clonal
evolution and architecture strikingly similar to that of other myeloid neoplasms,
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highlighting a potentially broader mechanism of disease pathogenesis in this disorder
(Lee and Abdel-Wahab, 2014).

1.14 Chronic Neutrophilic Leukaemia related mutations
The recent seminal discovery of activating mutations in the granulocyte colonystimulating factor receptor (CSF3R) in sporadic CNL has clarified diagnosis in these
patients and provided a useful tool for diagnoses (Maxson et al., 2013). In this study 89%
and 40% of CNL and aCML cases respectively, were found to harbour CSF3R mutations.
Two main types of mutational variants of CSF3R were identified: the more common
membrane proximal mutations consisting primarily of T618I and T615A point mutations,
and frameshift or non-sense mutations leading to premature truncation of the cytoplasmic
tail of CSF3R (D771fs, S783fs, Y752X, and W791Z) which typically coexisted with
membrane proximal or transmembrane CSF3R mutations as compound mutations (Figure
1.24).

Figure 1.24. Location and recurrence of CSF3R mutations found in CNL aCML (Maxson
et al., 2013).
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The proximal mutations prevent O-glycosylation of CSF3R, increase receptor
dimerisation and result in increased ligand independent receptor activation, whereas the
truncation mutations result in decreased receptor degradation, increased CSF3R
expression on the cell surface and STAT5 activity leading to cell transformation (Maxson
et al., 2014; Zhang et al., 2017). A follow up study by Pardanani et al. who divided WHO
defined CNL and aCML found that CSF3R mutations were found in WHO CNL only,
and endorsed the incorporation of the T618I mutation as a sensitive and specific marker
of WHO defined CNL (Pardanani et al., 2013).
The granulocyte-macrophage colony-stimulating factors are well-characterised
glycoproteins that interact to control the production, differentiation, and function of
granulocytes and monocyte-macrophages, with proliferation of myeloid leukaemia cells
dependent on stimulation by colony-stimulating factors (Metcalf, 1985). Specifically,
CSF3R-deficient mice have been found to be severely neutropenic which reinforces the
role of these cytokines in neutrophil production (Lieschke et al., 1994). Upon binding to
its receptor, G-CSF exerts its effects via classical downstream pathways that include
JAK-STAT, SRC family kinases, Ras/Raf/MAP kinases, and PI3K/Akt pathways,
inducing neutrophilic differentiation, proliferation, and survival as well as stimulating
neutrophil function (Beekman and Touw, 2010). In the Maxon et al. landmark study,
proximal and distal CSF3R mutations showed differential susceptibilities to different
TKIs with proximal mutations responding to the JAK inhibitor ruxolitinib whereas
truncation mutations displayed sensitivity to the SRC kinase inhibitor dasatinib thus
providing a rationale for molecularly directed therapeutic targeting of CNL (Figure 1.25).
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Figure 1.25. Model for Activation and Signalling of CSF3R Mutations (Maxson, et al.,
2013).

Truncation mutations in CSF3R (the receptor for G-CSF) result in increased expression
levels. Downstream signalling mediators - SRC family kinases and TNK2 are
preferentially activated by these truncation mutations. Consequently, leukaemic cells
harbouring the mutations are highly sensitive to dasatinib. Truncation mutations in
CSF3R may also show sensitivity to JAK kinase inhibitors in the context of JAK kinase
stimulation downstream of high ligand concentrations. In contrast, membrane proximal
mutations in CSF3R show completely ligand-independent function. In this capacity, the
dominant mode of signalling appears to operate through the JAK–STAT pathway. Thus,
patients with membrane proximal mutations may be candidates for treatment with JAK
kinase inhibitors, such as ruxolitinib (Maxson et al., 2013).
CNL is not a disease solely driven by CSF3R mutation, with subsequent studies
highlighting additional commonalities with other chronic myeloid malignancies at the
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genetic level, including mutations in SET Binding Protein 1 (SETBP1), spliceosome
proteins (SRSF2, U2AF1), and epigenetic modifiers (TET2, ASXL1) (Piazza et al., 2013;
Maxson and Tyner, 2017). In the case of SETBP1 mutations, exome sequencing of eight
aCMLs identified somatic alterations with extended analysis identifying SETBP1
mutations in 17 of 70 aCML’s (24.3%). Most mutations (92%) were located between
codons 858 and 871 and were identical to changes seen in individuals with SchinzelGiedion syndrome (Figure 1.26). Although enriched and recurrently mutated in aCML
SETBP1 mutations were also found in CMML, a disease considered to be very similar to
aCML that has overlapping diagnostic criteria, but with a prevalence almost seven times
greater, demonstrating for the first time a biological difference between these two entities
(Piazza et al., 2013). At present the functional significance of SETBP1 mutations in
aCML and CNL are not yet fully understood.

Figure 1.26. Distribution of alterations on the SETBP1 protein. Black circles represent
alterations found in aCML samples, green circles represent alterations found in other
diseases. Variants confirmed as somatic are indicated in bold (Piazza et al., 2013).
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1.15 Myelodysplastic Syndrome
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid diseases
characterised by inefficient haematopoiesis, peripheral cytopenias and risk of progression
to AML. MDS is primarily a disease of the elderly with an estimated incidence of up to
75/100,000 people over 65 years and is the leading cause of acquired bone marrow failure
in adults (Swerdlow et al., 2008; Bejar, Levine and Ebert, 2011; Cogle et al., 2011). The
outcome of MDS patients is extremely variable with median survival ranging from over
5 years to less than 6 months (Greenberg et al., 2012). Approximately 150 people in
Ireland receive a diagnosis of MDS every year, however, there are many more patients
for whom treatment decisions are withheld until the clinical picture clarifies or worsens
before that decision can be made.
MDS is usually suspected by the presence of cytopenia on a routine analysis of
peripheral blood. This prompts evaluation of bone marrow cell morphology (aspirate) and
cellularity (biopsy). A manual count of bone marrow blasts is fundamental for risk
assessment. Cytogenetic analysis helps in predicting risk and in selecting therapy. Once
this information is collected, the risk of the patient can be calculated (Montalban-Bravo
and Garcia-Manero, 2018). Diagnosis of MDS is largely determined by clinical and
morphologic parameters yet often remains a challenge, particularly in cases of cytopenias
with equivocal bone marrow morphology and normal cytogenetics (Gondek and DeZern,
2014).
MDS are classified into five subtypes of varying severity in the recent 2016 update
to the WHO classification of myeloid haematological malignancies (Arber et al., 2016),
which utilises clinical features, peripheral blood counts, bone marrow morphology and
cytogenetic analysis to distinguish sub-types. Recurrent chromosomal abnormalities are
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detected in half of MDS patients, with the most common aberrations being deletions of
chromosomes 5 and 7, monosomy of chromosomes 5 and 7, trisomy 8, and del(20q) (List
et al., 2006; Ebert et al., 2008; Giagounidis and Haase, 2013). Currently, the diagnosis of
MDS is established based on the presence of persistent and significant cytopenia, a
haemoglobin count < 10 mg/dL, absolute neutrophil count <1.8 x109/L, a platelet count
< 100 x 109/L, >10% bone marrow dysplasia in 1 or more lineages, <20% myeloblasts in
the bone marrow and/or abnormal karyotype (Bennett and Orazi, 2009). An iron stain is
performed on marrow aspirates to identify the presence and quantity of ring sideroblasts,
which should be at least 15% of the total erythroblasts to be diagnostic of MDS with
ringed sideroblasts. Cytogenetic patterns are heterogeneous and unstable in MDS with a
significant fraction of patients acquiring additional cytogenetic changes which can
increase the risk of transformation to AML. The most recent cytogenetic risk
classification in MDS includes 5 different subgroups and includes 20 different alterations
(Montalban-Bravo and Garcia-Manero, 2018) (Figure 1.27). Around 50% of de novo
MDS patients will be found to have a chromosomal abnormality. The only subtype of
MDS to be defined by a genetic abnormality is the group with isolated deletion of
chromosome 5q [del(5q)]. In the 10% of cases with the del(5q) as a sole abnormality, this
lesion is associated with a more favourable prognosis (Haase et al., 2007). In another 5–
10% of cases, del(5q) is found as part of a complex karyotype (3 or more cytogenetic
abnormalities): the prognosis in these cases is poorer (Adema and Bejar, 2013).
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Figure 1.27 Cytogenetic classification of MDS (Montalban-Bravo and Garcia-Manero,
2018).

The current myelodysplastic syndromes 2016 WHO classification is outlined below:









MDS with single lineage dysplasia
MDS with multilineage dysplasia
MDS with ring sideroblasts (MDS-RS)
o MDS-RS with single lineage dysplasia
o MDS-RS with multilineage dysplasia
MDS with isolated del(5q)
MDS with excess blasts (MDS-EB)
o MDS-EB I (5-9% Blasts)
o MDS-EB II (10-19% Blasts)
MDS, unclassifiable (MDS-U)
o with 1% blood blasts
o with single lineage dysplasia and pancytopenia
o based on defining cytogenetic abnormality
o Refractory cytopenia of childhood
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When a clear diagnosis of MDS is achieved, an accurate prediction of prognosis is
important to determine the clinical outcome as this can vary greatly between subtypes.
This is accomplished using the Revised International Prognostic Scoring System (IPSSR) to determine survival and risk of progression to AML. To achieve this a large number
of patients were evaluated from multiple coalesced databases (n = 7012) and integrated
with various independent clinical factors for MDS to produce a comprehensive model to
assess relative prognostic impact. This model can be used to predict an age-adjusted risk
category for individual patients (Figure 1.28).

Figure 1.28: Age-adjusted IPSS-R risk categories. The nomogram describes predicted
survival based on patient age and IPSS-R risk status (IPSS-RA) (Greenberg et al., 2012).
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An overview of the pathobiology observed across the MDS continuum is outlined below,
where IPSS low patients show a high level of bone marrow function, differentiation of
myeloid cells and functional apoptosis, whereas higher risk MDS patients show loss of
these normal functions and a propensity for myeloid cell proliferation and the presence
of blast cells (Figure 1.29).

Figure 1.29. Overview of pathobiology across MDS disease spectrum.

Diagnosis of MDS can be hampered by a lack of clear diagnostic information to
distinguish the disease from benign or reactive conditions that present with similar
clinical features such as ARCH or CHIP as discussed earlier. The clinical phenotype of
MDS patients is diverse, with this heterogeneity due to the variety of underlying genetic
lesions that contribute to disease pathogenesis. Some patients have persistent blood
cytopenias for which no explanation is apparent, so-called idiopathic cytopenias of
undetermined significance (ICUS), yet have unremarkable marrow morphology and lack
a known MDS-associated somatic mutation karyotypic abnormality (Steensma et al.,
2015).
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Recent large-scale sequencing studies have revealed acquisition of clonally restricted
somatic mutations in MDS-associated genes in blood cells of individuals with normal
blood counts and without any apparent disease and that they confer an increased risk of
subsequent haematological malignancy diagnosis, as well as higher all-cause mortality
(Busque et al., 2012; Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014).
Whereas, in some of these individuals, a myeloid neoplasm develops in the follow-up,
others will never develop an overt myeloid disorder during their lifetime. The risk of
developing a myeloid neoplasm depends on the type of mutations and other factors. The
recognition of the potential for clonal haematopoiesis to manifest as disease has led to
further splitting of this potential into clonal haematopoiesis with indeterminate potential
(CHIP) and clonal haematopoiesis with oncogenic potential (harbouring a driver
mutation) (CHOP) (Valent et al., 2019). Whereas some of these drivers may directly
induce the proliferation of neoplastic stem and progenitor cells, others induce
differentiation in distinct haematopoietic lineages and are therefore disease-specific and
lineage-related and often detected in premalignant chronic neoplasms. In the context of
multimutated sub-clones, oncogenic drivers contribute to the transformation to secondary
AML (Valent et al., 2019).
Efforts to understand the underlying genetic mutations in MDS has led to the
discovery of recurrently mutated genes involved in epigenetic regulation, chromatin
modification, spliceosomal machinery, signalling and DNA repair pathways, (M. J.
Walter et al., 2011; Yoshida et al., 2011). Recent application of high throughput genomic
techniques such as NGS has allowed the discovery of recurrent somatic mutations in over
40 genes in patients with MDS. These techniques allow for analysis of multiple genes,
often requiring coverage of several amplicons, to be sequenced in parallel on a single
operating platform. Genes mutated in MDS include those involved in transcriptional
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regulation (RUNX1, GATA2, EVI1), chromatin modification (EZH2, ASXL1), DNA
methylation (DNMT3A, IDH1, IDH2, TET2) RNA splicing (SF3B1, U2AF1, SRSF2,
ZRSR2), and signal transduction (JAK2, KRAS, CBL) (Bejar and Steensma, 2014). Large
studies have demonstrated at least one oncogenic mutation is present in up to 90% of
patients. The mutational profile in MDS shows that there is a large number of gene
mutations detected, producing a long tail of low-frequency mutations (Walter et al., 2013;
Haferlach et al., 2014; Papaemmanuil et al., 2015) (Figure 1.30, 1.31). Some of these
mutations impact on patient prognosis, e.g. mutations in TP53, ETV6, ASXL1, DNMT3A,
RUNX1 and EZH2 are associated with poor overall survival or more rapid progression to
AML (Bejar and Steensma, 2014). Mutations in the spliceosome gene Splicing Factor 3b
Subunit 1 (SF3B1) has been strongly associated with ring sideroblasts and these MDS
patients are unlikely to develop detrimental sub-clonal mutations and have an indolent
clinical course and favourable outcome (Papaemmanuil et al., 2011; Bacher et al., 2012;
Malcovati et al., 2015). Leukaemia free survival between clonal and sub-clonal mutations
for these genes has shown no significant difference and emphasises the importance of
detecting sub-clones to identify high risk patients (Papaemmanuil et al., 2013). In
addition, TET2 mutations have been shown to predict response in patients treated with
azacytidine (Bejar, et al., 2014).
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Figure 1.30 Landscape of MDS I (Papaemmanuil et al., 2013)

Figure 1.31 Landscape of MDS II (Haferlach et al., 2014)

Management of patients with MDS depends on whether they are defined as high or low
risk. Patients defined as high risk MDS have a 33-45% chance of progression to AML
and a median survival of around 12 months without intervention. Treatment options are
observation, red cell and platelet transfusions, erythropoiesis stimulating agents, and
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hypomethylating agents or ASCT depending on eligibility (Killick et al., 2014). Not all
patients with MDS require therapy, some can be safely observed with intermittent blood
count monitoring. When therapy is justified by the development of indices such as severe
cytopenia or increasing blasts, IPSS-R can aid in selection of therapy (Figure 1.32).

Figure 1.32. Treatment options for spectrum of MDS patients from low (observation) to
high risk disease (transplantation).

The ability to conclusively diagnose and treat MDS will be greatly enhanced with the
availability of new molecular information and forthcoming targeted therapies. Advances
in the molecular understanding of MDS are set to become part of routine clinical care for
patients with incorporation of molecular data into the prognostic algorithm (IPSS-RM)
already underway (Bejar and Steensma, 2014).
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1.16 Acute Myeloid Leukaemia
AML is the most common acute leukaemia in adults, accounting for ~80% of cases in
this group. Incidence of AML in the United States ranges from 3-5 cases per 100,000
population, and increases with age, from ~1.3/100,000 in patients less than 65 years old,
to 12.2/100 000 in those over 65 years (De Kouchkovsky and Abdul-Hay, 2016). In the
majority of cases AML arises as a de novo malignancy from a transformed multipotential
haematopoietic stem cell that has acquired successive genomic alterations, ultimately
evolving into clinically overt disease, however it can arise in patients with an underlying
haematological disorder such as MPN or MDS, or as a consequence of prior therapy such
as exposure to alkylating agents or radiation (Sill et al., 2011; Lowenberg and Rowe,
2016). Advances in the treatment of AML have led to significant improvements in
outcomes for younger patients, with 5-year survival rates in the United Kingdom between
1976-2016 dramatically increasing in those aged 15-24 years, from 7% to 53%. However
prognosis in the elderly who account for the majority of new cases remains poor (Shah et
al., 2013). Within defined cytogenetic risk groups, elderly AML patients still have a
higher relapse rate and show an inferior outcome compared to younger patients of the
same risk group (Büchner et al., 2009; Lazarevic et al., 2014; Tsai et al., 2016). In
addition to her pioneering work in CML in the 1970’s, Janet Rowley also established that
AML is a genetic disease, with the discovery of somatic chromosomal abnormalities
including the balanced translocations t(8;21) and t(15;17) in the leukaemic cells of some
patients (Rowley, Golomb and Dougherty, 1977). These studies paved the way for
identification of the genes disrupted at the chromosomal breakpoints of leukaemiaassociated translocations and inversions. The balanced chromosomal rearrangements
were found to give rise to in-frame chimeric fusion genes and recurrently target genes
encoding hematopoietic transcription factors (retinoic acid receptor alpha (RARA),
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RUNX1, or CBFβ subunits of the core binding factor [CBF] complex), epigenetic
regulators (MLL, CREB Binding Protein (CREBBP)), and components of the nuclear pore
complex (NUP98, NUP214), providing major insights into normal haematopoiesis and
uncovering common mechanistic themes in the pathogenesis of AML (Grimwade, Ivey
and Huntly, 2016). Molecular and cytogenetic abnormalities in AML involve mutations
in critical genes of normal cell development, cellular survival, proliferation, and
maturation.
1.16.1 Classification of Acute Myeloid Leukaemia
The first attempt to classify different types of AML was achieved with the FrenchAmercian-British (FAB) classification system established in 1976, that defined eight
subtypes (M0-M7) based on the morphological and cytochemical characteristics of the
leukemic cells (Bennett et al., 1976) (Table 1.6).

Table 1.6: FAB classification of Acute Myeloid Leukaemia.
M0

Undifferentiated acute myeloblastic leukaemia

M1

Acute myeloblastic leukaemia with minimal maturation

M2

Acute myeloblastic leukaemia with maturation

M3

Acute promyelocytic leukaemia (APL)

M4

Acute myelomonocytic leukaemia

M4eos

Acute myelomonocytic leukaemia with eosinophilia

M5

Acute monocytic leukaemia

M6

Acute erythroid leukaemia

M7

Acute megakaryocytic leukaemia
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This classification of AML was superseded in 2008 and subsequently in 2016 by the
WHO classification system. The WHO classification of AML distinguishes itself by
incorporating genetic information with morphology, immunophenotype and clinical
presentation to define six major disease entities with further delineation where applicable:
AML with recurrent genetic abnormalities; AML with myelodysplasia-related features;
therapy-related AML; AML not otherwise specified; myeloid sarcoma; and myeloid
proliferation related to Down syndrome (Table 1.7).
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Table 1.7: WHO classification of AML and related neoplasms.
with



AML with t(8:21)(q22;q22); RUNX1-RUNX1T1

genetic



AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11



APL with PML-RARA



AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2A



ML with t(6;9)(p23;q34.1); DEK-NUP214



AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM



AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1



AML with BCR-ABL1 (provisional entity)



AML with mutated NPM1



AML with biallelic mutations of CEBPA



AML with mutated RUNX1 (provisional entity)

AML
recurrent

abnormalities

AML

with

A history of MDS or morphological evidence of dysplasia in two or more

myelodysplasia-

myeloid cell lineages, the presence of myelodysplasia-related cytogenetic

related changes

abnormalities such as monosomy 5 or 7, and deletion 5q or 7q help identify
these cases.


AML with minimal differentiation



AML without maturation



AML with maturation



Acute myelomonocytic leukaemia



Acute monoblastic/monocytic leukaemia



Acute erythroid leukaemia



Pure erythroid leukaemia



Acute megakaryoblastic leukaemia



Acute basophilic leukaemia



Acute panmyelosis with myelofibrosis

Myeloid



Transient abnormal myelopoiesis

proliferations



ML associated with Down syndrome

Therapy-related
myeloid neoplasms

AML not otherwise
specified
Myeloid sarcoma

related

to

Down

syndrome
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1.16.2 Prognosis of Acute Myeloid Leukaemia
Stratification of AML patients according to their risk of resistance to treatment or
treatment related mortality helps define treatment approaches. Clinical factors such as
age, the performance status of the patient, whether the AML is a secondary malignancy
or therapy related affect treatment related mortality (Walter et al., 2011b; Hulegårdh et
al., 2015). Cytogenetic changes provide the strongest prognostic factor for overall
survival and are used to risk stratify patients into three main groups of favourable,
intermediate and adverse risk groups. Further incorporation of molecular changes has
helped to refine the risk stratification of patients with cytogenetically normal AML (CNAML), which represents nearly half of de novo AML cases. An outline of the impact of
cytogenetic and molecular lesions is outlined in Table 1.8 and Figure 1.33. This data is
used as a framework for risk stratification to predict risk of relapse in those with normal
karyotype and to further dissect out groups of patients with differing prognoses who share
particular cytogenetic abnormalities, or fall within the same cytogenetic-risk group
(Grimwade et al., 2010)
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Table 1.8 Prognostic risk grouping in AML based on cytogenetic and molecular
profile.
Prognostic risk group

Cytogenetic profile alone

Cytogenetic
profile
molecular abnormalities

and

Favourable

t(8:21)(q22;q22)

t(8:21)(q22;q22) with no c-KIT
mutation

inv(16)(p13;1q22)

inv(16)(p13;1q22)

t(15;17)(q22;q12)

t(15;17)(q22;q12)
Mutated NPM1 without FLT3ITD (CN-AML)
Mutated biallelic CEBPA (CNAML)

Intermediate

CN-AML

t(8:21)(q22;q22) with mutated cKIT

t(9;11)(p22;q23)

CN-AML other than those
included in the favourable or
adverse prognostic group

Cytogenetic abnormalities not
included in the favourable or
adverse prognostic risk groups
Adverse

inv(3)(q21q26.2)

TP53 mutation, regardless of
cytogenetic profile

t(6;9)(p23;q34)

CN with FLT3-ITD

11q abnormalities other than
t(9;11)

CN with DNMT3A

−5 or del(5q)

CN with KMT2A-PTD

−7

inv(3)(q21q26.2)

Complex karyotype

t(6;9)(p23;q34)
11q abnormalities other than
t(9;11)
−5 or del(5q)
−7
Complex karyotype
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Figure 1.33. Impact of cytogenetic entities recognized in 2008 WHO classification on
survival from the UK MRC trials (Grimwade et al., 2010).

1.16.3 Recurrent mutations in Acute Myeloid Leukaemia
Studies of animal models at the turn of the century led to the development of a two-hit
model of leukemogenesis, which offers a conceptual framework for classifying the
various mutations associated with AML. According to this model, class I mutations which
result in the activation of pro-proliferative pathways must occur in conjunction with class
II mutations which impair normal hematopoietic differentiation in order for leukaemia to
develop (Gilliland and Griffin, 2002). Common class I mutations, such as FLT3 internal
tandem duplications (FLT3-ITD), K/NRAS, TP53 and c-KIT are found in 28%, 12%, 8%
and 4% of cases, respectively. Class II mutations include NPM1 and CEBPA, which are
found in 27% and 6% of cases respectively, and confer a better prognosis (Cancer
Genome Atlas Research Network et al., 2013). Alterations in genes involved in epigenetic
regulation have recently emerged as a third class of mutations, with downstream effects
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on both cellular differentiation and proliferation. These include mutations in DNMT3A,
TET2, IDH-1 and IDH-2, which are found in more than 40% of AML cases (De
Kouchkovsky and Abdul-Hay, 2016).
During initial diagnostic workup, the European Leukaemia Net (ELN)
recommendations suggest screening for mutations in NPM1, CEBPA, RUNX1, ASXL1
and FLT3 at diagnosis (Döhner et al., 2017). In addition mutations in isocitrate
dehydrogenase two (IDH2) are also often tested for initially, due to their newly actionable
status in the relapsed or refractory setting (Döhner, Weisdorf and Bloomfield, 2015). In
younger adults, cytogenetic analyses of large cohorts of AML patients have shown that
translocations/inversions underlie disease pathogenesis in ∼50% and 30% of AML
arising in children and younger adults, respectively, whereas only a minority of AMLs
presenting in older adults have balanced rearrangements. The distribution of the defined
subsets in younger adults and the frequently associated cooperating mutations are shown
in Figure 1.34.

Figure 1.34 Distribution of cytogenetically and molecularly defined subsets of AML
presenting in younger adults and associated cooperating mutations (boxes) (Grimwade,
Ivey and Huntly, 2016).
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1.16.4 Genomic landscape of Acute Myeloid Leukaemia
The past two decades have seen major advances in the understanding of the mutational
landscape of AML providing an unprecedented view of the spectrum and frequency of
mutations, patterns of cooperativity and mutual exclusivity, subclonal architecture, clonal
evolution during the disease course, and the epigenetic landscape of the disease.
Beginning with the comprehensive analysis of The Cancer Genome Atlas Research
Network (TCGA) , who analysed the genomes of 200 clinically annotated adult cases of
AML using matched primary tumour and normal skin samples (50 patients by whole
genome sequencing and 150 with the use of whole-exome sequencing, RNA and
microRNA sequencing and DNA-methylation analysis) and revealed adult AML to have
the fewest mutations of adult cancer types sequenced (Figure 1.35). AML are clonally
heterogenous, show a pattern of mutual exclusivity for mutations in genes within certain
biologic classes, a high correlation between expression signature and state of
differentiation and corroborated methylation signatures in CpG islands for transcription
factor fusions and IDH mutations (Cancer Genome Atlas Research Network et al., 2013).
Subsequent work has shown the distribution of mutations across risk groups in AML and
that relapsed AML is associated with the addition of new mutations and dynamic clonal
evolution and may contribute therapy resistance (Papaemmanuil et al., 2013) (Ding et al.,
2012) (Figures 1.36, 1.37).
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Figure 1.35 Organisation of mutations into categories of related genes, (Cancer Genome
Atlas Research Network et al., 2013).

Figure 1.36 Identification of 5234 driver mutations involving 76 genes or regions in 1540
AML patients (Papaemmanuil et al., 2013).
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Figure 1.37. Representation of clonal evolution from a primary tumour to relapse in a
single case of AML (Ding et al., 2012).

Building on the understanding of the genomic landscape of AML, efforts have been made
to understand how the genetic diversity defines the pathophysiology of AML. Combining
driver mutation data with cytogenetic and clinical data has revealed distinct molecular
subgroups that reflect discrete paths in the evolution of AML and allow for a genomic
classification of AML. Mutations in epigenetic modification genes DNMT3A, ASXL1,
IDH1/2, and TET2, are often observed to be acquired early in the disease and are not
sufficient for overt disease as they are also found mutated in elderly populations with
clonal haematopoiesis (Busque et al., 2012; Genovese et al., 2014; Xie et al., 2014)

1.16.5 Familial Platelet Disorder with propensity to AML
Familial platelet disorder with propensity to AML (FPD-AML) is a rare, autosomal
dominant disorder characterised by quantitative and qualitative platelet abnormalities
with a propensity to develop an MDS or AML. FPD-AML kindred are defined by germline mutations of RUNX1 (Song et al., 1999), commonly dysregulated by translocations,
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mutations or amplification in de novo and secondary MDS and acute leukaemia. Most
germ line RUNX1 mutations are unique to the individual FPD-AML pedigree with
variability observed in the MDS or AML phenotype and the incidence of leukaemic
transformation of affected individuals (Nickels et al., 2013).
The spectrum of somatic genetic events associated with progression to MDS or
AML have not been fully appreciated but acquisition of cytogenetic abnormalities, single
gene defects that occur in de novo MDS and AML, and bi-allelic RUNX1 mutations have
all been demonstrated (Minelli et al., 2004; Preudhomme et al., 2009; Shiba et al., 2012).
More recently, mutations of CDC25C have been identified in approximately half of
affected FPD-AML patients. CDC25C mutations appear to disrupt a critical cell cycle
check point in pre-leukaemic clones, allowing subsequent acquisition of further subclonal mutations (Yoshimi et al., 2014).

1.16.6 Treatment of Acute Myeloid Leukaemia
The general therapeutic strategy in patients with AML has not changed substantially in
more than 30 years with initial assessment determining whether a patient is eligible for
intensive induction chemotherapy (Döhner, Weisdorf and Bloomfield, 2015). Patients
eligible for intensive treatment are considered for remission-induction chemotherapy and
depending on response and the risk profile of the disease, an allogeneic HSCT as
consolidation therapy can be considered. In eligible adults with newly diagnosed AML,
the traditional standard therapy is ‘7+3’ induction chemotherapy with infusional
cytarabine for 7 days with 3 days of anthracycline chemotherapy (daunorubicin or
idarubicin) (Roboz, 2012). A complete remission (CR) is achieved in 60%–85% of
patients younger than the age of 60, and in 40%–60% of patients greater than the age of
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60 (Davis, Benjamin and Jonas, 2018). For patients with an unfavourable-risk AML,
intensive chemotherapy is mainly considered when a donor for an ASCT is available and
a subsequent transplant can be foreseen. Otherwise, these unfavourable-risk patients and
patients ineligible for intensive chemotherapy will more likely be considered for lessintensive treatment approaches, or for a clinical trial with an investigational agent
(Ossenkoppele and Lowenberg, 2015) (Figure 1.38).

Figure 1.38 General Algorithm for the treatment of older patients with AML
(Ossenkoppele and Lowenberg, 2015).

1.16.7 New therapies in Acute Myeloid Leukaemia
With a growing understanding of the underlying genomic landscape of AML, several new
therapeutics have been put into development to target particular sub-populations and in
2017, four new therapies were approved.
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1.16.8 Midostaurin
Midostaurin was FDA approved after a phase 3 trial comparing the addition of
midostaurin, an oral multitargeted kinase inhibitor active in patients with a FLT3 mutation
to standard chemotherapy was shown to significantly prolong overall and event-free
survival among patients with AML and a FLT3 mutation. A median overall survival of
74.7 months in the midostaurin group versus 25.6 months with placebo was observed
(Stone et al., 2017).
1.16.9 Gemtuzumab Ozogamicin
Fractioned doses of gemtuzumab ozogamicin (GO) was approved for use with standard
first line chemotherapy in newly diagnosed CD33+AML and also relapsed or refractory
CD33+ AML. GO, a humanised immunoglobulin antibody directed against CD33 and
conjugated with calicheamicin, a cytotoxic antibiotic had been withdrawn almost 20 years
ago after a phase III study in patients with untreated AML comparing standard
7+3 induction chemotherapy plus GO versus 7+3 alone found a higher mortality rate in
the GO arm (5.5% vs 1.4%), without any improvement in complete remission, diseasefree or overall survival (Petersdorf et al., 2013).
1.16.10 CPX-351
CPX-351 a liposomal formulation of cytarabine and daunorubicin in a fixed 5:1 molar
ratio was compared in a phase III trial to standard 7+3 chemotherapy in patients aged 6075 years with high risk secondary AML and showed superior overall survival 9.56 vs 5.95
months (p=0.005) in the CPX-351 arm with similar adverse events in both arms, leading
to FDA approval for newly diagnosed therapy-related AML or AML with MDS-related
changes (Lancet et al., 2016).
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1.16.11 Enasidenib
Enasidenib a selective inhibitor of mutated IDH2 received FDA approval for IDH2mutant relapsed or refractory AML at a dosing of 100 mg orally once per day, after
showing a median overall survival among relapsed/refractory patients of 9.3 months, and
was 19.7 months for the 34 patients (19.3%) who attained complete remission in a phase
I/II study (Stein et al., 2017).
Cancer medicine continues to move toward immunotherapeutic strategies and the idea of
personalised medicine. To achieve this, a refined diagnosis and molecular profile of the
individual’s tumour will be required at presentation and throughout the disease course as
a patient responds to therapy. Developments in our understanding of the molecular drivers
of disease is fragmenting the traditional disease classifications and the application of
molecular diagnostics in relevant clinical scenarios, can enhance our ability to deliver on
the promise of personalised medicine.
The aim of the research in this thesis was to determine if mutation status in myeloid
malignancies can be used inform clinical insight. This was investigated using the
following objectives:
1: Validate the utility of specific mutations to monitor MPN disease burden post
transplantation
2: Investigate the incidence and significance of MPN mutations in various clinical
contexts.
3: Validate the introduction of next generation sequencing techniques for detection of
somatic mutations in AML clinical cohorts.

80

2.0 Materials and Methods

2.1 Ethical Statement
All studies were performed in accordance with the 1964 Helsinki declaration and its later
amendments and with the ethical standards of the institutional research committee. The
publications in this thesis are based on patient testing that was conducted within an
ISO15189 accredited department as part of routine clinical patient care. The studies were
retrospective in nature and consent for the testing performed was acquired by the referring
clinical consultant at the point of care. Samples for all studies were anonymised in
subsequent aggregate analysis. For case studies where identifiable information was
documented, individual consent for publication was acquired from the patient or
parent/legal guardian in a paediatric case by the physician in charge of care. Records and
pathological material were retained in accordance with Royal College of Pathology
guidelines 5th Edition. All records were kept on a secure PC under password protection
available to supervisor.

2.2 Sample selection and processing
For all studies, samples were processed in a routine molecular diagnostic facility that
adheres to international accreditation standards (ISO 15189). Samples were processed
using validated methods for DNA and RNA extraction as outlined below in section 2.3
and 2.5. Prior to arrival at the laboratory, peripheral blood samples were drawn into 6ml
purple topped BD Vacutainer® tubes containing EDTA anti-coagulant. For bone marrow
samples, 2ml of bone marrow aspirate was diluted into 12ml of Roswell Park Memorial
Institute (RPMI) 1640 Medium in a 30ml sterile universal container.
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2.3 DNA extraction from whole blood and bone marrow samples
DNA was extracted from 200µl of blood or bone marrow using the DNA Blood mini kit
(QIAGEN, Hilden, Germany), as per manufacturer instructions. Briefly, protease solution
was added to a 1.5 ml microcentrifuge tube to which 200μl of whole blood or bone
marrow sample was added, followed by RNase A solution (100 mg/ml). Samples were
homogenised by pulse-vortexing and incubated at 56°C for 10 minutes, before brief
centrifugation to remove condensation from the inside of the lid. Pure ethanol (96–100%)
(Merck KGaA, Darmstadt, Germany) was added to the samples before they were loaded
onto a QIAamp Mini spin column and centrifuged at 6000 x g for 1 minute in a Scanspeed
1524 centrifuge (LaboGene ApS, Bjarkesvej, Denmark). A series of kit buffer additions
to the column and centrifugation steps were carried out to complete the bind-wash-elute
protocol ensuring high quality DNA was eluted off the column. DNA samples were stored
at -20°C. DNA was quantified as outlined in section 2.7.

2.4 Red cell lysis
Prior to RNA extraction, removal of the red blood cells is required to enrich for leucocytes
and ensure a clean extraction eluate. Red cell lysis buffer (RCLB) was prepared by
dissolving 8.29g (155mM) Ammonium Chloride, (Sigma, Merck KGaA, Darmstadt,
Germany), 1.2g (12mM) Potassium Bicarbonate, (Sigma, Merck KGaA, Darmstadt,
Germany), and 200µl 0.5M EDTA (pH 7.4) (0.1mM) (Sigma, Merck KGaA, Darmstadt,
Germany) in 1 litre of sterile water. Samples were processed at a ratio of 1:10 blood (5ml)
or bone marrow (15ml): RCLB, were mixed well and the mixture was incubated at room
temperature for 10 minutes, before centrifugation at 1500 rpm (500g) for 10 minutes at
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room temperature in a Centra GP8 centrifuge (Thermo Scientific, Waltham, USA). The
supernatant was decanted, leaving a pellet of nucleated cells. A volume of 40ml of RCLB
was added to the pellet and resuspended before repeated centrifugation at 1500 rpm
(500g) for 10 minutes to ensure removal of red cell debris. The nucleated cells were
resuspended and washed in a total volume of 30ml phosphate buffered saline (PBS)
(Merck KgaA, Darmstadt, Germany) and centrifuged at 1500 rpm (500g) for 10 minutes.
The supernatant was decanted and remaining PBS was removed by gently inverting the
tubes onto blotting paper to draw off residual liquid. The pellet was fully resuspended by
repeated aspiration in 600µl RLT buffer (Qiagen, Hilden, Germany). The homogenised
samples were transferred to 1.5ml Sarstedt screw cap tubes for storage at -20°C.

2.5 RNA extraction from leucocytes
RNA was extracted from leucocyte lysates prepared during the Red Cell Lysis protocol
described above (Section 2.4), using the QIAGEN QIAamp RNA blood mini kit
(QIAGEN, Hilden, Germany). Briefly, 600µl lysate was spun through a QIAshredder spin
column (QIAGEN, Hilden, Germany) in a 2 ml collection tube to create a homogenous
solution. Following this, 600µl of 70% Ethanol (Merck KGaA, Darmstasdt, Germany)
was mixed into the sample before it was passed through a QIAamp spin column to bind
the RNA. Genomic DNA was removed using DNase I before a wash-elute protocol was
followed and the RNA was eluted in 50µl RNase-free water. Samples were stored at 20°C until quantified and at -80°C long term.
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2.6 cDNA synthesis
First strand cDNA was generated from RNA by reverse transcription. This process used
random hexamers to prime transcription of RNA, and Superscript III (Invitrogen,
Carlsbad, USA) reverse transcriptase to convert single stranded RNA into cDNA. One
microgram (1µg) of RNA in a total volume of 10µl was used in each cDNA reaction.
RNA samples with a concentration of less than 100ng/µl were placed into an Eppendorf
Concentrator (Eppendorf, Hamburg, Germany) at 60°C for 8 minutes and re-quantified
to ensure the concentration threshold was achieved. A water negative control was
generated for each batch of cDNA produced. RNA samples were slowly thawed on ice,
before 1µg RNA was added to a 0.2ml PCR tube and made up to a total volume of 10µl
with RNAse free water. Samples were incubated at 70°C for 10 minutes to denature any
secondary structures in the RNA before being stored on ice to ensure the RNA remained
in single stranded conformation prior to the reverse transcriptase reaction. A volume of
10µl of a mastermix containing 4µl of 5X RT Buffer (Invitrogen, Carlsbad, USA), 2µl of
dNTPs (10mM) (Promega, Wisconsin, USA), 2µl of DTT (0.1M) (Invitrogen, Carlsbad,
USA), 0.33µl of Random primers (3µg/µl) (Invitrogen, Carlsbad, USA), 0.5µl of
RnaseOut Ribonuclease inhibitor (40U/µl) (Invitrogen, Carlsbad, USA), 1µl of
SuperScript III Reverse transcriptase (200U/µl) (Invitrogen, Carlsbad, USA) and 0.67µl
nuclease free water was added to each RNA sample. Samples were vortexed and spun
down briefly to produce a homogenous 20µl cDNA reaction and placed into a Veriti
thermal cycler (Thermo Scientific, Waltham, USA) at 25°C for 10mins, followed by 42°C
for 45mins and 99°C for 3 minutes. Samples were placed on ice for 5 minutes, spun down
using a microfuge to remove condensation and stored at -20°C until required for use.
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2.7 Determination of DNA/RNA purity and concentration
To determine the concentration and purity of DNA/RNA extracted from peripheral blood
or bone marrow aspirates, a NanoDrop ND-1000 (Thermo Scientific, Waltham, USA)
spectrophotometer was used. This technology applies a surface tension for sample
retention and requires 2µl of sample applied directly. After the instrument was blanked
using nuclease free water/relevant elution buffer, 2µl of sample was applied to the
nanodrop and measured for absorbance at 260/280nm for nucleic acid purity and
260/230nm for sample contaminants. Samples were deemed sufficient for downstream
applications if the DNA absorbance ratio was ~1.8 and RNA absorbance was ~2.0 at
260/280 and ratios at 260/230 were greater than 2.0.

2.8 Primer sequences
All primers were ordered online from Eurofins Genomics® Ebersberg, Germany. On
receipt of lyophilised primers, 100 pmol/µl stocks were prepared by adding nuclease free
water as indicated on the synthesis report. The tubes were vortexed briefly and allowed
rest at room temperature for 30 minutes to ensure full dilution before storage at -20°C
until required. Primer sequences used for the study are provided in Table 2.1 below.
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Table 2.1 Primer sets used for target amplification
Forward Primer
name

Forward Primer 5’-3’

JAK2 V617F qualitative:
(Janus Kinase 2)

JAK2-F

AGCATTTGGTTTTAAATTATGGAGTATATT

JAK2 qPCR:

JAK2-Forward

Gene Name

Reverse Primer
name

Reverse Primer 5’-3’

JAK2-R

CTGAATAGTCCTACAGTGTTTTCAGTTTCA

JAK2-IC

ATCTATAGTCATGCTGAAAGTAGGAGAAAG

JAK2-Wild type

GTAGTTTTACTTACTCTCGTCTCCACATAC

JAK2-Mutated

GTAGTTTTACTTACTCTCGTCTCCACATAA

JAK2 probe

Chapter 3/4:

CTTTCTTTGAAGCAGCAAGTATGA

CALR
(calreticulin)
SETBP1
(SET binding protein 1)
SETBP1

CALR-ex-9-F

FAM-GGCAAGGCCCTGAGGTGT

CALR-ex9-R

Fam-TGAGCAAGCTTTCTCACAAGCATTTGGTTTTamra
GGCCTCAGTCCAGCCCTG

SETBP1_E_F

CAACACAGACAGTCTTACTGTGATC

SETBP1_E_R

TTGGTTGGAAGAGCACTGATG

SETBP1_F_F

CCACTTTCAACACAGTTAGGTG

SETBP1_F_R

TCTCGTGGTAGAAGGTGTAACTC

CSF3R
(Colony Stimulating Factor 3
Receptor)

CSF3R exon 14_F

GTAAAACGACGGCCAGTCCACGGAGGCAGCTTTA
C
GTAAAACGACGGCCAGTAGTGGCCCAAAGACACA
GTC

CSF3R exon 14_R

CAGGAAACAGCTATGACCAAATCAGCATCCTTTGG
GTG
CAGGAAACAGCTATGACCGGGAGTCCCATAACAG
CTCA

CSF3R Exon 17_F

CSF3R Exon 17_R

Chapter 5:
FLT3-ITD:
(fms-like tyrosine kinase 3)

11F

GCAATTTAGGTATGAAAGCCAGC

12R

CTTTCAGCATTTTGACGGCAACC

NPM1:
(nucleophosmin)
CDC25C
(Cell Division Cycle 25C)

NPM-F-FAM

FAM-GATGTCTATGAAGTGTTGTGGTTCC

NPM-R

GGACAGCCAGATATCAACTG

CDC25-F

TGCAGACACACTTGGAGGAG

CDC25-R

CCTTCCTGAGCTTTCCTTGG

86

2.9 PCR conditions
2.9.1 Standard PCR conditions
The following reaction conditions were used to generate PCR products for primer pairs unless
otherwise indicated. Total volume (25µl) PCR reactions were prepared in a 0.2ml PCR tube
(Table 2.2). Template cDNA (2.5µl) was added to each tube and mixed to generate a
homogenous solution. A water negative sample was included as a negative control. PCR
mixtures were inserted into a Veriti PCR machine under the following cycling conditions: 95°C
for 11 minutes hot start to activate enzyme, followed by 35 cycles of 95°C for 30 seconds
denature, 65°C for 30 seconds annealing, and 72°C for 60 seconds extension, with a final
extension at 72°C for 7 minutes, before being held at 4°C.

Table 2.2 Standard PCR reaction reagent preparation.
Reagent

Volume (l)

Forward Primer (10μM)

1

Reverse Primer (10μM)

1

dNTPs (10mM) (Promega, Wisconsin, USA)

0.5

10X AmpliTaq Buffer Gold (Thermo Scientific, Waltham, USA)

2.5

Magnesium Chloride (25mM) (Thermo Scientific, Waltham,

3

USA),
AmpliTaq Gold (5U/µl) (Thermo Scientific, Waltham, USA)

0.1

Nuclease Free Water

14.4

87

2.9.2 JAK2 V617F PCR
This assay was an allele-specific PCR that employs a common internal control reverse primer,
a mutation specific forward primer and a wild type forward primer to detect JAK2 V617F
mutations. The method is based on that published by Baxter et al., 2005 with modification
(Baxter et al., 2005). The method results in the amplification of a 203 base pair mutant product,
if present, and a 364 base pair band from wild type alleles that serve as an internal PCR control.
The assay is qualitative, with PCR products visualised by gel electrophoresis outlined in section
2.9.8. A homogenous mastermix was prepared for n+1 samples to produce a final volume of
11.2µl (Table 2.3). The mastermix (11.2µl) was added to 0.2ml PCR tubes, followed by 50ng
DNA and nuclease free water to a final volume of 25µl. The samples were vortexed and briefly
spun down before being placed into a Veriti PCR cycler. Cycling conditions were 95°C for 10
minutes, followed by 35 cycles of 94°C for 30 seconds, 58°C for 30 seconds, 72°C for 30
seconds, and a final extension of 72°C for 6 minutes. PCR products were electrophoresed on a
2% agarose gel at 100V for 45 minutes and photographed under a UV transilluminator as
outlined in section 2.9.8.
Table 2.3 JAK2 V617F mastermix
Reagent

Volume (l)

Forward primer (JAK-F) (10pmol/µl)

1.25

Internal control forward primer (JAK-IC) (10pmol/µl)

1.25

Reverse primer (JAK-R) (10pmol/µl)

2.5

dNTPs (1mM)

2

10X AmpliTaq Buffer Gold

2.5

Magnesium Chloride (25mM)

2.5

AmpliTaq Gold (5U/µl)

0.2
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2.9.3 JAK2 V617F semi-nested PCR
A homogenous mastermix was prepared for n+1 samples as outlined in Table 2.3. Cycling
conditions were as described above in Section 2.9.1. A volume of 1µl of the PCR product was
subsequently used as the template in a second, nested PCR reaction (Table 2.4) to produce a
final volume of 11.2µl. The mastermix was added to 0.2ml PCR tubes, 1µl template and
nuclease free water to a final volume of 25µl. Cycling conditions were as described above in
section 2.9.1. PCR products were electrophoresed on a 2% agarose gel at 100V for 45 minutes
and photographed under a UV transilluminator as outlined in section 2.9.8.

Table 2.4 JAK2 V617F semi-nested mastermix
Reagent

Volume (l)

Forward primer (JAK2-F) (10pmol/µl)

2.5

Reverse primer (JAK-R) (10pmol/µl)

2.5

dNTPs (1mM)

2

10X AmpliTaq Buffer Gold

2.5

Magnesium Chloride (25mM)

2.5

AmpliTaq Gold (5U/µl)

0.2

2.9.4 FLT3-ITD PCR
FLT3 internal tandem duplications (ITDs) are in-frame duplications within the juxtamembrane
domain of the protein, resulting in constitutive tyrosine kinase activity. The duplicated
sequence of the mutant FLT3 varies in length and involves exon 11, 12 or the intervening
intron. This protocol is derived from the method established by Kottaridis et al. with
modification and amplifies a 328bp wild type fragment which acts as an internal control and a
second longer fragment that contains the ITD if present (Kottaridis et al., 2001). Reactions
(20µl ) were prepared using 50ng template DNA and nuclease free water to a final volume of
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20µl (Table 2.5). Three control reactions, a FLT3-ITD positive sample (MV4-11 cell line
DNA), a FLT3-ITD wild type sample (HL-60 cell line DNA) and a water blank were included
in every run. Samples were placed into a Veriti thermal cycler and run under the following
cycling conditions: 95°C for 10 minutes denature, followed by 35 cycles of 94°C for 30
seconds, 65°C for 60 seconds, 72°C for 60 seconds, followed by a final extension of 72°C for
5 minutes. PCR products were electrophoresed on a 3% agarose gel at 100V for 90 minutes
and photographed under a UV transilluminator as outlined in section 2.9.8

Table 2.5 FLT3-ITD mastermix.
Reagent

Volume (l)

Forward primer (0.5pmoles/µl)

1

Reverse primer (0.5 pmoles/µl)

1

dNTPs (1mM)

4

10X AmpliTaq Gold Buffer

2

MgCl2 (25mM)

3.2

AmpliTaq Gold polymerase (5U/ml)

0.25

2.9.5 NPM1 exon 12 mutation PCR
Mutations in Nucleophosmin (NPM1) on chromosome 5q35 have been identified in normal
karyotype AML, of which 90-95% result in a heterozygous tetranucleotide insertion thought
likely to contribute to leukaemogenesis. Genomic DNA from patient samples is amplified with
a hi-fidelity DNA polymerase using a 6-FAM labelled forward primer located within the intron
between NPM1 exons 11 and 12, and a reverse primer that results in amplification of a fragment
containing the coding region of NPM1 exon 12. Wild type NPM1 allele is used as an internal
control for DNA extraction and amplification. Amplified product produces a 168-170 bp wild
type fragment and in mutated cases an additional 172 bp or 175 bp fragment (the latter in very
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rare cases of a net 5 bp insertion). Reactions to a final volume of 20l were prepared with 10ng
template DNA and nuclease free water to 20µl (Table 2.6). Samples were placed into a Veriti
thermal cycler under the following conditions: 94°C for 2 minutes, followed 35 cycles of 94°C
for 29 seconds, 60°C for 20 seconds, 72°C for 20 seconds, and a final extension of 72°C for 2
minutes. An NPM1 mutation positive control, negative control and a water template blank were
included in each run. Following amplification, NPM1 PCR products were visualised by
capillary electrophoresis (see section 2.10.1).
Table 2.6 NPM1 exon 12 mastermix
Reagent

Volume (l)

Forward primer (4pmol/µl)

1

Reverse primer (4pmol/µl)

1

dNTPs (1mmol/L)

4

10X Cloned Pfu DNA polymerase Reaction Buffer (Agilent, Santa

2

Clara, USA)
MgCl2 (25mmol/L)

1.6

Pfu Turbo Hotstart DNA polymerase (Agilent, Santa Clara, USA)

0.5

2.9.6 CALR exon 9 mutation PCR
Insertion and/or deletion mutations within exon 9 of the CALR gene result in a frame-shift
mutation producing a protein product with an altered C-terminal. For detection, genomic DNA
from patient peripheral blood or bone marrow is amplified using a 6-FAM labelled forward
primer and reverse primer spanning CALR exon 9. The wild type CALR allele is used as an
internal control for DNA extraction and amplification and produces a 262 bp wild type
fragment. Over 80% of mutated CALR indels are of type 1 (52 bp deletion) or type 2 (5 bp
insertion), however more than 40 types have been identified to date. This assay is based on that
of Klampfl et al., 2013 with modification. Reactions to a total volume of 20µl were prepared
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with 50ng template DNA and nuclease free water to 25µl in 0.2ml PCR tubes (Table 2.7).
Samples were placed into a Veriti thermal cycler under the following conditions: 95°C for 10
minutes denature, followed by 11 cycles (with a decreasing annealing temperature of 1°C) of
94°C for 15 seconds, 65°C-55°C annealing for 15 seconds, 72°C for 30 seconds extension, 21
cycles of 89°C for 15 seconds, 55°C for 15 seconds, 72°C for 30 seconds, followed by 72°C
for 20 minutes final extension. PCR products were visualised by capillary electrophoresis (see
section 2.10.2).
Table 2.7. CALR exon 9 mastermix
Reagent

Volume (l)

Forward primer (10pmol/µl)

1.25

Reverse primer (10pmol/µl)

1.25

dNTPs (1mmol/L)

2

10X GeneAmp Gold PCR Buffer (Thermo Scientific, Waltham,

2.5

USA)
MgCl2 (25mmol/L)

1.5

Amplitaq Gold polymerase (5U/µl)

0.2

2.9.7 Donor Chimerism STR-PCR
Short tandem repeat (STR) loci exhibit alleles that may differ in length between individuals.
STR loci have been identified throughout the human genome and consist of a core DNA
sequence, usually 2-8 bases long that is repeated a variable number of times within a discrete
genetic locus. Amplification of a selected number of these highly variable regions allows for
discrimination between closely related individuals and can be applied to screen donor/recipient
pairs prior to stem cell transplantation to identify informative STRs for use in monitoring
patient engraftment in the post-transplantation scenario. To monitor donor chimerism, the
Promega PowerPlex16 kit (Promega, Wisconsin, USA) was used as per manufacturer’s
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instructions. This kit amplifies 15 STR distributed across the genome, namely Penta E,
D18S51, D21S11, TH01, D3S1358, FGA, TPOX, D8S1179, vWA, Penta D, CSF1PO,
D16S539, D7S820, D13S317, D5S818 plus Amelogenin, a gene located on the sex
chromosomes that differs in intronic sequence on the X chromosome relative to the Y
chromosome and allows for sex discrimination in the majority of cases. Briefly, 10µl reactions
were prepared as laid out in Table 2.8. One positive and one negative amplification control was
included in each run. Samples were placed on a Veriti thermal cycler under the following
cycling conditions; 95°C for 11 minutes, 96°C for 1 minute, 10 cycles of 94°C for 30 seconds,
ramp to 68°C over 68 seconds, hold for 30 seconds, ramp to 70°C over 50 seconds, hold for 45
seconds. 21 cycles of 90°C for 30 seconds, ramp to 60°C over 60 seconds, hold for 30 seconds,
ramp to 70°C over 50 seconds, hold for 45 seconds. 60°C for 30 minutes final extension, hold
at 4°C. PCR products were visualised by capillary electrophoresis (see section 2.10.3).
Table 2.8 Powerplex16 PCR mastermix.
Reagent

Volume (l)

Gold Star 10xBuffer

1

PP16 10X Primer Pairs,

1

AmpliTaq Gold DNA polymerase

0.32

Nuclease-free H2O

6.68

DNA template (2ng/µl)

1
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2.9.8 Gel Electrophoresis and visualisation of PCR products
To visualise PCR products, 5µl of 6X Orange G, (Thermo Scientific, Waltham, USA) was
added into each 25µl PCR reaction tube and samples were added to wells on a 2% agarose
(Conda, Madrid, Spain) gel containing 5µl of SYBR Safe DNA Gel Stain/50 ml gel (Thermo
Scientific, Waltham, USA). Samples were electrophoresed in 1X Ultrapure TAE Buffer,
(Thermo Scientific, Waltham, USA) with 10µl of 100bp DNA ladder (Thermo Scientific,
Waltham, USA) loaded at either end of the gel (first and last well) for 40 minutes at 100Volts
and 500mA. The gel tray was removed and placed into the SynGene GeneGenius UV
transilluminator (SynGene, Cambridge, UK), and a photo was taken of the image under ultraviolet light illumination.
2.10 Capillary electrophoresis of PCR products
During capillary electrophoresis, the products of a PCR containing fluorescent labelled primers
are injected electrokinetically into capillaries filled with polymer. High voltage is applied so
that the fluorescent DNA fragments are separated by size and are detected by a laser/camera
system. The intensity of each fragment determines the relative fluorescence unit value (RFU)
and is shown as a peak height in the electropherogram (Figure 2.1).

Figure 2.1 Electropherogram of DNA fragments. Different coloured peaks correspond to
different fluorophores attached to the DNA fragments during previous PCR cycling.
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2.10.1 NPM1 PCR product capillary electrophoresis
A volume of 1µl of a 1:20 dilution of each PCR product was added to a 96 well PCR plate
containing 9µl HiDi formamide and 1µl GeneScan 400HD ROX Size Standard (Thermo
Scientific, Waltham, USA). Samples were denatured at 95°C for 3 minutes and placed on ice
for 5 minutes before being briefly spun down and loaded into a 3130XL Genetic analyser for
electrophoresis using POP-7 polymer and an injection setting of 2kV for 5 seconds.
Electropherograms were analysed using GeneMapper Version 4.0 Software (Applied
Biosystems, Foster City, CA, USA).
2.10.2 CALR capillary electrophoresis
A volume of 1µl of a 1:25 dilution of each PCR product was added to a 96 well PCR plate
containing 9µl HiDi formamide and 1µl GeneScan 400HD ROX Size Standard. Samples were
denatured at 95°C for 3 minutes and placed on ice for 5 minutes before being briefly spun down
and loaded into a 3130XL Genetic analyser for electrophoresis using POP-7 polymer and an
injection setting of 3kV for 23 seconds. Electropherograms were analysed using GeneMapper
Version 4.0 Software (Applied Biosystems, Foster City, CA, USA).
2.10.3 Donor chimerism capillary electrophoresis
A volume of 1µl of STR-PCR product was dissolved into 9µl of HiDi Formamide (Thermo
Scientific, Waltham, USA) containing 1µl internal lane standard ILS-600 (Promega,
Wisconsin, USA) denatured at 95°C for 5 minutes and held on ice for 5 minutes before being
electrophoresed on a 3130xl Genetic Analyzer 3130xl (Thermo Scientific, Waltham, USA) at
2kVolts for 5 seconds injection time. Electropherograms were analysed using GeneMapper
Version 4.0 Software (Applied Biosystems, Foster City, USA). Peak height analysis was used
to quantify the percentage donor chimerism (donor/donor + recipient)*100.
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2.11 JAK2 V617F qPCR
This assay was performed as defined by Larsen et al. with modification (Larsen et al., 2007).
The assay is composed of two allele-specific PCR reactions; one for the JAK2 V617F mutated
allele and one for the wild type allele. The reverse primers are mutation or wild type-specific
and primers differ only by the 3’ nucleotide. The mutation and wild type reactions use the same
forward primer and the same FAM-TAMRA probe. Reactions containing 25µl were prepared
with mastermix (Table 2.9) and 10µl of DNA at a concentration of 20 ng/µl added to make up
the final volume
Table 2.9 JAK2 qPCR Mastermix
Reagent

Volume (l)

10x concentrate of primer/probe mix

2.5

(300 nmol/l of primers, 200 nmol/l of probe)
2x TaqMan Universal PCR Master Mix (with UNG)

12.5

Cycling conditions were 2 minutes at 50°C (uracil-N-glycosylase (UNG) treatment), 10
minutes at 95°C to activate the Taq polymerase, followed by 50 cycles of 15 seconds at 95°C
for denaturation, and 60 seconds at 60°C for annealing and extension. PCR reactions for mutant
JAK2 V617F were performed in triplicate and for wild type JAK2 in duplicate on an Applied
Biosystems 7500 Real Time PCR System (Thermo Scientific, Waltham, USA) using standard
or 9600 emulation mode and a ramp rate -1.6°C/sec. Commercial plasmids were used in
duplicate for construction of both JAK2 V617F mutant and wild type standard qPCR four-point
standard curves (50, 500, 5000, 50,000 copies) (Ipsogen SA/QIAGEN, Marseille, France). All
assays included a wild type control, a JAK2 V617F positive control, and a water negative
control. An automatic baseline (3–15 cycles) and a fixed threshold of 0.1 (ΔRn) was selected
to ensure consistency of analysis. Copy number for both mutant and wild type JAK2 was
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calculated using the slope and Y-intercept from the standard curve, where copy number
=POWER(10;Y-intercept-Sample Ct)/slope. Results were expressed as a percentage of JAK2
V617F alleles of the total of JAK2 alleles. i.e. mutant copy number/(wild type copy number +
mutant copy number)*100. As the reverse primers used in both assays differed by only one
base at the 3′ end, non-specific amplification was observed in the JAK2 V617F assay when
performed on the target negative control sample, see Figure 2.2. The specificity and sensitivity
for each run was therefore calculated using the ΔCt value for the target negative sample
(number of cycles between wild type and V617F Ct values) where the specificity corresponds
to 2ΔCt (i.e. 2 to the power of the number of cycles between the two thresholds. For example if
the delta Ct was 14, specificity = 214 or >1:10000). The sensitivity was set at 10-fold less than
the value for specificity to ensure the identification of true positive measurements.

Non-specific
amplification

Figure 2.2. Non-specific amplification of JAK2 V617F observed in a wild type sample
generated by the JAK2 V617F primer set (Table 2.1).
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2.12 Sanger Sequencing process
This technique consists of target DNA being copied by DNA polymerase in the presence of
dNTPs that include fluorescently labelled dideoxy nucleotides (ddNTPs) present at a lower
ratio (~1:100). Incorporation of a ddNTPs during synthesis causes the strand to end as no
further dNTPs can be added. This process is repeated for multiple cycles, resulting in the
incorporation of ddNTPs at every position of the target DNA and production of fragments
varying in length by one base pair. As each ddNTP (ddATP, ddCTP, ddTTP, ddGTP) is
labelled with a fluorophore that emits light at a separate wavelength, capillary electrophoresis
on a genetic analyser generates a chromatogram that allows the sequence to be read base by
base and aligned to generate a contiguous sequence. To produce a clean chromatogram for
analysis, the relevant target region must be PCR amplified, purified, undergo a sequencing
reaction and be purified again before capillary electrophoresis. Target regions for sequencing
were PCR amplified using the relevant set of primers and standard PCR cycling conditions as
described in Section 2.9.

2.12.1 PCR product clean up
PCR products were cleaned using the QIAquick PCR purification kit (QIAGEN, Hilden,
Germany) as per manufacturer instructions. Briefly, Buffer PB and the PCR product were
mixed together and transferred to a QIAquick spin column for centrifugation at 13,000rpm for
1 minute. Buffer PE was added to the column and another centrifugation step was carried out.
PE Buffer was used to elute the purified PCR product.
2.12.2 PCR product sequencing
Each cleaned PCR product was sequenced using the BigDye™ Terminator v3.1 Cycle
Sequencing Kit (Thermo Scientific, Waltham, USA) with the relevant forward and reverse
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primer separately, leading to the generation of two sequencing products per sample as outlined
in Table 2.10 below.
Table 2.10 Sanger Sequencing Mix
Reagent

Volume (l)

5X sequencing buffer

4

Sequencing ready reaction mix RR-100

2

primer (2pmol/µl),

1.6

nuclease free water

2.4

DNA Template

10

A separate positive sequencing control from the kit was made up with 4µl of 5X sequencing
buffer, 2µl sequencing ready reaction mix RR-100, 12µl primer (M13), 1µl template (pGEM
plasmid) and 11µl nuclease free water. Tubes were transferred to a Veriti thermal cycler and
run under the following cycling conditions: 96°C for 1 min, followed by 25 cycles of 96°C for
10 seconds, 50°C for 5 seconds, 60°C for 4 minutes, followed by holding at 4°C. Sequencing
products were cleaned by removing unincorporated fluorescently labelled nucleotides using a
DyeEx 2.0 spin kit (QIAGEN, Hilden, Germany) as per manufacturer’s instructions, The
purified sequencing products were placed into an Eppendorf concentrator at 30°C for 30
minutes or until dry. Samples were resuspended in 10µl HiDi formamide, transferred to a 96
well plate and denatured at 95°C for 3 minutes before being placed on ice. The plate was
centrifuged briefly to remove condensation before being placed onto a 3130XL genetic
analyser and run using POP-7 polymer matrix (Thermo Scientific, Waltham, USA) for
separation. Sample files were analysed using SeqMan Pro (DNASTAR®, Madison, USA)
software by alignment against a reference sequence (RefSeq) imported from NCBI nucleotide.
Mutations detected were analysed using the Megalign (DNASTAR®, Madison, USA) software
for any potential alterations in the amino acid sequence.
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2.13 Next Generation Sequencing with AML targeted panel
The adoption of targeted gene panels comprising a refined set of disease relevant genes has
shown promise for translation of NGS into clinical practice (Kohlmann et al., 2013; McCourt
et al., 2013; Ivanova et al., 2015). To evaluate the utility of a newly available commercial
AML 19 gene panel, DNA from six pre-characterised AML patients with NPM1 and FLT3ITD mutation status previously assessed were used for quality control (QC#1-6), distributed to
each participating centre and processed using standardised workflows for the Ion Ampliseq
AML Panel (Life Technologies, Paisley, UK) before sequencing on an Ion Torrent
Personalized Genome Machine (PGM), (Life Technologies, Paisley, UK). A designated sample
(QC#3, QC#5, and QC#6) was repeated in duplicate on separate runs in centres 1, 3 and 2
respectively to assess inter- and intra-centre reproducibility. In addition, Acrometrix controls
(Life Technologies, Paisley, UK) a highly multiplexed quality control used to assess the
performance of NGS assays was employed in one centre to determine variant detection at
known low variant allelic frequencies.
2.13.1 Library preparation
The Ion AmpliSeq Library Kit 2.0 (Life Technologies, Paisley, UK) was used as per
manufacturer’s instructions, to prepare libraries using the Ion AmpliSeq AML Community
Panel primers which were split into 4 separate pools. Pools 1 and 2 contained approximately
120 primer pairs each and pools 3 and 4 contained 12 and 15 pairs respectively. Six/seven
samples were prepared per run. The AML Panel amplicon libraries generated 237 amplicons
covering 19 commonly mutated genes implicated in AML (Table 2.11). The entire coding
region of DNMT3A, CEBPA, GATA2, TET2 and TP53 and mutational hotspots of the others
including NPM1 and FLT-3 were amplified.
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Table 2.11. Overview of AML panel 19 gene targets, protein function, gene coverage and
number of amplicons generated for each gene.
Gene
Symbol

Gene Name

Protein Function

KIT

IDH2
WT1
NPM1

KIT Proto-Oncogene
Receptor Tyrosine Kinase
Neuroblastoma RAS Viral
Oncogene Homolog
Kirsten Rat Sarcoma Viral
Oncogene Homolog
GATA Binding Protein 2
Fms-Related Tyrosine
Kinase 3
B-Raf Proto-Oncogene,
Serine/Threonine Kinase
ASXL Transcriptional
Regulator 1
Janus Kinase 2
Isocitrate Dehydrogenase 1
Cbl Proto-Oncogene, E3
Ubiquitin Protein Ligase
Protein Tyrosine
Phosphatase, NonReceptor Type 11
Runt Related Transcription
Factor 1
Tet Methylcytosine
Dioxygenase 2
CCAAT Enhancer Binding
Protein Alpha
DNA (Cytosine-5-)Methyltransferase 3 Alpha
Isocitrate Dehydrogenase 2
Wilms Tumor 1
Nucleophosmin 1

TP53

Tumor Protein P53

NRAS
KRAS
GATA2
FLT3
BRAF
ASXL1
JAK2
IDH1
CBL
PTPN11

RUNX1
TET2
CEBPA
DNMT3A

Amplicons

Activated signalling

Panel
Target
(basepair)
632

Activated signalling

370

3

Activated signalling

370

4

Transcription factor
Activated signalling

1,643
66

20
3

Activated signalling

11

1

Chromatin
modification
Activated signalling
DNA Methylation
Ubiquitination

2,947

28

128
332
416

1
3
5

Activated signalling

427

5

Transcription factor

1,149

15

DNA Methylation

6,369

59

Transcription factor

1,117

9

DNA Methylation

3,619

42

DNA Methylation
Tumour suppressor
Protein Chaperone,
Cell proliferation
Tumour Suppressor

201
324
79

2
4
1

1,773

24

8

2.13.2 Amplify target sequences
To prepare libraries, a 10µl reaction containing 2µl 5X Ampliseq HiFi Mi,x 5µl 2x Ion
Ampliseq Primer pool, 10ng gDNA and nuclease free water to a final volume of 10µl was
created for each of the four primer pools. Pools 1 and 2 were placed into a Veriti thermal cycler
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at 99°C for 2 minutes followed by 18 cycles of 99°C for 20 seconds denature and annealing at
60°C for 4 minutes. Samples were then held at 10°C until required. Pools 3 and 4 were placed
into a Veriti thermal cycler at 99°C for 2 minutes followed by 21 cycles of 99°C for 20 seconds
denature, 62°C for 4 minutes annealing. Samples were then held at 10°C until required. The
four pools were then reduced to two on a 96 well plate by combining 3.7µl of pool 1, 10µl of
pool 3 and 6.3µl nuclease free water to produce one new pool and 3.7µl of pool 2, 10µl of pool
4 and 6.3µl nuclease free water to produce a second new pool.
2.13.3 Partially digest amplicons
To each primer pool 2µl of FuPa reagent (ThermoFisher) was added to partially digest the
primers and phosphorylate the amplicon, the sample was vortexed to mix and centrifuged to
collect droplets. Samples were placed into the Veriti thermal cycler for 50°C for 10 minutes,
55°C for 10 minutes, and 60°C for 20 minutes, 10°C hold.
2.13.4 Ligate adapters
Ion Xpress barcoded adapters were selected and prepared by diluting 1:4 individually by
combining 2µl Ion P1 Adapter, 2µl Ion Xpress Barcode (X- barcode of choice) and 4µl
nuclease free water. To the partially digested samples 4µl Switch solution, 2µl diluted Ion
Xpress barcode adapters and 2µl DNA Ligase were added sequentially. The samples were
vortexed, centrifuged and placed into a thermal cycler at 22°C for 30 minutes, 68°C for 5
minutes and 72°C for 5 minutes before holding at 10°C.
2.13.5 Library Purification
To each library preparation 45µl (1.5X) Agencourt™ AMPure™ XP reagent (Thermo
Scientific, Waltham, USA) was added, the suspension was mixed by pipetting and incubated
at room temperature for 5 minutes before being placed into a DynaMag™ -96 Side Magnet
(Thermo Scientific, Waltham, USA) and incubated for 2 minutes until the solution cleared. The
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supernatant was discarded without disturbing the bead pellet. The pellet was washed twice by
adding 150µl of 70% Ethanol and mixing the beads through the liquid by moving the plate
from side to side in the magnet, aspirating and repeating. Residual ethanol was removed by
pipetting and the beads were allowed air dry on the plate for 5 minutes whilst held in the
magnet.
2.13.6 Quantification of library by qPCR
Purified libraries were resuspended in 50µl Low TE (Promega, Wisconsin, USA), vortexed,
briefly centrifuged and incubated at room temperature for 2 minutes before being placed back
into the magnet. A volume of 2µl of supernatant was combined with 198µl nuclease free water
(1:100 dilution). Three 10-fold serial dilutions of E.Coli DH10B Ion Control Library
(68pMol/L) at 6.8pM, 0.68pM and 0.068pM were prepared as standards. Reaction mixtures for
each sample were prepared by combining 20µl of 2X TaqMan MasterMix and 2µl of 20X Ion
TaqMan Assay and mixing thoroughly. Aliquots (11µl) were dispensed into the wells of a 96
well PCR plate. A volume of 9µl of diluted library, control or samples were added (as
duplicates) to a final volume of 20µl. The qPCR plate was run on an Applied Biosystems 9700
PCR System with ROX™ Reference Dye as the passive reference. FAM™ was selected as the
TaqMan probe reporter and the standard concentrations were entered. Cycling was in standard
mode at 50°C for 2 minutes, 95°C for 2 minutes, followed by 40 cycles of 95°C for 15 seconds
and 60°C for 1 minute. Concentrations were calculated from the standard curve produced and
a dilution to 100pM for each library was determined. Diluted libraries were then combined by
adding 10µl of the six sample libraries to a single tube.
2.13.7 Library template amplification
Libraries were amplified using the Ion OneTouch 2 System (Thermo Scientific, Waltham,
USA) and the Ion PGM™ Template OT2 200 Reagent Mix which enables automated delivery
of templated Ion Sphere™ particles by creating millions of microreactors in which clonal
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amplification occurs and recovering the templated Ion Sphere™ particles (Thermo Scientific,
Waltham, USA) therefore allowing massively parallel clonal amplification and recovery. To a
1.5ml Eppendorf Lo-Bind™ tube (Eppendorf, Hamburg, Germany) at room temperature, 25µl
of nuclease free water, 500µl Ion PGM™ Template OT2 200 Reagent Mix, 300µl Ion PGM™
Template OT2 200 PCR reagent B, 50µl Ion PGM™ Template OT2 200 Enzyme Mix, 25µl
diluted library were added to a final volume of 900µl. The solution was vortexed and briefly
centrifuged and 100µl of Ion PGM™ Template OT2 200 Ion Sphere™ Particles were added.
The solution was vortexed for 5 seconds at full speed and 1000µl was added to the Ion PGM™
OneTouch reaction filter followed by 1500µl of Ion OneTouch™ Reaction Oil, inverted and
installed onto the Ion OneTouch™ 2 Instrument and run. When the run was completed,
template positive ISPs were recovered by centrifugation in Recovery Solution into two
Recovery tubes per sample. All but 50µl of solution was decanted off and the ISPs were
resuspended in the remaining solution. The sample (template-positive ISPs) was transferred
into the first well of an eight well strip (100µl total volume) and the other subsequent wells
were filled with 130 µL of Dynabeads™ MyOne™ Streptavidin C1 Beads resuspended in
MyOne™ Beads Wash (Thermo Scientific, Waltham, USA), three wells of 300 µL of Ion
OneTouch™ Wash Solution (Thermo Scientific, Waltham, USA), an empty well (no.6), 300µl
Melt-Off Solution (280µl Tween™ Solution (BioRad, Hercules, USA) plus 40µl 1M NaOH
(Merck KGaA, Darmstadt, Germany) and a final empty well. The strip was loaded on the Ion
OneTouch™ ES (Thermo Scientific, Waltham, USA) and initialised. Immediately after the run
the enriched ISPs are eluted into a 0.2ml PCR tube containing 10µl Neutralisation Solution.
The sample library was mixed by gentle inversion and sequenced on an Ion Torrent PGM using
the Ion PGM™ Sequencing 200 Kit v2 (Life Technologies, Paisley, UK) according to
manufacturer’s instruction.
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2.13.8 Library sequencing
Before sequencing the sample library, the Ion PGM™ system was cleaned with chlorite/water
and initialised according to the manufacturer’s instruction. For sequencing, 5µl of Control Ion
Sphere™ Particles were added to the enriched template-positive ISPs. The contents were mixed
and centrifuged for 2 minutes at 15,000g. The supernatant was removed without disturbing the
pellet with 15µl left in reserve. Sequencing Primer (12µl) was added to make a final volume
of 27µl. The mixture was mixed by pipetting to disrupt the pellet and create a homogenous
solution. The tube was then placed into a thermal cycler at 95°C for 2 minutes, followed by
37°C for 2 minutes using the heated lid option. Following a Chip Check on the Ion PGM to
ensure the chips used were functioning, 3µl of Ion PGM Sequencing 200 v2 Polymerase was
added to the ISPs and mixed by pipette to make a final volume of 30µl, left to stand at room
temperature for 5 minutes before being loaded onto the chip manually by dialling down a
pipette containing the 30µl sample. The chip was spun in the Ion Chip MiniFuge (Thermo
Scientific, Waltham, USA) to distribute the sample evenly across the chip, loaded onto the Ion
PGM™ and sequenced at 500 flows under the Ion PGM™ Sequencing 200 kit v2 settings.

2.13.9 Data Processing
Data was reviewed using Torrent Suite™ software v4.2.1.0 (Life Technologies, Paisley, UK)
using a low stringency parameter configuration. Samples were uploaded to Ion Reporter™ v4.2
cloud-based software (Life Technologies, Paisley, UK) as BAM or VCF files for subsequent
variant annotation. Coverage in highly sampled locations was capped at 2000X to reduce
computational time. Calling of somatic mutations was achieved using an algorithm that
excluded synonymous mutations, variants located within intronic or un-translated regions and
variants present at a frequency of <5%. Insertions/deletions called using Ion Reporter™ were
confirmed by reviewing data with the Broad Institute’s Integrative Genomics Viewer (IGV)
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(Broad Institute, Cambridge, MA, USA). To maximise confidence in variant calling, a
minimum target depth of coverage for variant calls was set at 500X, with potential somatic
variants reviewed and screened using relevant public databases including dbSNP, ClinVar,
COSMIC, and PubMed.
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3.0 Molecular monitoring post-allogeneic
transplantation in myeloproliferative neoplasms
The aim of this chapter is to validate the utility of specific mutations to monitor
myeloproliferative neoplasm disease burden post-transplantation. Data in this chapter is the
result of work that culminated in four publications (Appendix 1/2A). My personal contribution
to each paper is outlined below and confirmed by co-authors in Appendix 3.
1: Haslam K, Molloy KM, Conneally E, Langabeer SE. Evaluation of a JAK2 V617F
quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell
transplantation for myeloproliferative neoplasms. Clin Chem Lab Med. 2014;52(3):e29-3.
Personal Contribution: Designed original concept for the study, validated assay, gathered
patient material, performed analysis and data interpretation. Primary author and wrote original
draft. Finalised and approved manuscript for publication. Corresponding author.

2: Haslam K, Langabeer SE, Molloy K, McMullin MF, Conneally E. Assessment of CALR
mutations in myelofibrosis patients, post-allogeneic stem cell transplantation. Br J Haematol.
2014;166(5):800-2.
Personal Contribution: Collaborated on original concept for the study, gathered patient
material, performed CALR mutation analysis, collated all data and interpreted results from all
analyses. Wrote first draft and revised and approved finalised version prior to publication.

3: Langabeer SE, McCarron SL, Haslam K, O'Donovan MT, Conneally E. The CSF3R T618I
mutation as a disease-specific marker of atypical CML post allo-SCT. Bone Marrow
Transplant. 2014 Jun;49(6):843-4.
Personal Contribution: Input on design of study and collation of patient samples and details.
Carried out Sanger sequencing analysis and interpretation of results. Collated results
contributed to compilation and critical review of clinical data. Reviewed final draft of paper
prior to publication.

4: Langabeer SE, Nolan J, Haslam K, Clarke L, Flavin R, Conneally E. Evading Capture by
Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary
Myelofibrosis After Allogeneic Stem Cell Transplantation. Case Rep Hematol. 2015
Personal Contribution: Carried out technical analysis (donor chimerism – via short tandem
repeat multiplex PCR analysis of donor and recipient, JAK2 qualitative PCR and JAK2 realtime quantitative PCR), collated and interpreted all resultant data. Contributed to writing,
review and approval of paper.
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3.1 Introduction
Myeloproliferative neoplasms (MPN) are clonal haematopoietic stem cell disorders and whilst
some patients have an indolent course, all are at risk of progressing to severe marrow failure
or transforming into acute leukaemia, with allogeneic stem cell transplantation (ASCT) being
the only potential curative therapy at present (Salit and Deeg, 2014). In the past, ASCT was
only considered for those patients with advanced or transformed disease, however
improvements in candidate patient selection and stratification, timing of transplantation, and
conditioning regimens have significantly reduced the transplant related morbidity and
increased the overall survival for MPN patients undergoing this procedure (McLornan et al.,
2012; Fleischman and Maziarz, 2013). However, as relapse is a major cause of treatment failure
post-ASCT, with salvage options limited and subsequent outcome relatively poor,
identification of those patients at high-risk of relapse is highly desirable, and could potentially
enable therapeutic intervention before overt relapse.
The fact that relapse occurs even if transplantation was performed in complete
remission is evidence that minimal residual disease (MRD) remains in the recipient although
not morphologically evident. The clinical relationship between post-transplant MRD and the
risk of relapse was recognised early in chronic myeloid leukaemia (CML) using cytogenetic
techniques and the BCR-ABL1 fusion gene to monitor residual disease (Sawyers et al., 1990).
MRD detection can now be applied using immunophenotyping or molecular techniques in
acute and chronic leukaemia’s, however the clinical relevance of residual disease can be
markedly different depending on the disease type. Standardised and optimised MRD
monitoring schedules in the post-transplant period has been established for CML as the BCRABL1 fusion is a defining feature (Baccarani et al., 2006; Hughes et al., 2006). For other
myeloid malignancies such as acute myeloid leukaemia (AML) and MPN, the diseases are
more heterogenous, with diverse molecular and cytogenetic aberrations and the full utility of
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molecular monitoring yet to be established. Conventionally, donor chimerism status has been
used to assess engraftment and establishment of donor stem cells in the marrow of the recipient
post-ASCT for haematological malignancies. The major benefit of this approach is that it is
disease agnostic and can be applied in all cases, however the sensitivity of 1-2% routinely
achieved can be limiting.
Post-ASCT monitoring utilising additional patient-specific markers is most likely to
provide a more beneficial, personalised profile, with early studies demonstrating the
achievement of a molecular remission in JAK2 V617F-positive MPN post-ASCT using
qualitative PCR (Steckel et al., 2007). In those reported MPL-mutation positive MPN who have
undergone ASCT, rapid clearance of the MPL W515L mutation correlated well with peripheral
blood counts and donor chimerism status (Alchalby et al., 2010a). The JAK2 V617F mutation
has been shown to disappear post-ASCT and then reappear upon relapse (Ditschkowski et al.,
2006), and can be used as a stable MRD marker to help guide therapies such as donor
lymphocyte infusion (Kroger et al., 2006; Kroger et al., 2009). Patients who cleared JAK2
mutation level in peripheral blood 6 months after ASCT were also shown to have significantly
lower risk of relapse relative to those that did not (Alchalby et al., 2010b). In JAK2 V617F
positive MPN, the development of improved detection sensitivities using JAK2 V617F-specific
qPCR methodologies capable of detecting one mutant allele in 104 wild type copies has the
potential to provide improved clinical information on the rate of disease eradication and the
identification of patients, at defined time points post-ASCT, at an increased risk of relapse.
In addition, the recent discovery of insertion and/or deletion mutations within the CALR
gene in a significant proportion of JAK2-and MPL-unmutated ET and PMF patients which are
likely initiating events in MPN pathogenesis, affords an opportunity to assess these mutations
as potential markers of residual disease in myelofibrosis patients post-ASCT also (Klampfl et
al., 2013; Nangalia et al., 2013). Likewise, the recent characterisation of mutations within the
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genes encoding the G-CSF receptor (CSF3R) and SET binding protein 1 (SETBP1) in a
significant proportion of patients with aCML and CNL suggests that these mutations could also
be used for residual disease (Maxson et al., 2013; Piazza et al., 2013) Publications presented
in this chapter aimed to further develop an understanding of the use of patient-specific markers
to monitor disease burden and response to transplantation therapy, utilising disease specific
markers in different MPN cohorts post-transplantation. These studies assessed the performance
of three separate molecular approaches to monitor disease burden; quantitating JAK2 V617F
in JAK2 positive MPN, application of a semi-quantitative PCR assay to measure CALR exon 9
mutations in CALR positive MPN and Sanger sequencing of CSF3R p.Thr618Ile (T618I)
mutation (c.15482C>T) in atypical CML.
The methods used in this chapter are outlined in detail in Chapter 2 and include nucleic
acid extraction and QC (section 2.3-2.7), JAK2 V617F PCR (section 2.9.2, 2.11), Donor
Chimerism STR-PCR (section 2.9.7, 2.10.3), CALR exon 9 mutation PCR (section 2.9.6,
2.10.2) and Sanger Sequencing (section 2.12).

3.2 Results
3.2.1 Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease postallogeneic haematopoietic stem cell transplantation for myeloproliferative neoplasms
Developments in the field of transplantation have led to the application of reduced intensity
conditioning regimen in MPN patients and have shown improvement in overall survival for an
increasing number of patients (Kroger et al., 2009b). Traditionally in haematological
malignancies, engraftment post-transplantation is monitored by donor chimerism status, which
allows for comparison of donor and recipient profiles to estimate the level of engraftment
present in the peripheral blood or bone marrow within the context of clinical and
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haematological parameters. This can be used to predict full engraftment, failure to engraft or
indeed loss of engraftment and impending relapse. Donor chimerism is usually monitored at 13 monthly intervals depending on engraftment kinetics. A corollary of this idea is to use a
disease specific marker to monitor engraftment and response to the transplantation regimen. In
the first part of Chapter three, quantification of the burden of JAK2 V617F alleles post-ASCT
as a sensitive marker of residual disease was assessed. In order to gather the patient samples
that would inform the study, an audit of MPN patients that had received transplantation therapy
and had samples available for analysis was conducted. This required mining of the patient
sample database for patients with a diagnosed MPN who had results for both donor chimerism
and a positive JAK2 V617F. The audit returned 43 cases, of which 16 had JAK2 V617F detected
at diagnosis, with thirteen (11 male, 2 female) with an age range of 18–58 years (median 50
years) having sufficient sample for analysis. MPN types were PMF (n = 6), post-PV MF (n =
2), chronic myelomonocytic leukaemia transformed to AML (n = 3), PV transformed to AML
(n = 1) and AML (n = 1) with a median follow-up of 11 months (range 3–52 months) (Table
3.1).
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Table 3.1. Characteristics of JAK2 V617F positive MPN patients who received a transplant.
Patient Gender

Age @ ASCT

MPN

Donor type

ASCT

(years)

Follow up

Response to ASCT

(months)

1.

F

49

PV>MF

Related

RIC

4

Failure to engraft

2.

M

18

PMF

Related

My

52

Full engraftment

3.

M

54

PMF

Related

RIC

19

Full engraftment

4.

M

53

CMML>AML

Related

RIC

11

Failure to engraft

5.

M

52

PV>MF

Related

RIC

7

Full engraftment

6.

M

55

PMF

Related

RIC

38

Full engraftment

7.

M

45

PMF

Unrelated

RIC

6

Full engraftment → relapse

8.

M

49

PMF

Unrelated

RIC

11

Full engraftment

9.

M

58

CMML>AML

Related

RIC

3

Full engraftment

10.

M

55

AML

Unrelated

RIC

22

Full engraftment

11.

M

50

PMF

Unrelated

RIC

11

Failure to engraft

12.

M

46

CMML>AML

Unrelated

My

39

Full engraftment

13.

F

41

PV>AML

Related

My

34

Full engraftment

F; female, M; male, PV; Polycythaemia Vera, PMF; primary myelofibrosis, CMML; chronic myelomonocytic leukaemia, AML; acute myeloid leukaemia, RIC; reduced
intensity conditioning, MY; myeloablative conditioning.
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The JAK2 V617F allele-specific qPCR assay employed had a specificity of at least 2.0x10–3
which gave a routine sensitivity and cut-off value for sample negativity of 0.02% mutant
(Section 2.11). The slope and R2 value of the standard curves generated were robust across the
dynamic range of the assay, allowing for consistent and accurate quantification of JAK2 wild
type and JAK2 V617F mutant in the patient samples (Figure 3.1).

Figure 3.1. Example of linearity of JAK2 V617F qPCR standard curves across plasmid
dilutions. Ct; cycle threshold. Calculated Slope = -3.48, Y-intercept = 41.4, R2 = 0.98.Standard
curve prepared as per Section 2.11.

Donor chimerism was assessed using a standardised methodology (Section 2.9.7, 2.10.3).
Examples of electropherograms generated are outlined in Figure 3.2/3.3.
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A

B

C

Figure 3.2. An example of electropherograms generated during the study across 5 specific short
tandem repeat (STR) markers D3S1358, THO1, D21S11, D18S5, Penta E. A:
Electropherogram for a control DNA ladder containing all repeats for each marker, B: example
profile of a donor at the five STR. Donor is heterozygous at D3S1358, THO1, D21S11 and
Penta E, C: recipient specific profile. Recipient is heterozygous for all five markers. Donor
chimerism is estimated from markers where donor and recipient STR profiles are dissimilar at
a given STR (Section 2.10.3).

A

B
.
C

D

Figure 3.3. STR-PCR electropherogram at a single marker. A: Example of a heterozygous
recipient profile for a single marker pre-transplantation, B: a heterozygous donor profile for
the same marker, C: recipient profile post-transplantation showing predominance of the donor
profile, D: subsequent relapse showing predominance of the recipient profile.
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The percentage donor chimerism and percentage JAK2 V617F were calculated for each patient
at diagnosis and at specific time points post-transplantation where sufficient DNA was
available (Table 3.2). The values for donor chimerism and JAK2 V617F were subsequently
used to generate graphs to allow for a visual demonstration of the molecular kinetics of residual
disease for each patient post-transplantation (Figures 3.4 - 3.5).

Seven of 13 (54%) patients were homozygous for JAK2 V617F pre-ASCT (allelic burden
exceeding 50% mutant), with the remaining six patients being heterozygous. Of 49 samples
tested for both JAK2 V617F and donor chimerism, a significant Pearson’s correlation was
observed (r = −0.97) (Figure 3.6), however, it should be noted that 22 of these samples were
100% donor chimerism and the JAK2 V617F undetectable. Ten of 13 (77%) patients became
negative for JAK2 V617F post-ASCT with a follow-up of 3–52 months (median 6 months).
Three patients either failed to engraft or displayed autologous recovery. Post-ASCT, increasing
levels of the JAK2 V617F mutation were demonstrated three weeks prior to detection of
decreasing donor chimerism levels (100%–91%) in one PMF patient (Patient 7), highlighting
the higher sensitivity of the JAK2 V617F qPCR in detecting a biological change in the patient.
An inverse correlation between the kinetics of donor chimerism and JAK2 V617F across the
dynamic range was observed, showing the stability of the JAK2 V617F as a marker for
molecular monitoring throughout the disease course, which was reflected in the clinical
observation of donor stem cell engraftment and reduction of disease burden.
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Table 3.2. Percentage donor chimerism and JAK2 V617F quantification results for JAK2 positive patient cohort samples.
Patient No.

1

2

3

4

Time post
transplantation
(months)
0

%
Donor chimerism

%
JAK2 V617F

Patient No.

Time post
transplantation
(months)
0.0

%
Donor chimerism

N/A

44.9

7

Time post
transplantation
(months)
0.0

%
Donor
chimerism
N/A

%
JAK2 V617F

1.4

38

2.1

19

51.3

2.5

100

63.5

3.6

100

Not Detected

3.0

1

96.09

Not Detected

5.2

0

2.5

13

63.7

4.8

81.53

100

Not Detected

7.0

0

97.99

3.8

5

65.9

0.0

N/A

11.4

5.0

99

Not Detected

11.4

0

5.5

100

0.03

6.2

N/A

Not Detected

6.1

91.0

3.76

1.1

91

6.96

8.4

100

Not Detected

11.8

98

Not Detected

6.2

87

6.75

1.8

91

6.21

0.0

N/A

52.39

15.8

100

16.7

100

Not Detected

Not Detected

2.1

N/A

59.66

38.9

100

Not Detected

18.8
40.0

100

Not Detected

8.4

N/A

88.17

100

Not Detected

8.8

N/A

16.92

4.3

100

52.2

Not Detected

N/A

Not Detected

10.4

N/A

Not Detected

6.8

98

Not Detected

0.0

N/A

30.70

0

N/A

26.23

9.5

100

Not Detected

10.5

97

0.46

2.5

N/A

Not Detected

10.4

100

Not Detected

10.9

N/A

0.45

10.5

100

Not Detected

11.9

100

Not Detected

14.4

96

0.79

10.6

99

Not Detected

16.9

100

Not Detected

16.5

N/A

Not Detected

Not Detected

18.1

99

Not Detected

16.7

N/A

0.06

N/A

1.82

19.9

100

Not Detected

18.7

N/A

Not Detected

6.2

N/A

9.15

26.2

100

Not Detected

0.0

N/A

2.90

9.7

100

Not Detected

30.0

100

Not Detected

38.30

9.9

99

Not Detected

34.4

100

Not Detected

77.02

12.8

100

Not Detected

21.6

99

Not Detected

11.3
5

6

0.0

28
N/A

6.8

96

0.59

7.2

97

Not Detected

0.0
37.1
38.4

N/A
98
N/A

8

9

10

0.0

41.00
0.40
Not Detected
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N/A

%
JAK2 V617F

Patient No.

36.98

11

12

13

0.0

0.0

94.05

97.98
N/A

N/A

76.58

31.03

1

2

4

5

3

6

Figure 3.4 Patients 1-6, molecular kinetics of residual disease post-ASCT. Donor chimerism is denoted by filled squares and JAK2 V617F by open circles.
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7

8

9

10

11

12

13

Figure 3.5 Patients 7-13, molecular kinetics of residual disease post-ASCT. Donor chimerism is denoted by filled squares and JAK2 V617F by open circles.
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100

% JAK2 V617F
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20
0
0

20

40
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120

% Donor chimerism
Figure 3.6. Correlation of % JAK2 V617F and % donor chimerism (r = - 0.97). Data was
obtained from Table 3.2 where 49 patient samples had a % donor chimerism and % JAK2
V617F available for the same sample.

3.2.2 Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell
transplantation
The discovery of CALR exon 9 mutations in ET/PMF patients toward the end of 2013 showed
that the mutations were an early event occurring at the stem cell level and remained stable
throughout disease evolution (Klampfl et al., 2013; Nangalia et al., 2013). This observation
created an opportunity to assess the potential for CALR mutations to be used as markers of
residual disease in those MPN patients who were positive for the mutation and had received a
transplantation as part of their clinical treatment.
To initiate this study a review of JAK2 V617F negative MPN patients who had
progressed through a transplant regimen was carried out. Of 15 patients identified in an audit
of cases, screening for evidence of CALR exon 9 mutations by DNA fragment analysis
(Klampfl et al., 2013) in pre-ASCT samples identified four CALR mutation-positive patients,
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all of whom received reduced intensity conditioning (Table 3.3). CALR mutant allele burden
was calculated using area under the peak (mutated/mutated + wild type) x100 and compared to
known donor chimerism status performed according to guidelines (Lion et al., 2012). The
CALR assay allowed the reproducible detection of approximately 1% mutant allele burden for
type 1 (52 bp deletion) and type 2 (5 bp insertion) mutations. An example of the
electropherograms generated in the assay are outlined in Figure 3.7. All four patient donor
samples were wild type CALR exon 9. Characteristics of the four CALR mutated patients are
outlined (Table 3.4). A further 19 informative follow up samples evaluated for donor
chimerism status were available for retrospective mutant CALR allele burden estimation from
these four patients (Table 3.5).
Patients 3, 5 and 12 achieved full engraftment as assessed by donor chimerism (≥99%) at 5, 8
and 14 weeks respectively with very low levels of mutant CALR alleles (<1%) detectable in
patients 5 and 12 at these time points (Table 3.5). Patient 14 failed to achieve full donor
chimerism, reflected in levels of mutant CALR alleles of >1% (Fig 3.9). As with the JAK2
V617F kinetics observed previously, an inverse correlation between the kinetics of donor
chimerism and CALR mutation was observed. Loss of engraftment, indicated by falling donor
chimerism and mirrored by a significant increase in mutant CALR allele burden, prompted
clinical intervention with a donor lymphocyte infusion (DLI) at week 22 post-ASCT. The result
of this was further engraftment of the donor cells and a reduction in disease allele burden,
reflected in an increased donor chimerism of 99% and undetectable mutant CALR alleles.
By demonstrating both persistence and eradication of both type 1 and type 2 CALR
mutations and their correlation with the clinical course, this study provides initial validation of
serial monitoring of CALR mutations as a useful adjunct in the assessment of transplant efficacy
in myelofibrosis patients. CALR mutation burdens were shown to reflect clinical course and
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therapeutic intervention and remained stable markers of disease throughout the clinical course
of the patients assessed.
Table 3.3. Transplanted JAK2 V617F negative MPN patients identified and screened for
CALR exon 9 mutations.
Patient No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Diagnosis pre-transplantation
MDS/MPN
PMF
PMF>AML
PMF
Post-ET MF
PMF
PMF
PMF
MDS/AA with thrombocytosis
PMF pre-ASCT
PMF > AML
PMF
PMF
PMF
PMF

CALR mutation
Not Detected
Not Detected
Detected
Not Detected
Detected
Not Detected
Not Detected
Not Detected
Not Detected
Not Detected
Not Detected
Detected
Not Detected
Detected
Not Detected

MDS: Myelodysplastic syndrome, MPN: Myeloproliferative Neoplasms, PMF: Primary
Myelofibrosis, AML: Acute Myeloid Leukaemia, ET: Essential Thrombocythemia, AA:
Aplastic Anaemia, ASCT: Autologous Stem Cell Transplant
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Positive Control

A

C

B

Negative Control

D

Patient Y

Patient X

Figure 3.7. An example of the electropherograms generated for CALR exon 9 type 1 (52bp
deletion) mutation after PCR and fragment analysis (Section 2.9.6). A: Positive control sample
with internal control peak at 262bp and type 1 mutation at 210 bp (red arrow), B: Control
sample with internal peak at 262bp only, C: Patient sample with type 1 mutation detected, D:
patient sample with low level type 1 mutation detected.

Table 3.4. Patient Characteristics of CALR mutated JAK2 V617F negative MPN detected.
Patient

Gender

Age at ASCT (years)

Donor type

CALR mutation

3

Male

59

Unrelated

52-bp deletion

5

Male

46

Related

5-bp insertion

12

Male

48

Related

52-bp deletion

14

Female

52

Unrelated

5-bp insertion
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Table 3.5. Donor chimerism and CALR mutation burden status of CALR mutated patient
cohort post-transplantation.
Patient

Weeks post-

Donor chimerism

CALR mutation burden

No.

transplantation

(%)

(%)

3

N/A

N/A

55.7

5

100.0

0.0

11

100.0

0.0

22

100.0

0.0

N/A

N/A

42.0

8

100.0

1.0

26

100.0

0.0

26

100.0

0.0

N/A

N/A

55.2

4

96.0

1.0

14

99.0

1.0

25

100.0

0.0

37

100.0

0.0

N/A

N/A

58.3

7

87.0

2.0

13

76.0

5.0

20

54.0

20.0

24

86.0

1.0

27

99.0

0.2

5

12

14

The values for donor chimerism and CALR mutation burden were subsequently used to
generate a graph of the molecular kinetics of residual disease for each patient posttransplantation (Figure 3.8).
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3

5

12

14

DLI

Figure 3.8 Molecular kinetics of residual disease post-ASCT in Patients 3,5,12 and 14. Donor chimerism denoted by filled squares, CALR
mutation burden represented as open circles. Donor lymphocyte infusion (DLI).
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Figure 3.9 shows the electropherograms from patient 14 stacked on top of one another to enable
a clear visual of the reduction and re-emergence of the type 2 CALR mutation over time. The
peak on the left side of each pane is wild type CALR, which acts as an internal control for the
assay.

Figure 3.9. Electropherograms showing pre-ASCT and follow up samples for patient 14. Note
the reduction, re-emergence and subsequent reduction in type 2 mutation peak (5bp insertionblack arrow).
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3.2.3 The CSF3R T618I mutation as a disease-specific marker of atypical CML postASCT
The most prevalent CSF3R mutation in aCML and CNL is the membrane proximal T618I
(Maxson et al., 2013; Pardanani et al., 2013). The discovery of mutations in CSF3R in these
patients opened up the possibility that in addition to the potential for targeted therapy as
outlined in section 1.10, identification of aCML-specific CSF3R mutations affords the
opportunity for evaluation of these mutations as disease-specific markers of residual disease in
those patients undergoing ASCT.
To develop and extend this idea an audit was carried out of aCML, CNL, or atypical
MPN that had received transplantation therapy and had samples available at diagnosis for
analysis. The audit returned eight cases that were available for further analysis. Given the rarity
of these cases and the mutations they may possess, Sanger sequencing was applied to determine
the mutation status of the patients as this method was already developed and standardised and
could be deployed rapidly. Mutations of the SETBP1 Ski domain and CSF3R exons 14 and 17
were sought in this retrospective series. An overview of the available characteristics for the
eight cases are outlined in Table 3.6. Two patients were identified as having CSF3R T618I
mutations.
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Table 3.6. Characteristics and mutation status of eight patients analysed.
Patient
No.

Age at
Diagnosis

Initial
Diagnosis

1
2
3
4

57
62
59
48

aCML
aCML
aCML
aCML

SETBP1 SKI Domain
(706aa-917aa)
mutation status
Not Detected
Not Detected
Not Detected
Not Detected

5

61

aCML

Not Detected

6
7
8

53
58
33

aMPN
aMPN
aPMF

Not Detected
Not Detected
Not Detected

CSF3R exon 14/exon 17
mutation status
Not Detected
Not Detected
Not Detected
Detected
p. Thr618Ile (T618I)
(c.15482C>T)
Detected
p. Thr618Ile (T618I)
(c.15482C>T)
Not Detected
Not Detected
Not Detected

The two patients found positive for CSF3R T618I were followed up to determine their clinical
course. A 60-year-old woman (Patient #4) presented in 2002 with what appeared
morphologically to be CML but had a normal karyotype with no evidence of BCR-ABL1 by
fluorescence in situ hybridization (FISH) or reverse transcription-PCR. The karyotype was:
(46,XX[17] .nuc ish 9q34(ABLx2),22q11(BCRx2)[98] / 9q34(ABLx1),22q11(BCRx1)(ABL
con BCRx1)[2]). She had no haematological response to 1 month of imatinib and commenced
hydroxyurea. The pre-transplant work-up revealed worsening constitutional symptoms and
lymphadenopathy. Retrospectively, a CSF3R T618I mutation was detected three months pretransplant (Figure 3.10, A: upper panel). A reduced-intensity conditioning, sibling donor
(CSF3R wild type) ASCT was performed. The initial post-ASCT course was unremarkable;
however, by day 72, whole blood donor chimerism was only 20% with the T618I mutation
retrospectively still evident (Figure 3.10 A: centre panel). Full donor chimerism was not
achieved and the patient relapsed 9 months post-ASCT with increasing BM myeloblasts. Two
doses of DLI and a subsequent course of daunorubicin, cytarabine, thioguanine (3+10) did not
improve the chimerism status; the marrow remained hypoplastic with 10–15% blasts and
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continued evidence of the CSF3R T618I (Figure 3.10 A; lower panel). The patient became red
cell and platelet transfusion dependent, deteriorated and died 17 months post-ASCT.
In the second case, a 48-year-old man (Patient #5) presented with an elevated white cell
count and a hypercellular BM consistent with aCML. The patient had a normal karyotype, no
evidence of BCR-ABL1, PDGFRA or PDGFRB rearrangements by FISH (46,XY[20].nuc
ish(FIP1L1,CHIC2,PDGFRA,PDGFRB)x2[300]), with molecular studies demonstrating the
absence of the JAK2 V617F and BCR-ABL1 transcripts but the presence of the CSF3R T618I
mutation (Figure 3.10 B: upper panel). The patient commenced treatment with hydroxyurea
and six weeks prior to ASCT the CSF3R T618I clone remained evident but at a reduced level
(Figure 3.10, B: centre panel). He underwent a myeloablative ASCT with a sibling donor
(CSF3R wild type). At day 30 post-ASCT, the patient developed skin GvHD. The T618I
mutation was not detected by sequencing on day 46 in whole peripheral blood (Figure 3.10 B:
lower panel). At the time of reporting the patient remained well on a tapering steroid dose with
improving GvHD.
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A

B

Pre-ASCT

At Diagnosis

Day 72 post-ASCT

pre-ASCT

12 months post-ASCT

Day 46 post-ASCT

Figure 3.10. Sequencing of DNA isolated from unfractionated peripheral blood demonstrating
CSF3R c.15482C>T (p.Thr618Ile) mutation (arrows) throughout clinical course. A: Patient #4
pre-ASCT (upper panel), day 72 post-ASCT (centre panel) and 12 months post-ASCT (lower
panel). B: Patient #5 at diagnosis (upper panel), pre ASCT (centre panel) and day 46 postASCT (lower panel).

In this study, both persistence and eradication of the CSF3R T618I was described and
correlated well with the clinical course in both patients. This indicates that the CSF3R mutation
is a stable mutation that can persist post-ASCT and can reflect disease burden, suggesting serial
monitoring of CSF3R mutations in aCML patients undergoing allo-SCT is a useful adjunct in
the assessment of transplant efficacy.
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3.2.4 Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation
of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell
Transplantation.
Whilst tracking disease burden utilising patient-specific mutations has the potential to provide
an individualised assessment of disease clearance as described above, the biological and
clinical presentation of each patient is unique, and pitfalls and limitations of the technology
must be appreciated. To highlight this issue, a case study is described in which JAK2 V617F
residual disease monitoring failed to detect an extramedullary manifestation of PMF in a patient
after ASCT and serves to highlight a pitfall of this approach.
Whilst undergoing imaging of a knee replacement for osteoarthritis three years
previously, a 54-year-old male was noted to have patchy skeletal sclerosis. Further
investigations revealed splenomegaly with a nine-month history of progressive constitutional
symptoms (generalised un-wellness), lethargy, night sweats, and weight loss. Initial
haematological investigation revealed a haemoglobin of 10.3 g/dL, a white cell count of 7.8 ×
109/L, platelets of 53 × 109/L and elevated reticulocyte count (212 × 109/L) and lactate
dehydrogenase (LDH; 990 IU/L). The blood film was leucoerythroblastic with red cell
anisopoikilocytosis, tear drop cells, basophilic stippling, and 2% circulating blasts. Bone
marrow aspirate was unsuccessful; however, the bone marrow biopsy showed abnormal
marrow architecture and grade IV reticulin fibrosis. The JAK2 V617F mutation was detected
by qualitative PCR confirming the diagnosis of PMF. Four months later the platelet count had
fallen to 24 × 109/L with 3% blast cells in the peripheral blood. The patient proceeded to
reduced intensity conditioning ASCT with a matched sibling donor.
The JAK2 V617F qPCR assay described in section 2.11 was employed to determine the
allele burden prior to ASCT (30.7%). At two months post-ASCT, donor chimerism was 97%
and JAK2 V617F 0.46% and at six months after ASCT donor chimerism was 96% and JAK2
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V617F 0.79%. Full donor chimerism (100%) and undetectable JAK2 V61F were concurrently
noted at eleven months after ASCT and remained so at prospective three-monthly assessments
(Figure 3.11).

% Donor Chimerism / JAK2 V617F
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20
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20
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Figure 3.11. Molecular kinetics of residual disease post-ASCT. Donor chimerism; filled
squares, JAK2 V617F; clear circles.

In the long-term follow-up clinic at 32 months after ASCT, a 1 cm hard lump was noted beneath
the left eye. Subsequent imaging noted a mass lesion arising within the inferolateral aspect of
the left orbit, displacing the globe anteromedially and which appeared to lie within the
extraconal space (Figure 3.12, A: arrow). Excision of the periorbital bulk mass was undertaken
with histopathological examination revealing adipose/connective tissue infiltrated by blasts
(Figure 3.12, B: dark nuclei, arrows) which stained positively for CD34 (Figure 3.12, C),
CD117, and CD45 and negatively for CD20, TdT, Granzyme B, CD68, and CD1a suggesting
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a myeloid origin. The blasts were also JAK2 V617F-positive consistent with a diagnosis of
myeloid sarcoma, an extramedullary tumour.

A

B

C

Figure 3.12. Histopathological analysis of periorbital mass A: CT showing left periorbital
myeloid sarcoma (arrowed), B: periorbital biopsy showing blast infiltration by myeloid
sarcoma (yellow arrows) (Haematoxylin and Eosin; magnification ×40), C: positive
immunohistochemical staining for CD34 in the myeloid sarcoma (magnification ×40).

At this time the patient had a haemoglobin level of 14.0 g/dL, white cell count of 4.2 × 10 9/L,
neutrophils of 2.0 × 109/L, and an unchanged, maintained platelet count of 115 × 109/L. The
JAK2 V617F was undetectable in both the peripheral blood and the bone marrow aspirate, the
latter showing no morphological evidence of PMF. The patient was not a candidate for further
intensive chemotherapy and underwent involved field radiotherapy to the left orbit (30 Gy in
15 fractions) and at last follow-up 41 months after ASCT, the JAK2 V617F remained
undetectable in the peripheral blood.
Relapse is the major cause of treatment failure in PMF patients post-transplantation and
is often associated with an aggressive clinical course, primarily due to clonal evolution (Gupta
et al., 2014). Residual disease monitoring using JAK2 V617F qPCR in PMF after ASCT is
effective in predicting relapse in those patients in whom the disease is driven by this mutation
as described above. However, vigilance is required as extramedullary manifestations of PMF,
although rare, may evade early capture by this approach.
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3.3 Discussion
In this chapter the utility and potential for disease specific mutations to be used to monitor
disease burden post-transplantation therapy was explored. Given the continuous improvement
in transplantation science over the last few decades and the growing application of reduced
intensity conditioning regimens which are not fully ablative, there is a growing need for new
ways to monitor efficacy, including indicators of early relapse. Conventionally, STR-PCR
based donor chimerism is the molecular method of choice to monitor engraftment of donor
stem cells post-transplant. The major benefit of this approach is that it is disease agnostic and
can be applied in all cases, however the sensitivity of 1-2% routinely achieved can be limiting.
That said, there are more sensitive qPCR and digital droplet PCR based methodologies in
development (Debeljak et al., 2017; Waterhouse et al., 2018).
In the case of diseases where there is the ability to measure a specific and sensitive
marker of disease burden that remains stable over the course of the disease, there is the
potential, in tandem with donor chimerism to enhance a clinicians view of the clinicopathological state of disease in the patient, which will enhance their ability to intervene
therapeutically. In a series of retrospective analyses this potential was tested in three diagnostic
disease markers (JAK2 V617F, CALR exon 9 mutations, CSF3R T618I) in three separate MPN
cohorts. In the JAK2 V617F positive cohort study, the utility of a robust and sensitive qPCR
assay was proven and allowed for a thorough examination of mutation burden post-ASCT with
a strong correlation between donor chimerism and levels of JAK2 V617F observed. In patient
#7 the improved sensitivity of the JAK2 V617F assay over donor chimerism provided evidence
of rising mutational burden several weeks prior to a change in donor chimerism, thus providing
a potential window of opportunity for clinical intervention. In the study of CALR mutations
post-ASCT, the CALR mutated burden reflected the disease state and inversely correlated with
engraftment as measured by donor chimerism. Indeed, CALR mutation burden reflected the
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kinetics also observed in the JAK2 V617F study, particularly in patient #14, where posttransplantation and post subsequent intervention with donor lymphocyte infusion the allele
burden reflected the clinical course, proving that this marker was stable throughout the disease
and therapy and is useful as a clinical tool in the assessment of transplantation efficacy in
myelofibrosis patients.
This theme was extended again after the discovery of recurrent mutations in the CSF3R gene
strongly associated with aCML and CNL. This created the opportunity to apply the
methodology of molecular monitoring of disease burden post-transplant in this rare condition.
In the two cases described carrying CSF3R T618I mutations, the mutation burden reflected the
disease course in both cases and was stable throughout, adding clinical value as a robust marker
of disease post-transplant. For these rare cases where numbers are limited, confirmation in a
larger cohort would be warranted. The case study of extramedullary relapse of PMF serves to
highlight that whilst residual disease monitoring with disease specific markers in the peripheral
blood and bone marrow of MPN patients has great potential to enhance clinical knowledge and
understanding, vigilance is required when interpreting these test result data in the clinical
setting.
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4.0 Incidence and clinical application of molecular
diagnostic markers in myeloproliferative neoplasms
The aim of this chapter was to investigate the incidence and significance of MPN mutations in
various clinical contexts. The data in this chapter is the result of work that culminated in the
eleven publications listed below and in Appendix 1/2B. My personal contribution to the work
in each paper is outlined beneath each of the citations below and verified by my co-authors in
Appendix 3.
1. Haslam K, Conneally E, Flynn CM, Cahill MR, Gilligan O, O'Shea D, Langabeer SE. CALR
mutation profile in Irish patients with myeloproliferative neoplasms. Hematol Oncol Stem Cell
Ther. 2016;9(3):112-5.
Personal Contribution: Contribution to design of study, analysis of CALR mutation status and
interpretation of all analytical and clinical data. Wrote paper and contributed to finalised
version approval. Primary author of paper.
2. Haslam K, Langabeer SE. Incidence of CALR mutations in patients with splanchnic vein
thrombosis. Br J Haematol. 2015;168(3):459-60.
Personal Contribution: Conceived and designed study, carried out CALR mutation analysis.
Interpreted collated data. Reviewed and approved draft and final manuscript for submission.
Primary author of paper.
3. Langabeer SE, Haslam K, Linders J, Percy MJ, Conneally E, Hayat A, Hennessy B, Leahy
M, Murphy K, Murray M, Ni Ainle F, Thornton P, Sargent J. Molecular heterogeneity of
familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2,
CALR and MPL mutations. Fam Cancer. 2014 Dec;13(4):659-63.
Personal Contribution: Input on design of study and collation of patient samples and details.
Carried out JAK2/CALR mutation analysis and interpretation of results. Contributed to writing
and review of paper. Approved final version of manuscript for submission.
4. Langabeer SE, Haslam K, McMahon C. CALR mutations are rare in childhood essential
thrombocythemia. Pediatr Blood Cancer. 2014 Aug;61(8):1523.
5. Langabeer SE, Haslam K, McMahon C. Distinct driver mutation profiles of childhood and
adolescent essential thrombocythemia. Pediatr Blood Cancer. 2015 ;62(1):175-6.
Personal Contribution: Input on design of study and collation of patient samples and details.
Carried out CALR mutation and JAK2 V617F qualitative PCR analysis. Interpreted result of
experimental analysis and clinical context. Contributed to writing and review of manuscripts.
Approved final drafts prior to submission.
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6. Langabeer SE, Haslam K, McMahon C. A prenatal origin of childhood essential
thrombocythaemia. Br J Haematol. 2013 Dec;163(5):676-8. 5YIF: 5.31.
Personal Contribution: Input on design of study and collation of patient samples and details.
Carried out experimental analysis of JAK2 V617F qualitative and quantitative mutation
analysis and interpretation of all data. Contributed to writing, review and approval of all
manuscript drafts.
7. Haslam K, Conneally E, Langabeer SE. Capricious CALR mutated clones in
myeloproliferative neoplasms. Blood Cells Mol Dis. 2016;57:110-1.
Personal Contribution: Substantial contribution to design of study, carried out analysis and
interpretation of data. Primary author of paper. Reviewed and approved final draft for
submission.
8. Langabeer SE, Haslam K, Elhassadi E. The mutant CALR allele burden in essential
thrombocythemia at transformation to acute myeloid leukaemia. Blood Cells Mol Dis. 2017
Jun;65:66-67. doi: 10.1016/j.bcmd.2017.05.004
Personal Contribution: Input on study design, carried out experimental analysis of CALR
mutation. Collated and interpreted results. Contributed to writing, review and approval of draft
and final manuscript for submission.
9. Langabeer SE, Haslam K, O'Brien D, Enright H, Leahy M. Transient JAK2 V617F mutation
in an aplastic anaemia patient with a paroxysmal nocturnal haemoglobinuria clone. Br J
Haematol. 2013;161(2):297-8.
Personal Contribution: Input on study design, carried out JAK2 V617F quantitative analysis
and results interpretation. Contributed to writing and review of paper. Approved final version
of manuscript for submission.
10. Haslam K, Langabeer SE. Considerations and recommendations for a new molecular
diagnostic algorithm for the myeloproliferative neoplasms. Genet Test Mol Biomarkers.
2014;18(11):749-53.
Personal Contribution: Contributed to design of study, carried out data review and audit.
Collated and interpreted data. Designed final algorithm and recommendations. Primary author
of paper. Approved manuscript prior to submission.
11. Haslam K, Langabeer SE. Who to screen for CALR mutations? An audit of real-life
practice and review of current evidence. Eur J Intern Med. 2017 Jan 26. pii: S09536205(17)30040-7
Personal Contribution: Contributed to design of study, carried out data review and audit.
Collated and interpreted data. Designed final algorithm and recommendations. Primary author
of paper. Approved manuscript prior to submission.
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4.1 Introduction
As outlined in the WHO 2016 classification (Arber et al., 2016), identification of an MPN
associated driver mutation provides clear evidence for malignant, clonal haematopoiesis,
however further clinical and biological features are required to allow a final diagnosis.
According to the National Cancer Registry in Ireland, 124 cases of MPN were diagnosed per
year between 1994-2012 with trends in diagnosis unclear (Cancer Trends No 26.
Myeloproliferative neoplasms & myelodysplastic syndromes, 2015).
As the interpretation of molecular diagnostic results produced in MPN related clinical cohorts
is yet to be fully elucidated, this study sought to extend the breadth of knowledge in this arena.
Specifically, the incidence of MPN mutations ( i.e. JAK2 V617F, CALR exon 9 mutations and
where MPL exon 10 mutations where relevant) as molecular diagnostic markers in a clinically
relevant Irish patient population was examined, in specific patient cohorts including paediatric
MPN, familial MPN and patients presenting with splanchnic vein thrombosis. Using the data
from these studies with that from specific case reports an understanding of the biological and
clinical behaviour of MPN mutated clones was developed. In addition, clinical referral data
was used to audit the real-world application of molecular diagnostic testing which together,
enabled the development of a framework for a molecular diagnostic algorithm for MPN
molecular diagnostics and expanded current understanding of the application of molecular
diagnostic markers in MPN.
The methods used in this chapter are outlined in detail in Chapter 2 and include nucleic
acid extraction and QC (section 2.3-2.7), JAK2 V617F PCR (section 2.9.2, 2.9.3, 2.11), Donor
Chimerism STR-PCR (section 2.9.7, 2.10.3), CALR exon 9 mutation PCR (section 2.9.6,
2.10.2).
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4.2 Results

4.2.1 CALR mutation profile in Irish patients with myeloproliferative neoplasms
CALR exon 9 mutation analysis is now an essential component of the molecular diagnostic
algorithm for MPN, with initial studies of incidence showing that some geographical
heterogeneity exists in both the frequency and profile of CALR mutations in ET and PMF when
considering patients from North America (Tefferi et al., 2014), Europe (Klampfl et al., 2013;
Nangalia et al., 2013; Jeromin et al., 2015; Grinsztejn et al., 2016), Central and South America
(Labastida-Mercado et al., 2015; Nunes et al., 2015), India (Sazawal et al., 2015), and the Far
East (Li et al., 2014; Shirane et al., 2015). Given the importance of CALR mutational analysis
in the diagnosis and prognosis of ET and PMF, this study investigated the pattern of CALR
mutations in a cohort of adult Irish patients with MPN.
An audit conducted on a cohort of confirmed or suspected MPN patients from two large
Irish haematology centres returned 202 JAK2 V617F negative samples that were subjected to
retrospective CALR exon 9 mutational analysis as outlined in section 2.9.6. CALR mutations
were detected in archival genomic DNA from peripheral blood (n = 190) or bone marrow (n =
12) by fluorescent PCR followed by fragment length analysis (Appendix 4). CALR mutations
were detected in 58 patients (30 female and 28 male) from the 202 patient samples analysed,
with a median age of 56 years (range, 25–86 years). The differential diagnosis for these patients
was ET (n = 45), PMF (n = 10), post-ET myelofibrosis (n = 2), and myelodysplastic/MPNs (n
= 1). Type 1 CALR mutations were the most prevalent, being detected in 60.3% of patients
(35/58), followed by Type 2 mutations which were detected in 27.6% of patients (16/58) (Table
4.1). Of the remaining seven cases, 8.6% (5/58) had Type 1-like deletions, one had a Type 2like insertion, and one patient harboured two mutated clones. The distribution of these
mutations in the MPN subtypes is given in Table 4.1.
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Table 4.1. Incidence of CALR Mutations in Irish MPN Patients.

Type 1

Type 1-like

Type 2

Type 2-like

Other

ET (n=45)
PMF (n=10)
Post-ET-MF (n=2)
MDS/MPN (n=1)

26
8
1
0

5
0
0
0

12
2
1
1

1
0
0
0

1
0
0
0

Total

35 (60.3%)

5 (8.6%)

16 (27.6%)

1 (1.7%)

1 (1.7%)

ET = essential thrombocythemia; MDS/MPN = myelodysplastic/myeloproliferative neoplasm;
MF = myelofibrosis; PMF = primary myelofibrosis.

Given the near mutual exclusivity of the JAK2 V617F and CALR mutations but acknowledging
the rarity of these mutations co-existing (Broséus et al., 2014b; McGaffin et al., 2014; Mansier
et al., 2016), this retrospective study was limited to known and suspected ET and PMF patients
in whom the JAK2 V617F was previously undetected. The CALR mutation profile and
frequency in this cohort of Irish patients are broadly in line with that of other series from Europe
and North America, with Type 1 and Type 1-like mutations being more prevalent than Type 2
and Type 2-like in both ET and PMF patients and confirming these driver mutations as the
second most frequently observed in ET and PMF.

4.2.2 Incidence of CALR mutations in patients with splanchnic vein thrombosis.
MPNs are a common cause of splanchnic vein thrombosis (SVT) including Budd-Chiari
syndrome and portal vein thrombosis, with a substantial proportion of these patients being
JAK2 V617F positive, often in the absence of overt MPN symptoms (Boissinot et al., 2006).
Given the recent description of CALR exon 9 mutations in ET and PMF patients, the incidence
139

and significance of CALR mutations in SVT patients was investigated. An audit of patients
prospectively referred from 23 secondary/tertiary healthcare institutions within the Republic of
Ireland for JAK2 V617F molecular analysis with a presentation of confirmed SVT returned a
cohort of 144 patients. The median patient age was 52 years (range 1–87) and consisted of 77
male and 67 female patients. Patients were assigned to six distinct groups according to the site
of thrombosis: Budd Chiari syndrome (BCS), mesenteric vein thrombosis (MVT), portal vein
thrombosis (PVT), renal vein thrombosis (RVT), splenic vein thrombosis (SpVT), and
splanchnic vein thrombosis unspecified (SVT-U). The JAK2 V617F was detected in 18.8%
(27/144) of patients and specifically in 4/9 (44.4%) BCS, 4/19 (21.1%) MVT, 13/82 (15.9%)
PVT, 0/7 RVT (0%), 5/12 (41.7%) SpVT and 1/15 (6.7%) SVT-U patients. Fifty-nine of these
patients were previously screened for the presence of the common MPL exon 10 mutations of
which two patients (3.4%) possessed an MPL W515L mutation (McCarthy, McCarron and
Langabeer, 2010). CALR exon 9 mutations were not detected in any of the 144 SVT patients
(Appendix 5).
The finding of no CALR mutations in this group of patients is noteworthy when
considering the incidence of the JAK2 V617F (18.8%) in the entire cohort and the MPL W515L
in a subset of this cohort. Whether the absence of CALR mutations in SVT patients is a
reflection of the size of the study population is unknown, with verification of these results being
required in independent cohorts.

4.2.3 Molecular heterogeneity of familial myeloproliferative neoplasms revealed by
analysis of the commonly acquired JAK2, CALR and MPL mutations
While most cases of MPNs are sporadic in nature, a familial pattern of inheritance is well
recognised. Characterisation of these FMPN kindred allows for the investigation of molecular
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events that contribute to this inheritance and prompted an audit of MPN referrals where the
index case had at least one affected first-degree family member (parent, sibling, or child) and
a diagnosis of MPN was made according to WHO criteria.
Ten FMPN families were identified during the audit that met the above criteria (Figure
4.1). Affected individuals from nine of these families possessed the classical MPN phenotypes
of ET, PV and PMF whereas one family had a phenotype suggestive of hereditary
thrombocytosis (HT) (Figure 4.1. Family 5). Of the nine families with classical MPN
phenotypes, there were 24 affected individuals with ET (n = 13), PV (n = 8), PMF (n = 1), postPV MF (n = 1) and MPN of unknown phenotype (MPN unknown; n = 1). Samples were
unavailable for analysis from four ET patients (Figure 4.1. Family 7: I-2 and II-2; Family 9: I2 and II-2). Molecular testing was carried out for detection of the JAK2 exon 12 and MPL
W515L/K mutations as previously described (Percy et al., 2007; Daly, Conneally and
Langabeer, 2009). Analysis of the JAK2 V617F and MPL W515L/K mutations were performed
in all affected individuals. CALR mutation screening was only performed on those individuals
without the JAK2 V617F mutation. CALR mutation allele burden was calculated from the area
under the curve as mentioned in section 2.9.6. In selected patients, Sanger sequencing of JAK2
exons 13 and 14, MPL and THPO was performed (Hussein et al., 2014). No MPL W515L/K
mutations were detected in any of the affected patients. The JAK2 V617F was present in 3/8
(37.5 %) of ET cases, 7/8 (87.5 %) of PV cases, and in three patients with PMF, post-PV MF
and MPN unknown. CALR exon 9 mutations were detected in two ET patients, both of whom
were JAK2 V617F-negative (Figure 4.1. Family 7: II-1; Family 8: II-1). Both patients
harboured the common CALR Type 1 mutation L367fs*46 that results in a 52 base pair
deletion, at allele burdens of 9.9% and 38.1% respectively. Two kindred underwent further
molecular investigations. The index case of Family 1 (Figure 4.1. Family 1: II-1) presented
with thrombocytosis but no splenomegaly. Her bone marrow showed evidence of hyperplasia
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consistent with ET but had no evidence of either JAK2 exon 14 (including the V617F) or JAK2
exon 12 mutations. Her father (Figure 4.1. Family 1: I-2) has ischemic heart disease, peripheral
vascular disease and was diagnosed with JAK2 V617F-negative PV that is treated with
hydroxycarbamide and venesection for a raised haemoglobin and haematocrit.
The index case of Family 5 (Figure 4.1. Family 5: II-1) had a persistent thrombocytosis
noted for 9 years with no mutation evident within JAK2 exons 13 and 14, CALR exon 9 or the
coding exons of MPL and THPO, including the intron–exon boundaries of both genes. One
sibling (Figure 4.1. Family 5: II-5) and two daughters (Figure 4.1. Family 5: III-1 and III-2) of
the index case also have a mild thrombocytosis. The absence of demonstrable clonality in this
kindred suggests a HT phenotype as opposed to familial ET. The affected individuals from the
kindred described displayed considerable phenotypic heterogeneity, with ET and PV the most
prevalent phenotypes, whereas the genotypic incidence of JAK2 V617F, CALR exon 9 and
MPL W515L/K mutations was also in keeping with other studies (Malak et al., 2012; Ranjan
et al., 2013; Maffioli et al., 2014; Rumi et al., 2014d). Furthermore, JAK2 and CALR exon 9
mutations were mutually exclusive in this cohort and appear to be acquired independently. Two
of the three affected individuals from Family 1 had ET, with a further individual having JAK2
V617F-negative PV (Figure 4.1. Family 1: I-2). As both JAK2 exon 12 and exon 14 mutations
were not detected in the index case (II-1), non-JAK2 V617F germ-line variants are most likely
not a contributory factor for the FMPN (Mead et al., 2012; Etheridge et al., 2014; Rumi et al.,
2014d). The phenotype of PV in I-2 of Family 1 also argues against a germ-line mutation in
either THPO or MPL genes as responsible for the FMPN as inherited mutations in these genes
invariably result in a phenotype characterised by isolated thrombocytosis (Skoda, Duek and
Grisouard, 2015). As evidenced in Family 5, absence of any mutations in JAK2 exons 13 and
14, CALR exon 9, MPL or THPO, together with absence of hematopoietic clonality suggests
that these patients are likely to be cases of HT.
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Figure 4.1: Ten kindred with FMPN. ET; essential thrombocythemia, PV; polycythaemia vera, PMF; primary myelofibrosis, NT; not tested, wt;
wild type, mut; mutation detected. Squares; males, Circles; females. Filled shapes; affected individuals, empty shapes; unaffected individuals.
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4.2.4 CALR mutations are rare in childhood essential thrombocythemia
Given the discovery of CALR exon 9 mutations in adult ET/PMF and the understanding
that there is a prenatal origin of JAK2 positive MPN, an investigation of CALR mutations
in paediatric MPN was prompted. An audit of sporadic paediatric MPN, referred from a
single paediatric institution, classified according to established WHO haematological,
histo-morphological and molecular criteria (Swerdlow et al., 2008) returned a total of 17
patients. This cohort was comprised of JAK2 V617F-negative ET (n = 4), JAK2 V617Fpositive ET (n = 2), JAK2 V617F-positive PV (n=1), JAK2 V617F-negative
polycythaemia (n = 2), and reactive thrombocytosis (n = 8). The presence of CALR exon
9 mutations was retrospectively investigated in the blood or bone marrow DNA of the six
identified ET patients (Table 4.2). All MPN patients tested negative for MPL W515L or
W515K mutations. CALR mutations were not detected in the three JAK2 positive MPN
patients, the four JAK2 negative ET patients or in the eight children with reactive
thrombocytosis. Data for the ET patient subset is presented in Table 4.2 below.

Table 4.2. Clinical features of the six Essential Thrombocythaemia patients.
Case

Diagnosis Age
(years)

Platelet
JAK2
Count
V617F
Range
(x109/l)
ET
4
721-1167 Positive
1
ET
15
953-1240 Positive
2
ET
9
296-2718 ND
3
ET
9
343-3054 ND
4
ET
9
606-872
ND
5
ET
11
413-1233 ND
6
ET; essential thrombocythaemia, ND; not detected.
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MPL
515L/K

CALR
exon 9

ND
ND
ND
ND
ND
ND

ND
ND
ND
ND
ND
ND

This study demonstrates the absence of CALR exon 9 mutations in JAK2 V617F-positive
childhood MPN and in the four JAK2 V617F-negative children with ET. If the molecular
pathogenesis of paediatric and adult MPN was similar, one might expect to detect CALR
mutations in a certain proportion of young JAK2- and MPL-negative ET patients.
However as paediatric MPNs are rare disorders, and the patient numbers available in this
cohort are small, combination with a larger cohort can help to determine if CALR
mutations have a role in the diagnosis and classification of childhood MPN.
To further extend this analysis our initial findings were combined with a
subsequent larger analysis of thirty four patients diagnosed with ET when less than twenty
years of age (Giona et al., 2014). The JAK2 V617F, CALR, MPL and triple negative
mutation status of ET patients from these two studies was combined to create a larger
cohort (n=40). Analysis of this combined cohort revealed that adolescent ET patients had
a strikingly similar molecular profile to that observed in adults (Klampfl et al., 2013),
whereas the majority of childhood ET patients (diagnosed at ≤11 yrs) were triple negative,
i.e. no JAK2 V617F, CALR or MPL driver mutations (Figure 4.2). This analysis further
highlighted the difference in the molecular pathogenesis of adolescent and childhood ET
and gives an insight into age related distribution of CALR exon 9 mutations.
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Figure 4.2. Distribution of the common driver mutations in adult, adolescent (≥14 years
to ≤20 years) and childhood (≤11 years) ET at time of diagnosis. Adult data derived from
Klampfl et al. 2013. ET: essential thrombocythaemia.

4.2.5 A prenatal origin of childhood essential thrombocythaemia
Genetic analysis of antenatal blood spots has demonstrated that clonotypic translocations,
mutations and gene rearrangements associated with many subtypes of paediatric ALL,
and to a lesser extent, paediatric AML, are present at birth and have therefore been
generated in utero, providing significant insights into the pathogenesis, natural history
and aetiology of these leukaemia’s (Wiemels, Kang and Greaves, 2009). In children,
MPNs are estimated to have a prevalence of 40- to 90- fold lower than that seen in adults
with sporadic, paediatric ET patients exhibiting a significantly lower prevalence of the
JAK2 V617F and at lower allele burdens than observed in adult disease, inferring
differences in both the aetiology and molecular pathogenesis of these diseases in adults
and children (Teofili et al., 2008, 2009). Whether all genotypes and phenotypes of
paediatric MPNs, especially those seen in younger patients, have a prenatal origin is
unknown. However, a somatically acquired, in utero origin of the JAK2 V617F mutation
in an infant with PV has provided some insight into the origins of childhood MPN (Kelly
et al., 2008).
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The case of a four-and-a-half year-old female that presented with persistent
urinary tract infections associated with a thrombocytosis (platelet count 801–989 x 109/l)
is presented. Whilst antibiotic treatment ameliorated the infections, the thrombocytosis
remained. Significant platelet anisocytosis and giant platelets were observed on the
peripheral blood film. A bone marrow aspirate revealed a normocellular, particular
marrow with evidence of trilineage haematopoiesis. All cell lines were represented to
maturity with abundant megakaryocytes, some with dysmorphic features, such as
hyperchromatic and naked nuclei. Megakaryocyte clustering was evident and there was
no obvious reticulin fibrosis. The JAK2 V617F was detected in the peripheral blood by
qPCR and determined as 31.2% of total JAK2 alleles by quantitative PCR. Parental
consent was sought and granted to access the archived antenatal blood spots and DNA
was extracted from these spots which had been taken from the patient 4 days postnatally
using the method described by Wiemels et al., 2009. JAK2 V617F qPCR analysis was
unable to reliably detect the JAK2 V617F in these samples (Ct >40 cycles). A more
sensitive but qualitative, semi-nested allele-specific PCR (as described in section 2.9.3)
was used to amplify mutant JAK2 alleles. This semi-nested PCR had a limit of detection
of mutant alleles of approximately 1x10-5, determined by dilution of genomic DNA from
a known heterozygous JAK2 V617F patient into DNA from a pool of 20 normal controls.
Using this approach JAK2 V617F was detected in PCR duplicate reactions from both
antenatal blood spots (Figure 4.3).
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Figure 4.3. Agarose gel electrophoresis of JAK2 V617F-specific, semi-nested PCR
products. Lane 1 & 14: 100bp DNA ladder; Lanes 2-5: 1/1000, 1/10,000, 1/100,000,
1/1,000,000 dilution controls; Lanes 6,9 &12L: semi-nested PCR negative controls;
Lanes 7 & 8: PCR duplicates from ante-natal blood spot (ABS) 1, Lane 10 & 11: PCR
duplicates from antenatal blood spot 2; Lane 13: first round PCR negative control.

One-year post-diagnosis, the patients’ platelet count (841 x 109/l) and JAK2 V617F allele
burden (26.1%) remained stable, with no evidence of splenomegaly or thrombotic
episodes. No MPN specific treatment has been received by the patient to date. As both
parents of the child did not have a clinical history of sporadic or familial MPN, the
detection of JAK2 V617F mutation in the antenatal bloodspots suggests a sporadic, in
utero acquisition of the driver somatic mutation.

4.2.6 Capricious CALR mutated clones in myeloproliferative neoplasms
In a recently published large cohort of CALR mutated patients (n=685), it was found that
ten (1.5%) possessed complex CALR mutations of which four possessed multiple clones
(Jeromin et al., 2016). In a second study, Shuly et al. described a stable CALR mutant
allele burden in ET patients over time with moderate variability observed (Shuly et al.,
2015). To explore the implications of these findings, CALR mutation patterns in a
retrospective, independent cohort of JAK2 V617F negative CALR mutated ET and PMF
patients was examined.
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Of 55 CALR mutated patients identified, 34 (61.8%) had a type 1 (52-bp deletion)
mutation, 15 (27.3%) had a type 2 (5-bp insertion) mutation, four (7.3%) had a type 1like mutation and one (1.8%) had a type 2-like mutation. One (1.8%) further ET patient
who presented in July 2005 harboured both a type 1 (14.4% allele burden) and a 13-bp
deletion (28.1% allele burden) in their diagnostic peripheral blood (Figure 4.4 panel A).
Repeat analysis of peripheral blood more than ten years post presentation and after seven
years of hydroxyurea therapy revealed fluctuation in the level of the two different clones
with type 1 mutation and 13-bp deletion mutation allele burdens of 29.3% and 10.6%
respectively (Figure 4.4 panel B). This analysis confirmed the presence of multiple CALR
mutated clones in MPN patients at a frequency similar to that initially reported by Jeromin
et al. in 2016.

A

B

Figure 4.4. CALR mutation profile of patient with essential thrombocythemia at diagnosis
(panel A) and ten years later (panel B).
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4.2.7 The mutant CALR allele burden in essential thrombocythemia at
transformation to acute myeloid leukaemia
Transformation to AML occurs in approximately 5% of patients with ET. In the majority
of JAK2 V617F-positive MPN patients who undergo transformation, this mutation is also
present in the AML cell population. However, the phenomenon of JAK2 V617F-negative
AML following a JAK2 V617F-positive MPN implies the transformation of a myeloid
progenitor at a stage before acquisition of the JAK2 V617F or in a clone distinct from that
harbouring the JAK2 V617F (Campbell et al., 2006; Theocharides et al., 2007). In those
few CALR mutation-positive patients studied to date, this phenomenon has rarely been
described (P. Lundberg et al., 2014; Anelli et al., 2016).
Evidence for this latter course of disease evolution is outlined below in a patient
in whom ET transformed to AML. A 51 year-old male with a history of peptic ulcer
disease and hiatus hernia presented in February 2003 with a haemoglobin of 14.8 g/dL, a
white cell count of 6.2 x 109/L and a platelet count of 1160 x 109/L. Bone marrow aspirate
and biopsy showed increased, morphologically atypical megakaryocytes with clustering
and minor evidence of reticulin fibrosis in keeping with a diagnosis of ET. The patient
was commenced on hydroxyurea and aspirin. The JAK2 V617F was not detected in
peripheral blood in October 2009. By March 2017, the patient had developed anaemia
(haemoglobin 8.9 g/dL) with red cell anisocytosis and occasional myeloblasts noted on
the peripheral blood film. Bone marrow biopsy showed an infiltration of myeloblasts that
were CD34 positive by immunohistochemistry accounting for approximately 25% of
nucleated cells with no increase in reticulin fibrosis. Bone marrow aspirate
immunophenotyping revealed the myeloblasts were positive for MPO, HLA DR, CD13,
CD33, CD34, CD64 and CD117 consistent with AML. The patient had a complex
karyotype with aberrations involving chromosomes 5q, 7q, 8p, 12p, and 14q. Given the
150

previous absence of the JAK2 V617F mutation, CALR exon nine mutation analysis was
performed as previously described. In the bone marrow at the time of leukaemic
transformation, this approach detected a CALR type 1, 52 bp deletion mutation at a low
allele burden of 5.7%. Analysis of the archived October 2009 peripheral blood sample
demonstrated the CALR mutation allele burden to be 49.7% at that time, approximating
heterozygosity (Figure 4.5). The patient received one cycle of daunorubicin and
cytarabine 3 + 10 chemotherapy but did not achieve morphological remission with bone
marrow myeloblasts representing 15% of nucleated cells and repeat bone marrow CALR
analysis demonstrating an unchanged mutant allele burden of 5.6% (Figure 4.5 lower
panel).

Figure 4.5. CALR mutation fragment length analysis. CALR mutation at diagnosis (upper
panel), leukaemic transformation (centre panel), and post-chemotherapy (lower panel).
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Given that the mutant CALR allele burden generally increases over time and is largely
unaffected by hydroxyurea therapy (Verger et al., 2015; Cavalloni et al., 2017) the
significant reduction correlating with disease progression noted in the patient described
herein likely represents a true reflection of the underlying disease evolution.

4.2.8 Transient JAK2 V617F mutation in an aplastic anaemia patient with a
paroxysmal nocturnal haemoglobinuria clone
A recent report identifying a JAK2 V617F mutation in GPI-AP deficient cells of three
PNH patients suggested this coexistence could explain clonal expansion (Sugimori et al.,
2012). These findings prompted investigation into the frequency of the JAK2 V617F in
other patients harbouring a PNH clone. Archival DNA samples from blood (n = 3) and
bone marrow aspirate smears (n = 19) from 22 patients (PNH, n = 5; AA, n = 13;
hypoplastic MDS, n = 4) with an immunophenotypically detectable PNH clone of both
RBC and granulocytes were retrospectively analysed for JAK2 V617F by qualitative
allele-specific polymerase chain reaction (as described in section 2.9.2). The JAK2 V617F
mutation was detected in one AA patient.
This female patient, who presented with severe AA and no evidence of a PNH
clone (nor retrospectively the JAK2 V617F), was initially successfully treated with two
courses of anti-thymocyte globulin (ATG) and cyclosporin. She relapsed in pregnancy 2
years later and was treated with immunoglobulin, and RBC and platelet transfusions.
Post-partum treatment included G-CSF, ATG (2 courses) and ciclosporin, the latter being
discontinued after achieving RBC and platelet transfusion independence. Ten years after
the initial presentation, progressive pancytopenia suggested relapse of AA with a PNH
clone detected within the granulocytes (17.7%) and RBCs (5.4%). At this relapse, the
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JAK2 V617F was detected in the bone marrow and confirmed by qPCR at a reproducible
level of 18% of total JAK2 alleles. Ciclosporin was recommenced with a good response
attained. Three years post-relapse, the PNH clone remained stable in granulocytes
(18.9%) and RBCs (6.0%) with the JAK2 V617F not detected in the bone marrow by both
allele-specific and qPCR. At no point during the clinical course did the patient have a
persistent leucocytosis, erythrocytosis or thrombocytosis. The patient was subsequently
diagnosed with malignant melanoma to which she succumbed. An extended analysis for
JAK2 V617F was conducted in diagnostic or pre-allogeneic haematopoietic stem cell
transplantation samples from a further 38 AA patients without evidence of PNH, none of
which were found to harbour this mutation. This was the first report of JAK2 V617F
positivity in AA with PNH, which although transient was reproducibly detected at a
relatively high allelic frequency suggesting the development of a sizable clone in the bone
marrow sample.

4.2.9 Considerations and Recommendations for a New Molecular Diagnostic
Algorithm for the Myeloproliferative Neoplasms
By developing an understanding of the incidence, significance and behaviour of mutated
MPN clones across different cohorts and through time, the development of
recommendations for molecular diagnostic algorithms that can be implemented in the
clinical diagnostic setting can be achieved. However, to fully inform the development of
these algorithms, the ‘real-life’ experience of managing a testing service and the referrals
for testing it receives is required. To further understand if requests for CALR mutation
testing were being made on appropriate samples and given a previously noted referral
centre variation in JAK2 V617F requesting patterns in the Republic of Ireland, where
increasing numbers of JAK2 V617F requests were made despite the annual incidence of
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MPN diagnosis remaining steady (Langabeer, 2012), an audit was conducted on 1244
CALR mutation requests made both prospectively and retrospectively (2005-2016) since
the launch of the test. A total of 73 patients (5.9%) were found to harbour CALR exon 9
indel mutations, with the distribution of CALR positive patients on an annual basis
ranging from 3.3%-8.2% (Figure 4.6). With regard to requesting criteria, 513 requests
(41.2%) had no clinical details provided while the clinical details provided on the
remainder could be categorised as outlined in Table 4.3 below.
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Figure 4.6. Distribution of CALR mutation requests 2005-2016. CALR mutation positive
samples in black.
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Table 4.3: Incidence of CALR mutations according to requesting details category.
Category
Known JAK2 V617F negative ET
Known JAK2 V617F negative PMF
Known JAK2 V617F negative MPN
unspecified
? ET
? PMF
? MPN unspecified
Persistent thrombocytosis
Thrombocytosis
Erythrocytosis/raised haematocrit
Other
(splenomegaly/neutrophilia/thrombosis/etc.)
No clinical details provided 513 1 (0.2%)
Total

No.
Patients
74
18
17

CALR
Detected
44 (59.5%)
10 (55.5%)
2 (11.8%)

109
28
24
124
189
37
111

9 (8.3%)
2 (7.1%)
1 (4.2%)
3 (2.4%)
1 (0.5%)
0 (0%)
0 (0%)

513
1244

1 (0.2%)
73

mutation

CALR mutations were primarily detected in those patients with either a known or
suspected diagnosis of ET or PMF. The detection rate of CALR mutations did not differ
significantly between those patients analysed retrospectively (5.7%) and those analysed
prospectively (6.1%). Of note, no CALR mutations were detected in patients with clinical
details provided of erythrocytosis or raised haematocrit or in those patients with isolated
thrombosis, which has been supported elsewhere (Chauveau et al., 2017). A lack of clear
clinical details when submitting patient samples for referral in combination with testing
of cohorts such a SVT and patients with isolated thrombosis that do not benefit from
CALR mutation analysis highlights the constraints in implementing evolving diagnostic
guidelines in real-life practice, which is acknowledged to influence subsequent treatment
approaches and outcomes (Peterson et al., 2011) and affirms the requirement for continual
education and adoption of such guidelines for the systematic investigation of a suspected
MPN.
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To further understand the quality of test referral requests received in the Diagnostic
Laboratory, a review of the quality of clinical information and appropriateness of JAK2
V617F test requests over a 12 month period was conducted. A total of 1228 requests
received for JAK2 V617F testing during a 12-month period (January-December 2013)
were assigned to the following nine categories based on clinical details provided: No
clinical details provided (n = 525), PV/?PV (n = 321), ET/?ET (n = 266), PMF/?PMF (n
= 18), thrombosis (n= 57), splenomegaly (n = 17), neutrophilia/eosinophilia (n = 40),
other myeloid malignancies (n = 24), and miscellaneous (n = 20) (Figure. 4.7). Overall,
205 patients (15.9%) had evidence of the JAK2 V617F. Of immediate note was the
significant proportion (40.8%) of referrals received with no clinical details provided.

Figure 4.7. Indications for JAK2 V617F analysis. Black: JAK2 V617F detected; gray:
JAK2 V617F not detected.
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The capacity of a diagnostic laboratory service to provide a rational MPN molecular
diagnostic service is reliant upon sufficient clinical detail to best triage sample referrals
and assign appropriate testing. By combining the information gleaned from the CALR and
JAK2 referral audits, recommendations that could support a new MPN diagnostic
algorithm which incorporated CALR mutation analysis could be developed. The
recommendations are outlined below.

Recommendation 1: Provide sufficient, relevant clinical details, including
provisional diagnosis, to enable application of the testing algorithm.
These audits have demonstrated a consistent increase in requesting patterns despite the
number of newly diagnosed MPN patients remaining constant. Awareness of service
availability might explain this phenomenon yet the rising request rate most likely
represents an increasing use of testing as an inappropriate, advance exclusionary test in
the initial work up of patients for whom secondary causes have not been fully ruled out.

Recommendation 2: Ensure alternative causes of MPN-like haematological indices
are excluded prior to request for molecular diagnostic testing.
Recognising the impact of inappropriate referrals and adherence to best practice
guidelines when investigating cases of suspected MPN will directly increase the
prevalence of MPN diagnostic mutations in the tested population by reducing the number
of inappropriate samples received, improve the positive predictive value or proportion of
patients with a positive test result that have the disease, and reduce false positive results
issued.
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Recommendation 3: Acknowledge the effect of inappropriate referrals on the
predictive value of the testing algorithm.
In only those cases of suspected ET and PMF that are JAK2 V617F negative, next-step
reflexive testing for CALR mutations is advocated

(Tefferi and Pardanani, 2014)

reinforcing the inclusion of appropriate clinical details. This would minimise the
compounding effect on the clinical sensitivity of test results, and also ensure appropriate
allocation of resources at testing laboratories.

Recommendation 4: Adopt and adhere to the MPN molecular diagnostic algorithm.
To support the correct allocation of resource in this scenario, a rational testing algorithm
for the JAK2 V617F, CALR and BCR-ABL1 rearrangements was proposed (Figure 4.8).
Adoption of this algorithm has the capacity to streamline testing for those patients who
truly warrant investigation and to minimise turnaround times thus enabling prompt
clinical decision making.
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Figure 4.8. Proposed molecular diagnostic algorithm for suspected MPN. PV:
polycythaemia vera; CML: chronic myeloid leukaemia; ET: essential thrombocythemia;
PMF: primary myelofibrosis; BM: bone marrow.
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4.3 Discussion
This chapter investigated the incidence and significance of MPN mutations in various
clinical scenarios and cohorts. By establishing the existing rate of CALR mutations in
Irish patients and relevant cohorts such as SVT and paediatric MPN, considered
incorporation of CALR mutation testing into a relevant prospective MPN molecular
diagnostic algorithm can be achieved and will optimise the number of patients benefitting
from such testing within existing laboratory resources. Given the previously described
variability in requesting JAK2 V617F analysis within Ireland (Langabeer, 2012), limiting
testing to those patients with suspected ET and PMF appears judicious.
In the SVT cohort, the low incidence of CALR mutations detected (0/144) is supported
by initial data on the haematological and clinical phenotype suggesting CALR+ ET is a
distinct entity with an indolent clinical course associated with higher platelet counts,
lower white cell counts and a lower risk of thrombosis when compared to JAK2 V617F+
ET (Rotunno et al., 2014; Rumi et al., 2014c). Subsequent studies have since confirmed
the low rate of CALR mutations in this cohort (Turon et al., 2014). These studies have
implications for the diagnostic screening and workup of SVT patients in whom an
underlying MPN is suspected. Investigating the mutational profile of FMPN patients and
including CALR mutations in this study allowed for clarified molecular profiling and
enhanced our ability to deliver a definitive diagnosis to familial MPN patients. This is of
added importance due to the fact that there is evidence to suggest disease anticipation in
FMPN i.e. an earlier age of onset in subsequent generations (Rumi et al., 2007) and the
incidence of several non-haematological cancers is increased in FMPN (Olcaydu et al.,
2011). This apparent increased frequency of secondary malignancies might possibly be
due to an inherent underlying genomic instability (Scott and Rebel, 2012) or due to a
common environmental factor (Anderson et al., 2012). A thorough investigation of family
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history at the initial diagnosis of MPN patients is advocated with consideration given to
suggestive MPN-related symptoms in relatives.
Paediatric ET patients are a rare cohort of patients and understanding the
contribution of MPN mutations in driving the disease remains poorly understood. By
combining our data with that of Giona et al. to enhance cohort size and age distribution
of the cohort (Giona et al., 2014), it was shown that MPN mutations appear to be
represented in younger children at a lower rate to older adolescents and adults,
highlighting a difference in the pathogenesis of this disease in children or indeed in the
classification of the triple negative paediatric MPN cases, as has been suggested
(Langabeer, 2016).
To further develop our understanding of paediatric ET, a case for the potential for
the MPN mutation to be present in utero was investigated. Both parents of the child
assessed had normal full blood counts and no evidence of the JAK2 V617F. Indeed, there
was no clinical history of an MPN in either parent or their families, so the likelihood of
FMPN was diminished, suggesting that in this case the ET is non-familial and the JAK2
V617F detected in the antenatal bloodspots was somatically acquired in utero, further
extending our understanding of the aetiology and biology of MPN. An explanation as to
when this mutation arose remains elusive: an early acquisition during foetal
haematopoiesis is postulated as significant expansions of the JAK2 V617F clone must
have occurred both in utero and in the post-natal periods in tandem with normal foetal
and neonatal haematopoietic development. Other genetic or epigenetic events, be they
acquired or inherited, may have contributed to the acquisition of the JAK2 V617F and its
subsequent capacity to elicit the disease phenotype in early childhood in this case. Other
MPN relevant mutations, such as those in TET2, CBL, IDH1 and IDH2 have not been
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detected in a limited study of childhood MPN (Ismael et al., 2012). This was the first
report indicating a prenatal origin of childhood ET.
The identification of a patient case that harboured two different CALR clones that
were shown to fluctuate in allelic frequency after 10 years post presentation and seven
years after hydroxyurea therapy has implications for selection of molecular diagnostic
methodology. Sanger sequencing, fragment length analysis, high resolution melt curve
analysis, quantitative PCR, digital PCR and NGS technologies have been used to detect
CALR mutations (Jones et al., 2015; Park et al., 2015). The ability to detect low levels of
multiple CALR mutations in the same assay is advantageous, however considerations of
sensitivity, detection of the range of CALR mutation types, ease of use, availability and
cost must be weighed before clinical implementation. Initial reports suggest that unlike
interferon alpha, hydroxyurea therapy has no significant impact on the mutant CALR
allele burden (Verger et al., 2015) implying that the phenomenon described represents an
authentic variation in the clonal architecture of this patient. Given the variability in
mutated CALR allele burden over time, caution must be advised when interpreting
residual disease responses.
The description of a rare case of CALR+ ET that transformed to AML signified
that the AML clone was not derived from the CALR mutation-bearing MPN clone but
from either a myeloid progenitor prior to acquisition of the CALR mutation or in a clone
distinct from that with the CALR mutation similar to that previously encountered in
transformation of JAK2 V617F-positive MPN. Transformation of CALR+ ET to CALRAML is a rare event as the CALR mutation is generally acquired as an early event in the
clonal development of the disease. Transformation is thus usually to a CALR+ AML. In
this case, transformation to CALR- AML highlights potential for early clonal
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heterogeneity in ET and MPN patients and provides further insight into the pathogenetic
mechanisms of leukaemic transformation.
The description of the hitherto unreported detection of the JAK2 V617F in a PNHrelated bone marrow failure syndrome (AA) was at a similarly low frequency to that
previously described in classical PNH (Fouassier et al., 2009; Sugimori et al., 2012). As
this case was identified retrospectively, existence of the JAK2 V617F in the PNH clone
could not be verified by fluorescence-activated cell-sorting of the GPI-AP-negative
population. However, the transient nature of the JAK2 mutation in the presence of a
relatively stable PNH clone, taken together with the evidence of different JAK2 V617F
and PNH clone sizes signifies two distinct populations as opposed to the co-existence of
mutations within one clone. The phenomenon of transient JAK2 V617F-positivity may
be explained by the acquisition of the mutation in a more differentiated haematopoietic
progenitor than that in patients with MPN. If this progenitor had reduced self-renewal
potential and capacity for differentiation, then the clone generated might therefore be
short-lived and not result in a clinical phenotype (Passamonti et al., 2007).
Characterisation of the role of JAK2 signalling in PNH and PNH-related disorders may
provide some insight into JAK2 AA disease development, maintenance or progression.
The detection of the JAK2 V617F and other molecular lesions that contribute to clonal
expansion, such as deregulation of HMGA2 expression, evident in PNH (Inoue et al.,
2006) and both typical MPN and atypical myeloid malignancies (Odero et al., 2005; Ueda
et al., 2017) suggests some common pathogenetic mechanisms of PNH and MPN that
warrants further investigation.
Given the current knowledge of the frequencies and specificities of diagnostically
relevant MPN-associated mutations, adherence to recommendations and guidelines for
both the diagnosis and treatment of MPN is essential. Using information gleaned from
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CALR and JAK2 referral audits, recommendations to support a new MPN diagnostic
algorithm that would support appropriate allocation of resources to meet clinical need and
reinforce the value of interaction between the clinic and laboratory to enhance patient
care was developed.
To conclude, by examining the incidence of MPN mutations in the cohorts
described, insight into the clinical phenotype of CALR mutated MPN was developed, i.e.
that it is reflected in the low incidence of CALR mutation in SVT patients, that CALR
mutations can also occur in FMPN and have value as a diagnostic marker in these patients.
CALR mutations were also shown to occur infrequently in paediatric ET, suggesting
alternative disease mechanisms in the majority of these patients. However, it has been
shown here that MPN driver mutations can occur in utero. Also demonstrated was that
multiple CALR mutated clones can co-exist and remain stable over time, however the
individual clone size may fluctuate, suggesting caution with interpretation of mutation
data post treatment. Reflecting this phenomenon, it was shown that JAK2 V617F clones
can be transient in nature in some clinical settings also. Taken together, this new data
adds to the body of knowledge in understanding how to interpret MPN mutations in the
clinical setting, in both classical MPN and other cohorts.
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5.0 Application of somatic molecular diagnostic
markers in Acute Myeloid Leukaemia
The aim of this chapter was to validate the introduction of next generation sequencing
(NGS) techniques for detection of somatic mutations in AML clinical cohorts. The data
in this chapter is the result of work that culminated in the four publications listed below
(Appendix 1/2C). My personal contribution to the work in each paper is outlined beneath
each of the citations and verified by my co-authors in Appendix 3.
1. Haslam K, Chadwick N, Kelly J, Browne P, Vandenberghe E, Flynn C, Conneally E,
Langabeer SE. Incidence and significance of FLT3-ITD and NPM1 mutations in patients
with normal karyotype acute myeloid leukaemia. Ir J Med Sci. 2010 Dec;179(4):507-10.
Personal Contribution: Contributed to design of study, carried out analysis of FLT3-ITD
and NPM1 mutation status. Interpreted and collated experimental and clinical data.
Primary author of paper. Reviewed and approved final version of manuscript for
submission.
2. Haslam K, Catherwood MA, Dobbin E, Sproul A, Langabeer SE, Mills KI. InterLaboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid
Leukemia. Mol Diagn Ther. 2016 Oct;20(5):457-61.
Personal Contribution: Designed study. Performed experimental NGS work for Dublin
centre. Collated, analysed and interpreted data from all collaborating centres. Wrote
paper, reviewed and approved finalised version for publication. Corresponding author.
3. Haslam K, Appleby N, Armstrong C, Kelly J, Langabeer SE, Flynn CM, Conneally
E. Mutation profiling in patients with high-risk myeloid malignancies undergoing
fludarabine, cytosine, arabinoside, amsacrine, cyclophosphamide, and busulfan
conditioning and allogeneic transplantation. Manuscript.
Personal Contribution: Contributed to design of study, carried out all NGS technical
analysis. Collated, analysed and interpreted clinical and technical data. Primary author of
paper. Reviewed and approved final version for submission.
4. Haslam K, Langabeer SE, Hayat A, Conneally E, Vandenberghe E. Targeted nextgeneration sequencing of familial platelet disorder with predisposition to acute myeloid
leukaemia. Br J Haematol. 2016 Oct;175(1):161-3.
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Personal Contribution: Contributed to design of study, carried out NGS experimental
analysis. Analysed and interpreted mutational output data. Contributed to review and
approval of paper prior to publication.

5.1 Introduction
With the recent movement towards implementation of NGS in the clinical scenario,
application of this technology has the potential to further elucidate the mutational profile
of clinical cohorts, allow for molecular stratification and the identification of additional
markers for molecular monitoring prior to transplantation.
The Ion Torrent (ThermoFisher) NGS technology used in this chapter
allows for sequencing of a large number of targets in multiple samples in parallel. The
performance of this technology was assessed against the conventional ISO15189
accredited single gene assay methods (where available) as part of an interlaboratory
technology performance assessment between clinical molecular diagnostic facilities in
Dublin, Edinburgh and Belfast.
In AML for many years the only molecular markers tested for in a routine
setting were FLT3-ITD and NPM1 mutations, as they had a direct bearing on prognosis,
with CEBPα tested for in specialist centres. For other markers of significance there was
no methodology readily available for these patients, so the commercial development of a
NGS targeted panels that covered 19 genes that are recurrently mutated in AML was a
significant step forward for these patients and offered the potential to deploy this new
technology into specific cohorts to further understand the underlying genetic instability,
offering the potential to enhance genetic testing in these patients, and improve clinical
management.
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The methods used in this chapter are outlined in detail in Chapter 2 and include nucleic
acid extraction and QC (section 2.3- 2.7), FLT3-ITD PCR (section 2.9.4), NPM1 exon 12
mutation PCR (section 2.9.2, 2.10.1), Next generation sequencing protocol (section 2.13).

5.2 Results
5.2.1. Incidence and significance of FLT3-ITD and NPM1 mutations in patients
with normal karyotype acute myeloid leukaemia.
Up to half of AML intermediate risk group patients have a normal karyotype (NK-AML)
and a wide heterogeneity exists in terms of responses to treatment. At the molecular level,
the most common mutations in this group are FLT3-ITD (40%) and those in NPM1 exon
12 (50%) (Bacher et al., 2009) with the genotype of mutated NPM1 without FLT3-ITD
in NK-AML associated with a high remission rate and favourable outcome (Gale et al.,
2008), with no difference in relapse-free survival whether a sibling donor was available
for ASCT or not, suggesting that sibling ASCT may not improve outcome in first
remission in this group of patients (Schlenk et al., 2008). As the molecular genotype of
NK-AML has an increasingly important impact on clinical decision making, including
transplantation options, the incidence and significance of NPM1 and FLT3-ITD mutations
were therefore sought in a series of patients referred for molecular investigation.
A retrospective audit of patients with a diagnosis of NK-AML returned a
total of 44 adult patients all of whom were less than 65 years of age and therefore potential
recipients of ASCT. The median age of patients was 46 years (range 17–65) with 26 males
and 18 females and a median follow-up of 19 months (range 1–68 months). DNA was
extracted from presentation BM (n = 36) or peripheral blood (n = 8) with greater than
20% myeloblasts before FLT3-ITD and NPM1 mutation assays were performed. A
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representative agarose gel electrophoresis of a FLT3-ITD PCR (Figure 5.1A) and a NPM1
mutation electropherogram are shown below (Figure 5.1B).
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Figure 5.1. Agarose gel image of FLT3-ITD and electropherograms of NPM1 reactions.
A; Agarose gel electrophoresis of FLT3-ITD PCR reactions. Lanes 1 and 12, 100-bp
ladder; lanes 2–7, NK-AML patients; lane 8, 5% FLT3-ITD control; lane 9, FLT3 wildtype control; lane 10, 100% FLT3-ITD control; lane 11, water control. B;
Electropherogram of a wild type NPM1 sample (single peak, left panel) and a
heterozygous mutated NPM1 sample (additional mutated peak – black arrow, right panel).
Two peaks with a 4 base pair difference in size are clearly visible in the mutated sample.

FLT3-ITD mutations were identified in 20 (45.5%) and NPM1 mutations in 24 (54.5%)
of the 44 NK-AML patients investigated. Patients were further stratified into groups
according to genotype (Table 5.1). Thirteen (29.5%) patients were NPM1-/FLT3-ITD- , 7
(16%) were NPM1-/FLT3-ITD+, 11 (25%) were NPM1+/FLT3-ITD- and 13 (29.5%) were
NPM1+/FLT3-ITD+.
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Table 5.1 Distribution of NPM1 mutation and FLT3-ITD status.
Genotype

No. of patients

% of total

NPM1- / FLT3-ITD-

13

29.5

NPM1- / FLT3-ITD+

7

16.0

NPM1+ / FLT3-ITD-

11

25.0

NPM1+ / FLT3-ITD+

13

29.5

Follow-up data were evaluable for 84% (37/44) of the patients analysed. Kaplan–Meier
analysis showed no significant differences in the overall survival between those NKAML patients who were either FLT3-ITD positive or negative or in those who were
NPM1 mutation positive or negative (data not shown). No statistically significant
differences in overall survival were noted between each of the aforementioned four
genotypic subtypes but, of note, 8/11 (73%) of FLT3-ITD negative/NPM1 positive
patients remain alive, six of whom are in first complete remission.

5.2.2 Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for
Acute Myeloid Leukaemia.
Recent application of genomic techniques such as whole genome sequencing has yielded
a broad view of the mutational landscape of AML and highlighted 25–30 recurrent
somatic mutations. The adoption of targeted gene panels comprising a refined set of
disease relevant genes has shown promise for translation of NGS into clinical practice
(Kohlmann et al., 2013; McCourt et al., 2013; Ivanova et al., 2015). To evaluate the
utility of a newly available commercial AML gene panel, an inter-laboratory evaluation
was conducted across three clinical diagnostic centres in the UK (Belfast City Hospital,
Western General Hospital, Edinburgh) and Ireland (St. James’s hospital, Dublin). DNA
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from six pre-characterised AML patients were distributed to each centre, processed and
sequenced as outlined in section 2.13. Platform performance, somatic mutation detection
and reproducibility were determined.

5.2.2.1 Platform Performance
Performance of the Ion Torrent PGM platform and workflow at each centre was assessed
using the sequencing QC data generated for each sample. Variables assessed were the
number of reads generated, average depth of coverage across the bases (both highlighted
in grey), the AQ20 (1 % error rate) quality score of bases and the average read length
generated (Table 5.2). An average read count of 602,354 reads per sample (range
150,312–1,212,941) was generated. Mean read length at AQ20 was consistent at 123 bp
(CV 3.3 %) for all samples analysed. An average sample read depth of 2725X (range
629–5600) was achieved using six samples on a 318v2 chip, with significant variability
observed in the depth of coverage generated for individual QC samples and between
centres. AcroMetrix Oncology Hotspot controls (run alongside the duplicate of QC #6)
showed detection of applicable variants present in IDH1/2, KIT, NPM1, PTPN11, FLT3,
TP53, KRAS and NRAS at VAFs of between 5 and 10 % (25 % for NPM1) at 500X as
expected.
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Table 5.2 Performance variables for Ion Torrent Ampliseq AML Panel across six QC samples.

Criterion

QC #1

QC #2

QC #3

QC #4

QC #5

QC #6

Mean

Standard
Deviation

CV

602354.56

281704.44

46.8

Centre

1

2

3

1

2

3

1

2

3

1

2

3

1

2

3

1

2

3

Number of reads

161708

537984

851897

1212941

974719

802420

608123

150312

441551

762608

733111

722889

243565

502320

724439

520442

304244

587109

No. of Bases (Mbp)

22

72

114

164

129

108

77

18

56

102

96

95

32

67

98

67

39

75

79.48

38.22

48.1

No. of bases AQ20
(Mbp)

19

64

99

145

114

94

67

16

48

89

84

83

29

59

85

59

34

65

69.65

33.61

48.3

Mean base coverage
depth (fold)

750

2463

3905

5600

4451

3699

2639

629

1902

3485

3305

3260

1116

2290

3360

2294

1334

2581

2725.81

1309.67

48.0

Mean Read Length
AQ20

128

126

124

128

126

125

119

114

117

126

123

123

127

126

125

121

121

119

123.25

4.05

3.3

Mean reads per
sample
Standard Deviation
per sample
CV per sample

517196

996693

399995

739536

490108

470598

345564

206141

231717

20624

240669

147873

67

21

58

3

49

31
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5.2.2.2 Somatic Mutation Detection
To analyse somatic mutation detection, unfiltered data files from each centre were
downloaded from Ion Reporter and analysed using the algorithm outlined below in Figure
5.2. Unfiltered data was exported into Microsoft Excel, tabulated and filtered by column.
To exclude mutations with no effect on protein amino acid constitution, synonymous
mutations and those present within intronic and untranslated regions were removed.
Following this, non-synonymous mutations that were present at <5% allelic frequency
were excluded as the sensitivity of the assay could not guarantee a positive call at this
level from background interference.

Remaining non-synonymous mutations were

individually reviewed using IGV genome browser and various public databases to
confirm pathogenic potential (Figure 5.2).

Figure 5.2 Bioinformatic algorithm for filtering and calling of somatic mutations
detected.
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A total of 16 somatic mutations were identified in the six AML patient samples tested.
Centres 1 and 3 identified all 16 mutations, whereas Centre 2 identified 15/16, producing
an analytical specificity for the gene panel of 97.9 % (95 % CI 89–99 %) (Table 5.3). A
mean of 2.7 somatic mutations were detected in each AML patient sample (range 1–4),
representing nine genes on the panel (ASXL1, DNMT3A, IDH1, IDH2, NPM1, NRAS,
PTPN11, RUNX1, TET2), with ASXL1 and DNMT3A being the most frequent. NPM1
mutations were identified in one of the six QC samples, confirming results obtained at
diagnosis by standard methodology at the referring centre. In addition, two frameshift
deletions in ASXL1 not currently represented in COSMIC were identified in all centres
and confirmed using IGV. Allelic frequencies of the 16 mutations detected ranged from
5.6 to 53.3 % (median 44.4 %), with a high concordance between Centres for mutations
detected (Figure 5.3).
Of note, Centre 2 did not report detection of the PTPN11 c.215C>A
p.Ala72Asp mutation in sample three. Reanalysis of the data confirmed the presence of
the missed mutation at a read depth of 302X, initially omitted as the read depth was
<500X (in bold italics Table 5.3 and Figure 5.3, mutation number 7).

5.2.2.3 Reproducibility
Analysis of duplicate sample data showed both within and between run concordance, with
the same number of variants detected at similar frequencies by all centres (Figure 5.3).
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Table 5.3 Somatic mutations identified.
Centre

QC Sample

Locus

Gene

Exon

Type

Coverage

Frequency

Coding

Protein

1

1

chr2:25470011

DNMT3A

9

missense

723

46.6

c.1031T>A

p.Leu344Gln

chr5:170837546

NPM1

11

frameshiftInsertion

935

53.3

c.862_863insGCTC

p.Trp288fs

chr2:25470011

DNMT3A

9

missense

2000

48.6

c.1031T>A

p.Leu344Gln

chr5:170837546

NPM1

11

frameshiftInsertion

521

43.8

c.862_863insGCTC

p.Trp288fs

chr2:25470011

DNMT3A

9

missense

1996

48.2

c.1031T>A

p.Leu344Gln

chr5:170837546

NPM1

11

frameshiftInsertion

1983

46.7

c.862_863insGCTC

p.Trp288fs

chr1:115258747

NRAS|CSDE1

2

missense

1926

28.8

c.35G>A

p.Gly12Asp

chr1:115258748

NRAS|CSDE1

2

missense

2000

5.7

c.34G>A

p.Gly12Ser

chr4:106164778

TET2

6

nonsense

948

46.8

c.3646C>T

p.Arg1216Ter

chr21:36231773

RUNX1

6

missense

1997

47.3

c.611G>A

p.Arg204Gln

chr1:115258747

NRAS|CSDE1

2

missense

1919

28.5

c.35G>A

p.Gly12Asp

chr1:115258748

NRAS|CSDE1

2

missense

2000

6.9

c.34G>A

p.Gly12Ser

chr4:106164778

TET2

6

nonsense

2000

48.4

c.3646C>T

p.Arg1216Ter

chr21:36231773

RUNX1

6

missense

1997

46.0

c.611G>A

p.Arg204Gln

chr1:115258747

NRAS|CSDE1

2

missense

1919

30.3

c.35G>A

p.Gly12Asp

chr1:115258748

NRAS|CSDE1

2

missense

1999

5.6

c.34G>A

p.Gly12Ser

chr4:106164778

TET2

6

nonsense

1999

47.2

c.3646C>T

p.Arg1216Ter

chr21:36231773

RUNX1

6

missense

1993

48.4

c.611G>A

p.Arg204Gln

chr12:112888199

PTPN11

3

missense

1848

16.6

c.215C>A

p.Ala72Asp

chr20:31023180

ASXL1

12

frameshiftDeletion

1944

48.1

c.2666_2667delCT

p.Leu890fs

chr12:112888199

PTPN11

3

missense

1994

19.6

c.215C>A

p.Ala72Asp

chr20:31023180

ASXL1

12

frameshiftDeletion

1954

46.2

c.2666_2667delCT

p.Leu890fs

chr12:112888199

PTPN11

3

missense

302

24.2

c.215C>A

p.Ala72Asp

chr20:31023180

ASXL1

12

frameshiftDeletion

1135

48.0

c.2666_2667delCT

p.Leu890fs

chr12:112888199

PTPN11

3

missense

886

17.0

c.215C>A

p.Ala72Asp

chr20:31023180

ASXL1

12

frameshiftDeletion

1899

49.7

c.2666_2667delCT

p.Leu890fs

chr2:25457242

DNMT3A

23

missense

1976

46.1

c.2645G>A

p.Arg882His

2

1

3

1

1

2

2

3

2

2

1

3

1 duplicate

3

2

3

3

3

1

4

174

2

3

1

2

3

3 duplicate

4

4

5

5

5

5

chr2:209113113

IDH1

4

missense

1470

44.8

c.394C>T

p.Arg132Cys

chr20:31022592

ASXL1

12

nonsense

1990

45.5

c.2077C>T

p.Arg693Ter

chr20:31023408

ASXL1

12

nonframeshiftDeletion

1991

46.1

c.2894_2896delGAG

p.Gly966del

chr2:25457242

DNMT3A

23

missense

1991

44.6

c.2645G>A

p.Arg882His

chr2:209113113

IDH1

4

missense

1990

44.0

c.394C>T

p.Arg132Cys

chr20:31022592

ASXL1

12

nonsense

1986

45.9

c.2077C>T

p.Arg693Ter

chr20:31023408

ASXL1

12

nonframeshiftDeletion

1972

49.4

c.2894_2896delGAG

p.Gly966del

chr2:25457242

DNMT3A

23

missense

1997

46.3

c.2645G>A

p.Arg882His

chr2:209113113

IDH1

4

missense

1878

44.2

c.394C>T

p.Arg132Cys

chr20:31022592

ASXL1

12

nonsense

1993

46.4

c.2077C>T

p.Arg693Ter

chr20:31023408

ASXL1

12

nonframeshiftDeletion

1983

51.2

c.2894_2896delGAG

p.Gly966del

chr2:25457243

DNMT3A

23

missense

1374

24.1

c.2644C>T

p.Arg882Cys

chr2:25462032

DNMT3A

20

missense

1312

18.8

c.2375G>A

p.Arg792His

chr15:90631838

IDH2

4

missense

886

25.2

c.515G>A

p.Arg172Lys

chr2:25457243

DNMT3A

23

missense

1997

27.1

c.2644C>T

p.Arg882Cys

chr2:25462032

DNMT3A

20

missense

1998

20.4

c.2375G>A

p.Arg792His

chr15:90631838

IDH2

4

missense

2000

25.9

c.515G>A

p.Arg172Lys

chr2:25457243

DNMT3A

23

missense

1998

25.1

c.2644C>T

p.Arg882Cys

chr2:25462032

DNMT3A

20

missense

1997

21.5

c.2375G>A

p.Arg792His

chr15:90631838

IDH2

4

missense

1998

25.8

c.515G>A

p.Arg172Lys

chr2:25457243

DNMT3A

23

missense

2000

23.8

c.2644C>T

p.Arg882Cys

chr2:25462032

DNMT3A

20

missense

1995

18.1

c.2375G>A

p.Arg792His

chr15:90631838

IDH2

4

missense

1999

22.5

c.515G>A

p.Arg172Lys

1

6

chr20:31022904

ASXL1

12

frameshiftDeletion

1985

32.7

c.2390_2391delAA

p.Ser798fs

2

6

chr20:31022904

ASXL1

12

frameshiftDeletion

1718

25.8

c.2390_2391delAA

p.Ser798fs

2 duplicate

6

chr20:31022904

ASXL1

12

frameshiftDeletion

1976

28.4

c.2390_2391delAA

p.Ser798fs

3

6

chr20:31022904

ASXL1

12

frameshiftDeletion

1826

31.5

c.2390_2391delAA

p.Ser798fs
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Figure 5.3 Allelic frequency of mutations detected in quality-control samples. Mutation
1: DNMT3A p.Leu344Gln; Mutation 2: NPM1 p.Trp288fs; Mutation 3: NRAS
p.Gly12Asp; Mutation 4: NRAS p.Gly12Ser; Mutation 5: TET2 pArg1216Ter; Mutation
6: RUNX1 p.Arg204Gln; Mutation 7: PTPN11 p.Ala72Asp; Mutation 8: ASXL1
p.Leu890fs; Mutation 9: DNMT3A p.Arg882His; Mutation 10: IDH1 p.Arg132Cys;
Mutation 11: ASXL1 p.Arg693Ter; Mutation 12: ASXL1 p.Gly966del; Mutation 13:
DNMT3A p.Arg882Cys; Mutation14: DNMT3A p.Arg792His; Mutation 15: IDH2,
p.Arg172Lys; Mutation 16: ASXL1 p.Ser798fs.
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5.2.3 Mutation profiling in patients with high-risk myeloid malignancies undergoing
fludarabine, cytosine, arabinoside, amsacrine, cyclophosphamide, and busulfan
conditioning and haematopoietic allogeneic stem cell transplantation
The application of NGS technologies in myeloid malignancies has uncovered somatic
mutations associated with adverse outcomes including mutations affecting ASXL1, FLT3,
TP53, RUNX1, EZH2, (Patel et al., 2012; Bejar et al., 2014b; Patnaik et al., 2014) with
subsequent studies indicating an association between somatic mutations and response to
therapy (Klco et al., 2015; Woo et al., 2017). For high-risk MDS patients who undergo
ASCT, the use of pre-defined mutations can enable prediction of relapse risk (Fu et al.,
2014), with somatic mutation in ASXL1, RUNX1, TET2, DNMT3A and TP53 associated
with shorter survival in MDS and MDS/AML patients (Bejar et al., 2014b; Della Porta et
al., 2016). Moreover, detection of somatic mutations prior to transplantation have shown
potential as molecular targets of residual disease in the post-transplant setting (Bacher et
al., 2009b; Fu et al., 2014; Salem et al., 2017).
To further characterise the mutational profile in this context, a
retrospective analysis of patients with high-risk myeloid malignancies treated with
FLAMSA-Bu conditioned ASCT was conducted. Twenty-one patients (10 male, 11
female; median age 55 years; range 36-64 years) were included. Patients were identified
as having poor risk disease on the basis of AML with primary induction failure (n=5),
MDS with high or very high-risk Revised International Prognostic Scoring System (RIPSS) scores (n=8, 4 of whom had therapy-related MDS), therapy-related AML with
MLL rearrangement (n=1), intermediate-2 or high-risk

CMML-specific prognostic

scoring system (CPSS) chronic myelomonocytic leukaemia (CMML) (n=4), blast crisis
of chronic myeloid leukaemia (n=1), PMF with > 10% myeloblasts on bone marrow
(n=1), and mixed phenotype acute leukaemia (T/myeloid) with complex karyotype (n=1)
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(Table

5.4).

Karyotype

was

available

on

20/21

patient

samples

with

a

complex/monosomal karyotype detected in 10/21 (47.6%) patients, an intermediate risk
karyotype in 6/21 (28.6%), and a normal karyotype in 4/21 (19%) (Table 5.4). The median
Haematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) score for patients
was 4 (range 0-10). Patient details and previous induction chemotherapy are outlined in
Table 5.4.
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Table 5.4 Clinical details and transplant characteristics on 21 high-risk myeloid
malignancy patients analysed.
Number of Patients

21

Median age in years
(range)
Gender (male: female)

55 years (36-64
years)
10 male: 11 female

Patient/donor CMV
serostatus

5 (23.8%)
5 (23.8%)

Post-transplant
immunosuppression
Graft versus Host
Disease
Acute
Chronic

4 (19%)

Outcome

4 (19%)

Treatment related
mortality
Death from
relapsed disease
prior to 100 days
Survival at 100
days
Median Progression
Free Survival

WHO 2008 Diagnosis
Acute myeloid leukaemia
Therapy-related myeloid
neoplasm
Chronic myelomonocytic
leukaemia
Myelodysplasia

Transplant
characteristics
Donor type

Chronic myeloid
leukaemia; blast crisis

1 (4.8%)

Primary myelofibrosis

1 (4.8%)

Mixed phenotype acute
leukaemia, T/myeloid,
NOS
Cytogenetics

1 (4.8%)

Normal karyotype
Complex karyotype
Monosomal karyotype as
a sole abnormality
Other karyotype
abnormality
Not available
Initial
pre-transplant
chemotherapy
Azacytidine
DAT 3+10 induction
FLAG-IDA induction
Other pre-transplant
treatment
Bone marrow blasts prior
to ASCT
<5%
5-10%
>10%

4
8
2

Median Overall
Survival

6
1

3/21
11/21
3/21
5/21

11/21
7/21
3/21
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9 Sibling donors
12 Matched unrelated donors
4 Positive/Positive
2 Positive/Negative
1 Negative/Positive
13 Negative/Negative
1 Unknown
19 Ciclosporin/Mycophenolate
2 Tacrolimus/Mycophenolate

7/21
5/17

2/21
2/21

17/21
841 days

Not reached

5.2.3.1 Mutation profiling
Tumour genomic DNA was available on 17/21 patient samples (peripheral blood (n=4),
bone marrow (n=13)) prior to conditioning. FLT3-ITD were identified as previously
described. NGS was carried out using the Ion Ampliseq AML Panel as described in
section 2.13.
Results demonstrate an FLT3-ITD mutation in one patient sample (patient
9). All 17 patient samples were sequenced by NGS at a sufficient depth and quality to
permit bioinformatics analysis. A total of 423 variants were initially detected in 14/17
(82.4%) patient samples sequenced. Exclusion of non-exonic and synonymous variants
reduced the number of variants to 124, before bioinformatic analysis of the remaining
variants further reduced the field to a final number of 33 somatic driver mutations.
Missense mutations predominated (n=22), followed by frame-shift (n=6) and nonsense
(n=5). A median of 2 mutations (range 0-5) was detected, with 5/6 MDS, 4/5 AML, 3/3
CMML, and 2/3 other, harbouring mutations detectable by the panel. TET2 mutations
were the most common lesion, detected in 7/17 (41.2%) cases, followed by RUNX1 and
DNMT3A mutations in 4/17 (23.5%) patients each, (Figure 5.4). Allelic frequencies of
the 33 mutations detected ranged from 3% - 87%, with samples harbouring multiple
mutations displaying variable allelic frequencies. Details of somatic mutations detected
by NGS are given in Table 5.5.
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Figure 5.4. Frequency of mutated genes across patient cohort. The number of times an
individual gene on the panel was mutated in the patient population was determined. TET2;
Tet Methylcytosine Dioxygenase 2, RUNX1; Runt Related Transcription Factor 1,
DNMT3A; DNA (Cytosine-5-)-Methyltransferase 3 Alpha, ASXL1; ASXL
Transcriptional Regulator 1, TP53; Tumor Protein P53, KRAS; Kirsten Rat Sarcoma Viral
Oncogene Homolog, IDH2; Isocitrate Dehydrogenase 2, CBL; Cbl Proto-Oncogene, E3
Ubiquitin Protein Ligase, NPM1; Nucleophosmin 1, NRAS; Neuroblastoma RAS Viral
Oncogene Homolog, PTPN11; Protein Tyrosine Phosphatase, Non-Receptor Type 11,
GATA2; GATA Binding Protein 2; WT1; Wilms Tumor 1.
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Table 5.5. Frequency of mutated genes across patient cohort.
Patient

Locus

Gene

Exon

Coverage

Coding

Protein

Type

1993

Alellic
Frequency
53

1

chr4:106155920

TET2

3

c.822_822delC

p.Asn275fs

Frameshift Deletion

chr4:106156432

TET2

3

1995

27

c.1334_1334delT

p.Leu446fs

Frameshift Deletion

chr20:31024371

ASXL1

12

2000

47

c.3856C>T

p.Gln1286Ter

nonsense

chr21:36231782

RUNX1

6

1990

42

c.602G>A

p.Arg201Gln

missense

chr1:115256528

NRAS

3

1996

25

c.183A>T

p.Gln61His

missense

chr4:106164898

TET2

6

1253

51

c.3766G>C

p.Gly1256Arg

missense

chr20:31024274

ASXL1

12

1556

16

c.3759T>A|c.3759T>C

p.Ser1253Arg/p.(=)

missense/synonymous

chr12:112926888

PTPN11

13

821

4

c.1508G>T

p.Gly503Val

missense

3

chr4:106158490

TET2

3

1701

3

c.3391C>A

p.Pro1131Thr

missense

4

chr20:31022981

ASXL1

12

1990

47

c.2467_2467delT

p.Leu823fs

Frameshift Deletion

5

chr4:106155755

TET2

3

737

87

c.657_658delAC

p.His222fs

Frameshift Deletion

chr5:170837543

NPM1

11

233

43

c.859_860insTCTG

p.Trp288fs

Frameshift Insertion

chr2:25470554

DNMT3A

8

1191

45

c.920C>T

p.Pro307Leu

missense

chr2:25457243

DNMT3A

23

1629

30

c.2644C>T

p.Arg882Cys

missense

chr12:25398281

KRAS

2

799

21

c.38G>A

p.Gly13Asp

missense

chr12:25398284

KRAS

2

798

6

c.35G>T

p.Gly12Val

missense

chr11:119148919

CBL

8

915

4

c.1139T>C

p.Leu380Pro

missense

2

6

7
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8

9

10

11

12

13

14

chr2:25464535

DNMT3A

17

1891

70

c.1978T>C

p.Tyr660His

missense

chr15:90631838

IDH2

4

1636

32

c.515G>A

p.Arg172Lys

missense

chr4:106158490

TET2

3

1999

3

c.3391C>A

p.Pro1131Thr

missense

chr21:36231783

RUNX1

6

1997

38

c.601C>T

p.Arg201Ter

nonsense

chr4:106158228

TET2

3

1084

45

c.3129_3130insAA

p.Ala1045fs

Frameshift Insertion

chr11:119148877

CBL

8

1596

22

c.1097A>G

p.Glu366Gly

missense

chr17:7578212

TP53

6

1996

14

c.637C>T

p.Arg213Ter

nonsense

chr17:7578461

TP53

5

678

8

c.469G>T

p.Val157Phe

missense

chr3:128200073

GATA2

6

355

49

c.1232C>T

p.Ala411Val

missense

chr21:36231783

RUNX1

6

1103

24

c.601C>T

p.Arg201Ter

nonsense

chr21:36252866

RUNX1

5

665

5

c.496C>T

p.Arg166Ter

nonsense

chr12:25398285

KRAS

2

750

35

c.34G>A

p.Gly12Ser

missense

chr17:7578190

TP53

6

212

78

c.659A>G

p.Tyr220Cys

missense

chr15:90631838

IDH2

4

387

12

c.515G>A

p.Arg172Lys

missense

chr11:32417832

WT1

7

366

7

c.1220A>G

p.His407Arg

missense

chr2:25457249

DNMT3A

23

816

43

c.2638A>G

p.Met880Val

missense

15

No pathogenic mutations detected

16

No pathogenic mutations detected

17

No pathogenic mutations detected
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Circos plots were used to order mutations by disease group. These plots are generated to
visualise the data in a circular layout, making it easier to explore relationships between
positions. The plots revealed predominant associations of RUNX1 and TP53 within the
MDS group, ASXL1 and TET2 within the CMML group, TET2 and DNMT3A within the
AML group, and KRAS within the other grouping (Figure 5.5).

Figure 5.5. Circos plot connecting disease groups and mutated genes. Each segment on
the plot corresponds to a gene or disease group. Genes mutated in a particular disease
group are linked to that disease group by a line. The width of the linking line shows the
percentage of disease group patients that have mutations in the associated gene. For
example, 30% of CMML patients have an ASXL1 mutation, whereas all ASXL1 mutations
are found in CMML patients.
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Analysis of gene-gene co-mutation within samples revealed the underlying heterogeneity
within samples (Figure 5.6) with TET2 as the gene with the highest number of associated
mutations (n=12), followed by DNMT3A (n=9). Two de novo AML samples detected
possessed an IDH2 R172 mutation with co-mutated DNMT3A (patients 8 and 14, Table
5.5).

Figure 5.6. Circos plot showing gene-gene co-mutation in patient cohort. For example,
TP53 mutations were associated with mutations in CBL, GATA2, KRAS and TET2,
whereas GATA2 was found only associated with TP53 mutations.
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5.2.3.2 Statistical Analysis
Estimates of overall survival (OS) and progression free survival (PFS) were calculated
using GraphPad Prism® 7 (GraphPad Software, California, USA) and expressed as
Kaplan-Meier curves. OS and PFS were calculated from time of transplantation to event,
which was defined as death and progression or death for OS and PFS respectively. Nonrelapse mortality (NRM) was defined as death from any cause other than refractory
disease or relapse. Statistical significance was set as a p value <0.05, i.e. the observed
quantitative difference occurs by chance <5% of the time.

5.2.3.3 Mutations versus outcome
Assessment of age and number of mutations detected showed no significance, with
patients <49 years versus those >50 years with a PFS/OS p-value of 0.8384 and 0.9166
respectively. Both groups had a median of two mutations (range 0-4) (p 0.7414). Analysis
of the impact of individual genes on outcome was precluded by the limited patient cohort.

5.2.3.4 Clinical outcome
Twelve (57.1%) patients received stem cells from fully HLA matched unrelated donors.
All patients achieved neutrophil engraftment, occurring at a median of 24 days (range 11124 days) and platelet engraftment at a median of 26 days (range 10-221 days) postASCT. Ten (47.6%) patients received planned donor lymphocyte infusions and seven
(33.3%) patients developed acute GvHD. Two treatment-related deaths occurred; one
from sepsis in the context of steroid-refractory GvHD and another from toxoplasmosis
infection. Ten (47.6%) patients remain alive and disease-free after a median of 513 days
follow-up. Nine (42.9%) patients have relapsed post-ASCT, three of whom remain alive
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following salvage therapy. The median time to relapse was 109 days (62-751), with
median progression free survival (PFS) at 841 days and median overall survival (OS)
having not yet been reached. The impact of donor source (related versus unrelated donor)
did not impact on PFS (p=0.2568) or OS (p=0.7389). Of note, all four CMML patients
relapsed at a median of 694 days post-FLAMSA-Bu ASCT. The median PFS for de novo
AML and MDS has not been reached (Figure 5.7). Overall non-relapse mortality (NRM)
was 9.5%, with a median predicted two-year NRM of 41% using the HCT-CI Score.

Figure 5.7 Progression free survival of FLAMSA patient cohort by WHO 2008 disease
category.
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5.2.4 Targeted NGS of familial platelet disorder with predisposition to acute
myeloid leukaemia
The application of emerging NGS technologies, platforms and disease targeted panels
allow the simultaneous identification of numerous mutational events. Such a targeted
NGS approach was applied to a known RUNX1 mutated FPD-AML kindred to identify
additional molecular events that co-operate with the germ line RUNX1 mutation in driving
leukaemic transformation. A 56-year-old male and a 45-year-old female sibling both
presented with AML with myelodysplastic features (Figure 5.8, I–3 and I–7 respectively).
At diagnosis, I-3 had trisomy 8 and I-7 had monosomy 7. The eldest son of patient I-7
(Figure 5.9, II-1) has thrombocytopenia. The history of familial thrombocytopenia
coupled with development of AML suggested a diagnosis of FPD-AML, which was
confirmed by Sanger sequencing identification of a heterozygous RUNX1 p.Arg166X
mutation in the leukaemic blasts and constitutional buccal scrapes of both affected
patients (Figure 5.9).

Figure 5.8 Pedigree of the familial platelet disorder with propensity to acute myeloid
leukaemia (FPD-AML) kindred. The index cases (I-3, I-7) are indicated as black symbols.
II-1 (grey symbol) suffered from thrombocytopenia.
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Figure 5.9 Sanger Sequencing electropherogram showing RUNX1 c.496C>T
heterozygous mutation in bone marrow and buccal swab of patient.

Patient I-3 underwent a reduced intensity conditioning ASCT from RUNX1 wild type
sibling donor I-5. Patient I-7 underwent a myeloablative ASCT from RUNX1 wild type
sibling donor I-6. Both patients achieved 100% donor chimerism by day-100 post-ASCT.
For NGS, amplicon libraries were generated from AML diagnostic bone marrow DNA of
I-3 and I-7 using the Ion Ampliseq AML panel as previously detailed. Criteria to allow
confident calling of somatic mutations were set to a minimum target coverage of 500X,
the presence of a mutation at >5% and a predicted change in amino acid sequence. Sanger
sequencing was also performed on exon 8 of CDC25C, encompassing the mutation
hotspot previously described (Yoshimi et al., 2014). Analysis of the NGS data confirmed
the presence of the heterozygous RUNX1 p.Arg166X mutation and also demonstrated the
presence of further mutations in the genes known to disrupt epigenetic (ASXL1, IDH1,
TET2) and transcription factor (CEBPA, RUNX1) function in AML (Table 5.6).
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Table 5.6 Mutations identified by targeted next-generation sequencing in two affected siblings (I-3 and I-7 as presented in Figure 5.9).

Patient Mutated gene

Nucleotide change

Amino acid change

Variant effect % Mutant allele

COSMIC (Disease association)

I-3

RUNX1

c.496C>T

p.Arg166X

nonsense

53%

COSM24769 (AML, ETP-ALL)

ASXL1

c.2083C>T

p.Gln695X

nonsense

26%

COSM1738037

IDH1

c.394C>T

p.Arg132Cys

missense

14%

COSM28747 (AML, Glioma)

RUNX1

c.608C>G

p.Pro203Arg

missense

6%

---

RUNX1

c.496C>T

p.Arg166X

nonsense

50%

COSM24769 (AML, ETP-ALL)

TET2

c.5162T>G

p.Leu1721Trp

missense

50%

---

RUNX1

c.497G>A

p.Arg166Gln

missense

11%

COSM36055 (AML)

CEBPA

c.898C>T

p.Arg300Cys

missense

5%

---

I-7

(MDS)

RUNX1; Runt Related Transcription Factor 1, ASXL1; ASXL Transcriptional Regulator 1, IDH1; Isocitrate Dehydrogenase 1, TET2; Tet
Methylcytosine Dioxygenase 2, CEBPA; CCAAT Enhancer Binding Protein Alpha, AML; Acute Myeloid Leukaemia, ETP-ALL, Early T-cell
precursor acute lymphoblastic leukaemia, MDS; myelodysplastic syndrome.
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Although matched germ line material was not studied by NGS, the fact that several of
these mutations outlined in Table 5.6 have been previously described in haematological
malignancies and that they are present at allele frequencies less than 50%, implies they
are somatic and not heterozygous germ line in nature. No mutations of CDC25C exon 8
were detected in either patient.

5.3 Discussion
The ability to routinely apply molecular methods to stratify patients based on genotype
in a clinical setting has rapidly evolved. In the last decade there has been a move from
single-gene test methods toward the application of NGS panel-based approaches. As this
evolution has occurred, this study applied these techniques and methodologies to
interrogate their value in AML related patient cohorts and to develop a deeper
understanding of disease genotype in clinical cohorts.
In an initial study, the incidence of the four different FLT3-ITD/NPM1 genotypes
in the cohort studied was found to be consistent with that previously reported in larger
studies (Gale et al., 2008; Schlenk et al., 2008; Schneider et al., 2009). Unfortunately, no
differences in overall survival were observed and this may be attributable to the fact that
this study was retrospective, small numbers of patients were studied and that these
patients had a relatively short follow-up. Nevertheless, identification of both FLT3-ITD
and NPM1 mutations is now considered the minimum molecular diagnostic requirement
for NK-AML patients contributing to a prognostic stratification (Mrozek et al., 2007) and
is therefore advocated in all new NK-AML patients.
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With the availability of NGS technology, the inter- and intra-laboratory reproducibility
and robustness of a commercial 19-gene AML panel in three separate clinical centres in
the UK and Ireland was evaluated. Performance of the panel was assessed using six AML
patient samples run on the Ion Torrent PGM platform across all centres. A high level of
concordance was observed, with 15/16 mutations detected. Centre 2 did not report a
PTPN11 c.215C>A p.Ala72Asp mutation, that was excluded as the number of reads
generated for the sample was low (150,312) and the subsequent read depth at the target
site did not achieve 500X. As a depth of coverage of 500X is necessary for confidence in
calling low-level mutations (25 mutated reads are required for a 5 % burden), it is
therefore essential to ensure appropriate coverage of all relevant amplicons to enable
appropriate interrogation and interpretation of data produced. Improving efficiencies
during the pre-analytic stages can help achieve this and would reduce the variability in
reads generated between samples and between centres. Optimisation of library
equalisation or implementation of automated template preparation and chip loading
(using the Ion Chef in this case) could increase reads generated and improve preanalytical
consistency. Reduction of sample number per chip or repeat testing and combination of
results for samples that prove difficult to sequence would help deliver sufficient read
depth for further analysis. Nevertheless, given the variation in reads generated per sample
by each centre, the high concordance in the identification and coverage depth of somatic
mutations in the samples tested proved the capacity of the Ion Ampliseq AML Research
Panel and Ion Torrent as a robust platform for generating reproducible results in a clinical
diagnostic setting.
A limitation of this study was the limited number of genes available for
analysis. Expansion of the panel to incorporate a greater number of relevant genes
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mutated in AML (e.g. splicing factors) would further improve its applicability. The
implementation of common platforms and workflows to interrogate the mutational profile
of AML patients will further enable standardisation of results and collaborative efforts
between centres.
Once the performance of the Ion Torrent using the AML panel had been
established, the technique was applied in specific clinical cohorts. The mutational
landscape of myeloid diseases has been delineated in recent years (Bejar et al., 2011;
Patel et al., 2012; Papaemmanuil et al., 2013; Haferlach et al., 2014), however the
mutational profile in specific clinical scenarios such as ASCT has yet to be fully explored,
with variation in mutational impact observed (Christopeit et al., 2015). The mutation
status and clinical outcome in a cohort of high-risk myeloid malignancy patients
uniformly treated with FLAMSA-Bu conditioning and ASCT was investigated. This
study was funded through a HAI Fellowship Award (Appendix 6). Fourteen out of 17
(82.4%) patients had somatic mutations detected, with a median of 2 mutations per
patient. The frequency of mutations in this cohort was consistent with that observed in
myeloid disorders reported elsewhere, (Papaemmanuil et al., 2013; Haferlach et al., 2014;
Christopeit et al., 2015) with variable allelic burdens observed in patients harbouring
multiple mutations indicating the presence of subclones and a complex clonal
architecture. Of note, two AML patient samples displayed an IDH2 R172 mutation, which
has recently been proposed as a distinct AML genomic entity with a prevalence of
approximately 1% based on mutual exclusivity with NPM1 or other class defining lesions
and a gene-expression and DNA methylation profile that differs from other IDH
mutations leading to more severe aberrations in metabolic activity (Papaemmanuil,
Gerstung, Bullinger, Verena I Gaidzik, et al., 2016).
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Further analysis by disease group reflected the high-risk status of the patients with
mutations associated with poor outcome such as RUNX1 and TP53 predominant within
the MDS group and ASXL1 within the CMML group. Clear gene-gene co-mutation
associations were not found, likely reflecting the underlying heterogeneity of the patients
and the limited number of patients studied. An association between patient age and
number of mutations was not detected, nor between individual mutated genes and patient
outcome, again probably due to the low patient number. A recent large-scale landmark
study matching mutation and clinical data in MDS has reinforced the poor risk of TP53
mutation regardless of conditioning intensity prior to transplant, questioning the benefit
of conventional myeloablative conditioning over reduced intensity approaches in patients
with TP53-mutated MDS (Lindsley et al., 2017). It is therefore interesting to speculate
on a growing role for FLAMSA-Bu based conditioning in these patients in the future,
however further larger scale studies are needed to determine the true effect of
conditioning on TP53-mutated patients.
In the cohort tested, the FLAMSA-Bu regimen was clinically well
tolerated with an NRM below that predicted by HCT-CI scoring (9.5% versus 41%).
However, the outcome for CMML patients and those with therapy related myeloid
neoplasms was poor indicating a need for alternative therapeutic approaches.
Notwithstanding the limitations of a small patient cohort and a limited gene panel,
mutational profiling of patients prior to ASCT aids clinical understanding of patient
genotype. Knowledge of the clonal/subclonal architecture provides potential markers for
disease monitoring post-ASCT in this cohort of patients at high risk of relapse.
In an FPD-AML kindred the AML gene panel was applied to determine
its feasibility to reveal additional driver mutations present in these kindred. In addition to
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the expected RUNX1 mutations, disrupted epigenetic (ASXL1, IDH1, TET2) and
transcription factor (CEBPA, RUNX1) mutations in AML was revealed, allowing for an
appreciation of the underlying genotype and genetic instability beyond the diagnostic
germ-line RUNX1 mutation. While no CDC25C mutations were detected in the two FPDAML affected patients described, the role of these abnormalities requires clarification in
other FPD-AML kindred. Given that the AML panel is limited to 19 genes, this approach
offers several advantages over standard sequencing methodologies in familial AML:
identification of the causative germ line mutation may be possible where the phenotype
may be uninformative (Obata et al., 2015); the simultaneous detection of co-operating
mutations that may be clinically actionable, such as IDH and TET2 demonstrated in the
FPD-AML kindred described herein (Falini et al., 2015); the ability to infer patterns of
clonal evolution in patients with overt AML (Tawana et al., 2015). It also affords an
opportunity to monitor identified thrombocytopenic individuals from FPD-AML kindred
to identify progression to MDS or AML, thus allowing earlier clinical intervention. If
NGS technologies become integrated into routine practice, more cases of familial
leukaemia are likely to be resolved with this approach which could enhance genetic
testing and improve clinical management.
Whilst application of the AML specific panel in the clinical molecular
diagnostic setting proved robust and reproducible, the limited number of genes on the
panel combined with the limited number of applicable patients for testing would make it
difficult to justify from a resource or cost perspective. For NGS implementation in the
clinical molecular diagnostic setting, the majority of laboratories would require a panel
that allowed for the interrogation of a greater number of relevant genes that would be
applicable to a larger set of patients. Since publication of these studies, further
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collaboration has taken place with the commercial company involved in producing the
AML panel assay. In this instance, the authors have acted as subject matter experts on
gene and hotspot content for the development of a broader myeloid specific commercial
panel that incorporates more genes and mutations to expand the clinical relevance and
applicability of the assay to other myeloid disorders such as MPN and MDS in addition
to AML.
Taken together these studies allow for a greater clinical appreciation of patient
genotype and can inform clinical decision making with regard to patient stratification,
monitoring of disease evolution and gauging response to therapy.
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6.0 General Discussion
The last decade has seen significant developments in the understanding of the genetic
basis of myeloid disorders, with the underlying somatic mutational landscape revealed by
whole genome and whole exome sequencing (Welch et al., 2012; Cancer Genome Atlas
Research Network et al., 2013; Klampfl et al., 2013b; Nangalia et al., 2013b; Haferlach
et al., 2014; Papaemmanuil, Gerstung, Bullinger, Verena I. Gaidzik, et al., 2016).
Subsequent studies have revealed a biological impact for some of these mutations and
their consequence in some clinical scenarios (Patnaik et al., 2012; Ayalew Tefferi et al.,
2014; R. Bejar, Stevenson, et al., 2014; Rumi, Daniela Pietra, Ferretti, Klampfl,
Harutyunyan, Jelena, et al., 2014; O’Sullivan and Harrison, 2017). However, there
remains a range of clinically relevant scenarios for which the incidence and significance
of these mutations needs to be elucidated, including whether some of these mutations
have potential to be used as clinical markers of response to therapeutic modalities such
as allogeneic transplantation. This thesis investigated whether mutation burden was
correlated with response to allogeneic transplantation therapy and also whether
knowledge of mutation status informs clinical insight in myeloid neoplasia. By
conducting a series of original investigations into the relevance of somatic mutations in
myeloid neoplasia, an insight into the utility and clinical application of these disease
markers has been developed. The result of this work has culminated in the 19 peer
reviewed publications that form the basis of this thesis.
Chapter 3 sought to establish whether recently identified disease specific
molecular markers could be used to measure the burden of disease in MPN patients and
correlate the results with the more established donor chimerism method. Three different
197

technical approaches were used in separate studies on different MPN disease cohorts in
order to determine the allelic burden of the mutation. Methods used included qPCR for
the JAK2 V617F mutation, capillary electrophoresis and area under the curve analysis, a
semi quantitative method for measurement of CALR mutations and Sanger sequencing
for detection of CSF3R mutations. In the JAK2 V617F study, a sensitive and robust qPCR
assay for JAK2 V617F detection was evaluated and offered improved detail of patient
responses to therapy relative to the conventional donor chimerism method. This approach
offers the potential for clinical intervention earlier than previously available using less
sensitive methods such as donor chimerism, immunophenotyping or morphology. From
a minimal residual disease perspective, an assay that is specific and sensitive such as the
JAK2 qPCR method, requires further validation before deployment on a routine clinical
basis. In subsequent work, we contributed to an international external quality assurance
(EQA) programme using this method to identify parameters critical for the quantification
of JAK2 V617F. In this programme as members of the MPN&MPNr-EuroNet group, an
EU sponsored network of experts on the molecular diagnosis of myeloproliferative
neoplasm (MPN) and MPN-related congenital diseases (MPNr), we participated in two
rounds of EQA with up to 25 laboratories from 17 countries across Europe. The EQA
samples were quantified for JAK2 V617F and results were returned to the central
laboratory in Denmark for analysis. This study showed that variations in methods due to
the starting material, assay set-up, or qPCR equipment did not result in significant outliers
in the EQA programme carried out and was a significant step towards standardisation of
the methodology for use in a molecular diagnostic laboratory (Asp et al., 2019).
In the second study CALR mutations were used as a marker of disease burden,
with a capillary based method of detection chosen to reliably detect CALR exon 9
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mutations. Although a semi-quantitative method, the assay detected CALR mutations at
levels that reflected disease burden across a dynamic range and were stable throughout
disease course. In the diagnostic setting, CALR mutation levels are usually detected at
>15% allele burden and therefore assay sensitivity below this level is generally sufficient
to consistently make a diagnosis of CALR mutation positive MPN. This is in contrast to
JAK2 positive MPN where levels of 1% mutant allele burden have been shown to be of
diagnostic and clinical relevance (Langabeer et al., 2015). In a minimal residual disease
context, that a semi-quantitative method can be used to reflect clinical response to therapy
and therefore can be used to make clinical decisions was shown. The ability of this assay
to identify the majority of CALR exon 9 mutation types clinically observed and to detect
the common Type I/II mutations at a sensitivity of approximately 1% makes it attractive
for routine application in a clinical diagnostic setting. There have been a number of recent
efforts to develop more sensitive and specific quantitative methods targeted at the CALR
Type I/II mutations. A range of approaches have been developed using pyrosequencing,
digital droplet PCR, quantitative PCR and NGS and offer enhanced sensitivities that
allow for MRD monitoring at a deeper level (Fehse et al., 2015; Badbaran et al., 2016;
Gardner et al., 2016; Kjær et al., 2016; Mansier et al., 2016; Keaney et al., 2017; Oh et
al., 2018). Orthogonal verification of the quantification of Type I/II CALR mutations
detected by the capillary based method used in this thesis and a qPCR based method
showed an r2 value of 0.96 (Kjaer L & Langabeer S, personal communication). Our initial
validation of serial monitoring of CALR mutations proved its utility as a useful adjunct in
the assessment of transplant efficacy in myelofibrosis patients.
The final study in this chapter followed up on the recent discovery of CSF3R
T618I mutations in aCML. Sanger sequencing was deployed as a readily available
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methodology to follow the clinical course post-transplantation in two cases where both
persistence and eradication of the mutation was described and correlated well with the
clinical course in both patients. As Sanger sequencing has a sensitivity of approximately
20%, it is not suited to minimal residual disease monitoring, however in rare diseases
such as aCML it is well suited as a screen at diagnosis to enhance and support other
clinicopathological indices. Incorporation of CSF3R mutations into panel based NGS
methods by commercial companies or in-house designs using bespoke economical
methods such as molecular inversion probe based panels would allow for accurate
quantification of allelic burden and lower sensitivities that allow for MRD level
monitoring and can provide clinically relevant information on disease course (Waalkes et
al., 2017). Taken together, the data generated in these studies affirms that mutation burden
is inversely correlated with response to allogeneic transplantation therapy. All three
mutation markers were shown to be stable and robust for monitoring purposes throughout
the disease course and are therefore a useful adjunct in the assessment of transplantation
efficacy.
Chapter 4 investigated the incidence and significance of MPN mutations in
various clinical scenarios and cohorts. A baseline for the incidence of CALR mutations in
Irish patients referred for suspected MPN was established, which could then be
incorporated into the development of a molecular diagnostic algorithm for suspected
MPN. Our group was the first to identify the low incidence of CALR mutations in patients
presenting with SVT, an important finding that complemented clinical observations of a
lower risk of thrombosis and more indolent clinical course in CALR+ ET patients. This
finding has been cited over 40 times in subsequent publications. We went on to establish
CALR mutations in familial MPN cases, which gives our clinical colleagues an additional
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tool to clarify some of these cases in the future. Also clarified, was the understanding of
MPN mutations in paediatric ET patients, detecting for the first time JAK2 V617F
mutations in the blood spots of a paediatric ET patient, suggesting the mutation can be
acquired in utero in this disease, a theory which has been supported by the identification
of intra-placental spread of a CALR+ MPN-precursor hematopoietic stem cell clone
between two monozygotic twins that developed ET symptoms at 16 years of age (ValdesMas et al., 2016) and the detection of JAK2 V617F in DNA extracted from the Guthrie
Card of a paediatric PRV case (Kelly et al., 2008).
We published several reports that highlighted the dynamic nature of MPN disease
clones (Langabeer et al., 2013; Haslam, Conneally and Langabeer, 2016; Langabeer,
Haslam and Elhassadi, 2017). The identification of two CALR mutated clones in a MPN
patient that fluctuated but remained stable throughout the disease course of over a decade,
a transient JAK2 V617F positive clone that was transient in a case of PNH positive
aplastic anaemia and a CALR+ ET case that transformed to AML that was CALR mutation
negative. These identifications informed clinical insight into the underlying clonal
heterogeneity of MPN patients. From a routine diagnostic perspective, this information
has helped inform the choice of method used to detect CALR mutations. Whilst specific
quantitative methods that target select mutations can be highly sensitive and specific, they
will miss rare cases, such as the bi-clonal case outlined. These considerations need to be
evaluated when making decisions on how to screen and follow up patients with suspected
and confirmed MPN. All of the information generated in this chapter was used to help
develop and refine a molecular diagnostic algorithm that would suit a busy clinical
molecular diagnostic service. The written article associated with this study was published
in an Irish medical journal as a means of engaging and informing clinical colleagues
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throughout the country and opening up a conversation on the application of best practice
in the real world. The diagnostic algorithm has been implemented into the routine
molecular diagnostic test setting, with scientific/clinical dialogue to refine best practice
referral ongoing.
In a subsequent study, and given that the detection of mutations in CALR, JAK2
and MPL has been incorporated into the recent World Health Organization (WHO)
diagnostic criteria for MPN, a targeted next-generation sequencing (NGS) assay for the
detection of MPN-associated mutations located in JAK2 exon 14, JAK2 exon 12, CALR
exon 9, and MPL exon 10 to provide a single platform alternative to reflexive, stepwise
diagnostic algorithms such as that outlined above was developed. This assay showed
100% concordance between previously-identified mutations and those detected by NGS,
with no false positives, nor any known mutations missed and a provides a novel solution
to step-wise screening in suspected classical MPN (Frawley et al., 2018). Taken together,
the studies in Chapter 4 have informed the conversation between clinical scientists and
our clinical consultant colleagues that has opened a path to a more refined MPN
diagnostic service, borne out of a deeper understanding of the interplay between the
clinical, diagnostic and biological aspects of MPNs. The application of NGS technologies
is continuously moving from the research environment into the clinical diagnostic service
space, as health services develop the capacity, resources and technical capability to
deliver consistent high-quality results back to the clinic (Haslam and Langabeer, 2016).
In Chapter 5, the application of methods for detection of somatic mutations in
AML related cohorts was investigated. In an early study (Haslam et al., 2010), a
conventional single assay approach to determine the incidence of FLT3-ITD and NPM1
mutation status in Irish AML patients was used. This study allowed us to understand the
202

mutation profile of Irish AML patients for the first time and to use this information to
stratify the patients based on genotype. Our results showed that the profile of Irish patients
was consistent with that observed in larger European cohort studies and led to the
subsequent launch of the NPM1 mutation status assay as a validated clinical service
offering to inform clinical insight in these patients. As NGS based approaches became
available, our group worked on an early-access basis to evaluate a commercial 19 gene
AML panel. As part of this process, this panel was evaluated by three clinical molecular
diagnostic centres in Ireland and the United Kingdom, with our laboratory coordinating
the process. This study proved the technology to be robust and stable across all centres
and would further enable standardisation of results and collaborative efforts between
centres. The study also highlighted the limitations of a 19 gene panel for use in a clinical
diagnostic setting. For clinical molecular diagnostic laboratories to deliver an NGS based
assay in the area of myeloid malignancies, any panel-based approach would need to have
a broader base of genes available for interrogation for example, myeloid differentiation
primary response 88 (MYD88), Splicing Factor 3b Subunit 1 (SF3B1), BCL6 Corepressor (BCOR), Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit
(EZH2) or U2 Small Nuclear RNA Auxiliary Factor 1 (U2AF1).
In addition, recognition that targeting AML patients alone was not sustainable for
a clinical molecular diagnostic service due to the limited number of diagnostic cases seen
by services covering populations of up to 3 million people was realised. Increasing the
number of genes present in the assay would allow more common associated myeloid
malignancies such as MDS and MPN to be incorporated into a run, therefore making the
panel a more viable option for the clinical setting. This information was communicated
to the commercial manufacturer of the panel (ThermoFisher) and led to our involvement
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in the development of a broader myeloid panel by the company, highlighting the potential
for collaboration in applied research between industry and clinical/scientific services to
ensure products launched on the market are optimised for the intended end users.
In subsequent studies, the application of the 19 gene AML panel in specific
clinical cohorts was assessed, namely high risk MDS-AML patients that underwent
transplantation therapy and FPD-AML patients. In both cases mutational profiling using
the panel gave a clearer understanding of the genotype and clonal/sub-clonal architecture
of the patients and informed clinical insight, such as identification of additional driver
mutations in both studies that are currently being exploited as therapeutic targets. Of note,
NPM1 was identified in one case (AML), whereas no JAK2 or FLT3 mutations were
detected in this high risk cohort.
The research work in this thesis is original in its design and has positively
impacted on the field of myeloid malignancies as evidenced by its acceptance as peer
reviewed publications. These studies inform clinical decision-making by providing
reliable data on minimal residual disease burdens post-transplant, allowing for early
therapeutic intervention, delineating potentially aggressive sub-clones occurring within
individual patients for which targeted therapeutics may be clinically available and
providing novel insight into the molecular mechanisms driving myeloid malignancies.
The association between the aetiology of splanchnic vein thrombosis and the low rate of
CALR mutation and that JAK2 mutations can occur in utero for example, extends our
knowledge of the molecular pathogenesis of the diseases and the involvement of JAKSTAT pathway mutations throughout all cohorts investigated. The data has shown that
utilising these molecular tools can deliver actionable results and clarify the underlying
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biological behaviour and responses of MPN cohorts, thus informing and enabling
optimised clinical treatment of MPN patients.

6.1 Future work
As technologies that allow for broader and deeper mutation analysis become available in
the clinical molecular diagnostic setting, multiple lines of investigation can be pursued to
build on the work achieved in this thesis. Further investigation of molecular monitoring
in the post-therapy setting is warranted. A recent proof of principle study that utilised
NGS in a small number of genes to identify molecular mutations in MDS/MPN patients
pre- ASCT, showed detection of the corresponding mutation in the post-ASCT period to
be predictive of relapse (Fu et al., 2014). The application of a pan-myeloid NGS gene
panel at patient diagnosis to identify multiple markers for monitoring in a post-transplant
or post-therapy setting using NGS is of interest for further investigation. The ability of
NGS methodologies to quantify multiple markers in parallel would also enable studies
focused on the clonal evolution of a patients disease over time and the potential for
clinical interventions in cases where emerging clones carried actionable mutations
(Langabeer, Haslam and Conneally, 2014; Haslam and Langabeer, 2016).
The addition of highly sensitive digital PCR based methods in tandem with NGS
panel screening to monitor stable markers in the MRD setting could enable absolute
quantitation of mutant alleles and lead to detection of a greater number of impending
relapses. The optimal testing frequency required for each therapeutic modality remains to
be determined. In MPN specifically, the clinical validity of determining JAK2, CALR,
and MPL responses to novel targeted agents in development - alone or in combination
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with established therapies, is still outstanding and requires assessment of efficacy. These
agents include specific JAK2 protein inhibitors, CALR mutated protein inhibitors, histone
deacetylase inhibitors, hypomethylating agents, PI3-AKT-mTOR inhibitors, and
telomerase inhibitors (Geyer and Mesa, 2015; Pronier et al., 2018). Together these studies
could enable further provision of an individual and optimised pathway of patient
management.
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To the Editor,
Myeloproliferative neoplasms (MPN) are a group of clonal
hematopoietic diseases characterized by bone marrow proliferation of one or more of the myeloid cell lineages with
no marked alterations in cellular maturation. The Philadelphia chromosome-negative MPNs classically comprise
of the clinically and pathologically related polycythemia
vera (PV), essential thromobocythemia (ET) and primary
myelofibrosis (PMF). Identification of an acquired mutation within exon 14 of the JAK2 gene (G1849T) resulting
in a V617F has revolutionized the molecular diagnosis of
MPN as this mutation is present in 95% of patients with
PV, approximately 50% of patients with ET and PMF and is
also detected at a lower frequency in several other myeloid
malignancies. In PV and ET patients, the disease can
transform to a myelofibrotic stage or acute myeloid leukemia (AML). Front-line therapy for these disorders includes
venesection for maintenance of hematocrit and aspirin for
low-risk PV and ET whereas hydroxyurea and -interferon
may be used for higher risk PV and ET cases. In PMF, observation may be adequate for low-risk disease with splenectomy and conventional or experimental drug therapy
required for higher risk patients [1]. While the introduction

of targeted inhibitors of the JAK pathway has improved the
outlook for some patients with PMF, allogeneic hematopoietic stem cell transplantation (AHSCT) remains the only
curative option. Though AHSCT was previously only considered for those patients with advanced or transformed
disease, improved selection of PMF patients using refined
scoring systems and the adoption of reduced intensity conditioning regimens has led to significant improvements in
overall survival for an increasing number of patients [2].
For hematological malignancies, comparison of
donor and recipient profiles allows assessment of donor
chimerism (DC) status which complements hematological
and clinical parameters providing information on engraftment kinetics, graft rejection or impending relapse and is
usually performed at monthly to three monthly intervals
post-AHSCT [3]. Techniques to quantify hematopoietic
donor and recipient cells possess a level of sensitivity of
approximately 1–2%, dependent upon methodology. The
presence of the JAK2 V617F in MPN patients undergoing
AHSCT therefore affords the opportunity to use this mutation as a sensitive marker of residual disease with studies
previously demonstrating clearance of the JAK2 V617F
post-AHSCT [4]. A qPCR assay was evaluated to determine
whether quantitation of JAK2 V617F alleles post-AHSCT
could serve as a sensitive marker of residual disease.
Thirteen JAK2 V617F-positive MPN patients who underwent an AHSCT were identified (11 male, 2 female) with an
age range of 18–58 years (median 50 years). MPN types
were PMF (n=6), post-PV MF (n=2), chronic myelomonocytic leukemia transformed to AML (n=3), PV transformed
to AML (n=1) and AML (n=1) with a median follow-up of
11 months (range 2–48 months). DNA was extracted from
peripheral blood samples collected in accordance with the
Helsinki Declaration. For the JAK2 V617F quantitation,
patient DNA was amplified in two allele-specific PCR reactions, one for the JAK2 V617F mutated allele and one for
the wild type JAK2 allele where the same forward primer
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and probe are used but reverse primers are mutation or
wild-type specific [5]. Commercial plasmids were used
for construction of both JAK2 V617F mutant and wild type
standard qPCR standard curves (Ipsogen SA, Marseille,
France). PCR reactions were performed in duplicate in a
7500 Real Time PCR System (Applied Biosystems, Foster
City, CA, USA). All qPCR assays included a wild type control,
a JAK2 V617F positive control, and a water negative control.
An automatic baseline (3–15 cycles) and a fixed threshold
of 0.1 (Rn) were selected to ensure consistency of analysis. Results were expressed as a percentage of JAK2 V617F
alleles of the total of JAK2 alleles. As the reverse primers
used in both assays differed by only one base at the 3′ end,
non-specific amplification is observed in the JAK2 V617F
assay when performed on the target negative control
sample (Figure 1A). The specificity and sensitivity for each
run was calculated using the Ct value for the target negative sample (number of cycles between wild type and V617F
Ct values) where the specificity corresponds to 2 Ct. The
sensitivity was set at 10-fold less than the value for specificity to ensure the identification of true positive measurements. DC status was assessed using the PowerPlex ® 16
System (Promega, Madison, WI, USA). Donor and recipient
(pre- and post-AHSCT) DNA samples were amplified separately and products electrophoresed on a 3130xl Genetic
Analyzer prior to analysis with GeneMapper® Version 4.0
Software (both Applied Biosystems, Foster City, CA, USA).
Peak height analysis was used to quantify the percentage
DC with the assay capable of detecting 1–2% of the minor
cell population consistent with guidelines [6].
The JAK2 V617F allele-specific qPCR assay had a specificity of at least 2.010–3 which gave a routine sensitivity

A

10

and cut-off value for sample negativity of 0.02% mutant.
The slope and R2 value of the standard curves gener- ated
were robust across the dynamic range of the assay
(Figure 1B). Seven of 13 (54%) patients were homozygous for JAK2 V617F pre-AHSCT (50% mutant), with
the remaining six patients heterozygous. Of 49 samples
tested for both JAK2 V617F and DC a significant Pearson’s
correlation was observed (r=−0.98), however, it should
be noted that 22 of these samples were 100% donor chimerism and the JAK2 V617F undetectable. Ten of 13 (77%)
patients became negative for JAK2 V617F post-AHSCT with
a follow-up of 1–48 months (median 6 months). Three
patients either failed to engraft or displayed autologous
recovery. Post-AHSCT, increasing levels of the JAK2 V617F
mutation were demonstrated 3 weeks prior to detection
of decreasing DC levels (100%–91%) in one PMF patient
(Figure 2).
The identification of the JAK2 V617F mutation in a significant proportion of MPN patients provides a means of
assessing the response to a number of treatment modalities. In the AHSCT setting, a qPCR approach allows for
specific and sensitive measurement of the allele burden
at very low levels and is therefore an appropriate methodology. The primer/probe combination of this JAK2
V167F qPCR assay showed a high degree of specificity
and was capable of distinguishing between wild type and
mutated alleles to a level of 0.002% mutant in peripheral
blood DNA. Using a cut-off for routine sensitivity of 0.02%
mutant to ensure true JAK2 V617F positivity, the assay
provided a gain of approximately two logs in sensitivity
over the routine STR PCR-based DC assay and has a sensitivity comparable to those achieved by alternative qPCR
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Figure 1 (A) Amplification of wild type JAK2 alleles from normal controls and non-specific amplification with JAK2 V617F primers;
(B) Linearity of JAK2 V617F qPCR standard curves across plasmid dilutions.
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be robust and reliable, performing consistently across a
range of platforms [8].
Both the presence of a JAK2 V617F mutation and the
allelic burden in PMF patient’s pre-AHSCT impact on
survival, with rapid clearance of the mutation associated with a reduced risk of relapse [9]. In cases where
residual disease persists post-AHSCT, pre-emptive donor
lymphocyte infusions guided by JAK2 V617F qPCR can
induce molecular remissions [10]. This sensitive qPCR
assay to serially monitor JAK2 V617F-positive MPN
patients post-AHSCT permits detection of changes in
disease burden and has the potential to augment clinical
decision-making.
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Figure 2 Molecular kinetics of residual disease post-AHSCT.
Increasing JAK2 V617F levels preceding loss of engraftment and
subsequent relapse. DC: white circles; JAK2 V617F: black diamonds.

methods for JAK2 V617F [7]. Previously, there has been
no consistent approach to JAK2 V617F quantitation with
qPCR assays varying markedly in performance thus limiting clinical applicability. Most recently, the qPCR primer/
probe combination employed herein has been shown to
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Assessment of CALR mutations in myelofibrosis patients,
post-allogeneic stem cell transplantation

The recent discovery of insertion and/or deletion mutations
within the CALR gene in a significant proportion of JAK2- and
MPL-unmutated essential thrombocythaemia (ET) and primary
myelofibrosis (PMF) patients compels the incorpora- tion of
CALR exon 9 mutational analysis into the molecular diagnostic
algorithm for these myeloproliferative neoplasms (MPN)
(Klampfl et al, 2013; Nangalia et al, 2013; Tefferi & Pardanani,
2014). Identification and monitoring of the com- mon MPNassociated mutations of JAK2 and MPL have been shown to be
of prognostic value and enhance assessment of treatment
effectiveness in those MPN patients undergoing allogeneic stem
cell transplantation (ASCT) (Alchalby et al, 2010a,b). Despite
the introduction of JAK inhibitors for the treatment of PMF,
ASCT remains the only potentially cura- tive option.
Improvements in candidate patient selection and stratification,
timing of transplantation and conditioning regimens have
significantly reduced the transplant-related morbidity and
increased the overall survival for patients undergoing this
procedure (McLornan et al, 2012). Post- ASCT monitoring
utilizing additional patient-specific mark- ers could provide a
more beneficial, individualized approach.

As CALR mutations are likely initiating events in MPN pathogenesis, the scenario arises to assess these mutations as potential
markers of residual disease in myelofibrosis patients, postASCT.
Screening for evidence of CALR exon 9 mutations by DNA
fragment analysis (Klampfl et al, 2013) of pre-ASCT samples
from 15 JAK2 V617F-negative MPN patients identified four
CALR mutation-positive patients, all of whom received reduced
intensity conditioning (Table I). CALR mutant allele burden was
calculated using area under the peak (mutated/ mutated + wild
type) x100 and compared to known donor chimerism status
performed according to guidelines (Lion et al, 2012). The
CALR assay allowed the reproducible detec- tion of
approximately 1% mutant allele burden. All four donors were
wild type CALR exon 9. A further 14 informative follow up
samples evaluated for donor chimerism status were available for
retrospective mutant CALR allele burden estima- tion. Patients
1–3 achieved full engraftment as assessed by donor chimerism
(≥99%) at 5, 8 and 14 weeks respectively with very low levels
of mutant CALR alleles (<1%) detectable in patients 2 and 3
at these time points (Table I). Patient 4

Table I. Features and molecular follow up of four myelofibrosis patients with CALR mutations.

Patient

Gender

Age at
ASCT (years)

MPN

Donor type

CALR mutation

1

Male

59

PMF > AML

Unrelated

52-bp deletion

2

Male

46

Post-ET MF

Related

5-bp insertion

3

Male

48

PMF

Related

52-bp deletion

4

Female

52

PMF

Unrelated

5-bp insertion

Weeks
post-ASCT

Mutant CALR
allele burden (%)

Donor
chimerism (%)

Pre-ASCT
5
11
22
Pre-ASCT
8
26
Pre-ASCT
4
14
25
37
Pre-ASCT
7
13
20
24
27

55·7
ND
ND
ND
42·0
0·7
ND
55·2
0·6
0·5
ND
ND
58·3
1·9
5·0
19·8
1·3
ND

–
100
100
100
–
100
100
–
96
99
100
100
–
87
81
54
86
99

ASCT, allogeneic stem cell transplant; MPN, myeloproliferative neoplasm; AML, acute myeloid leukaemia; ET, essential thrombocythaemia; MF,
myelofibrosis; ND, not detected.
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Fig 1. Correlation of CALR mutation allele burden with donor chimerism status in Patient 4. ASCT, allogeneic stem cell transplant; DLI, donor
lymphocyte infusion.

failed to achieve full donor chimerism, reflected in levels of
mutant CALR alleles of >1% (Fig 1). Loss of engraftment,
indicated by falling donor chimerism and mirrored by a significant increase in mutant CALR allele burden, prompted donor
lymphocyte infusion (DLI) at week 22 post-ASCT with
subsequent attainment of 99% donor chimerism and
undetectable mutant CALR alleles.
The utility of MPN-specific mutations to monitor disease
kinetics post-ASCT has been demonstrated for those patients
harbouring a JAK2 V617F mutation. Assessment of the JAK2
V617F allele burden at 1 month post-ASCT can be highly
predictive of outcome and risk of relapse (Lange et al, 2013)
whereas serial monitoring of JAK2 V617F levels has been used
to trigger pre-emptive intervention with DLI (Kro€ger et al,
2009). Initial data suggests that the CALR mutation status is a
valuable prognostic marker in myelofibrosis patients who
undergo ASCT, with CALR mutation-positive patients having a
superior overall survival and a lower rate of non-relapse
mortality (Panagiota et al, 2014). The presence of CALR
mutations in the majority of JAK2 V617F- and MPL exon 10negative MPN patients therefore allows these mutations to serve
as disease-specific markers of residual dis- ease in conjunction
with donor chimerism analysis. It is envisaged that development
of CALR mutation-specific quan- titative polymerase chain
reaction assays, similar to those established for the JAK2
V617F, will further improve the limit of mutation detection.
By demonstrating both persistence and eradication of CALR
mutations that correlate with the clinical course, this brief

References
Alchalby, H., Badbaran, A., Zabelina, T., Kobbe, G.,
Hahn, J., Wolff, D., Bornh€auser, M., Thiede, C.,
Baurmann, H., Bethge, W., Hildebrandt, Y.,
Bacher, U., Fehse, B., Zander, A.R. & Kro€ger, N.

2
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The CSF3R T618I mutation as a disease-speciﬁc marker
of atypical CML post allo-SCT
Bone Marrow Transplantation (2014) 49, 843–844; doi:10.1038/
bmt.2014.35; published online 10 March 2014

Atypical CML (aCML) is a rare myelodysplastic/myeloproliferative
neoplasm (MDS/MPN) characterized by neutrophilia with left-shift
maturation and dysgranulopoietic features. Diagnosis also requires
the exclusion of BCR-ABL1, PDGFRA and PDFRB rearrangements.1
The prognosis of aCML is poor with survival times of generally o30
months: patients may undergo transformation to AML or succumb
to the effects of BM failure.2 To date, allo-SCT in the chronic phase
of the disease has been the only option to improve OS.3
No speciﬁc, recurrent cytogenetic or molecular abnormalities
have been described in aCML until the recent characterization of
mutations within the genes encoding the G-CSF receptor (CSF3R)
and SET binding protein 1 (SETBP1) in a signiﬁcant proportion of
patients with aCML and chronic neutrophilic leukaemia (CNL).4,5
Whereas the functional signiﬁcance of SETBP1 mutations in aCML
and CNL are not yet fully understood, the characterization of
CSF3R mutations has revealed a possibility for targeted therapeutic intervention with tyrosine kinase inhibitors. Approximately
50–60% of CNL and aCML patients harbour an acquired CSF3R
mutation that can be either membrane proximal or in the
cytoplasmic tail of the receptor. These two classes of mutations
exhibit different downstream signalling patterns: membrane
proximal mutations activate the JAK/STAT pathway and are
therefore potentially amenable to inhibition with JAK inhibitors
such as ruxolitinib, whereas truncation mutations predominantly
signal through SRC family kinases and therefore may be targeted
by SRC inhibitors such as dasatinib. The most prevalent CSF3R
mutation in aCML and CNL is the membrane proximal T618I.4,6 In
addition to this potential for targeted therapy, identiﬁcation of
aCML-speciﬁc CSF3R mutations affords the opportunity for
evaluation of these mutations as disease-speciﬁc markers of
residual disease in those patients undergoing allo-SCT. Mutations
of SETBP1 and CSF3R exons 14 and 17 were sought by Sanger
sequencing in a retrospective series of eight patients with aCML,
CNL or atypical MPN. The clinical courses of two aCML patients are
described, both of whom possessed a heterozygous CSF3R p.
Thr618Ile (T618I) mutation (c.15482C>T, reference sequence
NG_016270.1).
A 60-year-old woman (Patient #1) presented in 2002 with what
appeared to be morphologically CML but had a normal karyotype
with no evidence of BCR-ABL1 by ﬂuorescence in situ hybridization
(FISH) or reverse transcription-PCR. She had no haematological
response to 1 month of imatinib and commenced hydroxyurea.
The pre-transplant work-up revealed worsening constitutional
symptoms and adenopathy. Retrospectively, a CSF3R T618I
mutation was detected 3 months pre-transplant (Figure 1a,
upper). A reduced-intensity conditioning, sibling donor (CSF3R
wild type) allo-SCT was performed. The initial post-allo-SCT course
was unremarkable; however by day 72, whole blood donor
chimerism was only 20% with the T618I mutation retrospectively
still evident (Figure 1a, centre). Full donor chimerism was not
achieved and she relapsed 9 months post allo-SCT with increasing
BM myeloblasts. Two doses of DLI and a subsequent course of
daunorubicin, cytarabine, thioguanine (3+10) did not improve the

chimerism status; the marrow remained hypoplastic with 10–15%
blasts and continued evidence of the CSF3R T618I (Figure 1a,
lower). The patient became red cell and platelet transfusion
dependent, deteriorated and died 17 months post allo-SCT. No
constitutional material was available from Patient #1 to demonstrate the somatic nature of the CSF3R T618I mutation.
A 48-year-old man (Patient #2) presented with an elevated white
cell count and a hypercellular BM consistent with aCML. The patient
had a normal karyotype, no evidence of BCR-ABL1, PDGFRA or
PDGFRB rearrangements by FISH, with molecular studies demonstrating the absence of the JAK2 V617F and BCR-ABL1 transcripts
but the presence of the CSF3R T618I mutation (Figure 1b, upper).
He commenced treatment with hydroxyurea and 6 weeks before
allo-SCT the CSF3R T618I clone remained evident but at a reduced
level (Figure 1b, centre). He underwent a myeloablative allo-SCT
with a sibling donor (CSF3R wild type). At day 30 post allo-SCT, he
developed skin GvHD. The T618I mutation was not detected by
sequencing on day 46 in whole peripheral blood (Figure 1b, lower).
He remains well on a tapering steroid dose with improving GvHD.
In other forms of MPN, allele-speciﬁc monitoring of diseaseassociated mutations, such as the JAK2 V617F and those within
MPL exon 10 at deﬁned time points, has been shown to be of
value in predicting response to allo-SCT and may also aid in

ATGACCTTG

ATGACCTTG

ATGACCTTG

ATGACCTTG

ATGACCTTG

ATGACCTTG

Figure 1. Sequencing of DNA isolated from unfractionated peripheral blood demonstrating CSF3R c.15482C>T (p.Thr618Ile) mutation
(arrows) throughout clinical course. (a) Patient #1 pre-allo-SCT
(upper), day 72 post allo-SCT (centre) and 12 months post allo-SCT
(lower). (b) Patient #2 at diagnosis (upper), pre-allo-SCT (centre) and
day 46 post allo-SCT (lower).
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directing adoptive immunotherapy in those patients who
relapse.7–10 Such approaches would improve the detection
sensitivity above that of Sanger sequencing and potentially allow
quantitation of mutation level. Both persistence and eradication of
the CSF3R T618I described above, correlating with the clinical
course in both patients, indicate that serial monitoring of CSF3R
mutations in aCML patients undergoing allo-SCT is a useful
adjunct in the assessment of transplant efﬁcacy.
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Monitoring of the JAK2 V617F allele burden in myeloproliferative neoplasms after allogeneic stem cell transplantation is useful to
determine levels of residual disease and has the potential to detect early relapse and guide subsequent clinical intervention. A case is
described of a JAK2 V617F-positive primary myelofibrosis patient who underwent allogeneic stem cell transplantation. Prospective
residual disease monitoring of the peripheral blood failed to detect an extramedullary manifestation of the disease, a periorbital
myeloid sarcoma, arising nearly three years after transplant. This case serves to highlight a pitfall in residual disease monitoring for
myeloproliferative neoplasm-associated mutations in the post-allogeneic stem cell transplantation setting.

1. Introduction
Primary myelofibrosis (PMF) is one of the classical Philadelphia chromosome-negative myeloproliferative neoplasms
and is clinically characterized by cytopenias, splenomegaly,
and multiple disease-related symptoms that reduce the quality of life. The clinical course of PMF is variable with an
increased risk of progression to acute myeloid leukemia
(AML) as compared to essential thrombocythemia and polycythemia vera [1]. While the introduction of JAK2 inhibitors
has improved the outlook for many patients with PMF [2],
the only curative option that remains is allogeneic stem cell
transplantation (ASCT). Improvements in candidate patient
selection and stratification, timing of transplantation, and
conditioning regimens have significantly reduced the transplant related morbidity and increased the overall survival for
patients undergoing this procedure [3]. The most commonly
observed acquired mutations in PMF are the JAK2 V617F,
CALR exon 9 mutations, and MPL exon 10 mutations with
JAK2 V617F and CALR mutation status indicative of overall

survival after ASCT [4, 5]. Tracking disease burden utilising
these patient-specific mutations provides an individualized
approach allowing assessment of disease clearance and providing a marker with which to guide adoptive immunotherapy [6–9].
A case is described in which JAK2 V617F residual disease
monitoring failed to detect an extramedullary manifestation
of PMF in a patient after ASCT and which serves to highlight
a pitfall of this approach.

2. Case Report
Whilst undergoing imaging of a knee replacement for
osteoarthritis three years previously, a 54-year-old male was
noted to have patchy skeletal sclerosis. Further investigations
revealed splenomegaly with a nine-month history of progressive constitutional symptoms (generalised unwellness),
lethargy, night sweats, and weight loss. Initial hematological
investigation revealed a hemoglobin of 10.3 g/dL, a white cell
count of 7.8 × 10 9/L, platelets of 53 × 109 /L, and elevated
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(a)
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Figure 1: (a) CT showing left periorbital myeloid sarcoma (arrowed); (b) periorbital biopsy showing blast infiltration by myeloid sarcoma
(Hematoxylin and Eosin; magnification×40); (c) positive immunohistochemical staining for CD34 in the myeloid sarcoma (magnification
×40).

reticulocyte count (212×10 9/L) and lactate dehydrogenase
(LDH; 990 IU/L). The blood film was leukoerythroblastic
with red cell anisopoikilocytosis, tear drop cells, basophilic
stippling, and 2% circulating blasts. Bone marrow aspirate
was unsuccessful; however the bone marrow biopsy showed
abnormal marrow architecture and grade IV reticulin fibrosis. The JAK2 V617F mutation was detected by qualitative
PCR confirming the diagnosis of PMF. Four months later the
platelet count had fallen to 24 × 109 /L with 3% blast cells
in the peripheral blood. The LDH was markedly elevated at
1912 IU/L with the patient now noted to have a splenomegaly
12 cm below the costal margin. His risk status based on International Prognostic Scoring System was intermediate-2 [10].
The patient proceeded to reduced intensity conditioning
ASCT [11] with a matched sibling donor. The posttransplant
course was complicated by Klebsiella bacteremia and grade II
skin graft-versus-host disease (GVHD). With the introduction of corticosteroids the patient developed Cytomegalovirus
reactivation requiring readmission, steroid-induced hypomania, and steroid-induced insulin-dependent diabetes mellitus. A robust and validated quantitative PCR (qPCR) assay
for JAK2 V617F [12–14] was employed to determine the
allele burden before ASCT (30.7%). At two months after
ASCT donor chimerism (DC) was 97% and JAK2 V617F

0.46% and at six months after ASCT DC was 96% and JAK2
V617F 0.79%. Full DC (100%) and undetectable JAK2 V61F
were concurrently noted at eleven months after ASCT and
remained so at prospective three monthly assessments.
In the long-term follow-up clinic at 32 months after
ASCT,a1 cm hard lump was noted beneath the left eye. Subsequent imaging noted a mass lesion arising within the
inferolateral aspect of the left orbit, displacing the globe
anteromedially and which appeared to lie within the extraconal space (Figure 1(a)). Excision of the periorbital bulk
mass was undertaken with histopathological examination
revealing adipose/connective tissue infiltrated by blasts
(Figure 1(b)) which stained positively for CD34, CD117, and
CD45 (Figure 1(c)) and negatively for CD20, TdT, Granzyme
B, CD68, and CD1a. The blasts were also JAK2 V617F-positive consistent with a diagnosis of myeloid sarcoma, an extramedullary tumor (EMT). At this time the patient had a hemoglobin level of 14.0 g/dL, white cell count of 4.2 × 109 /L, neutrophils of 2.0× 109/L, and an unchanged, maintained platelet
count of 115 × 10 /L. The JAK2 V617F was undetectable in9
both the peripheral blood and the bone marrow aspirate, the
latter showing no morphological evidence of PMF.
The patient was not a candidate for further intensive
chemotherapy and underwent involved field radiotherapy to
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the left orbit (30 Gy in 15 fractions) and at last follow-up 41
months after ASCT, the JAK2 V617F remained undetectable
in the peripheral blood.

[2] A. Rosenthal and R. A. Mesa, “Janus kinase inhibitors for the
treatment of myeloproliferative neoplasms,” Expert Opinion on
Pharmacotherapy, vol. 15, no. 9, pp. 1265–1276, 2014.

3. Discussion

[3] D. Babushok and E. Hexner, “Allogeneic transplantation for
myelofibrosis: for whom, when, and what are the true benefits?”
Current Opinion in Hematology, vol. 21, no. 2, pp. 114–122, 2014.

Despite the fact that ASCT remains the only curative option
for PMF, the five-year overall survival with reduced intensity
conditioning is approximately 50%, with relapse being the
major cause of treatment failure which is often associated
with an aggressive clinical course, primarily due to clonal
evolution [15]. Close molecular monitoring after ASCT is
employed to determine the rate and status of disease clearance
and to predict impending relapse allowing prompt clinical
intervention. In those PMF patients in whom sensitive,
residual disease monitoring of the JAK2 V617F allele burden
has been performed, reemergence of this clone in either the
peripheral blood or bone marrow precedes loss of DC and
clinical relapse [16, 17]. A potential confounding factor of
this qPCR approach is the possibility of clonal evolution in
which the JAK2 V617F relinquishes its role as the main
driving mutation of this disease. While early detection of
extramedullary relapse of AML cases using residual disease
monitoring of AML-associated genetic markers has been
documented, evidence for a similar benefit in JAK2 V617Fpositive PMF, particularly after ASCT, is scarce [18–20].
EMT arising after ASCT for hematological malignancies appears to be predominantly associated with an initial
diagnosis of AML but has been noted in association with
other myeloid and lymphoid malignancies and they may
occur in the skin and soft tissues, central nervous system, and
gastrointestinal tract and at other sites [21]. EMTs are due to
the migration of abnormal neoplastic hematopoietic
precursor cells into the tissues and therefore formation
should be considered a metastatic process [22, 23]. EMTs
occurring after ASCT may possess different clinical characteristics compared to bone marrow relapses such as a
longer duration of onset and an association with GVHD, both
apparent in the case described herein [21]. The mechanism(s)
by which extramedullary disease relapse remains molecularly
undetected in the peripheral blood remains unknown: one
possibility is evasion of PMF stem cells from immunological
detection by residing in a shielded niche.
Residual disease monitoring using JAK2 V617F qPCR in
PMF after ASCT is effective in predicting relapse in the
majority of those patients in whom the disease is driven by
this mutation. However, vigilance is required as
extramedullary manifestations of PMF, although rare, may
evade early capture by this approach.
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Abstract
Insertion and/or deletion mutations of the CALR gene have recently been demonstrated to be
the second most common driver mutations in the myeloproliferative neoplasms (MPNs) of
essential thrombocythemia (ET) and primary myelofibrosis (PMF). Given the diagnostic and
emerging prognostic significance of these mutations, in addition to the geographical heterogeneity reported, the incidence of CALR mutations was determined in an Irish cohort of
patients with MPNs with a view to incorporate this analysis into a prospective screening program. A series of 202 patients with known or suspected ET and PMF were screened for the presence of CALR mutations. CALR mutations were detected in 58 patients. Type 1 and Type 1-like
deletion mutations were the most common (n = 40) followed by Type 2 and Type 2-like insertion
mutations (n = 17). The CALR mutation profile in Irish ET and PMF patients appears similar to
that in other European populations. Establishment of this mutational profile allows the introduction of a rational, molecular diagnostic algorithm in cases of suspected ET and PMF that will
improve clinical management.
© 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).
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The classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) comprise the clinically and
pathologically related polycythemia vera (PV), essential
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thrombocythemia (ET), and primary myelofibrosis (PMF).
These diseases are characterized by an over production of
mature hematopoietic cells, extramedullary hematopoiesis,
and clinically by a tendency for thrombosis, hemorrhage,
and a potential to transform into acute leukemia. While
almost all PV patients are characterized by the Exon 14
JAK2 V617F and Exon 12 mutations, until recently, the only
known driver mutations of ET and PMF were the JAK2 V617F
and MPL Exon 10 mutations present in up to two-thirds of
patients. The landmark discovery of insertion and/or deletion (indel) CALR Exon 9 mutations in 60–80% of JAK2 V617Fand MPL Exon 10-negative ET and PMF cases compels the
inclusion of CALR mutation analysis into the molecular
diagnostic algorithm for these MPNs. The two common CALR
mutations are the Type 1 52-bp deletion (p.L367fs*46) and
the Type 2 5-bp insertion (p.K385fs*47), which account for
more than 85% of indels [1,2] with most other mutations
being Type 1-like deletions or Type 2-like insertions. CALR
mutations are thought to exert their function by perturbation of the intracellular Janus kinase/signal transducers and
activators of transcription (JAK/STAT) signaling path- way
by activation of MPL [3]. Molecular analysis of these three
driver mutation types is likely to be a major criterion in the
next revision of the World Health Organization classification of hematopoietic tumors [4]. Aside from their diagnostic importance, it is becoming increasingly apparent that
the different types of CALR mutations impart prognostic
information about thrombotic potential and leukemic transformation [5–7]. Furthermore, some geographical heterogeneity exists in both the frequency and profile of CALR
mutations in ET and PMF when considering patients from
North America [8,9], Europe [1,2,10,11], Central and South
America [12,13], India [14], and Far East Asia [15,16].
Given the importance of CALR mutational analysis in the
diagnosis and prognosis of ET and PMF, the pattern of CALR
mutations was investigated in a cohort of adult Irish patients
with MPN. These data are likely to provide information about
how to efficiently incorporate CALR mutation analysis into a
prospective MPN molecular diagnostic service.

Materials and methods
A series of 202 confirmed and suspected MPN cases from two
large Irish hematology centers were subjected to retrospective CALR mutational analysis. None of the patients had evidence of the JAK2 V617F mutation by allele-specific
polymerase chain reaction (PCR) [17]. CALR mutations were
detected in archival genomic DNA from peripheral blood

(n = 190) or bone marrow (n = 12) by fluorescent PCR followed by fragment length analysis. The CALR assay has been
previously demonstrated to possess a detection sensitivity
of ~1% mutant allele burden [18].

Results
CALR mutations were detected in 58 patients (30 female
and 28 male) with a median age of 56 years (range, 25–86
years) in whom the diagnosis was ET (n = 45), PMF (n = 10),
post-ET myelofibrosis (n = 2), and myelodysplas- tic/MPNs
(n = 1). Type 1 CALR mutations were the most prevalent, (n
= 35) followed by Type 2 mutations (n = 16; Table 1). Of the
remaining seven cases, five had Type 1-like deletions, one
had a Type 2-like insertion, and one previously described
patient harbored two mutated clones [19]. The distribution
of these mutations in the MPN sub- types is given in Table
1.

Discussion
The description of CALR Exon 9 mutations in ET and PMF
patients has changed the molecular diagnostic algorithm for
MPN as they are now considered the second most com- mon
type of driver mutations in ET and PMF cases. Provision of a
confirmatory molecular diagnosis in a significantly higher
number of patients will enhance risk stratification and
allows for appropriate treatment: retrospective screen- ing
has demonstrated the efficacy of existing therapeutic
modalities such as interferon-alpha and JAK inhibitors in
CALR-mutated MPN patients [20,21].
Because of the diagnostic and emerging prognostic significance of these mutations, in addition to the geographical
and ethnic variation previously reported, the incidence of
CALR indels was investigated in a retrospective cohort of
Irish MPN patients to determine the existing mutational
spectrum. Given the near mutual exclusivity of the JAK2
V617F and CALR mutations but acknowledging the rarity of
these mutations co-existing in ET and a report of CALR
mutations in JAK2-negative PV [22–24], this retrospective
study was limited to known and suspected ET and PMF
patients in whom the JAK2 V617F was previously undetected. Although a number of methodological approaches
exist to detect CALR mutations [25], the sensitivity of the
fragment length analysis used in this study was deemed sufficient to detect clinically relevant mutations: CALR mutant
allele burdens are usually much higher [26].

Table 1 Incidence of CALR Mutations in Irish MPN Patients
ET (n = 45)
PMF (n = 10)
Post-ET MF (n = 2)
MDS/MPN (n = 1)
Total

Type 1

Type 1 like

Type 2

Type 2 like

Other

26
8
1
0
35 (60.3%)

5
0
0
0
5 (8.6%)

12
2
1
1
16 (27.6%)

1
0
0
0
1 (1.7%)

1
0
0
0
1 (1.7%)

Note: ET = essential thrombocythemia; MDS/MPN = myelodysplastic/myeloproliferative neoplasm; MF = myelofibrosis; PMF = primary
myelofibrosis.
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The CALR mutation profile and frequency in this cohort
of Irish patients are broadly in line with that of other series
from Europe and North America, with Type 1 and Type 1-like
mutations being more prevalent than Type 2 and Type 2-like
in both ET and PMF patients. Establishing this mutational
profile allows considered incorporation of CALR mutation
testing into a prospective MPN molecular diagnostic algorithm so as to optimize the number of patients who would
benefit from such testing within existing laboratory
resources. Given the previously described variability in
requesting JAK2 V617F analysis within this country [27],
together with the knowledge of the near absence of CALR
mutations in splanchnic, cerebral, and other cases of unprovoked venous thrombosis [28–30], limiting testing to those
patients with suspected ET and PMF appears judicious.
In conclusion, the incidence and spectrum of CALR
mutations in Irish MPN patients are similar to those of other
European cohorts confirming these driver mutations as the
second most frequently observed in ET and PMF. This
knowledge allows the effective incorporation of CALR
mutation analysis into a prospective testing algorithm, thus
enabling an enhanced diagnosis and improved clinical
management.
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Incidence of CALR mutations in patients with splanchnic vein
thrombosis

Splanchnic vein thrombosis (SVT) is a common and serious
complication of both overt and latent myloproliferative neoplasms (MPN) with molecular features such as the JAK2
V617F, MPL exon 10 mutations and the JAK2 46/1 haplo- type,
risk factors for SVT (Kiladjian et al, 2008; Smalberg
et al,
2011; Sekhar et al, 2013). Given the notable occurrence of the
JAK2 V617F mutation in SVT patients, the recent description
of CALR exon 9 insertion and/or deletion muta- tions in up to
80% of JAK2- and MPL-unmutated essential thrombocythaemia
(ET) and primary myelofibrosis patients (Klampfl et al, 2013;
Nangalia et al, 2013) prompted investi- gation of the incidence
and significance of CALR mutations in SVT patients.
A cohort of 144 patients prospectively referred from 23
institutions within the Republic of Ireland for JAK2 V617F
analysis with a presentation of confirmed SVT was identi- fied.
The median patient age was 52 years (range <1–87) and
consisted of 77 male and 67 female patients. Patients could be
assigned to six distinct groups according to site of thrombosis:
Budd Chiari syndrome (BCS), mesenteric vein thrombosis
(MVT), portal vein thrombosis (PVT), renal vein thrombosis
(RVT), splenic vein thrombosis (SpVT), and splanchnic vein
thrombosis unspecified (SVT-U). CALR exon 9 mutations were
detected by fluorescent polymerase chain reaction fragment
analysis (Klampfl et al, 2013) capa- ble of detecting an allele
burden of 1% (Haslam et al, 2014). The JAK2 V617F was
detected in 18·8% (27/144) of patients and specifically in 4/9
(44·4%) BCS, 4/19 (21·1%) MVT, 13/82 (15·9%) PVT, 0/7
RVT, 5/12 (41·7%) SpVT
and 1/15 (6·7%) SVT-U patients. Fifty nine of these patients
were previously screened for the presence of the common MPL
exon 10 mutations of which two patients (3·4%) pos- sessed a
MPL W515L mutation (McCarthy et al, 2010). CALR exon 9
mutations were not detected in any of the 144 SVT patients.
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The finding of no CALR mutations in this group of patients
is noteworthy when considering the incidence of the JAK2
V617F (18·8%) in the entire cohort and the MPL W515L in a
subset of this cohort. Whether the absence of CALR mutations
in SVT patients is a reflection of the size of the study population
is unknown with verification of these results required in
independent cohorts. Initial data on the haematological and
clinical phenotype suggests CALR+ ET is a distinct entity with
an indolent clinical course associated with higher platelet
counts, lower white cell counts and a lower risk of thrombosis
when compared to JAK2 V617F+ ET (Rotunno et al, 2014;
Rumi et al, 2014); the latter sup- ported by this study. These
initial data may also have impli- cations for the diagnostic
screening and workup of SVT patients in whom an underlying
MPN is suspected.
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Aldehyde dehydrogenase-2 polymorphism contributes to the
progression of bone marrow failure in children with idiopathic
aplastic anaemia

Aplastic anaemia is a syndrome of bone marrow failure (BMF)
that is characterized by peripheral pancytopenia and marrow
hypoplasia. Injury to haematopoietic stem cells (HSCs), such as
immune-mediated cytotoxicity, can cause aplastic anaemia; the
successful
treatment
of
aplastic
anaemia
using
immunosuppressive therapy (IST) supports this hypothesis
(Kulagin et al, 2014). Another proposed mecha- nism is an
intrinsic defect of HSCs, which is the presumed major cause of
congenital BMF. However, this has not been definitively
established in idiopathic aplastic anaemia.
The aldehyde dehydrogenases (ALDHs) are a group of
enzymes that are involved in critically important biological
processes, such as detoxification of exogenous and endogenous aldehydes. ALDH2 deficiency, resulting from a
Glu504Lys substitution (rs671, c.1510G>A) in the ALDH2
gene, is prevalent in the Japanese population. AA homozygotes show very low catalysis of aldehydes, and GA heterozygotes display strongly reduced catalysis compared with GG
homozygotes. Recently, ALDH2 deficiency was shown to be
associated with accelerated progression of BMF in Japanese
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patients with Fanconi anaemia (FA), the most frequent inherited
cause of BMF (Hira et al, 2013).
We hypothesized that ALDH2 deficiency underlies the
progression of BMF in patients with idiopathic aplastic anaemia as well as in FA patients.
Seventy-nine Japanese children aged ≤15 years, referred
to our institution between January 1990 and April 2011, were
included in this study. Patients were excluded if they had
paroxysmal nocturnal haemoglobinuria (PNH), expo- sure to
toxic chemicals, chromosomal fragility, or mutations in TERC,
TERT, SBDS or SH2D1A (Liang et al, 2006; Wang et al, 2007).
Disease severity was classified based on the cri- teria of the
International Aplastic Anaemia Study Group (Camitta et al,
1975; Bacigalupo et al, 1988). The ALDH2 Glu504Lys
polymorphism was genotyped using a duplex polymerase chain
reaction with confronting two-pair prim- ers (Tamakoshi et al,
2003). Statistical analysis was per- formed using the Fisher’s
exact test and the Kruskal-Wallis test. Failure-free survival
(defined by survival in the absence of relapse, additional
therapy, PNH, or secondary malignancy)
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Abstract The myeloproliferative neoplasms (MPN) are
clonal, hematological malignancies that include polycythemia vera, essential thrombocythemia and primary myelofibrosis. While most cases of MPN are sporadic in nature, a
familial pattern of inheritance is well recognised. The phenotype and status of the commonly acquired JAK2 V617F,
CALR exon 9 and MPL W515L/K mutations in affected
individuals from a consecutive series of ten familial MPN
(FMPN) kindred are described. Affected individuals display
the classical MPN phenotypes together with one kindred
identified suggestive of hereditary thrombocytosis. In
affected patients the JAK2 V617F mutation is the most
commonly acquired followed by CALR exon nine mutations
with no MPL W515L/K mutations detected. The JAK2
V617F and CALR exon 9 mutations appear to occur at
approximately the same frequency in FMPN as in the sporadic forms of these diseases. The familial nature of MPN
may often be overlooked and accordingly more common

than previously considered. Characterisation of these FMPN
kindred may allow for the investigation of molecular events
that contribute to this inheritance.
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Introduction
The myeloproliferative neoplasms (MPN) are clonal,
hematopoietic stem cell-derived diseases characterised by
bone marrow proliferation of one or more of the myeloid
cell lineages with the main classical subtypes of MPN being
polycythemia vera (PV), essential thrombocythemia (ET),
and primary myelofibrosis (PMF). The primary goal of
therapy in PV and ET is to prevent thrombotic or
hemorrhagic complications and in PMF, to alleviate anemia, symptomatic splenomegaly or constitutional
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symptoms [1, 2]. A potential exists in a minority of cases for
these disorders to progress to a myelofibrotic stage or acute
leukemia. The most commonly acquired mutation
associated with MPN is the JAK2 exon 14 V617F, occurring in greater than 98 % of PV cases and in approximately
half of ET and PMF patients [3]. This mutation disrupts the
function of the intracellular JAK2 molecule that is required
for normal hematopoietic cytokine signalling and has
become a target for therapeutic intervention [4]. Mutations
within JAK2 exon 12 can be detected in those remaining
JAK2 V617F-negative PV patients [5]. The next most
frequent mutations observed in sporadic MPN are those
more recently described in CALR, a gene that encodes the
endoplasmic reticulum-associated, calcium binding protein, calreticulin. These mutations occur exclusively in
CALR exon nine, appear not to be found in PV, but are
present in up to 80 % of ET and PMF patients who are JAK2
V617F-negative [6, 7]. Several other genetic abnor- malities
have described in MPN which occur at a much lower
frequency than the JAK2 V617F and CALR muta- tions, the
most common of which are those of MPL which encodes the
receptor for thrombopoietin, a major regulator of
megakaryocyte and platelet development. Most MPNassociated mutations of MPL are located within exon 10
with the W515L and W515K mutations the most frequent
and detected in approximately 5 and 3 % of PMF and ET
patients respectively [8]. Other genetic and epigenetic
events that disrupt myeloid cell differentiation and proliferation have been described at a lower frequency in MPN
but are usually associated with rare phenotypes or leukemic
transformation [9].
While the vast majority of MPN cases are sporadic in
nature, familial clusters do occur. Patients usually have
classical MPN phenotypes with the incidence of thrombotic complications and risk of progression to myelofibrosis or leukemia not appearing to differ between the
sporadic and familial forms of the disease [10–12]. Familial
MPN (FMPN) should be distinguished from the non-clonal,
inherited disorders of single hematopoietic lineage
proliferation, namely hereditary erythrocytosis (HE) and
hereditary thrombocytosis (HT). HE or congen- ital
erythrocytosis/polycythemia is a rare and heterogenous
clinical entity that may be primary due to EPOR mutations
or secondary due to mutations of genes involved in the
hypoxia sensing pathway such as VHL, EPAS1 and EGLN1
[13]. Similar to HE, the genetic basis for the majority of HT
cases has not been fully elucidated yet germ-line mutations
in MPL, THPO and JAK2 have all been reported [14, 15].
Although a particular inherited haplotype has been
identified that is associated with the development of sporadic JAK2 V617F-positive, JAK2 exon 12-positive and
MPL exon 10 mutation-positive MPN [16–20], it remains
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largely unknown as to what germ-line factors are responsible for inheritance of the majority of FMPN. Characterisation of FMPN kindred may therefore be of value in
identification of putative germ-line factors. Here we report
the phenotypes and the incidence of the three most commonly observed molecular abnormalities associated with
sporadic MPN in a series of FMPN kindred.

Materials and methods
A review of the referral institutions’ MPN database identified families with the index case having at least one
affected first-degree family member (parent, sibling, or
child) with MPN. The diagnosis of MPN was made
according to WHO criteria [21]. Detection of the common
JAK2 V617F, JAK2 exon 12, CALR exon 9, and MPL
W515L/K mutations and assessment of hematopoietic
clonality was performed as previously described [6, 22– 25].
Analysis of the JAK2 V617F and MPL W515L/K mutations
were performed in all affected individuals. As CALR
mutations appear to be mutually exclusive of the JAK2
V617F [6, 7], CALR mutation screening was only performed
on those individuals without the JAK2 V617F mutation.
Where appropriate, CALR mutation allele burden was
calculated from area under the curve mutant allele / (mutant
? wild type) 9 100 post-PCR fragment analysis. In selected
patients, Sanger sequencing of JAK2 exons 13 and 14, MPL
and THPO sequencing was performed [26].

Results
Ten FMPN families were identified who met the above
criteria for FMPN (Fig. 1). Affected individuals from nine
of these families possessed the classical MPN phenotypes of
ET, PV and PMF whereas one family has a phenotype
suggestive of HT (Fig. 1. Family 5).
Of the nine families with classical MPN phenotypes, there
were 24 affected individuals with ET (n = 13), PV (n = 8),
PMF (n = 1), post-PV MF (n = 1) and MPN of unknown
phenotype (MPN unknown; n = 1). Samples were unavailable for analysis from four ET patients (Fig. 1. Family 7: I-2
and II-2; Family 9: I-2 and II-2). No MPL W515L/K mutations were detected in any of the affected patients. The JAK2
V617F was present in 3/8 (37.5 %) of ET cases, 7/8 (87.5 %)
of PV cases, and in those three patients with PMF, post-PV
MF and MPN unknown. CALR exon 9 mutations were
detected in two ET patients, both of whom were JAK2
V617F-negative (Fig. 1. Family 7: II-1; Family 8: II-1). Both
patients harboured the common CALR Type 1 mutation
L367fs*46 that results in a 52 base pair deletion [6, 7], at
allele burdens of 9.9 and 38.1 % respectively.
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Fig. 1 Ten kindred with FMPN. ET essential thrombocythemia, PV polycythemia vera, PMF primary myelofibrosis, NT not tested, wt wild type,
mut mutation detected

Two kindred underwent further molecular investigations. The index case of Family 1 (Fig. 1. Family 1: II-1)
presented with thrombocytosis but no splenomegaly. Her
bone marrow showed evidence of hyperplasia consistent
with ET but had no evidence of either JAK2 exon 14
(including the V617F) or JAK2 exon 12 mutations. Her
father (Fig. 1. Family 1: I-2) has ischemic heart disease,
peripheral vascular disease and was diagnosed with JAK2
V617F-negative PV that is treated with hydroxycarbam- ide
and venesection for a raised hemoglobin and hematocrit.
The index case of Family 5 (Fig. 1. Family 5: II-1) has a
persistent thrombocytosis noted for 9 years with no
mutation evident within JAK2 exons 13 and 14, CALR exon
9 or the coding exons of MPL and THPO, including the
intron–exon boundaries of both genes. One sibling (Fig. 1.
Family 5: II-5) and two daughters (Fig. 1. Family 5: III-1
and III-2) of the index case also have a mild thrombocytosis.
Therefore demonstrable absence of clo- nality in this

kindred suggests a HT phenotype as opposed to familial ET.
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Discussion
FMPN has been estimated to comprise between approximately 1–7 % of all MPN [11] with the commonly observed
JAK2 V617F mutation acquired as in sporadic cases. The
recent identification of mutations within CALR in a significant number of patients with JAK2 V617F-negative, MPL
exon 10 mutation-negative, sporadic ET and PMF [6, 7]
prompted investigation into the mutational status of the
these three sets of mutations (JAK2 V617F, CALR exon 9,
and MPL W515L/K) in patients with FMPN.
The affected individuals from the kindred described
herein display considerable phenotypic heterogeneity with
ET and PV the most prevalent phenotypes. This variety in
presenting phenotypes is in keeping with previous reports
[11, 12]. The incidence of the common JAK2 V617F,
CALR exon 9 and MPL W515L/K mutations confirms the
frequency noted in two recent reports. In a study of 10
FMPN pedigrees, 68 % of affected patients with known
mutational status for JAK2 were JAK2 V617F positive with
two of six JAK2 wild type patients harbouring CALR exon
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9 mutations [27]. A subsequent investigation of a larger
FMPN cohort again found 94/127 (74 %) patients to carry
JAK2 mutations with 12 of 75 (16 %) with ET and PMF
[28]. No FMPN patients with ET or PMF within this study
had evidence of the common MPL W515K/L mutations in
keeping with that previously reported [27, 28]. Furthermore, JAK2 and CALR exon 9 mutations are mutually
exclusive in this cohort and appear to be acquired
independently.
Two of the three affected individuals from Family 1 had
ET, with a further individual having JAK2 V617F- negative
PV (Fig. 1. Family 1: I-2). As both JAK2 exon 12 and exon
14 mutations were not detected in the index case (II-1), nonJAK2 V617F germ-line variants [15, 29, 30] are most likely
not a contributory factor the FMPN. The phenotype of PV
in I-2 of Family 1 also argues against a germ-line mutation
in either THPO or MPL genes as responsible for the FMPN
as inherited mutations in these genes invariably result in a
phenotype charac- terised by isolated thrombocytosis [14].
As evidenced in Family 5, absence of any mutations in JAK2
exons 13 and 14, CALR exon 9, MPL or THPO, together
with absence of hematopoietic clonality suggests that these
patients are likely to be cases of HT.
Identification of FMPN is important for several reasons.
There is evidence to suggest disease anticipation in FMPN
i.e. an earlier age of onset in subsequent generations. A
study of 35 FMPN pedigrees has shown a significantly
younger age at diagnosis in second-generation patients [31]:
a phenomenon apparent in other FMPN studies [27]. In
addition to the inherent increased risk of MPN, the incidence
of several non-hematological cancers also appears to be
increased in FMPN with a differing spectrum of
malignancies to that observed in patients with sporadic
MPN [32]. This apparent increased frequency of secondary
malignancies might possibly be due to an inherent underlying genomic instability [33]. Nevertheless, it remains a
possibility that members of the same family could be
affected with an MPN either by chance or due to a common
environmental factor [34].
While the JAK2 46/1 haplotype is a strong predisposition factor for JAK2-mutated, sporadic MPN, what genetic
variants predispose to FMPN are largely unknown. Identification of these elusive variants may prove difficult due to
the phenotypic and genotypic heterogeneity described
herein. The inherited factors that predispose to the development of MPN are also likely to influence the clinical
course [35]. Further genome sequencing and genome wide
association studies are required to define these risk variants. Finally, a thorough investigation of the family history
at the initial diagnosis of MPN patients is therefore advocated with regard paid to suggestive MPN-related symptoms in relatives.
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LETTER TO THE EDITOR
CALR Mutations are Rare in Childhood Essential Thrombocythemia

To the Editor: The incidence of childhood myeloproliferative
neoplasms is significantly lower than that in adults. Also, the
common JAK2 V617F mutation and other MPN-associated
mutations are detected less frequently [1] inferring differences in
both the etiology and molecular pathogenesis of these diseases in
adults and children. Two recent reports have identified acquired
insertion/deletion mutations of CALR, exclusively in exon 9, in
approximately 70–80% of adult essential thrombocythemia (ET)
and primary myelofibrosis (PMF) that do not possess JAK2 or MPL
mutations by exome sequencing approaches. Furthermore they have
demonstrated a previously unrecognized molecular complexity to
these malignancies [2,3]. These two studies prompted the
investigation of CALR mutations in pediatric MPN.
The presence of CALR exon 9 mutations was retrospectively
investigated using fluorescent PCR fragment analysis [2] in the
blood or bone marrow DNA from a relatively small single-center
cohort of unrelated, sporadic pediatric MPN classified according to
established hematological, histo-morphological and molecular
criteria [4]. This comprised of JAK2 V617F-negative ET (n
¼ 4),
JAK2 V617F-positive ET (n¼2) (Table I), JAK2 V617F-positive
polycythemia vera (PV; n 1),
¼ JAK2 V617F-negative polycythe- mia
(n 2), and
¼ reactive thrombocytosis (n 8). All¼MPN patients had no
MPL W515L or W515K mutations. Two different mutations found
in adult MPN acted as positive controls. CALR mutations were not
detected in the four JAK2 V617F-negative ET patients. Also, no
CALR mutations were detected in three JAK2 V617F- positive
MPN patients or in the eight children with reactive thrombocytosis
(Table I).
While this brief study demonstrates absence of CALR exon 9
mutations in JAK2 V617F-positive childhood MPN, no CALR exon
9 mutations were found in the four JAK2 V617F-negative children
with ET. If the molecular pathogenesis of pediatric and adult MPN

was similar then one might expect to detect CALR mutations in a
certain proportion of young JAK2- and MPL-negative ET patients.
Whether CALR mutations are present and will have a role in the
diagnosis and classification of childhood MPN requires verification
in a larger cohort. This study serves to highlight another potential
biological difference between childhood and adult MPN.
Stephen E. Langabeer, PhD*
Cancer Molecular Diagnostics
St. James’s Hospital
Dublin, Ireland
Karl Haslam, MPhIL
Cancer Molecular Diagnostics
St. James’s Hospital
Dublin, Ireland
Corrina McMahon, MD
Department of Haematology
Our Lady’s Children’s Hospital Crumlin
Dublin, Ireland
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TABLE I. Features of the Six ET Patients
Case
1.
2.
3.
4.
5.
6.

Diagnosis

Age (years)

Median platelet
9
count (×10 /l)

Platelet count
9
range (×10 /l)

JAK2 V617F

MPL W515L/K

CALR exon 9

ET
ET
ET
ET
ET
ET

4
15
9
9
9
11

915
1,192
1,355
879
773
613

721–1,167
953–1,240
296–2,718
343–3,054
606–872
413–1,233

Positive
Positive
ND
ND
ND
ND

ND
ND
ND
ND
ND
ND

ND
ND
ND
ND
ND
ND

ND, not detected.
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LETTER TO THE EDITOR
Distinct Driver Mutation Profiles of Childhood and Adolescent Essential
Thrombocythemia

To the Editor: The incidence of the Philadelphia chromosomenegative myeloproliferative neoplasms (MPN), polycythemia vera
(PV), essential thrombocythemia (ET) and primary myelofibrosis
(PMF) is significantly lower in children than in adults with the most
commonly acquired molecular drivers, JAK2 V617F and myeloproliferative leukemia (MPL) exon 10 mutations, detected in fewer
pediatric patients. Childhood MPN therefore appears to be more
genetically na¨ıve than adult MPN suggesting an alternative
molecular pathogenesis in the majority of cases. Most studies
investigating the presence and consequences of driver mutations in
childhood MPN have included both younger children and
adolescents up to 18–20 years of age [1].
Disease-initiating insertion and/or deletion mutations within
exon nine of the CALR gene, that encodes the intracellular calcium
binding protein calreticulin, have been described in up to 80% of
adult ET and PMF patients without JAK2 or MPL mutations [2,3].
This revelatory discovery compels the incorporation of CALR
mutational analysis into the molecular diagnostic algorithm for
MPN. To date, two studies have investigated the incidence of CALR
mutations in childhood ET: a small, single-centre study in which no
CALR mutations were detected and a larger analysis of 34 patients
diagnosed with ET when less than 20 years of age [4,5]. Inspection
of the ages of presentation in the latter study reveals a conspicuous
divergence between those adolescent ( 14 yrs;
≤ n 22) and ¼childhood
( 11 yrs; n 12)
≤ ET patients
¼ [5]. The JAK2 V617F, CALR, MPL and
triple negative mutation status of ET patients from these two studies
may be combined to create a larger cohort (n 40). Analysis of
this¼ combined cohort reveals that adolescent ET patients have a
strikingly similar molecular profile to that

Adult ET
(n=311)

the pathogenesis of adolescent and childhood ET, but raises further
questions regarding the causes and treatment of pediatric ET.
Whether adolescent ET patients should be considered the same as
adults for treatment purposes is certainly debatable: the most
pressing clinical issues in adult ETare thrombosis and myelofibrotic
or leukemic transformation, yet the incidence of these events is
much lower in childhood and adolescent ET, even with substantial
follow up [1]. A pre-natal origin of the disease has been established
in cases of JAK2 V617F-positive PVand ET [6,7]: demonstration of
an in-utero acquisition of CALR mutations in those younger patients
would provide further insights into disease initiation and natural
history. It is clear that in the majority of young children with ET,
disease initiating and driving mutations remain unknown. While
whole exome sequencing has been successful indentifying CALR
mutations and other mutational events in adult MPN, these
approaches have yet to be applied to pediatric MPN patients.
Identification of these elusive driver mutations could potentially
uncover targets for therapeutic intervention.
Stephen E. Langabeer, PhD*
Karl Haslam, MPHIL
Cancer Molecular Diagnostics
St. James’s Hospital
Dublin, Ireland
Corrina McMahon, MD
Department of Haematology
Our Lady’s Children’s Hospital
Crumlin, Dublin, Ireland

Adolescent ET
(n=23)

Triple negative

Childhood ET
(n=17)

Triple negative

MPL

Triple negative

CALR

JAK2 V617F

CALR
CALR
JAK2 V617F

JAK2 V617F

Fig. 1. Distribution of the common driver mutations in adult, adolescent (≤14 to ≤20 yrs) and childhood (≤11 yrs) ET at time of diagnosis.

observed in adults [2], whereas the majority of childhood
(diagnosed at 11
≤ yrs) ET patients are triple negative, that is, no
JAK2 V617F, CALR or MPL driver mutations (Fig. 1).
Acknowledging that the numbers of ET patients are comparatively small, not only does this observation highlight differences in
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A prenatal origin of childhood essential thrombocythaemia

In children, the myeloproliferative neoplasms (MPN) polycythaemia vera (PV) and essential thrombocythaemia (ET) are
estimated to have a prevalence of approximately 40- to 90- fold
lower than that seen in adults with sporadic, paediatric ET
patients exhibiting a significantly lower prevalence of the JAK2
V617F (Teofili et al, 2008). The incidence of the JAK2 V617F
is known to increase with age, in both ET and PV, through
adolescence, into adulthood and old age (Cario et al, 2008;
Randi et al, 2011), suggesting that an increasing degree of
underlying genomic instability is partly responsible for the
acquisition of this mutation. Furthermore, those chil- dren with
ET harbouring this mutation also display a lower JAK2 V617F
allele burden (Teofili et al, 2009). Although sev- eral clinical
and biological similarities exist between adult and paediatric
ET, these aforementioned observations suggest differences in
the aetiology of this disease in childhood and implicate some
alternative pathogenetic mechanism(s).
Genetic analysis of antenatal blood spots (ABS; Guthrie
cards) has demonstrated that clonotypic translocations,
mutations and gene rearrangements associated with many
subtypes of paediatric acute lymphoblastic leukaemia, and to a
lesser extent, paediatric acute myeloid leukaemia, are pres- ent
at birth and have therefore been generated in utero. These
backtracking studies have provided significant insights into the
pathogenesis, natural history and aetiology of these
676

leukaemias (Wiemels et al, 2009). We have previously
described the somatically acquired, in utero origin of the JAK2
V617F mutation in an infant with PV, thus providing some
insight into the origins of childhood MPN (Kelly et al, 2008).
Whether all genotypes and phenotypes of paediatric MPN,
especially those seen in younger patients, have a pre- natal
origin is unknown. To expand on this theme, we describe
herein the prenatal origin of the JAK2 V617F in a child with
ET.
A four-and-a-half year-old female presented with persis- tent
urinary tract infections associated with a thrombocytosis
(platelet count 801–989 9 109/l). Antibiotic treatment ameliorated the infections yet the thrombocytosis remained. Significant platelet anisocytosis and giant platelets were observed
on the peripheral blood film. A bone marrow aspirate revealed a normocellular, particular marrow with evi- dence
of trilineage haematopoiesis. All cell lines were represented to
maturity with abundant megakaryocytes, some with
dysmorphic features, such as hyperchromatic and naked nuclei.
Megakaryocyte clustering was evident and there was no
obvious reticulin fibrosis. The JAK2 V617F was detected in the
peripheral blood by qualitative polymerase chain reac- tion
(PCR) (Baxter et al, 2005) and determined as 31·2% of total
JAK2 alleles by quantitative PCR (qPCR; Larsen et al, 2007).
Parental consent was sought and granted to access the
ª 2013 John Wiley & Sons Ltd
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Fig 1. Agarose gel electrophoresis of JAK2 V617F-specific, seminested polymerase chain reaction (PCR) products. Lanes 1 & 14: 100
bp ladder; Lanes 2–5: 1/103, 1/104, 1/105, 1/106 dilution controls; Lanes
6, 9 & 12: semi-nested PCR negative controls; Lanes 7 & 8: PCR
duplicates from ABS 1; Lane 10 & 11: PCR duplicates from ABS 2;
Lane 13: first round PCR negative control.

archived antenatal blood spots. DNA extractions were performed from sections of two separate ABS taken from the
patient 4 days post-natally (Wiemels et al, 2009). qPCR analysis was unable to reliably detect the JAK2 V617F in these
samples (Ct >40 cycles). A more sensitive but qualitative, seminested allele-specific PCR was used to amplify both wild type
and mutant JAK2 alleles using a first round for- ward primer
(Larsen et al, 2007) with a common reverse pri- mer (Baxter et
al, 2005). A second round of PCR used a forward JAK2
V617F-specific primer (Baxter et al, 2005).
This semi-nested PCR had a limit of detection of mutant alleles
of approximately 1 9 10—5, determined by dilution of genomic
DNA from a known heterozygous JAK2 V617F patient into
DNA from a pool of 20 normal controls (Fig 1). This approach
was able to demonstrate the presence of the
JAK2 V617F in PCR duplicate reactions from both ABS (Fig
1). Both parents had normal full blood counts and had
no
evidence of the JAK2 V617F. Furthermore, there was no clinical
history of an MPN in either parent or their families, thus
diminishing the likelihood of familial MPN. A younger female
sibling was not investigated. We therefore conclude that in this
case, the ET is non-familial and the JAK2 V617F was
somatically acquired in utero. One year post-diagnosis,
the patients’ platelet count (841 9 109/l) and JAK2 V617F
allele burden (26·1%) remain stable. The patient is closely
monitored, shows no evidence of splenomegaly or throm- botic
episodes, and has not received any MPN-specific treatment.
Paediatric ET is a rare disease with most patients reported
within single institution studies. Nevertheless, it is apparent that
this disease in children, analogous to many other haematological malignancies, has certain clinical and molecular
dissimilarities with the same disease observed in adults. The

presence of the JAK2 V617F in this case of typical ET allowed
the retrospective demonstration of the mutation at the time of
birth, indicating a prenatal origin. An explanation as to when
this mutation arose remains elusive: an early acquisition during
fetal haematopoiesis is postulated as significant expansions of
the JAK2 V617F clone must have
occurred both in utero and in the post-natal periods in tan- dem
with normal fetal and neonatal haematopoietic develop- ment.
Other genetic or epigenetic events, be they acquired or
inherited, may have contributed to the acquisition of the JAK2
V617F and its subsequent capacity to elicit the disease
phenotype in early childhood in this case.
Do other childhood MPNs have a similar prenatal origin?
The next most commonly acquired mutations in adult ET are
those of MPL exon 10, however to date, this mutation
has
rarely been documented in paediatric ET (Farruggia et al, 2013).
Other mutations, such as those in TET2, CBL, IDH1 and IDH2
have not been detected in a limited study of child- hood MPN
(Ismael et al, 2012). The identification of further markers of
clonality is necessary to expand the limited molecular
comprehension of childhood MPN and
improve
our
understanding of the natural history of these diseases.
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Normal prion protein is expressed on exosomes isolated from
human plasma
Four probable cases of blood products spreading variant
Creutzfeldt-Jakob Disease (vCJD) have been reported, with two
additional cases linked through possible receipt of blood
products from a single donor (Chohan et al, 2010). In the UK,
leucodepletion and donor-exclusion have been employed to
minimize the risk of blood product-mediated transmission.
However uncertainty regarding the sources and risks of vCJD
transmission mean asymptomatic carriers may inadvertently
cause transmission of vCJD through blood donation.
The causative agent of vCJD is the abnormally folded form
of the prion protein (PrPSc), and this protein is also known to
cause other transmissible spongiform encephalopa- thies
(TSEs). The prion protein normally exists in a native, cellular
form (PrPC). The paucity of samples from vCJD- infected
humans, plus difficulties in distinguishing PrP C and PrPSc, mean
that the experimental focus of human in vivo studies has been
on PrPC, while animals models and in vitro work has been able
to explore both. Animal models have clearly shown that TSEs
can be transmitted by blood transfu- sion (Houston et al, 2000;
Hunter et al, 2002; Siso et al, 2006; McCutcheon et al, 2011).
Exosomes are the smallest recognized subset of microvesicles, being under 100 nm in diameter, and are released through
the fusion of multivesicular bodies with the plasma membrane.
They have a distinctive protein composition and can be detected
in human plasma (Caby et al, 2005; Ren et al, 2011). Work
by others has shown that both PrPC and PrPSc can be detected in
association with exosomes generated in vitro by animal cell
lines, and that such exosomes can spread TSEs (Fevrier et al,
2004; Vella et al, 2007; Alais et al, 2008). These findings have
highlighted exosomes as a poten- tial source of transmission for
TSEs, but it is not known whether such concerns are valid for
circulating exosomes in human blood. Here, we confirm that
PrPC is indeed
678

associated with exosomes isolated from human plasma. These
findings are consistent with the potential for exosomes in human
plasma to spread vCJD.
Plasma units from healthy donors were obtained from
National Health Service Blood and Transplant (NHSBT,
Bristol, UK), mixed 1:1·5 with phosphate-buffered saline, and
vesicles isolated following the technique of Caby et al (2005).
Electron microscopy revealed a heterogeneous population of
membrane-bound vesicles ranging in size from 30 to 250 nm,
with the majority of vesicles in the 50 to 100 nm range (Fig
1A), demonstrating that vesicles that have the morpho- logical
characteristics of exosomes make up the bulk of the vesicle
preparation. Western blotting revealed the presence of the
exosome-associated tetraspanins CD9 and CD63; the
endoplasmic reticulum marker calnexin was absent (Fig 1B).
Flow cytometric analysis of exosomes bound to anti-CD63
coated beads confirmed that the isolated vesicles expressed the
typical surface-marker profile of exosomes: they strongly
expressed the exosome-associated tetraspanin molecules CD9,
CD63, and CD81, as well as HLAI (Fig 1C). To explore the
cellular source/s of these exosomes, markers previously associated with exosomes from various cell types were analysed.
There was no detectable staining for human leucocyte anti- gen
(HLA) Class II (antigen presenting cells), CD3 (T cells), CD11c
(myeloid dendritic cells), CD20 (B cells), or CD86 (dendritic
cells and B cells), while there was strong staining for CD41a
(platelets and megakaryocytes) (Fig 1C). This sug- gests that the
majority of exosomes isolated were derived from platelets
and/or their precursors. This finding is consis- tent with the only
previously published report on CD41a and human plasma
exosomes (Caby et al, 2005), although the absence of HLA
Class II on human plasma exosomes was contrary to the
findings of two previous studies (Caby et al, 2005; Ren et al,
2011). It remains possible that other cell
ª 2013 John Wiley & Sons Ltd
British Journal of Haematology, 2013, 163, 674–687
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Letter to the Editor
Capricious CALR Thutated clones in
Thyeloproliferative neoplasThs

primarily distinguish multiple clones and lacking sufﬁcient sensitivity, as most minor clones appear to be present at low levels [2], would
clearly be disadvantageous for diagnostic purposes.

To the Editor.
Insertion and/or deletion mutations of CALR, the gene that encodes
the endoplasmic reticulum-associated, calcium binding protein
calreticulin, are the second most common driver mutations observed in the
myeloproliferative neoplasms (MPN) of essential thrombocythemia (ET)
and primary myeloﬁbrosis (PMF). Identiﬁcation of CALR mutations, along
with the JAK2 V617F and MPL exon 10 mutations, is likely to be a major
diagnostic criterion for these two entities in the forthcoming revi- sion of
the World Health Organization classiﬁcation of haematopoietic
malignancies [1]. CALR mutations are usually heterozygous with a single
mutated clone present in most ET and PMF patients. In a recently published large cohort of CALR mutated patients (n = 685), it was shown
that ten (1.5%) possessed complex CALR mutations of which four patients
had multiple clones [2]. Furthermore, in a recent Blood Cells, Molecules
and Diseases report, Shuly et al. describe a stable CALR mutant allele burden in ET patients over time: the mean length of time between ﬁrst and
second assessments was 3.7 years, however, despite revealing a modest,
mean increase in CALR mutant allele burden of 5.7% over this period,
there existed a considerable inter-patient heterogeneity [3].
In order to explore the implications of these ﬁndings, we examined CALR mutation patterns in an independent cohort of CALR mutated ET and PMF patients. Retrospective screening of JAK2 V617F
negative ET and PMF patients was performed by fragment length
analysis with a validated detection sensitivity of 1% mutant allele
burden as previously described [4]. Of 55 CALR mutated patients
34 (61.8%) had a type 1 (52-bp deletion) mutation, 15 (27.3%)
had a type 2 (5-bp insertion) mutation, four (7.3%) had a type 1like mutation and one (1.8%) had a type 2-like mutation. One
(1.8%) further ET patient who presented in July 2005 harboured
both a type 1 (14.4% allele burden) and a 13-bp deletion (28.1% allele burden) in their diagnostic peripheral blood (Fig. 1). Repeat
analysis of peripheral blood more than ten years post presentation
and after seven years of hydroxyurea therapy revealed ﬂuctuation
in the level of the two different clones with type 1 mutation and
13-bp deletion mutation allele burdens of 29.3% and 10.6% respectively (Fig. 1).
Firstly, we conﬁrm the presence of multiple CALR mutated clones
in MPN patients at a frequency similar to that initially reported [2].
The presence of multiple clones in a minority of patients therefore
has implications for selection of molecular diagnostic methodology.
Sanger sequencing, fragment length analysis, high resolution melt
curve analysis, quantitative PCR, digital PCR and next-generation sequencing can all be used for CALR mutation detection in the diagnostic and residual disease monitoring settings, with each approach
possessing advantages and disadvantages in regard to sensitivity,
ease of use, availability and cost [5–7]. Those methods unable to

http://dx.doi.org/10.1016/j.bcmd.2016.01.001
1079-9796/© 2016 Elsevier Inc. All rights reserved.

Fig. 1. CALR mutation proﬁle of patient with essential thrombocythemia at diagnosis
(upper panel) and ten years later (lower panel).
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Secondly, initial reports suggest that unlike interferon alpha, hydroxyurea therapy has no signiﬁcant impact on the mutant CALR allele
burden [8] implying that the phenomenon described represents an authentic variation in the clonal architecture of this patient. Given the acknowledged moderate variability in mutated CALR allele burden also
observed by Shuly et al. [3], caution must therefore be advised when
interpreting residual disease responses. Further studies are warranted
in larger cohorts comparing ET and PMF patients with similar diagnostic
characteristics and similar treatment modalities to identify any biological effects of CALR mutant clonal diversity over time.
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The mutant CALR allele burden in essential thrombocythemia at transformation to acute myeloid leukemia
To the Editor.
Transformation to acute myeloid leukemia (AML) occurs in approximately 5% of patients with the myeloproliferative neoplasm (M PN) of
essential thrombocythemia (ET). Risk factors for leukemic transformation include advancing age, degree of anemia, platelet co unt, the presence of
two or more somatic mutations, and prior treatment with either radioactive phosphorus or alkylating agents. Also, AML following ET is often
associated with an unfavorable karyotype and a poor prognosis [1]. Advances in understanding the underlying pathogenesis of MPN have led to the
demonstration of molecularly annotated, clonally divergent routes to leukemic transformation in patients with MPN. In the majority of JAK2 V617Fpositive MPN patients who undergo transformation, this mutation is also present in the AML cell population. However, the phen omenon of JAK2
V617F-negative AML following a JAK2 V617F-positive MPN implies the transformation of a myeloid progenitor at a stage before acquisition of the
JAK2 V617F or in a clone distinct from that harboring the JAK2 V617F [2,3]. In those few CALR mutation-positive patients studied to date, this
phenomenon has not been described [4,5]. Evidence for this latter course of disease evolution is outlined below in a patient in whom ET transformed
to AML.
A 51 year-old male with a history of peptic ulcer disease and hiatus hernia presented in February 2003 with a hemoglobin of 14.8 g/dL, a white
cell count of 6.2 × 109/L and a platelet count of 1160 × 109/L. Bone marrow aspirate and biopsy showed increased, morphologically atypical
megakaryocytes with clustering and minor evidence of reticulin ﬁbrosis in keeping with a diagnosis of ET. The patient commenced on hydroxyurea
and aspirin. The JAK2 V617F was not detected in peripheral blood in October 2009. By March 2017, the patient had developed anemia (hemoglobin
8.9 g/dL) with red cell anisocytosis and occasional myeloblasts noted on the peripheral blood ﬁlm. Bone marrow biopsy showed an inﬁltration of
myeloblasts that were CD34 positive by immunohistochemistry accounting for approximately 25% of nucleated cells with no increase in reticulin
ﬁbrosis. Bone marrow aspirate immunophenotyping revealed the myeloblasts were positive for MPO, HLA DR, CD13, CD33, CD34, CD64 and CD117
consistent with AML. The patient had a complex karyotype with aberrations involving chromosomes 5q, 7q, 8p, 12p, and 14q. Giv en the previous
absence of the JAK2 V617F mutation, CALR exon nine mutation analysis was performed by fragment length analysis with a validated detection
sensitivity of 1% mutant allele burden as previously described [6]. In the bone marrow at the time of leukemic transformation, this approach detected
a CALR type 1, 52 bp deletion mutation at a low allele burden of 5.7%. Analysis of the archived October 2009 peripheral blood sample demonstrated
the CALR mutation allele burden to be 49.7% at that time, approximating heterozygosity (Fig. 1). The patient received one cycle of daunorubicin and
cytarabine 3 + 10 chemotherapy but did not achieve morphological remission with bone marrow myeloblasts representing 15% of nucleated cells
and repeat bone marrow CALR analysis demonstrating an unchanged mutant allele burden of 5.6% (Fig. 1).
Mutations in JAK2, CALR and MPL are recognised as driver mutations of MPN yet the timing and order of acquisition of both these driver and
additional disease modifying mutations, and in which clone these mutations prevail, is becoming more pertinent to understanding mechanisms of
disease progression [4,5]. Given that the mutant CALR allele burden generally increases over time [7] and is largely unaﬀected by hydroxyurea
therapy [8], the signiﬁcant reduction correlating with disease progression noted in the patient described herein likely represents a true reﬂection of
the underlying disease evolution. This ﬁnding signiﬁes that the AML clone is not derived from the CALR mutation-bearing MPN clone but from either
a myeloid progenitor prior to acquisition of the CALR mutation or in a clone distinct from that with the CALR mutation similar to that previously
encountered in transformation of JAK2 V617F-positive MPN. This hitherto unreported phenomenon in a CALR mutated case of ET provides further
insights into the pathogenetic mechanisms of leukemic transformation and emphasizes the underlying clonal heterogeneity in ET and MPN patients.
This observation requires conﬁrmation in other CALR mutant ET patients transformed to AML.

http://dx.doi.org/10.1016/j.bcmd.2017.05.004
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Fig. 1. CALR mutation fragment length analysis of a patient with essential thrombocythemia at diagnosis (upper panel), leukemic transformation (center panel), and post-chemotherapy (lower panel).
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Transient JAK2 V617F mutation in an aplastic anaemia patient
with a paroxysmal nocturnal haemoglobinuria clone

In 1969, William Dameshek proposed that paroxysmal
nocturnal haemoglobinuria (PNH) should be considered a
candidate myeloproliferative neoplasm (MPN) based on the
evidence of red blood cell abnormalities in the context of bone
marrow pancytopenia, low leucocyte alkaline phospha- tase and
the potential for leukaemic transformation (Dame- shek, 1969).
Further similarities between MPN and PNH include expansion
of subsequent or simultaneous myeloid clones and an increased
frequency of abdominal vein throm- bosis. PNH is an acquired,
stem cell disorder associated with mutations of the PIGA gene
that encodes a protein required
for the synthesis of
glycosylphosphatidyl-inositol anchored proteins (GPI-AP).
PNH blood cells are therefore deficient in cell surface proteins
that use the GPI anchor and may be detected
immunophenotypically by absent or reduced expres- sion of
CD55 and CD59 on red blood cells (RBC) and CD16, CD24,
CD66b and FLAER (fluorescence labelled aer- olysin) on
granulocytes. PNH clones are also present in a sig- nificant
number of patients with the related marrow failure syndromes
aplastic anaemia (AA) and hypoplastic myelodys- plastic
syndrome (MDS). Although PNH originates from a multipotent
haematopoietic stem cell, PIGA mutations are insufficient to
drive clonal expansion and several models have attempted to
explain this phenomenon: GPI-AP may be immunogenic and
their deficiency enables evasion from immunological
surveillance or the possibility that PIGA mutations themselves
confer an intrinsic resistance to apop- tosis (Brodsky, 2008).
Another theory postulates the acquisi- tion of a second genetic
event that enables clonal expansion in co-operation with the
PIGA mutation, some evidence for which comes from the
deregulated expression of HMGA2 in
a minority of PNH
patients (Inoue et al, 2006).
A recent report identified the JAK2 V617F mutation in
GPI-AP deficient cells of three PNH patients and suggested this
coexistence could explain clonal expansion (Sugimori et al,
2012). These findings prompted investigation into the
frequency of the JAK2 V617F in other patients harbouring a
PNH clone. Archival DNA samples from blood (n = 3) and bone
marrow aspirate smears (n = 19) from 22 patients (PNH, n =
5; AA, n = 13; hypoplastic MDS, n = 4) with an
immunophenotypically detectable PNH clone of both RBC and
granulocytes were retrospectively analysed for JAK2 V617F by
qualitative allele-specific polymerase chain reaction (PCR)
(Baxter et al, 2005) with a sensitivity of 2% mutant alleles. The
JAK2 V617F mutation was detected in one patient with AA.
This female patient, who presented with severe AA

ª 2013 Blackwell Publishing Ltd

and no evidence of a PNH clone (nor retrospectively the JAK2
V617F), was initially successfully treated with two courses of
antithymocyte globulin (ATG) and cyclosporin. She relapsed
in pregnancy 2 years later and was treated with
immunoglobulin, and RBC and platelet transfusions. Post
partum treatment included G-CSF, ATG (2 courses) and
ciclosporin, the latter being discontinued after achieving RBC
and platelet transfusion independence. Ten years after the initial
presentation, progressive pancytopenia suggested relapse of AA
with a PNH clone detected within the granulocytes (17·7%) and
RBCs (5·4%). At this relapse, the JAK2 V617F was detected in
the bone marrow and confirmed by quantita- tive PCR (qPCR;
Larsen et al, 2007) at a reproducible level of 1·8% of total JAK2
alleles (Fig 1). Ciclosporin was recom- menced with a good
response attained. 3 years post-relapse, the PNH clone remained
stable in granulocytes (18·9%) and RBCs (6·0%) with the JAK2
V617F not detected in the bone marrow by both allele-specific
and qPCR. At no point during the clinical course did the patient
have a persistent leucocyto- sis, erythrocytosis or
thrombocytosis. The patient was subse- quently diagnosed with
malignant melanoma to which she succumbed. Diagnostic or
pre-allogeneic haematopoietic stem cell transplantation samples
from a further 38 AA patients without evidence of PNH were
screened for the JAK2 V617F, none of which were found to
harbour this mutation.
We describe the hitherto unreported detection of the JAK2
V617F in a PNH-related bone marrow failure syndrome at a
similarly low frequency to that previously described in classical PNH (Fouassier et al, 2009; Sugimori et al, 2012). As this
case was identified retrospectively, existence of the JAK2
V617F in the PNH clone could not be verified by fluores- cenceactivated cell-sorting of the GPI-AP-negative popula- tion
(Sugimori et al, 2012). However, the transient nature of the
JAK2 mutation in the presence of a relatively stable PNH clone,
taken together with the evidence of different JAK2 V617F and
PNH clone sizes implies two distinct populations as opposed to
the co-existence of mutations within one clone. The
phenomenon of transient JAK2 V617F-positivity may be
explained by the acquisition of the mutation in a more
differentiated haematopoietic progenitor than that in patients
with MPN. If this progenitor had reduced self- renewal
potential and capacity for differentiation then the clone
generated might therefore be short-lived and not result in a
clinical phenotype (Passamonti et al, 2007).
Characterization of the role of JAK2 signalling in PNH
and PNH-related disorders may provide some insight into
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Fig 1. Quantitative polymerase chain reaction (qPCR) standard curves were derived from diluted commercial plasmids (MutaQuante; Ipsogen SA,
Marseille, France) ranging from 25 000 to 25 copies of JAK2 V617F (A). The assay was composed of two allele-specific PCR reactions in duplicate:
one for the JAK2 V617F and one for the wild type allele. As the reverse primers used in both reactions differed by only one base at the 30 end, nonspecific amplification is observed in the JAK2 V617F assay when performed on target negative controls. The specificity and sensitivity was calculated
using the DCt value for the target negative control (number of cycles between wild type and JAK2 V617F Ct values) where the specificity corresponds
to 2DCt . The assay sensitivity (0·02%) was set at ten-fold less than this value to ensure the identification of true positive measurements (B).

disease development, maintenance or progression. The detection of the JAK2 V617F and other molecular lesions that
contribute to clonal expansion, such as deregulation of HMGA2
expression, evident in PNH (Inoue et al, 2006) and both typical
MPN and atypical myeloid malignancies (Odero et al, 2005;
Bruchova et al, 2008) suggests some common pathogenetic
mechanisms of PNH and MPN that warrant further
investigation.
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Considerations and Recommendations
for a New Molecular Diagnostic Algorithm
for the Myeloproliferative Neoplasms
Karl Haslam and Stephen E. Langabeer

The classical Philadelphia chromosome-negative myeloproliferative neoplasms consist of three main pathological
and clinical entities with the recurrent JAK2 V617F mutation present in *98% of patients with polycythemia vera
and *50% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF). The recent discovery
of mutations within the CALR gene in up to 80% of JAK2 V617F-negative ET and PMF patients compels employment of CALR mutational analysis for the molecular diagnosis of these diseases. Evidence derived from a
retrospective audit of JAK2 V617F testing provides a framework for the proposal of a diagnostic algorithm that
incorporates CALR mutation assessment. It is recommended that relevant clinical details, including a provisional
morphological and clinical diagnosis, are provided and that exclusion of alternative causes of erythrocytosis, leucocytosis, or thrombocytosis is required before molecular testing. It should be acknowledged that over-requesting
such investigations can impact on the clinical predictive value of these tests when considering the disease specificity
of such mutations, with adherence to the diagnostic algorithm necessary to ensure appropriate use of resources.

Introduction

T

he myeloproliferative neoplasms (MPN) are clonal
hematopoietic stem cell-derived diseases characterized
by bone marrow proliferation of one or more of the myeloid
cell lineages, with the main subtypes of MPN being polycythemia vera (PV), essential thrombocythemia (ET), and
primary myelofibrosis (PMF). The diagnosis and classification
of these diseases are dependent on clinical, hematological,
histomorphological, and molecular genetic findings (Swerdlow
et al., 2008).
The most commonly acquired mutation associated with
MPN is the JAK2 V617F, occurring in 98% of PV cases and
in approximately half of ET and PMF patients (Gong et al.,
2013). This mutation disrupts the function of the intracellular
JAK2 molecule that is required for normal hematopoietic
cytokine signaling and has become a target for therapeutic
intervention (Gäbler et al., 2013). Alternative mutations of
JAK2 within exon 12 can be detected in the majority of those
remaining V617F-negative PV patients (Scott et al., 2007).
Several other genetic abnormalities have been described in
MPN, which occur at a much lower frequency than the JAK2
V617F. Mutations in MPL exon 10, which encodes the receptor for thrombopoietin, a major regulator of megakaryocyte and platelet development, are present in *5% and 3% of
PMF and ET patients, respectively (Pardanani et al., 2006).
Recent whole-exome sequencing studies of MPN patients

have led to the discovery of insertion and/or deletion mutations in exon 9 of CALR, a gene that encodes the endoplasmic
reticulum-associated calcium-binding protein, calreticulin.
These disease-driving mutations of CALR result in a frameshift of the coding sequence, altered amino acid composition
of the translated protein, and loss of the endoplasmic reticulum retention motif. CALR mutations do not occur in PV
patients, but are present in up to 80% of ET and PMF patients
who are JAK2 V617F and MPL mutation negative (Klampfl
et al., 2013; Nangalia et al., 2013). In rare instances of MPN,
CALR and MPL mutations may coexist with the JAK2 V617F
(Lasho et al., 2006; Lundberg et al., 2014; McGaffin et al.,
2014; Tefferi et al., 2014). Other mutational events that result in
disruption of myeloid cell differentiation and proliferation have
been described in MPN but are usually associated with rare
phenotypes or leukemic transformation and are also observed
in other myeloid malignancies, thus limiting their diagnostic
relevance (Tefferi, 2010). Despite these recent advances, bone
marrow aspirate and biopsy remain essential for the assessment of megakaryocyte morphology and degree of reticulin
fibrosis required to differentiate ET from early PMF (Tefferi
and Vardiman, 2008; Qureshi and Harrison, 2013).
Not only is the detection of BCR-ABL1 transcripts necessary for the diagnosis of chronic myeloid leukemia (CML)
but also the exclusion of this rearrangement was, before the
description of CALR mutations, a diagnostic criterion for
many other MPN such as PMF, ET, chronic myelomonocytic
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leukemia, and chronic neutrophilic leukemia that may present with a leucocytosis and/or thrombocytosis (Swerdlow et
al., 2008). As CML also can rarely present as an isolated
thrombocytosis, the identification of BCR-ABL1 transcripts
can also be incorporated into the diagnostic algorithm for
such cases (Harrison et al., 2013). Bone marrow examination
is also necessary for staging CML at diagnosis; increased
myeloblast numbers, extra copies of the Philadelphia chromosome, or other additional cytogenetic abnormalities are all
indicators of advanced disease, which require a more intensive treatment approach (Vardiman, 2009).
Given the high frequency and specificity of CALR mutations in ET and PMF, there is an urgent need to incorporate
identification of these mutations into the diagnostic algorithm
of patients with suspected MPN to facilitate the increasing
demand for confirmatory molecular diagnostics (Tefferi and
Pardanani, 2014). Previous efforts to streamline this process, in which BCR-ABL1 testing was advocated as a firstor second-line investigation (Schnittger et al., 2012; Bench
et al., 2013), require revisiting in light of the description of
CALR mutations to avoid en masse screening deemed scientifically irrational and economically irresponsible in this
clinical scenario (Tefferi et al., 2011).
Materials and Methods

To provide a comprehensive MPN molecular diagnostic
service and to manage future demand for such a service, a
review of the quality of clinical information provided and the
appropriateness of JAK2 V617F tests requested at a
molecular diagnostic facility for testing of hematological
malignancies over a 12-month period was performed. This
information, together with results from previous audits and
incorporating current knowledge of the molecular landscape
of MPN, was used to develop recommendations that could
support a new MPN diagnostic algorithm, which incorporates CALR mutation analysis.

FIG. 1. Indications for
JAK2 V617F analysis.
Black: JAK2 V617F detected; gray: JAK2 V617F
not detected.
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Results and Recommendations

A total of 1228 requests received for JAK2 V617F testing
during a 12-month period were assigned to the following nine
categories based on clinical details provided: No clinical details
provided (n = 525), PV/?PV (n = 321), ET/?ET (n = 266), PMF/
?PMF (n = 18), thrombosis (n = 57), splenomegaly (n = 17),
neutrophilia/eosinophilia (n = 40), other myeloid malignancies
(n = 24), and miscellaneous (n = 20) (Fig. 1). Overall, two
hundred five patients (15.9%) had evidence of the JAK2 V617F.
Of immediate note was the significant proportion (40.8%) of
referrals received with no clinical details provided. The capacity
of a laboratory to provide a rational MPN molecular diagnostic
service is reliant upon sufficient clinical detail to best triage
sample referrals and assign appropriate testing.
Recommendation 1: Provide sufficient relevant clinical
details, including provisional diagnosis, to enable application
of the testing algorithm.
The incidence of JAK2 V617F-positive patient samples
across all categories varied from 0% to 27% (median across
all nine categories 16.7%) with a notably low prevalence in
those patients with suspected PV (10.3%). While investigation of the JAK2 V617F in patients presenting with persistent
erythrocytosis or persistent thrombocytosis is necessary, a
tendency to prematurely refer samples for up-front testing of
both the JAK2 V617F and BCR-ABL1 rearrangement has
been previously described (Langabeer, 2012; McCarron and
Langabeer, 2014). These audits have demonstrated consistently increasing requesting patterns, despite the number of
newly diagnosed JAK2 V617F-positive MPN and CML patients remaining constant. Awareness of service availability
might explain this phenomenon, yet the rising request rate
most likely represents an increasing use of JAK2 V617F and
BCR-ABL1 testing as an inappropriate advance exclusionary
test in the initial work up of patients for whom secondary
causes have not been fully ruled out. For example, according
to guidelines, diagnosis of ET requires documentation of a
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FIG. 2. Proposed molecular diagnostic algorithm for
suspected MPN. PV, polycythemia vera; CML, chronic
myeloid leukemia; ET, essential thrombocythemia;
PMF, primary myelofibrosis;
BM, bone marrow.

sustained, as opposed to a transient, thrombocytosis with
exclusion of all other possible causes (Swerdlow et al., 2008;
Harrison et al., 2010).
Recommendation 2: Ensure alternative causes of MPNlike hematological indices are excluded before testing.
The benefit of clinical information acquired from testing in
these scenarios must be weighed against the potential negative
impact of inappropriate requests upon the clinical predictive
value of the test, which itself is directly influenced by the
prevalence of the disease in the population tested. The sensitivity of the JAK2 V617F screening assay employed (Baxter
et al., 2005) or its capacity to correctly identify those patients
with disease is 99%, that is, 1% of patients will remain undetected (false negatives). This is due to the limit of detection
of the assay (1% JAK2 V617F allele burden), below which
positive patients will evade detection by this method. The
clinical relevance of such low allele burdens remains controversial (Lippert et al., 2014). The specificity of the test or
its ability to correctly identify patients without disease is
> 99%, that is, < 1% of patients without disease will test
positive (false positive) by this method. Calculation of the
positive predictive value (PPV) or proportion of patients with
a positive test result who have the disease, and the negative
predictive value (NPV) or proportion of patients with a negative test result who do not have the disease, can help define
this impact (O’Brien et al., 2014). The positive and negative
predictive values are calculated using the formulae below.
PPV: (sensitivity)(prevalence)/(sensitivity)(prevalence) + (1 specificity)(1 - prevalence)
NPV: (specificity)(1 - prevalence)/(specificity)(1 prevalence) + (1 - sensitivity)(prevalence)
Given the frequency of 15.9% JAK2 V617F-positive samples in the audited population, the PPV and NPV predictive

values are 0.949 and 0.998, respectively. In the population
audited, this translates into the potential for *10 false-positive
and 2 false-negative results per annum. Recognizing the impact of inappropriate referrals and adherence to best practice
guidelines when investigating cases of suspected MPN will
directly increase the prevalence of JAK2 V617F in the tested
population by reducing the number of inappropriate samples
received, improving the PPV, and reducing false-positive
results issued; a prevalence of 50% would result in a predicted
two false-positive results per annum.
Recommendation 3: Acknowledge the effect of inappropriate referrals on the predictive value of the testing algorithm.
In only those cases of suspected ET and PMF that are JAK2
V617F negative, next-step reflexive testing for CALR mutations is now advocated (Tefferi and Pardanani, 2014), reinforcing the inclusion of appropriate clinical details. This
would minimize the compounding effect on the clinical sensitivity of test results, and also ensure appropriate allocation of
testing laboratory resources. It must also be noted that a significant center-to-center variation exists in JAK2 V617F requesting criteria (Langabeer, 2012). To support the correct
allocation of resources in this scenario, a rational testing algorithm for the JAK2 V617F, CALR, and BCR-ABL1 rearrangements is proposed (Fig. 2). Adoption of this algorithm
has the capacity to streamline testing for those patients who
truly warrant investigation and to minimize turnaround times,
thus enabling prompt clinical decision-making.
Recommendation 4: Adopt and adhere to the MPN molecular diagnostic algorithm.
Discussion

The underlying molecular landscape of the MPNs is continually evolving. Currently, mutations found within just two
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genes, JAK2 and CALR, are diagnostically relevant in up to
80% of the three most common subtypes of MPN (Cazzola
and Kralovics, 2014). However, which patients with suspected MPN should be tested when for these abnormalities
remains debatable. It has been previously shown that considerable center-to-center variation already exists within requesting patterns for the JAK2 V617F (Langabeer, 2012)
with variation also likely from the requesting clinician to
requesting clinician dependent on the presenting medical
scenario (Xavier et al., 2011). Addition of further genetic
markers such as CALR exon 9 mutations into the diagnostic
algorithm requires considered implementation so as to match
the optimum number of patients who would benefit from this
testing with the ability to provide such a service within the
existing laboratory resources. Clearly, given the current
knowledge of the frequencies and specificities of those diagnostically relevant MPN-associated mutations, reflexive
testing for CALR mutations in those 1083 JAK2 V617Fnegative patients analyzed in a single year audited above
would be irrational from a scientific and economical perspective. Adherence to recommendations and guidelines for
both the diagnosis and treatment of the common MPN is
essential; reports from real-life practice have shown that
implementation of such guidelines is suboptimal with the
lack of adoption of molecular diagnostic strategies capable of
impacting on subsequent therapeutic interventions (Peterson
et al., 2011; Roda et al., 2014).
It is likely that in the near future, emerging technologies
such as next-generation sequencing, capable of detecting
numerous mutations in multiple genes simultaneously, already demonstrated to have diagnostic and prognostic values
in other myeloid malignancies with multigenic pathologies
such as acute myeloid leukemia and myelodysplastic syndromes (White and DiPersio, 2014), will demonstrate sufficient flexibility to address this evolving diagnostic issue.
It is acknowledged that guidelines such as those outlined
above require a degree of flexibility in implementation as a
significant heterogeneity exists within the molecular, morphological, and clinical features of MPN patients. Debate on
implementation of these recommendations is welcomed that
would intentionally reinforce the value of interaction between
the clinic and laboratory, ultimately ensuring improved patient diagnoses and outcomes.
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The myeloproliferative neoplasms (MPN) are clonal, hematopoietic
stem cell-derived diseases characterised by bone marrow proliferation
of one or more of the myeloid cell lineages with the main subtypes being
polycythemia vera (PV), essential thrombocythemia (ET), and primary
myeloﬁbrosis (PMF). The diagnosis and classiﬁcation of these diseases
is dependent on clinical, hematological, histo-morphological and
molecular genetic ﬁndings. The most commonly acquired mutation
associated with MPN is the JAK2 V617F, occurring in approximately 95%
of PV cases and in 50–60% of ET and PMF patients. Further mutations in
MPL exon 10 are present in approximately 5% and 3% of PMF and ET patients respectively. In 2013, whole exome sequencing studies reported
insertion and/or deletion (indel) mutations in exon 9 of CALR, the gene
that encodes the endoplasmic reticulum-associated, calcium bind- ing
protein, calreticulin. These MPN disease driving mutations of CALR
result in a frame shift of the coding sequence, altered amino acid composition of the translated protein and loss of the endoplasmic reticulum
retention motif. CALR mutations appear not to occur in PV patients but
are present in up to 80% of ET and PMF patients who are JAK2 V617Fand MPL-mutation negative [1]. Analysis of CALR mutations has rapidly
been adopted into MPN molecular diagnostic algorithms with identiﬁcation now a major diagnostic criterion for ET and PMF [2]. In addition
to their diagnostic value, CALR mutations are associated with a higher
platelet count, a reduced hemoglobin level and a reduced risk of thrombosis when compared to their JAK2 V617F-positive counterparts with
patients responding to therapies such as interferon and JAK 1/2 inhibitors. While numerous studies have addressed the technical aspects of
CALR mutation identiﬁcation and mutant allele burden estimation and
despite guidelines clearly indicating analysis for the diagnosis of ET and
PMF, limited information exists on the criteria for requesting molecular testing of CALR mutations and the reproducibility of application of
these criteria in a real world situation. Given the previously noted referral centre variation in JAK2 V617F requesting patterns in the Republic
of Ireland [3], an audit was performed on the CALR mutation requests in
order to determine if requests were being made on appropriate patients
and to reﬁne the currently adopted molecular diagnostic algorithm for
MPN.
A retrospective audit was performed of CALR mutations requests received at a hematological malignancy molecular diagnostic laboratory
for the three calendar years since introduction of testing (2014–2016

inclusive) and for the previous eight years since introduction of JAK2
V617F testing (in order to capture those tests performed on archived
material: 2006–2013 inclusive). In addition to testing frequency, the
clinical comments provided on each request form were collated. Mutation analysis was performed by ﬂuorescent PCR followed by fragment
length analysis allowing detection of all CALR exon 9 insertion and/or
deletion mutations with a sensitivity of detection of 1% mutant allele
burden and was unchanged throughout the audit period.
From January 1st, 2014 until December 31st, 2016 inclusive, 1244 requests were received for CALR mutation analysis of which 632 (50.8%)
were retrospective and 612 (49.2%) were prospective. A total of 73 patients (5.9%) were found to harbour CALR exon 9 indel mutations with
the highest number of requests received during 2016 (n = 398). The
detection rate of CALR mutations did not differ signiﬁcantly between
those patients analysed retrospectively (5.7%) and those analysed prospectively (6.1%). With regard to requesting criteria, 513 requests
(41.2%) had no clinical details provided while the clinical details provided on the remainder could be categorised as per Table 1. CALR mutations
were primarily detected in those patients with either a known or
suspected diagnosis of ET or PMF. Of note, no CALR mutations were detected in patients with clinical details provided of erythrocytosis or
raised hematocrit and in those patients with isolated thrombosis.
Indel mutations of CALR exon 9 are the second most common disease
driving mutations in patients with ET or PMF. While the JAK2 V617F mutation is present in a proportion of myelodysplastic syndromes (MDS)
and MDS/MPN, CALR mutations are rare in these diseases. To date,
CALR mutations have been demonstrated primarily in ET and PMF, but
nevertheless, two cases not entirely fulﬁlling all diagnostic criteria for
PV have been reported to harbour such mutations [4]. Analysis of further 578 cases of JAK2-negative unexplained erythrocytosis revealed
two patients with CALR exon 9 mutations, one of which was reclassiﬁed as ET [5], and together with the data presented herein, emphasizes the unproductive practice in this group of patients. It is acknowledged that some patients with ET possess a high normal or raised
hemoglobin level, however several studies have established that CALRpositive ET patients display a signiﬁcantly lower hemoglobin level
than those patients with the JAK2 V617F. Both CALR and JAK2 mutations
may be present in a small minority of MPN patients however the diagnostic or prognostic value of this association has yet to be proven.
Splanchnic vein thrombosis (SVT) can be the presenting feature of either an overt or latent MPN: the JAK2 V617F mutation is present in up
to 40% of SVT patients. Several groups have sought to determine the incidence of CALR mutations in SVT cohorts with a recent review clearly
demonstrating that screening for CALR mutations is ineffective unless
other clinical or laboratory features of an MPN are also present [6]. Similarly, CALR mutations have not been detected in sizeable patient cohorts with a ﬁrst unprovoked venous thromboembolism (VTE), with
recurrent VTE, and in coronary patients including those with peripheral
arterial disease [7–9].
We have previously documented an increasing number JAK2 V617F
requests despite the annual incidence of MPN diagnosis remaining
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Table 1
Incidence of CALR mutations according to requesting details category.
Category

No. patients CALR
mutation
detected

Known JAK2 V617F negative ET
Known JAK2 V617F negative PMF
Known JAK2 V617F negative MPN unspeciﬁ ed

74
18
17

44
10
2

(59.5%)
(55.5%)
(11.8%)

? ET
? PMF
? MPN unspeciﬁed
Persistent thrombocytosis
Thrombocytosis
Erythrocytosis/raised hematocrit
Other (splenomegaly/neutrophilia/thrombosis/etc.)
No clinical details provided

109
28
24
124
189
37
111
513

9
2
1
3
1
0
0
1

(8.3%)
(7.1%)
(4.2%)
(2.4%)
(0.5%)
(0%)
(0%)
(0.2%)

Total

1244

73

constant [3] consequently prompting this audit of the more recently introduced CALR analysis. Subsequently to introduction of testing, a revised classiﬁcation of MPN [4] has been introduced which includes
detection of a CALR mutation as a major diagnostic criterion for ET and
PMF but not PV. This brief but informative audit highlights the constraints in implementing evolving diagnostic guidelines in real-life practice, acknowledged to inﬂuence subsequent treatment approaches and
outcomes [10] and afﬁrms the requirement for awareness, adoption and
adherence of such guidelines for the systematic investigation of a
suspected MPN.
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Abstract
Background Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haematopoietic progenitor
cells. Approximately half of all adult AML patients have a
normal karyotype (NK-AML) and an intermediate risk
prognosis.
Aims To determine the incidence and prognostic significance of NPM1 and FLT3-ITD mutations in a population of
patients with NK-AML.
Methods FLT3-ITD and NPM1 mutation status was retrospectively sought in presentation samples from 44 NKAML patients.
Results FLT3-ITD and NPM1 mutations were detected in
45.5 and 54.5% of patients, respectively, allowing stratification according to genotype.
Conclusions FLT3-ITD and NPM1 mutation status can be
defined in NK-AML. Prospective screening for these
mutations is advocated in all NK-AML patients, as the
genotype is of clinical importance when considering
treatment options including stem cell transplantation.
Keywords AML · Nucleophosmin · FLT3-ITD · Normal
karyotype · Prognosis · Genotype
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Introduction
Acute myeloid leukaemia (AML) is a clonal, malignant
disorder that results from genetic alterations in normal
haematopoietic progenitor cells. A diagnosis of AML is
made by the presence of at least 20% myeloblasts in the
bone marrow and is a clinically, morphologically, cytogenetically, and molecularly heterogeneous disease [1].
Despite advances in the understanding of the molecular
biology of AML, treatment remains a challenge with most
standard regimens using cytarabine and anthracylines for
induction followed by some form of postremission therapy
that may include allogeneic haematopoietic stem cell
transplantation (ASCT). The outcome of AML depends on
several factors including age, presenting white cell count
and the absence or presence of specific cytogenetic
abnormalities present in the myeloblasts [2].
Over the last 12 years, the karyotype at diagnosis in adult
AML patients less than 60 years of age has become one of
the principal predictors of treatment response and of which
three groups may be distinguished. The rela- tively
favourable group consists of patients with the
t(8;21)(q22;q22), inv(16)(p13q22), t(16;16)(p13;q22) and
t(15;17)(q22;q21) abnormalities, associated with specific
clinical, morphological and immunophenotypic characteristics. The high risk patients have either monosomies or
deletions of chromosomes 5 and 7, abnormalities of chromosome 3q or abnormalities that involve multiple chromosomes (complex abnormalities). The remaining group
has an intermediate risk prognosis and includes patients with
various trisomies and other less frequently occurring
abnormalities, with the majority having a normal karyotype
[3]. More recent studies of large numbers of AML patients
with these less frequently occurring abnormalities has
enabled a better understanding of each of their prognostic
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significance [4] but, nevertheless, 40–50% of patients are
considered to have a normal karyotype (NK-AML) and
within this group a wide heterogeneity exists in terms of
responses to treatment.
Insights into the complex network of molecular aberrations responsible for the underlying diversity of NK-AML
have come from the detection of acquired mutations, rearrangements and atypical expression of several genes
involved in normal myeloid cell growth, proliferation and
maturation. Each of these genetic abnormalities is postulated to potentially have its own prognostic significance [5].
The most common molecular mutations in NK-AML
involve the FLT3, NPM1, MLL, CEBPA, NRAS, C-KIT and
RUNX1 genes with internal tandem duplications of the FLT3
gene (FLT3-ITD, approximately 40%) and mutations in
NPM1 (approximately 50%) being the most frequent [6].
FLT3 is a receptor tyrosine kinase normally expressed on
early myeloid cell precursors. The gene encoding FLT3 is
located on chromosome 13q12 and in AML; in-frame ITD
mutations in the juxta-membrane region or point mutations
in the tyrosine kinase domain may occur that result in constitutive tyrosine kinase activity [7]. Indication that the
presence of an FLT3-ITD had an impact on overall survival
in NK-AML was noted over 10 years ago [8] and was subsequently shown to stratify NK-AML patients in several
larger series of patients with the ITD, predicting an increased
relapse risk and a poorer overall survival [9–11]. Nucleophosmin (NPM1) is a phosphoprotein that shuttles between
the nucleus and cytoplasm, and is thought to be involved in
the regulation of function and stability of various other
nuclear proteins [12]. NPM1 is located on chromosome 5q35
with specific mutations of this gene in AML patients first
described in 2005, which were associated with a normal
karyotype and responsiveness to induction chemotherapy
[13]. Heterozygous mutations occur in NPM1 exon 12 and
the majority result in a tetranucleotide insertion that creates
an additional nuclear export signal motif, leading to dislocation of the mutant protein into the cytoplasm. The relatively high incidence of NPM1 mutations and their
association with specific biological and clinical features in
NK-AML have been confirmed [14–16]. More recently, the
genotype of mutated NPM1 without FLT3-ITD in NK-AML
has been associated with a high remission rate and favourable outcome [17], with no difference in relapse-free survival whether a sibling donor was available for ASCT or not,
suggesting that sibling ASCT may not improve outcome in
first remission in this group of patients [18].
As the molecular genotype of NK-AML has an
increasingly important impact on clinical decision making,
including transplantation options, the incidence and significance of NPM1 and FLT3-ITD mutations were therefore
sought in a series of patients referred for molecular
investigation.
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Fig. 1 Agarose gel electrophoresis of FLT3-ITD PCR reactions.
Lanes 1 and 12, 100-bp ladder; lanes 2–7, NK-AML patients; lane 8,
5% FLT3-ITD control; lane 9, FLT3 wild-type control; lane 10, 100%
FLT3-ITD control; lane 11, water control

Methodology
A total of 44 adult patients with a diagnosis of NK-AML
were retrospectively identified. All patients were less than
65 years of age and therefore potential recipients of ASCT.
The median age of patients was 46 years (range 17–65) with
26 males and 18 females and a median follow-up of 19
months (range 1–68 months). All DNA from presenta- tion
BM (n = 36) or peripheral blood (n = 8) with greater than
20% myeloblasts was extracted using the QIAmp DNA
Blood Mini Kit (Qiagen, Crawley, UK).
FLT3-ITD mutations were identified as previously
described [9]. Briefly, the duplicated sequence involves
exons 11, 12 or the intervening intron. Wild-type FLT3
produces a 328-bp fragment, whilst alleles possessing an
ITD are between 3 and\420 bp greater in length. Genomic
DNA PCR products were electrophoresed on 3% agarose
gels containing SYBr Green (Invitrogen, Oregon, USA)
(Fig. 1). Detection of NPM1 mutations was performed using
a capillary electrophoresis methodology as previ- ously
described [19]. Genomic DNA was amplified with a highfidelity DNA polymerase using a 6-FAM labelled forward
primer located within the intron between NPM1 exons 11
and 12, and a reverse primer that resulted in amplification
of a fragment containing the coding region of NPM1 exon
12. Wild-type NPM1 allele was used as an internal control
for DNA extraction and amplification. The amplified
product produces a 169-bp wild-type fragment and in
mutated cases an additional 173- or 174-bp fragment (the
latter in very rare cases of a net 5-bp insertion) (Fig. 2).
This methodology enables identification of all reported
heterozygous NPM1 mutations to date. Mutated patient
DNA was serially diluted into DNA of haemato- logically
normal controls to determine assay sensitivities.

Results
From serial dilution experiments, both assays were found to
consistently detect heterozygous FLT3-ITD and NPM1
mutations when present at a level of \5% of total DNA.
FLT3-ITD mutations were identified in 20 (45.5%) NKAML patients and NPM1 mutations in 24 (54.5%). Patients
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Fig. 2 Electropherogram of wild-type NPM1 (upper panel) and
heterozygous mutated NPM1 (lower panel) PCR reactions: two peaks
with a four base pair difference in size are clearly visible

could be further stratified into groups according to genotype:
FLT3-ITD negative/NPM1 negative, n = 13 (29.5%); FLT3ITD negative/NPM1 positive, n = 11 (25.0%); FLT3- ITD
positive/NPM1 negative, n = 7 (16.0%) and FLT3-ITD
positive/NPM1 positive, n = 13 (29.5%). Follow-up data
were evaluable for 84% (37/44) of patients. By Kaplan–
Meier analysis no significant differences were observed in
the overall survival between those NK-AML patients who
were either FLT3-ITD positive or negative or in those who
were NPM1 mutation positive or negative. No statistically
significant differences in overall survival were noted
between each of the aforementioned four genotypic subtypes but, of note, 8/11 (73%) of FLT3-ITD negative/NPM1
positive patients remain alive, six of whom are in first
complete remission.

Discussion
Many adult AML cases are characterised by the presence of
a number of recurring chromosomal abnormalities and in
many instances these abnormalities correlate closely with
specific clinical characteristics. The karyotype at diagnosis
therefore provides a framework for treatment stratification.

Approximately, 40–50% of patients with adult AML do not
have any evidence of such chromosome aberrations and are
classified as having an intermediate risk prognosis, but
within this group a spectrum of responses to treatment and
long-term outcomes exists. It has become increasingly
apparent that numerous molecular abnormalities within NKAML patients underlie this heterogeneity and that these
specific molecular genetic alterations are associated with
prognostic significance. Recently, the combined FLT3-ITD
and NPM1 mutation status has been shown to confer particular responses to standard induction therapy in NK-AML
with the mutant NPM1 without FLT3-ITD patients possessing a relatively favourable outcome [18]. Molecular
screening was therefore performed to determine the incidence and any potential prognostic importance of these
mutations in NK-AML patients referred for molecular
analysis.
The assays utilised to detect FLT3-ITD and NPM1
mutations were validated, reproducible and found to reliably
detect these mutations when present at a clinically relevant
level. The incidence of the four different FLT3-ITD/NPM1
genotypes in the cohort studied was consistent with that
previously reported in larger studies [17, 18, 20]. Unfortunately, no differences in overall survival were observed and
this may be attributable to the fact that this study was retrospective, small numbers of patients were studied and that
these patients had a relatively short follow-up. Nevertheless,
identification of both FLT3-ITD and NPM1 mutations is
now considered the minimum molecular diagnostic
requirement for NK-AML patients contributing to a prognostic stratification [21].
In addition to FLT3-ITD and NPM1, mutations and overexpression of numerous other genes associated with either
myeloid cell proliferation or differentiation have been
reported in NK-AML. These include mutations of CEBPA,
FLT3 kinase domain, NRAS, MLL, WT1, C-KIT
and dysregulated expression of BAALC, ERG, MN1 and
specific microRNAs with each of these abnormalities
potentially associated with a particular prognosis [22].
Molecular findings, along with clinical, morphological,
immunophenotypic and cytogenetic features, are becoming
of increasing value in determining the optimal therapy for
AML patients. In addition, new molecularly targeted
therapies are becoming available, e.g. FLT3 inhibitors.
These agents may be integrated into current treatment
strategies for AML, although their optimal usage remains to
be determined. Identification of FLT3-ITD and NPM1
mutation status is therefore advocated in all new NK-AML
patients.
Acknowledgments The authors are grateful to all clinicians who
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Abstract
Introduction Acute myeloid leukemia (AML) is a heterogeneous clonal disorder often associated with dismal overall
survival. The clinical diversity of AML is reflected in the
range of recurrent somatic mutations in several genes, many
of which have a prognostic and therapeutic value. Targeted
next-generation sequencing (NGS) of these genes has the
potential for translation into clinical practice. In order to
assess this potential, an inter-laboratory evalu- ation of a
commercially available AML gene panel across three
diagnostic centres in the UK and Ireland was performed.
Methods DNA from six AML patient samples was distributed to each centre and processed using a standardised
workflow, including a common sequencing platform,
sequencing chips and bioinformatics pipeline. A duplicate
sample in each centre was run to assess inter- and intralaboratory performance.
Results An average sample read depth of 2725X (range 629–
5600) was achieved using six samples per chip, with some
variability observed in the depth of coverage

generated for individual samples and between centres. A
total of 16 somatic mutations were detected in the six AML
samples, with a mean of 2.7 mutations per sample (range 1–
4) representing nine genes on the panel. 15/16 mutations
were identified by all three centres. Allelic frequencies of
the mutations ranged from 5.6 to 53.3 % (median 44.4 %),
with a high level of concordance of these frequencies
between centres, for mutations detected.
Conclusion In this inter-laboratory comparison, a high
concordance, reproducibility and robustness was demonstrated using a commercially available NGS AML gene
panel and platform.
Key Points

Inter-laboratory evaluation of a commercial nextgeneration sequencing, acute myeloid leukemia panel
proves robust, with high concordance and
reproducibility.
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1 Introduction
Acute myeloid leukemia (AML) is a heterogeneous clonal
disorder characterised by infiltration of the bone marrow,
blood and other tissues by abnormal or poorly differentiated myeloid cells of the haematopoietic system. Diagnosis
is based on bone marrow and peripheral blood morphology,
immunophenotype and the presence of typical chromosomal alterations or recurrent mutations. Treatment for AML
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patients is primarily based on delivery of an intensive
course of induction chemotherapy, such as cytarabine plus
anthracycline, followed by post-remission consolidation
chemotherapy. Up to 80 % of patients achieve complete
remission, however a significant proportion will eventually
relapse [1]. Allogeneic transplantation offers the potential
of a curative therapy in eligible patients after careful
assessment of co-existing morbidities based on donor
availability and genetic profile. Recurrent genetic lesions
such as Fms-related tyrosine kinase 3 (FLT3), CCAAT/
enhancer binding protein-a (CEBPA) and nucleophosmin
(NPM1) are commonly used as prognostic markers in
clinical practice, with markers associated with poor outcome, such as tumour protein 53 (TP53), additional sex
combs like transcriptional regulator 1 (ASXL1) and runtrelated transcription factor 1 (RUNX1), likely to be recommended for stratification in forthcoming guidelines [2].
Next-generation sequencing (NGS) technologies allow
massive parallel sequencing of multiple DNA regions of
interest, including large or GC-rich genes, and offer the
potential for increased throughput, sensitivity and quantification of variant allelic frequencies relative to standard
Sanger sequencing. Recent application of genomic techniques such as whole genome sequencing have yielded a
broad view of the mutational landscape of AML, and
highlighted 25–30 recurrent somatic mutations that can be
organised into functional categories. These genes encode
for transcription factors and tumour suppressors, genes
related to DNA methylation, haematopoietic cytokine signalling, chromatin modification, the cohesin complex and
the spliceosome complex [3]. Further studies have described patterns of clonal and subclonal evolution, mutation
clearance rates post-induction therapy and the monitoring
of minimal residual disease [4–7]. Together, these advances are helping unravel the potential for new personalised
therapies and targeted treatments with specific agents used
in combinations with standard chemotherapy to maintain
remission or bridge to transplantation [2, 8]. The adoption
of targeted gene panels comprising a refined set of diseaserelevant genes has shown promise for translation of NGS
into clinical practice [9–11]. Here we present an interlaboratory evaluation of a commercially available AML
gene panel across three clinical diagnostic centres in the
UK and Ireland.

2 Material and Methods
To evaluate the AML NGS panel, DNA from six precharacterised AML patients (NPM1 and FLT3-ITD mutation status assessed by polymerase chain reaction [PCR] and
capillary electrophoresis using alternative laboratory
methods) was used for quality control (QC#1–6),

distributed to each centre and processed using standardised
workflows for the Ion AmpliseqTM AML Panel (Life
Technologies/Thermo Fisher Scientific, Paisley, UK) before
sequencing on an Ion Torrent Personalized Genome
Machine (PGMTM; Life Technologies/Thermo Fisher Scientific). A designated sample (QC#3, QC#5, and QC#6) was
repeated in duplicate on separate runs in centres 1, 3 and 2,
respectively, to assess inter- and intra-centre reproducibility.
Amplicon libraries covering 19 commonly mutated genes
implicated in AML and covering the entire coding region of
DNA (cytosine-5-)-methyltransferase 3-a (DNMT3A),
CEBPA, GATA binding protein 2 (GATA2), tet
methylcytosine dioxygenase 2 (TET2), TP53 and mutational hot-spot regions of ASXL1, B-raf proto-oncogene,
serine/threonine kinase (BRAF), Cbl proto-oncogene, E3
ubiquitin protein ligase (CBL), FLT3 (tyrosine kinase
domain mutations), isocitrate dehydrogenase 1 (IDH1),
isocitrate dehydrogenase 2 (IDH2), Janus kinase 2 (JAK2),
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene
homolog (KIT), Kirsten rat sarcoma viral oncogene
homolog (KRAS), NPM1, neuroblastoma RAS viral (v-ras)
oncogene homolog (NRAS), protein tyrosine phosphatase,
non-receptor type 11 (PTPN11), RUNX1 and Wilms tumour
1 (WT1), were generated using 10 ng genomic DNA in each
of four primer-pooled reactions generating 264 amplicons.
Amplified targets were combined from four pools to two,
primer sequences were partly digested and barcoded
adapters were ligated for sample identification. The
resulting product was purified using Agencourt® AMPure®
XP beads as per the manufacturer’s instructions (Beckman
Coulter, Brea, CA, USA). The unamplified libraries were
quantified using qPCR with the Ion Library Quantification
Kit (Life Technologies/Thermo Fisher Scientific) and
equalised to 100 pM prior to combination. Emulsion PCR,
recovery and enrichment of templated Ion SphereTM particles (ISP) was performed using the Ion OneTouchTM 2
System or Ion ChefTM System (automated), before loading
onto Ion 318TM v2 chips and sequencing on the Ion Torrent
PGMTM platform with the Ion PGMTM Sequencing 200 Kit
v2. Data were reviewed using Torrent SuiteTM software
v4.2.1.0 (Thermo Fisher Scientific/Life Technologies) using
a low stringency parameter configuration. Samples were
uploaded to Ion ReporterTM v4.2 cloud-based soft- ware
(Thermo Fisher Scientific/Life Technologies) as BAM or
VCF files for subsequent variant annotation.
Coverage in highly sampled locations was capped at
2000X to reduce computational time. Calling of somatic
mutations was achieved using an algorithm that excluded
synonymous mutations, variants located within intronic or
untranslated regions, and variants present at a frequency of
\5 %. Insertions/deletions called using Ion ReporterTM
were confirmed by reviewing data with the Broad
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Institute’s Integrative Genomics Viewer (IGV) [12]. In
addition, AcroMetrix controls (Life Technologies/Thermo
Fisher Scientific), a highly multiplexed QC used to assess
the performance of NGS assays, was employed in one centre
to determine variant detection at low variant allele
frequencies (VAFs). To maximise confidence in variant
calling, a minimum target depth of coverage for variant calls
was set at 500X based on these data, with potential somatic
variants reviewed and screened using relevant public
databases, such as dbSNP, ClinVar, COSMIC, and PubMed.
No homozygous mutations of somatic relevance were
detected using the aforementioned public databases.

frameshift deletions in ASXL1 not currently represented in
COSMIC were identified in all centres and confirmed using
IGV.
Allelic frequencies of the 16 mutations detected ranged
from 5.6 to 53.3 % (median 44.4 %), with a high concordance between centres for mutations detected (Fig. 1). Of
note, Centre 2 did not report detection of the PTPN11
c.215C[A p.Ala72Asp mutation in sample three. Reanalysis of the data confirmed the presence of the missed
mutation at a read depth of 302X, initially omitted as the
read depth was \500X (in italics in electronic supplementary Table 2 and Fig. 1, mutation number 7).
3.3 Reproducibility

3 Results
3.1 Platform Performance
Performance of the Ion PGM TM platform and workflow at
each centre was assessed using the QC data generated for
each sample. Variables assessed were the number of reads
generated, the number and AQ20 (1 % error rate) quality
score of bases, the average depth of coverage across the bases
and the average read length generated. A mean read count of
602,354 reads per sample (range 150,312–1,212,941) was
generated. Mean read length at AQ20 was consistent at 123
bp (CV 3.3 %) for all samples analysed. An average sample
read depth of 2725X (range 629–5600) was achieved using
six samples on a 318TM v2 chip, with significant variability
observed in the depth of coverage generated for individual
QC samples and between centres (electronic supplementary
Table 1). AcroMetrix controls showed detection of
applicable variants present in IDH1/2, KIT, NPM1,
PTPN11, FLT3, TP53, KRAS and NRAS at VAFs of
between 5 and 10 % (25 % for NPM1) at 500X as expected.
3.2 Somatic Mutation Detection
Unfiltered data files from each centre were downloaded
from Ion ReporterTM and analysed using the filtering
algorithm outlined above. A total of 16 somatic mutations
were identified in the six AML patient samples tested.
Centres 1 and 3 identified all 16 mutations, whereas Centre
2 identified 15/16, producing an analytical specificity for the
gene panel of 97.9 % (95 % CI 89–99 %) [electronic
supplementary Table 2]. A mean of 2.7 somatic mutations
were detected in each AML patient sample (range 1–4),
representing nine genes on the panel (ASXL1, DNMT3A,
IDH1, IDH2, NPM1, NRAS, PTPN11, RUNX1, TET2), with
ASXL1 and DNMT3A being the most frequent. NPM1
mutations were identified in one of the six QC samples,
confirming results obtained at diagnosis by standard
methodology at the referring centre. In addition, two

Analysis of duplicate sample data showed both within and
between run concordance, with the same number of variants detected at similar frequencies by all centres (electronic supplementary Table 2).

4 Discussion
There is considerable interest in translating targeted NGS of
AML into clinical laboratories for routine detection of
therapeutically actionable disease mutations [10, 11, 13, 14].
In this report, we have evaluated the inter- and intra-laboratory reproducibility and robustness of a commercial 19gene AML panel in three separate clinical centres in the UK
and Ireland. Performance of the panel was assessed using six
AML patient samples run on the Ion PGMTM platform
across all centres. A high level of concordance was observed,
with 15/16 mutations detected. Centre 2 did not report a
PTPN11 c.215C[A p.Ala72Asp mutation that was excluded
as the number of reads generated for the sample was low
(150,312) and the subsequent read depth at the target site did
not achieve 500X. As a depth of coverage of 500X is necessary for confidence in calling low-level mutations (25
mutated reads are required for a 5 % burden), it is therefore
essential to ensure appropriate coverage of all relevant
amplicons to enable appropriate interrogation and interpretation of data produced. Improving efficiencies during the
preanalytic stages could help achieve this and would reduce
the variability in reads generated between samples and
between centres. Optimisation of library equalisation or
implementation of automated template preparation and chip
loading (Ion ChefTM) could increase reads generated and
improve preanalytical consistency. Reduction of sample
number per chip or repeat testing and combination of results
for samples that prove difficult to sequence would help
deliver sufficient read depth for further analysis.
Nevertheless, given the variation in reads generated per
sample by each centre, the high concordance in the
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Fig. 1 Allelic frequency of mutations detected in quality-control
samples. Mutation 1: DNMT3A p.Leu344Gln; Mutation 2: NPM1
p.Trp288fs; Mutation 3: NRAS p.Gly12Asp; Mutation 4: NRAS
p.Gly12Ser; Mutation 5: TET2 pArg1216Ter; Mutation 6: RUNX1
p.Arg204Gln; Mutation 7: PTPN11 p.Ala72Asp; Mutation 8: ASXL1

p.Leu890fs; Mutation 9: DNMT3A p.Arg882His; Mutation 10: IDH1
p.Arg132Cys; Mutation 11: ASXL1 p.Arg693Ter; Mutation 12: ASXL1
p.Gly966del; Mutation 13: DNMT3A p.Arg882Cys; Mutation 14:
DNMT3A p.Arg792His; Mutation 15: IDH2, p.Arg172Lys; Mutation
16: ASXL1 p.Ser798fs

identification and coverage depth of somatic mutations in
the samples tested proves the capacity of the Ion
AmpliseqTM AML Research Panel and Ion Torrent as a
robust platform for generating reproducible results in a
clinical diagnostic setting. Incorporation of this gene panel
would complement and enhance the armoury of tools
available for identification of relevant diagnostic and
prognostic somatic mutations in AML patients.
A limitation of this study was the limited number of
genes available for analysis. Expansion of the panel to
incorporate a greater number of relevant genes mutated in
AML (e.g. splicing factors) would further improve its
applicability.

Compliance with Ethical Standards

5 Conclusions
The use of targeted panels in AML has the potential to
overcome the limitations of standard Sanger sequencing in
terms of time, the potential to sequence multiple gene targets
at once, and the ability to quantify variant allelic
frequencies. In a clinical diagnostic setting, these benefits
translate into additional clinically relevant information and
justify the application of limited resources to generate
relevant information for clinical decision making. The
implementation of common platforms and workflows to
interrogate the mutational profile of AML patients will
enable standardisation of results and further collaborative
efforts between centres.
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Abstract
Introduction: For patients diagnosed with high-risk myeloid neoplasms the prognosis is poor
with allogeneic stem cell transplantation offering the only potential cure. Preclusion of
patients from standard conditioning on the basis of age or refractory disease has led to
development of regimen combining cytoreduction and transplant conditioning, for example
fludarabine, cytosine, arabinoside, amsacrine, cyclophosphamide, and busulfan (FLAMSA).
The relevance of somatic mutations in the FLAMSA transplantation scenario remains to be
fully elucidated. The profile of somatic mutations in twenty one patients uniformly treated
with a FLAMSA transplant is reported. Methods: Targeted next generation sequencing was
performed using a panel covering nineteen genes. Results: Thirty three somatic driver
mutations were detected with a median of two mutations per patient. TET2 mutations were
most common at 41.2%, followed by RUNX1 and DNMT3A at 23.5% each. Grouping mutations
by disease classification revealed predominant associations of RUNX1 and TP53 within the
myelodysplastic syndrome group, ASXL1 and TET2 within the chronic myelomonocytic
leuekmia group (CMML), TET2 and DNMT3A within the acute myeloid leukemia group. The
FLAMSA regimen was well tolerated with a non-relapse mortality below that predicted by
Hematopoietic Cell Transplantation-Comorbidity Index scoring (9.5% versus 41%), however
the outcome for CMML patients and those with therapy related myeloid neoplasms was
inferior indicating a need for alternative therapeutic approaches. Conclusion: Profiling of
somatic mutations enhances clinical insight in patients with high-risk myeloid malignancies
prior to transplantation.
Keywords: FLAMSA, next generation sequencing, transplantation, molecular diagnostics

Introduction

For patients with high-risk refractory or relapsed myeloid neoplasms the prognosis is poor
and outcome after standard chemotherapy alone rarely results in cure. Although allogeneic
stem cell transplantation (ASCT) offers a potential cure, relapse rates are high and patients
can be precluded from standard protocols on the basis of older age, refractory or relapsed
disease, and presence of co-morbidities.
Whereas reduced intensity conditioning (RIC) transplantation regimens offer lower rates of
non-relapse mortality (NRM) in aggressive disease this may not be sufficient to control
disease until a graft versus leukaemia (GvL) effect occurs. In an attempt to overcome this,
intermediate sequential conditioning regimen incorporating a short course of chemotherapy
combining fludarabine, cytosine, arabinoside, amsacrine, cyclophosphamide, and either total
body irradiation or busulfan (FLAMSA) to reduce disease burden prior to reduced intensity
conditioning have been designed and implemented in high-risk myeloid neoplasms [1-3].
Using next generation sequencing technologies, a range of somatic mutations have been
associated with adverse outcome in myeloid malignancies including mutations affecting
ASXL1, FLT3, TP53, RUNX1, EZH2, [4-6] with subsequent studies indicating an association
between somatic mutations and response to therapy [7,8]. For high-risk myelodysplastic
syndrome (MDS) patients who undergo ASCT, the use of pre-defined mutations can enable
prediction of relapse risk [9], with somatic mutation in ASXL1, RUNX1, TET2, DNMT3A and
TP53 associated with shorter survival in MDS and MDS/acute myeloid leukaemia (AML)
patients [10,11]. Moreover, detection of somatic mutations prior to transplantation have
shown potential as molecular targets of residual disease in the post-transplant setting [9, 12,
13].
To further characterise the mutational profile in this context, a retrospective analysis of
patients with high-risk myeloid malignancies treated with FLAMSA-Bu conditioned ASCT was
conducted.

Methods

Patients
Twenty-one patients (10 male, 11 female; median age 55 years; range 36-64 years) were
included. Patients were identified as having poor risk disease on the basis of AML with
primary induction failure (n=5), MDS with high or very high-risk Revised International
Prognostic Scoring System (R-IPSS) scores (n=8: 4 of whom had therapy-related MDS),
therapy-related AML with MLL rearrangement (n=1), intermediate-2 or high-risk CMMLspecific prognostic scoring system (CPSS) chronic myelomonocytic leukaemia (CMML) (n=4),
blast crisis of chronic myeloid leukaemia (n=1), primary myelofibrosis (PMF) with > 10%
myeloblasts on bone marrow (n=1), and mixed phenotype acute leukaemia (T/myeloid) with
complex karyotype (n=1).
Karyotype was available on 20/21 patient samples with a complex/monosomal karyotype
detected in 10/21 (47.6%) patients, an intermediate risk karyotype in 6/21 (28.6%), and a
normal karyotype in 4/21 (19%). The median Hematopoietic Cell Transplantation-Comorbidity
Index (HCT-CI) score for patients was 4 (range 0-10). Patient details and previous induction
chemotherapy are outlined in Table 1.

Transplant conditioning
All 21 patients underwent ASCT with FLAMSA-Bu conditioning. This consisted of cytoreductive
treatment with fludarabine 30mg/m2, cytarabine 2g/m2 and amsacrine 100mg/m2 from days
-12 to -9 followed by two days of rest before a reduced intensity conditioning (RIC) protocol
consisting of fludarabine 30mg/m2, busulphan 8mg/kg intravenously, and rabbit antithymocyte globulin 10-20mg/kg from days -6 to -1 before transplantation with peripheral
blood stem cells (PBSC) with a CD34+ count of >2.5X106/kg. Graft versus host disease (GvHD)
prophylaxis was initiated on day 0 and composed of mycophenolate mofetil 1g tds up to day
+35 in the absence of GvHD and cyclosporin 1.5mg/kg/bd, adjusted based on drug levels and
tapered from day +60 to +90. Patients in complete remission (CR) without evidence of GvHD

at day +120 and day +150 received escalating doses of donor lymphocyte infusions (DLI) at 1
or 5x106 CD34+ cells/kg.

Mutation profiling
Tumour genomic DNA was available on 17/21 patient samples (peripheral blood (n=4), bone
marrow (n=13) prior to conditioning. Internal tandem duplications (ITD) in FLT3 were
identified as previously described [14]. For next generation sequencing, 10ng of DNA was
used to generate amplicon libraries using a targeted sequencing approach with 264 amplicons
generated covering 19 genes commonly mutated in myeloid disorders. Amplicons covered
the entire coding region of DNMT3A, CEBPA, GATA2, TET2, TP53 and mutational hot spot
regions of ASXL1, BRAF, CBL, FLT3 (tyrosine kinase domain mutations), IDH1, IDH2, JAK2, KIT,
KRAS, NPM1, NRAS, PTPN11, RUNX1 and WT1. Sequencing was carried out on the Ion Torrent
Personalised Genome Machine (PGMTM) (Thermo Fisher Scientific, Paisley, UK).
Quality control for the methodology including the bioinformatics pipeline and capacity of the
platform and panel to generate reproducible results of sufficient quality in AML samples was
assessed. Briefly, samples that achieved >200X depth of coverage on >97% of amplicons were
considered for further analysis and subjected to a bioinformatics algorithm that excluded
non-exonic variants such those detected in the intronic or 3’untranslated regions of genes on
the panel and excluded synonymous or silent mutations that result in no effect on the amino
acid profile of the associated protein. Remaining potential somatic mutations were then
cross-checked using an array of on-line databases such as dbSNP, ClinVar, PubMed, COSMIC,
Sift and Polyphen to exclude germ-line SNPs, mutations of known benign impact and to assess
the impact of amino acid substitution on protein function. Insertions or deletions were
manually reviewed using the Broad Institutes Integrated Genomics Viewer as previously
described [15,16-21].

Statistics
Estimates of overall survival (OS) and progression free survival (PFS) were calculated using
GraphPad Prism® 7 (GraphPad Software, California, USA) and expressed as Kaplan-Meier
curves. OS and PFS were calculated from time of transplantation to event, which was defined
as death and progression or death for OS and PFS respectively. Non-relapse mortality (NRM),
was defined as death from any cause other than refractory disease or relapse. Cumulative
incidence was calculated using a competing risk model. Circos plots were generated from
tabular data using Circos online software [22].

Results

Somatic mutations
Tumour genomic DNA was available on 17/21 patient samples at the time of diagnosis for
mutational profiling. A FLT3-ITD mutation was detected in one patient sample (patient 9). All
17 patient samples were sequenced by NGS at a sufficient depth and quality to permit
bioinformatics analysis. A total of 423 variants were initially detected in 14/17 (82.4%) patient
samples sequenced. Exclusion of non-exonic and synonymous variants reduced the number
of variants to 124, before bioinformatic analysis of the remaining variants further reduced the
field to a final number of 33 somatic driver mutations. Missense mutations predominated
(n=22), followed by frame-shift (n=6) and nonsense (n=5).
A median of 2 mutations (range 0-5) was detected, with 5/6 MDS, 4/5 AML, 3/3 CMML, and
2/3 other, harbouring mutations detectable by the panel. TET2 mutations were the most
common lesion, detected in 7/17 (41.2%) cases, followed by RUNX1 and DNMT3A mutations
in 4/17 (23.5%) patients each. Allelic frequencies of the 33 mutations detected ranged from
3%-87%, with samples harbouring multiple mutations displaying variable allelic frequencies.
Details of somatic mutations detected by NGS are given in Table 2.
Ordering mutations by disease group revealed predominant associations of RUNX1 and TP53
within the MDS group, ASXL1 and TET2 within the CMML group, TET2 and DNMT3A within

the AML group, and KRAS within the other grouping (Figure 1). Analysis of gene-gene comutation within samples revealed the underlying heterogeneity within samples with TET2 as
the gene with the highest number of associated mutations (n=12), followed by DNMT3A
(n=9). Two de novo AML samples detected possessed an IDH2 R172 mutation with comutated DNMT3A (patients 8 and 14, Table 2).

Mutations versus outcome
Assessment of age and number of mutations detected showed no significance, with patients
<49 years versus those >50 years with a PFS/OS p-value of 0.8384 and 0.9166 respectively.
Both groups had a median of two mutations (range 0-4) (p 0.7414). Analysis of the impact of
individual genes on outcome was precluded by the limited patient cohort.

Clinical outcome
Twelve (57.1%) patients received stem cells from fully HLA matched unrelated donors. All
patients achieved neutrophil engraftment, occurring at a median of 24 days (range 11-124
days) and platelet engraftment at a median of 26 days (range 10-221 days) post-ASCT. Ten
(47.6%) patients received planned donor lymphocyte infusions and seven (33.3%) patients
developed acute GvHD. Two treatment-related deaths occurred; one from sepsis in the
context of steroid-refractory GvHD and another from toxoplasmosis infection. Ten (47.6%)
patients remain alive and disease-free after a median of 513 days follow-up. Nine (42.9%)
patients have relapsed post ASCT, three of whom remain alive following salvage therapy. The
median time to relapse is 109 days (62-751), with median progression free survival (PFS) at
841 days and median overall survival (OS) has not yet been reached. The impact of donor
source (related versus unrelated donor) did not impact on PFS (p=0.2568) or OS (p=0.7389).
Of note, all four CMML patients relapsed at a median of 694 days post FLAMSA-Bu ASCT. The
median PFS for de novo AML and MDS has not been reached (Figure 2). Overall non relapse
mortality (NRM) was 9.5%, with a median predicted two year NRM of 41% using the HCT-CI
Score.

Discussion

The potential to integrate somatically acquired mutation status into clinical decision making
has been greatly enhanced by adoption of NGS technologies which allow for simultaneous
detection of multiple mutations. Whereas the mutational landscape of myeloid diseases has
been delineated in recent years [4, 5, 23, 24] the mutational profile in specific clinical
scenarios such as ASCT has yet to be fully explored, with variation in mutational impact
observed [25]. Data is presented on mutational status and clinical outcome in a cohort of
high-risk myeloid malignancy patients uniformly treated with FLAMSA-Bu conditioning and
ASCT. Using a gene panel covering 19 myeloid relevant genes, 14/17 (82.4%) patients had
somatic mutations detected, with a median of 2 mutations per patient. The frequency of
mutations in this cohort is consistent with that observed in myeloid disorders reported
elsewhere [23, 24, 25] with variable allelic burdens observed in patients harbouring multiple
mutations indicating the presence of subclones and a complex clonal architecture. Of note,
two AML patient samples displayed an IDH2 R172 mutation, which has recently been
proposed as a distinct AML genomic entity with a prevalence of approximately 1% based on
mutual exclusivity with NPM1 or other class defining lesions and a gene-expression and DNA
methylation profile that differs from other IDH mutations leading to more severe aberrations
in metabolic activity [26].
Further analysis by disease group reflected the high-risk status of the patients with mutations
associated with poor outcome such as RUNX1 and TP53 predominant within the MDS group
and ASXL1 within the CMML group. Clear gene-gene co-mutation associations were not found
likely reflecting the underlying heterogeneity of the patients and the limited number of
patients studied.
An association between patient age and number of mutations was not detected, nor between
individual mutated genes and patient outcome, again probably due to the low patient
number. A recent large scale landmark study matching mutation and clinical data in MDS has
reinforced the poor risk of TP53 mutation regardless of conditioning intensity prior to
transplant, questioning the benefit of conventional myeloablative conditioning over reduced
intensity approaches in patients with TP53-mutated MDS [27]. It is therefore interesting to

speculate on a growing role for FLAMSA-Bu based conditioning in these patients in the future,
however further larger scale studies are needed to determine the true effect of conditioning
on TP53-mutated patients.
In the cohort tested, the FLAMSA-Bu regimen was clinically well tolerated with a NRM below
that predicted by HCT-CI scoring (9.5% versus 41%). However, the outcome for CMML
patients and those with therapy related myeloid neoplasms was poor indicating a need for
alternative therapeutic approaches.

Conclusion
Notwithstanding the limitations of a small patient cohort and a limited gene panel, mutational
profiling of patients prior to ASCT aids clinical understanding of patient genotype. Knowledge
of the clonal/subclonal architecture provides potential markers for disease monitoring post
ASCT in this cohort of patients at high risk of relapse.
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Table Legends:
Table 1: Patient Characteristics.
Table 2: Mutation profile of patient cohort.

Figure Legends:
Figure 1: Circos plot connecting disease groups and mutated genes.
Figure 2: Progression free survival of patient cohort by WHO 2008 category.

Table 1:
Number of Patients

21
Median age in years (range)
Gender (male: female)

55 years (36-64 years)
10 male: 11 female

WHO 2008 Diagnosis
Acute myeloid leukaemia

5 (23.8%)

Therapy-related myeloid neoplasm

5 (23.8%)

Chronic myelomonocytic leukaemia

4 (19%)

Myelodysplasia

4 (19%)

Chronic myeloid leukaemia; blast crisis

1 (4.8%)

Primary myelofibrosis

1 (4.8%)

Mixed phenotype acute leukaemia, T/myeloid, NOS

1 (4.8%)

Cytogenetics
Normal karyotype

4

Complex karyotype

8

Monosomal karyotype as a sole abnormality

2

Other karyotype abnormality

6

Not available

1

Initial pre-transplant chemotherapy
Azacytidine

3/21

DAT 3+10 induction

11/21

FLAG-IDA induction

3/21

Other pre-transplant treatment

5/21

Bone marrow blasts prior to ASCT
<5%

11/21

5-10%

7/21

>10%

3/21

Transplant characteristics
Donor type

9 Sibling donors
12 Matched unrelated donors

Patient/donor CMV serostatus

4 Positive/Positive
2 Positive/Negative
1 Negative/Positive
13 Negative/Negative
1 Unknown

Post-transplant immunosuppression

19 Ciclosporin/Mycophenolate
2 Tacrolimus/Mycophenolate

Graft versus Host Disease
Acute

7/21

Chronic

5/17

Treatment related mortality

2/21

Death from relapsed disease prior to 100 days

2/21

Outcome

Survival at 100 days
Median Progression Free Survival
Median Overall Survival

17/21
841 days
Not reached

Table 2:
Pati
ent

1

2

3
4

5

6

7

8

9

10

11

12

13

14

Locus
chr4:10615
5920
chr4:10615
6432
chr20:3102
4371
chr21:3623
1782
chr1:11525
6528
chr4:10616
4898
chr20:3102
4274
chr12:1129
26888
chr4:10615
8490
chr20:3102
2981
chr4:10615
5755
chr5:17083
7543
chr2:25470
554
chr2:25457
243
chr12:2539
8281
chr12:2539
8284
chr11:1191
48919
chr2:25464
535
chr15:9063
1838
chr4:10615
8490
chr21:3623
1783
chr4:10615
8228
chr11:1191
48877
chr17:7578
212
chr17:7578
461
chr3:12820
0073
chr21:3623
1783
chr21:3625
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Targeted next-generation sequencing of familial platelet
disorder with predisposition to acute myeloid leukaemia

Familial platelet disorder with propensity to acute myeloid
leukaemia (FPD-AML) is a rare, autosomal dominant disor- der
characterized by quantitative and qualitative platelet
abnormalities with a propensity to develop a myelodysplastic
syndrome (MDS) or AML. FPD-AML kindred are defined by
germ-line mutations of RUNX1 (Song et al, 1999), which
encodes a transcription factor essential for definitive haematopoiesis and myeloid cell differentiation, commonly dysregulated by translocations, mutations or amplification in de novo
and secondary MDS and acute leukaemias. Most germ line
RUNX1 mutations are unique to the individual FPD- AML
pedigree with variability observed in the MDS or AML
phenotype and the incidence of leukaemic transformation of
affected individuals (Nickels et al, 2013). The spectrum of
somatic genetic events associated with progression to MDS or
AML have not been fully appreciated but acquisition of
cytogenetic abnormalities, single gene defects that occur in de
novo MDS and AML, and bi-allelic RUNX1 mutations have all
been demonstrated (Minelli et al, 2004; Preudhomme et al,
2009; Shiba et al, 2012). More recently, mutations of CDC25C
have been identified in approximately half of affected FPDAML patients. CDC25C mutations appear to disrupt a critical
cell cycle check point in pre-leukaemic clones, allowing
subsequent acquisition of further sub-clonal mutations
(Yoshimi et al, 2014). Emerging next-generation sequencing
(NGS) technologies, platforms and disease- targeted panels
allow the simultaneous identification of numerous mutational
events. Such a targeted NGS approach was applied to a known
RUNX1 mutated FPD-AML kindred to identify additional
molecular events that co-operate with the germ line RUNX1
mutation in driving leukaemic transformation.
A 56-year-old male and a 45-year-old female sibling both
presented with AML with myelodysplastic features (Fig 1, I–
3 and I–7 respectively). At diagnosis, I-3 had trisomy 8

and I-7 had monosomy 7. The eldest son of patient I-7 (II-1, Fig
1) has thrombocytopenia. The history of familial thrombocytopenia coupled with development of AML suggested a
diagnosis of FPD-AML, which was confirmed by Sanger
sequencing identification of a heterozygous RUNX1 p.Arg166X
mutation in the leukaemic blasts and constitu- tional buccal
scrapes of both affected patients. Patient I-3 underwent a
reduced intensity conditioning allogeneic stem cell transplant
(ASCT) from RUNX1 wild type sibling donor I-5. Patient I-7
underwent a myeloblative ASCT from RUNX1 wild type
sibling donor I-6. Both patients achieved 100% donor
chimerism by day-100 post-ASCT.
For NGS, amplicon libraries were generated from AML
diagnostic bone marrow DNA of I-3 and I-7 using the Ion
AmpliseqTM AML Panel (Thermo Fisher Scientific, Life Technologies, Paisley, UK), a four primer-pool panel that gener- ates
237 amplicons to allow interrogation of 19 commonly mutated
genes implicated in AML. Amplicons cover the entire coding
region of DNMT3A, CEBPA, GATA2, TET2, TP53 and
mutational hot spot regions of ASXL1, BRAF, CBL, FLT3,
IDH1, IDH2, JAK2, KIT, KRAS, NPM1, NRAS,
PTPN11, RUNX1 and WT1. Sequencing was performed on an
Ion PGMTM with data analysed and reviewed using Tor- rent
Browser and Ion Reporter 4·2 software (Thermo Fisher
Scientific, Life Technologies). Criteria to allow confident calling of somatic mutations were a minimum target coverage of
500X, the presence of a mutation at >5% and a predicted change
in amino acid sequence. Sanger sequencing was also performed
of exon 8 of CDC25C, encompassing the muta- tion hotspot
previously described (Yoshimi et al, 2014).
In addition to confirmation of the heterozygous RUNX1
p.Arg166X mutation, targeted NGS demonstrated the presence
of further mutations in the genes known to disrupt epigenetic
(ASXL1, IDH1, TET2) and transcription factor (CEBPA,
RUNX1) function in AML (Table I). Although

I
Fig 1. Pedigree of the familial platelet disorder
with propensity to acute myeloid leukaemia
(FPD-AML) kindred. The index cases (I-3, I-7)
are indicated as black symbols. II-1 (grey symbol) suffered from thrombocytopenia
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Table I. Mutations identified by targeted next-generation sequencing in the two affected siblings.
Patient

Mutated gene

Nucleotide change

Amino acid change

Variant effect

% Mutant allele

COSMIC (Disease association)

I-3

RUNX1
ASXL1
IDH1
RUNX1
RUNX1
TET2
RUNX1
CEBPA

c.496C>T
c.2083C>T
c.394C>T
c.608C>G
c.496C>T
c.5162T>G
c.497G>A
c.898C>T

p.Arg166X
p.Gln695X
p.Arg132Cys
p.Pro203Arg
p.Arg166X
p.Leu1721Trp
p.Arg166Gln
p.Arg300Cys

nonsense
nonsense
missense
missense
nonsense
missense
missense
missense

53%
26%
14%
6%
50%
50%
11%
5%

COSM24769 (AML, ETP-ALL)
COSM1738037 (MDS)
COSM28747 (AML, Glioma)
–
COSM24769 (AML, ETP-ALL)
–
COSM36055 (AML)
–

I-7

COSMIC, Catalogue of somatic mutations in cancer (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/); AML, acute myeloid leukaemia;
ETP-ALL, early T cell precursor-acute lymphoblastic leukaemia; MDS, myelodysplastic syndrome.

matched germ line material was not studied by NGS, the fact
that several of these mutations have been previously described
in haematological malignancies (Table I) and that they are
present at allele frequencies less than 50% implies they are
somatic and not heterozygous germ line in nature. No
mutations of CDC25C exon 8 were detected in either patient.
Proof of principle feasibility and utility of a targeted NGS
approach are demonstrated in a FPD-AML kindred with a
known germ line RUNX1 mutation. A targeted NGS approach
using more comprehensive MDS- and AML-asso- ciated gene
panels or whole exome sequencing is likely to offer several
advantages over standard sequencing method- ologies in
familial AML: identification of the causative germ line
mutation is possible where the phenotype may be uninformative (Obata et al, 2015); the simultaneous detection of cooperating mutations that may be clinically actionable, such as
IDH and TET2 demonstrated in the FPD-AML kin- dred
described herein (Falini et al, 2015); the ability to infer patterns
of clonal evolution in patients with overt AML (Tawana et al,
2015); and affords the opportunity to monitor identified
thrombocytopenic individuals from FPD-AML kin- dred to
identify progression to MDS or AML, thus allowing earlier
clinical intervention. While no CDC25C mutations were
detected in the two FPD-AML affected patients described, the
role of these abnormalities requires clarifica- tion in other FPDAML kindred. If NGS technologies become integrated into
routine practice, more cases of famil- ial leukaemia are likely
to be resolved (Churpek et al, 2013)
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Nerve growth factor negatively regulates bone marrow
granulopoiesis during small intestinal inflammation

The regulation of haematopoiesis during inflammation is the
subject of intense study with respect to anti-tumour immu- nity
and chronic disease. In particular, the generation of neu- trophils
is crucial for host survival, yet the restoration of steady state
haematopoiesis is also essential for return to health. It is known
that neutrophil homoeostasis is positively regulated by Toll-like
receptor signalling and inflammatory cytokines (Wirths et al,
2014), but the negative regulation of ‘emergency’
granulopoiesis is still poorly understood (Manx & Boettcher,
2014).
Bone marrow stromal cells have been shown to both synthesize nerve growth factor (NGF) and express a functional
p75NTR/TrkA receptor, suggesting that NGF is involved in the
regulation of haematopoiesis (Tomellini et al,2014). Cur- rent
literature presents conflicting evidence concerning the effect of
NGF on myeloid progenitor colonies and their dif- ferentiation
into mature cells. We hypothesized that NGF, a known survival
factor for granulocytes, could also play a role in emergency
granulopoiesis. Here we use a parasite infection model,
Trichinella spiralis, to study an on-demand yet natu- rally
resolving haematopoietic response during acute small intestinal
inflammation (Pennock & Grencis, 2004). It has been shown
previously that NGF is expressed by gut epithe- lium (Torrents
et al, 2002) during T. spiralis infection. We were interested in
the effect that systemic NGF may have on myelopoiesis in vivo
during acute gut inflammation and, in particular, any effects on
the generation of granulocytes, as these are thought to
contribute to parasite survival and the control of inflammation.
During infection we found that there was no significant
difference in either total monocytic (CD11b+Ly6G—CD115+)
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or granulocytic (Ly6G+) cell types in the bone marrow,
although a trend towards reduced monocyte numbers could be
seen. However, gut homing neutrophils (CD11b+Ly6G+CD115-a4b7+) were significantly increased in the bone marrow
(P < 0·01) at day 1 post-infection and in the blood at day 7 postinfection (P < 0·01, Fig 1A, B). This population was
CD11blo/intLy6Gint, suggesting an immature phenotype similar
to granulocytic myeloid-derived suppressor cells (Gr-MDSC)
described previously (Van Ginderachter et al, 2010). Napthol
AS-D chloroacetate staining of jejunum showed granulocytes
were present the small intestine at day 7 post-infection (Fig
1C ii) correlating with the egress of gut homing cells from the
bone marrow. Interestingly, infection induced a reduction in the
ability of myeloid-committed progenitor cells to respond to ex
vivo growth factors in every colony type, most significantly for
granulocyte (CFU-G) and granulocyte/ macrophage colonyforming units (CFU-GM) (Fig 1D). When incubated with
whole bone marrow from uninfected NIH mice, serum from
infected animals reproduced the observed in vivo inhibition of
myelopoiesis (Fig 1E), confirm- ing the presence of systemic
inhibitory factors and suggesting a dose response. These effects
were inhibited by neutralizing anti-NGF antibody (Fig 1F) and
could be replicated by co- culture of na€ıve bone marrow for 7
days with exogenous recombinant NGF (1–500 ng/ml), causing
a dose responsive inhibition of CFU-G (P < 0·001, data not
shown). Of note, inhibition of serum NGF did not rescue CFUM, suggesting that NGF acted primarily on the granulocyte
lineage.
To test the role of NGF in granulopoiesis in vivo during
immunological challenge, T. spiralis infected mice were treated
with a neutralizing anti-NGF antibody. Treatment induced
163
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Appendix 4: JAK2 V617F Negative MPN patients screened for CALR mutation
status. PB; peripheral blood, BM; bone marrow.
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Appendix 5: Characteristics of SVT patients referred for molecular testing
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Appendix 6: Award
Haematology Association of Ireland/Novartis Educational Fellowship Award 2016:
(€10,000).
Awarded for study entitled: “Utility of Targeted Next Generation Sequencing to
Identify Clonal Somatic Mutations in Patients with Myelodysplastic Syndromes” .
Findings presented at:
Haematology Association for Ireland Annual Meeting, October 2016, Athlone, Ireland.
American Society Haematology Annual Meeting, November 2016, San Diego, U.S.A.
Citation:
Haslam, K., Appleby, N., Armstrong, C., Flynn, C. M., Langabeer, S., & Conneally, E.
(2016). Impact of Somatic Mutations on Clinical Outcomes Following Flamsa-Bu
Conditioning and Allogenic Stem Cell Transplantation in Patients with Poor-Risk
Myeloid Malignancies. Blood, 128(22), 2277.
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